Fused heteroaromatic pyrrolidinones

ABSTRACT

Disclosed are compounds of Formula 1, 
     
       
         
         
             
             
         
       
     
     and pharmaceutically acceptable salts thereof, wherein G, L 1 , L 2 , R 1 , R 2 , R 3 , and R 4  are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, pharmaceutical compositions containing them, and their use for treating disorders, diseases, and conditions involving the immune system and inflammation, including rheumatoid arthritis, hematological malignancies, epithelial cancers (i.e., carcinomas), and other disorders, diseases, and conditions for which inhibition of SYK is indicated.

RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Application No.61/289,969, filed Dec. 23, 2009, and U.S. Provisional Application No.61/386,964, filed Sep. 27, 2010, which are herein incorporated byreference.

FIELD OF THE INVENTION

This invention relates to fused heteroaromatic pyrrolidinone compounds,to pharmaceutical compositions containing them, and to the use of thecompounds for treating disorders and conditions involving the immunesystem and inflammation, including rheumatoid arthritis. Theheteroaromatic pyrrolidinones are inhibitors of spleen tyrosine kinase.

BACKGROUND OF THE INVENTION

Spleen tyrosine kinase (SYK) is a 72 kDa non-receptor cytoplasmictyrosine kinase. SYK has a primary amino acid sequence similar to thatof zeta-associated protein-70 (ZAP-70) and is involved inreceptor-mediated signal transduction. The N-terminal domain of SYKcontains two Src-homology 2 (SH2) domains, which bind todiphosphorylated immunoreceptor tyrosine-based activation motifs (ITAMs)found in the cytoplasmic signaling domains of many immunoreceptorcomplexes. The C-terminus contains the catalytic domain, and includesseveral catalytic loop autophosphorylation sites that are responsiblefor receptor-induced SYK activation and subsequent downstream signalpropagation. SYK is expressed in many cell types involved in adaptiveand innate immunity, including lymphocytes (B cells, T cells, and NKcells), granulocytes (basophils, neutrophils, and eosinophils),monocytes, macrophages, dendritic cells, and mast cells. SYK isexpressed in other cell types, including airway epithelium andfibroblasts in the upper respiratory system. See, e.g., Martin Turner etal., Immunology Today (2000) 21(3):148-54; and Michael P. Sanderson etal., Inflammation & Allergy-Drug Targets (2009) 8:87-95.

SYK's role in ITAM-dependent signaling and its expression in many celltypes suggest that compounds which inhibit SYK activity may be usefulfor treating disorders involving the immune system and inflammation.Such disorders include Type I hypersensitivity reactions (allergicrhinitis, allergic asthma, and atopic dermatitis); autoimmune diseases(rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus,psoriasis, and immune thrombocytopenic purpura); and inflammation of thelung (chronic obstructive pulmonary disease). See, e.g., Brian R. Wonget al., Expert Opin. Investig. Drugs (2004) 13(7):743-62; Sanderson etal. (2009); Jane Denyer & Vipul Patel, Drug News Perspective (2009)22(3):146-50; Esteban S. Masuda & Jochen Schmitz, Pulmonary Pharmacology& Therapeutics (2008) 21:461-67; Malini Bajpai et al., Expert Opin.Investig. Drugs (2008) 17(5):641-59; and Anna Podolanczuk et al., Blood(2009) 113:3154-60. Other disorders include hematological malignancies,such as acute myeloid leukemia, B-cell chronic lymphocytic leukemia,B-cell lymphoma (e.g., mantle cell lymphoma), and T-cell lymphoma (e.g.,peripheral T-cell lymphoma); as well as epithelial cancers, such as lungcancer, pancreatic cancer, and colon cancer. See, e.g., Cynthia K. Hahnet al., Cancer Cell (2009) 16:281-294; D. H. Chu et al., Immunol. Rev.(1998) 165:167-180; A. L. Feldman et al., Leukemia (2008) 22:1139-43; A.Rinaldi et al., Br. J. Haematol. (2006) 132:303-316; B. Streubel et al.,Leukemia (2006) 20:313-18; Maike Buchner et al., Cancer Research (2009)69(13):5424-32; A. D. Baudot et al., Oncogene (2009) 28:3261-73; andAnurag Singh et al., Cancer Cell (2009) 15:489-500.

Various SYK inhibitors have been described in published patentapplications. See, e.g., EP 1184376 A1; WO 01/83485 A1; WO 03/057695 A1;WO 2006/129100 A1; WO 01/09134 A1; WO 03/063794 A1; WO 2005/012294 A1;WO 2004/087699 A2; WO 2009/026107 A1; WO2009136995 A2; and WO2009/145856A1.

SUMMARY OF THE INVENTION

This invention provides fused heteroaromatic pyrrolidinone derivatives,including 6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-ones,1H-pyrrolo[3,4-c]pyridin-3(2H)-ones, and pharmaceutically acceptablecomplexes, salts, solvates, and hydrates thereof. This invention alsoprovides pharmaceutical compositions containing the heteroaromaticpyrrolidinone derivatives, and uses of the heteroaromatic pyrrolidinonederivatives to treat disorders and conditions involving the immunesystem and inflammation, including rheumatoid arthritis.

One aspect of the invention provides compounds of Formula 1:

or pharmaceutically acceptable salts thereof, wherein:

-   G is selected from N and C(R⁵);-   L¹ and L² are each independently selected from —NH— and a bond;-   R¹ and R² are each independently selected from hydrogen, halo, C₁₋₃    alkyl, and C₁₋₃ haloalkyl, or R¹ and R², together with the atom to    which they are attached, form a C₃₋₆ cycloalkyl;-   R³ is selected from C₂₋₆ alkyl, C₃₋₈ cycloalkyl, C₂₋₅ heterocyclyl,    and C₁₋₉ heteroaryl, each optionally substituted with from one to    five substituents independently selected from halo, oxo, —NO₂, —CN,    R⁶, and R⁷;-   R⁴ is selected from C₃₋₈ cycloalkyl, C₂₋₅ heterocyclyl, C₆₋₁₄ aryl,    and C₁₋₉ heteroaryl, each optionally substituted with from one to    five substituents independently selected from halo, oxo, —CN, R⁶,    and R⁷;-   R⁵ is selected from hydrogen, halo, —CN, C₁₋₄ alkyl, C₂₋₄ alkenyl,    C₂₋₄ alkynyl, C₂₋₅ heterocyclyl, C₁₋₅ heteroaryl, and R¹⁰, wherein    the alkyl, alkenyl, alkynyl moieties are each optionally substituted    with from one to five substituents independently selected from halo,    —CN, oxo, and R¹⁰, and wherein the heterocyclyl moiety has 3 to 6    ring atoms and the heteroaryl moiety has 5 or 6 ring atoms, and the    heterocyclyl and heteroaryl moieties are each optionally substituted    with from one to four substituents independently selected from halo,    —NO₂, —CN, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₁₋₄ haloalkyl,    and R¹⁰;-   each R⁶ is independently selected from —OR⁸, —N(R⁸)R⁹, —NR⁸C(O)R⁹,    —C(O)R⁸, —C(O)OR⁸, —C(O)N(R⁸)R⁹, —C(O)N(R⁸)OR⁹, —C(O)N(R⁸)S(O)₂R⁹,    —N(R⁸)S(O)₂R⁹, —S(O)_(n)R⁸, and —S(O)₂N(R⁸)R⁹;-   each R⁷ is independently selected from C₁₋₆ alkyl, C₂₋₆ alkenyl,    C₂₋₆ alkynyl, C₃₋₆ cycloalkyl-(CH₂)_(m)—, C₆₋₁₄ aryl-(CH₂)_(m)—,    C₂₋₅ heterocyclyl-(CH₂)_(m)—, and C₁₋₉ heteroaryl-(CH₂)_(m)—, each    optionally substituted with from one to five substituents    independently selected from halo, oxo, —NO₂, —CN, C₁₋₆ alkyl, C₁₋₆    haloalkyl, and R¹⁰;-   each R⁸ and R⁹ is independently selected from hydrogen or from C₁₋₆    alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₆ cycloalkyl-(CH₂)_(m)—, C₆₋₁₄    aryl-(CH₂)_(m)—, C₂₋₅ heterocyclyl-(CH₂)_(m)—, and C₁₋₉    heteroaryl-(CH₂)_(m)—, each optionally substituted with from one to    five substituents independently selected from halo, oxo, —NO₂, —CN,    C₁₋₆ alkyl, C₁₋₆ haloalkyl, and R¹⁰;-   each R¹⁰ is independently selected from —OR¹¹, —N(R¹¹)R¹²,    —N(R¹¹)C(O)R¹², —C(O)R¹¹, —C(O)OR¹¹, —C(O)N(R¹¹)R¹²,    —C(O)N(R¹¹)OR¹², —C(O)N(R¹¹)S(O)₂R¹², —NR¹¹S(O)₂R¹², —S(O)_(n)R¹¹,    and —S(O)₂N(R¹¹)R¹²;-   each R¹¹ and R¹² is independently selected from hydrogen and C₁₋₆    alkyl;-   each n is independently selected from 0, 1 and 2; and-   each m is independently selected from 0, 1, 2, 3, and 4;-   wherein each of the aforementioned heteroaryl moieties has one to    four heteroatoms independently selected from N, O, and S, and each    of the aforementioned heterocyclyl moieties is saturated or    partially unsaturated and has one or two heteroatoms independently    selected from N, O, and S.

Another aspect of the invention provides a compound which is selectedfrom the following group of compounds and their pharmaceuticallyacceptable salts:

-   2-((1R,2S)-2-Aminocyclohexylamino)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one;-   2-((1R,2S)-2-Aminocyclohexylamino)-4-(3-fluorophenylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one;-   2-((1R,2S)-2-Aminocyclohexylamino)-4-(3-chlorophenylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one;-   4-(1H-Indazol-6-ylamino)-2-((1R,2S)-2-aminocyclohexylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one;-   2-((1R,2S)-2-aminocyclohexylamino)-4-(3-(trifluoromethyl)phenylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one;-   cis-2-(2-aminocyclohexylamino)-4-(3-(trifluoromethyl)phenylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one;-   2-(1-Methyl-1H-pyrazol-4-yl)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one;-   2-(4-Ethylpiperazin-1-yl)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one;-   2-(Cyclohexylamino)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one;-   cis-2-(2-Hydroxycyclohexylamino)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one;-   2-(3-Aminopiperidin-1-yl)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one;-   6-((1R,2S)-2-Aminocyclohexylamino)-4-(m-tolylamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;-   2-((1R,2S)-2-Aminocyclohexylamino)-4-(1-methyl-1H-pyrazol-4-yl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one;-   2-((1R,2S)-2-Aminocyclohexylamino)-4-(1-isobutyl-1H-pyrazol-4-yl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one;-   2-((1R,2S)-2-Aminocyclohexylamino)-4-phenyl-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one;-   2-((1R,2S)-2-Aminocyclohexylamino)-4-(benzo[b]thiophen-3-yl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one;-   2-((1R,2S)-2-Aminocyclohexylamino)-4-(1-ethyl-1H-pyrazol-4-yl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one;-   2-((1R,2S)-2-Aminocyclohexylamino)-4-(1-benzyl-1H-pyrazol-4-yl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one;-   2-((1R,2S)-2-Aminocyclohexylamino)-4-(imidazo[1,2-a]pyridin-3-yl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one;-   2-((1R,2S)-2-Aminocyclohexylamino)-4-(1-propyl-1H-pyrazol-4-yl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one;-   2-((1R,2S)-2-Aminocyclohexylamino)-4-(1-(2-methoxyethyl)-1H-pyrazol-4-yl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one;-   4-(1H-Indazol-6-ylamino)-6-((1R,2S)-2-aminocyclohexylamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;-   6-((1R,2S)-2-Aminocyclohexylamino)-4-(4-fluoro-3-methylphenylamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;-   6-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-4-(m-tolylamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;-   6-((1R,2S)-2-Aminocyclohexylamino)-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;-   6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;-   6-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;-   6-((1R,2S)-2-Aminocyclohexylamino)-7-chloro-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;-   6-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-4-(pyrazolo[1,5-a]pyridin-3-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;-   2-(2-(Aminomethyl)piperidin-1-yl)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one;-   6-((1R,2S)-2-Aminocyclohexylamino)-4-(3-(methylsulfonyl)phenylamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;-   6-((1R,2S)-2-Aminocyclopentylamino)-4-(3-(methylsulfonyl)phenylamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;-   (R)-4-Methyl-2-(4-(3-(methylsulfonyl)phenylamino)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)pentanamide;-   (R)-4-Methyl-2-(4-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)pentanamide;-   2-((1R,2S)-2-(Dimethylamino)cyclohexylamino)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one;-   2-((1R,2S)-2-(Methylamino)cyclohexylamino)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one;-   2′-((1R,2S)-2-Aminocyclohexylamino)-4′-(m-tolylamino)spiro[cyclopropane-1,7′-pyrrolo[3,4-d]pyrimidin]-5′(6′H)-one;-   2-(2-Aminoethylamino)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one;-   2-(2-Amino-2-methylpropylamino)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one;-   2-(5-oxo-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-ylamino)acetamide;-   2-((2-Aminoethyl)(methyl)amino)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one;-   2-(Pyrrolidin-2-ylmethylamino)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one;-   2-(3-Aminopyrrolidin-1-yl)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one;-   2-((1R,2S)-2-Aminocyclohexylamino)-4-(1,5-dimethyl-1H-pyrazol-4-yl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one;-   2-((1R,2S)-2-Aminocyclohexylamino)-4-(1H-indol-2-yl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one;-   2-((1R,2S)-2-Aminocyclohexylamino)-4-(1H-pyrazol-5-yl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one;-   2-(3-Aminopropyl)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one;-   6-((1R,2S)-2-Aminocyclohexylamino)-4-(benzofuran-3-yl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;-   6-((1R,2S)-2-aminocyclohexylamino)-7-fluoro-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;-   6-((1R,2S)-2-aminocyclohexylamino)-4-(benzo[b]thiophen-3-yl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;-   6-((1S,2R)-2-Aminocyclohexylamino)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;-   (R)-6-(2-Amino-3-ethoxypropylamino)-4-(m-tolylamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;-   (R)-6-(2-Amino-3-ethoxypropylamino)-7-fluoro-4-(m-tolylamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;-   6-(2-Amino-3,3,3-trifluoropropylamino)-4-(m-tolylamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;-   (R)-4-Methyl-2-(3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)pentanamide;-   6-(cis-4-Aminotetrahydrofuran-3-ylamino)-4-(m-tolylamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;-   6-((1R,2S)-2-Aminocyclohexylamino)-4-(1-ethyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;-   6-((1R,2S)-2-Aminocyclohexylamino)-4-(1-ethyl-1H-pyrazol-4-yl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;-   6-((1R,2S)-2-Aminocyclohexylamino)-4-(1-cyclopropyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;-   6-((1R,2S)-2-Aminocyclohexylamino)-4-(1-(difluoromethyl)-1H-pyrazol-4-yl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;-   6-((1R,2S)-2-Aminocyclohexylamino)-4-(1-cyclopropyl-1H-pyrazol-4-yl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;-   cis-6-(2-Aminocyclohexylamino)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;-   6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;-   6-(cis-2-Amino-4,4-difluorocyclopentylamino)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;-   6-(cis-2-Amino-3,3-difluorocyclohexylamino)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;-   6-(cis-2-Amino-3,3-difluorocyclohexylamino)-4-(1-(difluoromethyl)-1H-pyrazol-4-yl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;-   6-(cis-2-amino-3,3-difluorocyclohexylamino)-4-(1-cyclopropyl-1H-pyrazol-4-yl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;-   (R)-2-(7-Fluoro-4-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-4-methylpentanamide;-   (R)-2-(4-(1-(Difluoromethyl)-1H-pyrazol-4-yl)-7-fluoro-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-4-methylpentanamide;-   (R)-2-(4-(1-Cyclopropyl-1H-pyrazol-4-yl)-7-fluoro-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-4-methylpentanamide;-   (R)-2-(4-(Benzofuran-3-yl)-7-fluoro-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-4-methylpentanamide;-   (R)-2-(7-Fluoro-3-oxo-4-(pyrazolo[1,5-a]pyridin-3-yl)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-4-methylpentanamide;-   6-((1R,2S)-2-Aminocyclohexylamino)-7-chloro-4-(m-tolylamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;-   6-((1R,2S)-2-Aminocyclohexylamino)-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-7-carbonitrile;-   (R)-6-(2-Amino-3-methoxypropylamino)-4-(m-tolylamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;-   (R)-6-(2-Amino-3-methoxypropylamino)-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-7-carbonitrile;-   (R)-6-(2-Amino-3-methoxypropylamino)-7-fluoro-4-(m-tolylamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;-   7-Acryloyl-6-((1R,2S)-2-aminocyclohexylamino)-4-(m-tolylamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;-   6-((1R,2S)-2-Aminocyclohexylamino)-7-iodo-4-(m-tolylamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;-   6-((1R,2S)-2-Aminocyclohexylamino)-7-(1H-pyrazol-4-yl)-4-(m-tolylamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;-   6-(cis-2-Amino-3,3-difluorocyclohexylamino)-4-(m-tolylamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;-   6-((1R,2S)-2-Aminocyclohexylamino)-7-(1-methyl-1H-pyrazol-5-yl)-4-(m-tolylamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;-   6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-4-(m-tolylamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;-   6-((3R,4R)-4-Aminotetrahydro-2H-pyran-3-ylamino)-4-(m-tolylamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;-   tert-Butyl    (1S,2R)-2-(3-oxo-7-phenyl-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate;-   6-((1R,2S)-2-Aminocyclohexylamino)-7-methyl-4-(m-tolylamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;-   6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-7-fluoro-4-(m-tolylamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;-   6-((1R,2S)-2-Aminocyclohexylamino)-7-methyl-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;-   (R)-6-(2-Amino-3-methoxypropylamino)-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;-   6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-7-fluoro-4-(pyrazolo[1,5-a]pyridin-3-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;-   6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-4-(1-(difluoromethyl)-1H-pyrazol-4-yl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;-   6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-4-(benzofuran-3-yl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;-   (S)-6-(3-Aminopyrrolidin-1-yl)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;-   (S)-6-(3-Aminopiperidin-1-yl)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;-   6-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-4-(1-isopropyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;-   7-Fluoro-4,6-bis(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;-   6-((1R,2S)-2-Aminocyclohexylamino)-7-bromo-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;-   2-((1R,2S)-2-Aminocyclohexylamino)-4-(1-(4-fluorophenyl)-1H-pyrazol-4-yl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one;-   (R)-6-(2-Amino-3-methoxypropylamino)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;-   6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-7-fluoro-4-(thiophen-3-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;-   6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-7-fluoro-4-(4-methylthiophen-2-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;-   6-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-4-(4-methylthiophen-2-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;-   6-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-4-(thiophen-3-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;-   (R)-2-(7-Fluoro-4-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-N,4-dimethylpentanamide;-   6-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-4-(5-methylthiophen-2-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;-   (R)-2-(7-Fluoro-4-(4-methylthiophen-2-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-4-methylpentanamide;-   (R)-2-(7-Fluoro-3-oxo-4-(thiophen-3-yl)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-4-methylpentanamide;-   (R)-2-(7-Fluoro-4-(5-methylthiophen-2-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-4-methylpentanamide;-   6-((1R,2S)-2-Aminocyclohexylamino)-4-(2-aminothiazol-5-yl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;-   (R)-2-(7-Fluoro-4-(furan-2-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-4-methylpentanamide;-   (R)-2-(7-Fluoro-4-(furan-3-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-4-methylpentanamide;-   (R)-2-(7-Fluoro-4-(furan-2-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-4-methylpentanamide;-   (R)-2-(4-(5-Cyanothiophen-2-yl)-7-fluoro-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-4-methylpentanamide;-   (R)-2-(4-(4-Cyanothiophen-2-yl)-7-fluoro-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-4-methylpentanamide;-   (R)-2-(7-Fluoro-3-oxo-4-(thiazol-5-yl)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-4-methylpentanamide;-   (R)-2-(7-Fluoro-4-(isothiazol-5-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-4-methylpentanamide;-   6-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-1,1-dimethyl-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;    ((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-4-(1-methyl-1H-pyrazol-3-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;-   6-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-4-(2-methylthiazol-5-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;-   6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-7-fluoro-4-(5-methylthiophen-2-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;-   6-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-1-methyl-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;-   (R)-2-(7-Fluoro-3-oxo-4-(thiophen-2-yl)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-4-methylpentanamide;-   6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-7-fluoro-4-(thiophen-2-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;-   6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-7-fluoro-4-(thiazol-5-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;-   6-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-4-(thiophen-2-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;-   6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-7-fluoro-4-(4-(trifluoromethyl)-1H-imidazol-1-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;-   6-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-4-(4-methyl-1H-imidazol-1-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;-   6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-7-fluoro-4-(3-methylisothiazol-5-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;-   6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-7-fluoro-4-(2-methylthiazol-5-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;-   (R)-2-(7-Fluoro-4-(2-methylthiazol-5-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-4-methylpentanamide;-   6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-4-(5-chlorothiophen-2-yl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;-   6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-4-(1-cyclopropyl-1H-pyrazol-4-yl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;    and-   a stereoisomer of any of the aforementioned compounds and their    pharmaceutically acceptable salts.

A further aspect of the invention provides a pharmaceutical compositionwhich includes: a compound of Formula 1, as defined above, or apharmaceutically acceptable salt thereof, or a compound selected fromthe group of compounds defined in the preceding paragraph, or apharmaceutically acceptable salt thereof and a pharmaceuticallyacceptable excipient.

An additional aspect of the invention provides a use as a medicament ofa compound of Formula 1, as defined above, or a pharmaceuticallyacceptable salt thereof, or a compound selected from the group ofcompounds defined above, or a pharmaceutically acceptable salt thereof.

Another aspect of the invention provides a use of a compound of Formula1, as defined above, or pharmaceutically acceptable salt thereof, or acompound selected from the group of compounds defined above, or apharmaceutically acceptable salt thereof, for the manufacture of amedicament for the treatment of a disease or condition for which a SYKinhibitor is indicated.

A further aspect of the invention provides a method of treating adisease or condition in a subject for which a SYK inhibitor isindicated, the method comprising administering to the subject aneffective amount of a compound of Formula 1, as defined above, or acompound selected from the group of compounds defined above, or apharmaceutically acceptable salt thereof.

An additional aspect of the invention provides a method of treating adisease or condition in a subject, the method comprising administeringto the subject an effective amount of a compound of Formula 1, asdefined above, or a pharmaceutically acceptable salt thereof, or acompound selected from the group of compounds defined above, or apharmaceutically acceptable salt thereof, wherein the disease orcondition is selected from allergic rhinitis, allergic asthma, atopicdermatitis, rheumatoid arthritis, multiple sclerosis, systemic lupuserythematosus, psoriasis, immune thrombocytopenic purpura, inflammatorybowel disease, chronic obstructive pulmonary disease, and thrombosis.

Another aspect of the invention provides a method of treating a diseaseor condition in a subject, the method comprising administering to thesubject an effective amount of a compound of Formula 1, as definedabove, or pharmaceutically acceptable salt thereof, or a compoundselected from the group of compounds defined above, or apharmaceutically acceptable salt thereof, wherein the disease orcondition is selected from a hematological malignancy and an epithelialcancer.

A further aspect of the invention provides a combination of an effectiveamount of a compound of Formula 1, as defined above, or pharmaceuticallyacceptable salt thereof, or a compound selected from the group ofcompounds defined above, or a pharmaceutically acceptable salt thereof,and at least one additional pharmacologically active agent.

DETAILED DESCRIPTION OF THE INVENTION

Unless indicated otherwise, this disclosure uses definitions givenbelow.

“Substituted,” when used in connection with a chemical substituent ormoiety (e.g., an alkyl group), means that one or more hydrogen atoms ofthe substituent or moiety have been replaced with one or morenon-hydrogen atoms or groups, provided that valence requirements are metand that a chemically stable compound results from the substitution.

“About” or “approximately,” when used in connection with a measurablenumerical variable, refers to the indicated value of the variable and toall values of the variable that are within the experimental error of theindicated value or within ±10 percent of the indicated value, whicheveris greater.

“Alkyl” refers to straight chain and branched saturated hydrocarbongroups, generally having a specified number of carbon atoms (e.g., C₁₋₃alkyl refers to an alkyl group having 1 to 3 carbon atoms, C₁₋₆ alkylrefers to an alkyl group having 1 to 6 carbon atoms, and so on).Examples of alkyl groups include methyl, ethyl, n-propyl, i-propyl,n-butyl, s-butyl, i-butyl, t-butyl, pent-1-yl, pent-2-yl, pent-3-yl,3-methylbut-1-yl, 3-methylbut-2-yl, 2-methylbut-2-yl,2,2,2-trimethyleth-1-yl, n-hexyl, and the like.

“Alk-1-yl” refers to an alkyl group, as defined above, which is attachedto a parent group or substrate through a carbon atom located at the 1position of the alkyl group.

“Alkenyl” refers to straight chain and branched hydrocarbon groupshaving one or more carbon-carbon double bonds, and generally having aspecified number of carbon atoms. Examples of alkenyl groups includeethenyl, 1-propen-1-yl, 1-propen-2-yl, 2-propen-1-yl, 1-buten-1-yl,1-buten-2-yl, 3-buten-1-yl, 3-buten-2-yl, 2-buten-1-yl, 2-buten-2-yl,2-methyl-1-propen-1-yl, 2-methyl-2-propen-1-yl, 1,3-butadien-1-yl,1,3-butadien-2-yl, and the like.

“Alkynyl” refers to straight chain or branched hydrocarbon groups havingone or more triple carbon-carbon bonds, and generally having a specifiednumber of carbon atoms. Examples of alkynyl groups include ethynyl,1-propyn-1-yl, 2-propyn-1-yl, 1-butyn-1-yl, 3-butyn-1-yl, 3-butyn-2-yl,2-butyn-1-yl, and the like.

“Halo,” “halogen” and “halogeno” may be used interchangeably and referto fluoro, chloro, bromo, and iodo.

“Haloalkyl,” “haloalkenyl,” and “haloalkynyl,” refer, respectively, toalkyl, alkenyl, and alkynyl groups substituted with one or more halogenatoms, where alkyl, alkenyl, and alkynyl are defined above, andgenerally having a specified number of carbon atoms. Examples ofhaloalkyl groups include fluoromethyl, difluoromethyl, trifluoromethyl,chloromethyl, dichloromethyl, trichloromethyl, and the like.

“Cycloalkyl” refers to saturated monocyclic and bicyclic hydrocarbongroups, generally having a specified number of carbon atoms thatcomprise the ring or rings (e.g., C₃₋₈ cycloalkyl refers to a cycloalkylgroup having 3 to 8 carbon atoms as ring members). Bicyclic hydrocarbongroups may include isolated rings (two rings sharing no carbon atoms),spiro rings (two rings sharing one carbon atom), fused rings (two ringssharing two carbon atoms and the bond between the two common carbonatoms), and bridged rings (two rings sharing two carbon atoms, but not acommon bond). The cycloalkyl group may be attached to a parent group orto a substrate at any ring atom unless such attachment would violatevalence requirements. In addition, the cycloalkyl group may include oneor more non-hydrogen substituents unless such substitution would violatevalence requirements.

Examples of monocyclic cycloalkyl groups include cyclopropyl,cyclobutyl, cyclopentyl, cyclohexyl, and the like. Examples of fusedbicyclic cycloalkyl groups include bicyclo[2.1.0]pentanyl (i.e.,bicyclo[2.1.0]pentan-1-yl, bicyclo[2.1.0]pentan-2-yl, andbicyclo[2.1.0]pentan-5-yl), bicyclo[3.1.0]hexanyl,bicyclo[3.2.0]heptanyl, bicyclo[4.1.0]heptanyl, bicyclo[3.3.0]octanyl,bicyclo[4.2.0]octanyl, bicyclo[4.3.0]nonanyl, bicyclo[4.4.0]decanyl, andthe like. Examples of bridged cycloalkyl groups includebicyclo[2.1.1]hexanyl, bicyclo[2.2.1]heptanyl, bicyclo[3.1.1]heptanyl,bicyclo[2.2.2]octanyl, bicyclo[3.2.1]octanyl, bicyclo[4.1.1]octanyl,bicyclo[3.3.1]nonanyl, bicyclo[4.2.1]nonanyl, bicyclo[3.3.2]decanyl,bicyclo[4.2.2]decanyl, bicyclo[4.3.1]decanyl, bicyclo[3.3.3]undecanyl,bicyclo[4.3.2]undecanyl, bicyclo[4.3.3]dodecanyl, and the like. Examplesof spiro cycloalkyl groups include spiro[3.3]heptanyl,spiro[2.4]heptanyl, spiro[3.4]octanyl, spiro[2.5]octanyl,spiro[3.5]nonanyl, and the like. Examples of isolated bicycliccycloalkyl groups include those derived from bi(cyclobutane),cyclobutanecyclopentane, bi(cyclopentane), cyclobutanecyclohexane,cyclopentanecyclohexane, bi(cyclohexane), etc.

“Cycloalk-1-yl” refers to a cycloalkyl group, as defined above, which isattached to a parent group or substrate through a carbon atom located atthe 1 position of the cycloalkyl group.

“Cycloalkenyl” refers to partially unsaturated monocyclic and bicyclichydrocarbon groups, generally having a specified number of carbon atomsthat comprise the ring or rings. As with cycloalkyl groups, the bicycliccycloalkenyl groups may include isolated, spiro, fused, or bridgedrings. Similarly, the cycloalkenyl group may be attached to a parentgroup or to a substrate at any ring atom and may include one or morenon-hydrogen substituents unless such attachment or substitution wouldviolate valence requirements. Examples of cycloalkenyl groups includethe partially unsaturated analogs of the cycloalkyl groups describedabove, such as cyclobutenyl (i.e., cyclobuten-1-yl and cyclobuten-3-yl),cyclopentenyl, cyclohexenyl, bicyclo[2.2.1]hept-2-enyl, and the like.

“Aryl” refers to fully unsaturated monocyclic aromatic hydrocarbons andto polycyclic hydrocarbons having at least one aromatic ring, bothmonocyclic and polycyclic aryl groups generally having a specifiednumber of carbon atoms that comprise their ring members (e.g., C₆₋₁₄aryl refers to an aryl group having 6 to 14 carbon atoms as ringmembers). The aryl group may be attached to a parent group or to asubstrate at any ring atom and may include one or more non-hydrogensubstituents unless such attachment or substitution would violatevalence requirements. Examples of aryl groups include phenyl, biphenyl,cyclobutabenzenyl, indenyl, naphthalenyl, benzocycloheptanyl,biphenylenyl, fluorenyl, groups derived from cycloheptatriene cation,and the like.

“Heterocycle” and “heterocyclyl” may be used interchangeably and referto saturated or partially unsaturated monocyclic or bicyclic groupshaving ring atoms composed of carbon atoms and 1 to 4 heteroatomsindependently selected from nitrogen, oxygen, and sulfur. Both themonocyclic and bicyclic groups generally have a specified number ofcarbon atoms in their ring or rings (e.g., C₂₋₅ heterocyclyl refers to aheterocyclyl group having 2 to 5 carbon atoms and 1 to 4 heteroatoms asring members). As with bicyclic cycloalkyl groups, bicyclic heterocyclylgroups may include isolated rings, spiro rings, fused rings, and bridgedrings. The heterocyclyl group may be attached to a parent group or to asubstrate at any ring atom and may include one or more non-hydrogensubstituents unless such attachment or substitution would violatevalence requirements or result in a chemically unstable compound.Examples of monocyclic heterocyclyl groups include oxiranyl, thiaranyl,aziridinyl (e.g., aziridin-1-yl and aziridin-2-yl), oxetanyl, thiatanyl,azetidinyl, tetrahydrofuranyl, tetrahydrothiopheneyl, pyrrolidinyl,tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, 1,4-dioxanyl,1,4-oxathianyl, morpholinyl, 1,4-dithianyl, piperazinyl, 1,4-azathianyl,oxepanyl, thiepanyl, azepanyl, 1,4-dioxepanyl, 1,4-oxathiepanyl,1,4-oxaazepanyl, 1,4-dithiepanyl, 1,4-thiazepanyl, 1,4-diazepanyl,3,4-dihydro-2H-pyranyl, 5,6-dihydro-2H-pyranyl, 2H-pyranyl,1,2,3,4-tetrahydropyridinyl, and 1,2,5,6-tetrahydropyridinyl.

“Heteroaryl” refers to unsaturated monocyclic aromatic groups and topolycyclic groups having at least one aromatic ring, each of the groupshaving ring atoms composed of carbon atoms and 1 to 4 heteroatomsindependently selected from nitrogen, oxygen, and sulfur. Both themonocyclic and polycyclic groups generally have a specified number ofcarbon atoms as ring members (e.g., C₁₋₉ heteroaryl refers to aheteroaryl group having 1 to 9 carbon atoms and 1 to 4 heteroatoms asring members) and may include any bicyclic group in which any of theabove-listed monocyclic heterocycles are fused to a benzene ring. Theheteroaryl group may be attached to a parent group or to a substrate atany ring atom and may include one or more non-hydrogen substituentsunless such attachment or substitution would violate valencerequirements or result in a chemically unstable compound. Examples ofheteroaryl groups include monocyclic groups such as pyrrolyl (e.g.,pyrrol-1-yl, pyrrol-2-yl, and pyrrol-3-yl), furanyl, thiopheneyl,pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, isothiazolyl, thiazolyl,1,2,3-triazolyl, 1,3,4-triazolyl, 1-oxa-2,3-diazolyl,1-oxa-2,4-diazolyl, 1-oxa-2,5-diazolyl, 1-oxa-3,4-diazolyl,1-thia-2,3-diazolyl, 1-thia-2,4-diazolyl, 1-thia-2,5-diazolyl,1-thia-3,4-diazolyl, tetrazolyl, pyridinyl, pyridazinyl, pyrimidinyl,and pyrazinyl.

Examples of heteroaryl groups also include bicyclic groups such asbenzofuranyl, isobenzofuranyl, benzothiopheneyl, benzo[c]thiopheneyl,indolyl, 3H-indolyl, isoindolyl, 1H-isoindolyl, indolinyl, isoindolinyl,benzimidazolyl, indazolyl, benzotriazolyl, 1H-pyrrolo[2,3-b]pyridinyl,1H-pyrrolo[2,3-c]pyridinyl, 1H-pyrrolo[3,2-c]pyridinyl,1H-pyrrolo[3,2-b]pyridinyl, 3H-imidazo[4,5-b]pyridinyl,3H-imidazo[4,5-c]pyridinyl, 1H-pyrazolo[4,3-b]pyridinyl,1H-pyrazolo[4,3-c]pyridinyl, 1H-pyrazolo[3,4-c]pyridinyl,1H-pyrazolo[3,4-b]pyridinyl, 7H-purinyl, indolizinyl,imidazo[1,2-c]pyridinyl, imidazo[1,5-c]pyridinyl,pyrazolo[1,5-c]pyridinyl, pyrrolo[1,2-b]pyridazinyl,imidazo[1,2-c]pyrimidinyl, quinolinyl, isoquinolinyl, cinnolinyl,quinazolinyl, quinoxalinyl, phthalazinyl, 1,6-naphthyridinyl,1,7-naphthyridinyl, 1,8-naphthyridinyl, 1,5-naphthyridinyl,2,6-naphthyridinyl, 2,7-naphthyridinyl, pyrido[3,2-d]pyrimidinyl,pyrido[4,3-d]pyrimidinyl, pyrido[3,4-d]pyrimidinyl,pyrido[2,3-d]pyrimidinyl, pyrido[2,3-b]pyrazinyl,pyrido[3,4-b]pyrazinyl, pyrimido[5,4-d]pyrimidinyl,pyrazino[2,3-b]pyrazinyl, and pyrimido[4,5-d]pyrimidinyl.

“Oxo” refers to a double bonded oxygen (═O).

“Leaving group” refers to any group that leaves a molecule during afragmentation process, including substitution reactions, eliminationreactions, and addition-elimination reactions. Leaving groups may benucleofugal, in which the group leaves with a pair of electrons thatformerly served as the bond between the leaving group and the molecule,or may be electrofugal, in which the group leaves without the pair ofelectrons. The ability of a nucleofugal leaving group to leave dependson its base strength, with the strongest bases being the poorest leavinggroups. Common nucleofugal leaving groups include nitrogen (e.g., fromdiazonium salts); sulfonates, including alkylsulfonates (e.g.,mesylate), fluoroalkylsulfonates (e.g., triflate, hexaflate, nonaflate,and tresylate), and arylsulfonates (e.g., tosylate, brosylate,closylate, and nosylate). Others include carbonates, halide ions,carboxylate anions, phenolate ions, and alkoxides. Some stronger bases,such as NH₂ ⁻ and OH⁻ can be made better leaving groups by treatmentwith an acid. Common electrofugal leaving groups include the proton,CO₂, and metals.

“Opposite enantiomer” refers to a molecule that is a non-superimposablemirror image of a reference molecule, which may be obtained by invertingall of the stereogenic centers of the reference molecule. For example,if the reference molecule has S absolute stereochemical configuration,then the opposite enantiomer has R absolute stereochemicalconfiguration. Likewise, if the reference molecule has S,S absolutestereochemical configuration, then the opposite enantiomer has R,Rstereochemical configuration, and so on.

“Stereoisomer” and “stereoisomers” of a compound with givenstereochemical configuration refer to the opposite enantiomer of thecompound and to any diastereoisomers, including geometrical isomers(Z/E) of the compound. For example, if a compound has S,R,Zstereochemical configuration, its stereoisomers would include itsopposite enantiomer having R,S,Z configuration, and its diastereomershaving S,S,Z configuration, R,R,Z configuration, S,R,E configuration,R,S,E configuration, S,S,E configuration, and R,R,E configuration. Ifthe stereochemical configuration of a compound is not specified, then“stereoisomer” refers to any one of the possible stereochemicalconfigurations of the compound.

“Substantially pure stereoisomer” and variants thereof refer to a samplecontaining a compound having a specific stereochemical configuration andwhich comprises at least about 95% of the sample.

“Pure stereoisomer” and variants thereof refer to a sample containing acompound having a specific stereochemical configuration and whichcomprises at least about 99.5% of the sample.

“Subject” refers to a mammal, including a human.

“Pharmaceutically acceptable” substances refers to those substanceswhich are within the scope of sound medical judgment suitable for use incontact with the tissues of subjects without undue toxicity, irritation,allergic response, and the like, commensurate with a reasonablebenefit-to-risk ratio, and effective for their intended use.

“Treating” refers to reversing, alleviating, inhibiting the progress of,or preventing a disorder, disease or condition to which such termapplies, or to reversing, alleviating, inhibiting the progress of, orpreventing one or more symptoms of such disorder, disease or condition.

“Treatment” refers to the act of “treating,” as defined immediatelyabove.

“Drug,” “drug substance,” “active pharmaceutical ingredient,” and thelike, refer to a compound (e.g., compounds of Formula 1 and compoundsspecifically named above) that may be used for treating a subject inneed of treatment.

“Therapeutically effective amount” of a drug refers to the quantity ofthe drug that may be used for treating a subject and may depend on theweight and age of the subject and the route of administration, amongother things.

“Excipient” refers to any substance that may influence thebioavailability of a drug, but is otherwise pharmacologically inactive.

“Pharmaceutical composition” refers to the combination of one or moredrug substances and one or more excipients.

“Drug product,” “pharmaceutical dosage form,” “dosage form,” “finaldosage form” and the like, refer to a pharmaceutical composition that isadministered to a subject in need of treatment and generally may be inthe form of tablets, capsules, sachets containing powder or granules,liquid solutions or suspensions, patches, films, and the like.

The following abbreviations are used throughout the specification: Ac(acetyl); ACN (acetonitrile); AIBN (azo-bis-isobutyronitrile); API(active pharmaceutical ingredient); aq (aqueous); Boc(tert-butoxycarbonyl); BSA (bovine serum albumin); Cbz (carbobenzyloxy);dba (dibenzylideneacetone); DCC (1,3-dicyclohexylcarbodiimide); DCM(dichloromethane); DIPEA (N,N-diisopropylethylamine, Hünig's Base); DMA(N,N-dimethylacetamide); DMAP (4-dimethylaminopyridine); DMARD (diseasemodifying antirheumatic drug); DME (1,2-dimethoxyethane); DMF(N,N-dimethylformamide); DMSO (dimethylsulfoxide); dppf(1,1′-bis(diphenylphosphino)ferrocene); DTT (dithiothreitol); EDAethoxylated dodecyl alcohol, Brj®35); EDCI(N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide); EDTA(ethylenediaminetetraacetic acid); ee (enantiomeric excess); eq(equivalents); Et (ethyl); Et₃N (triethyl-amine); EtOAc (ethyl acetate);EtOH (ethanol); FAM (5-carboxyfluorescein); HATU(2-(3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-1,1,3,3-tetramethyluroniumhexafluorophosphate(V)); HEPES(4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid); HOAc (aceticacid); HOBt (1H-benzo[d][1,2,3]triazol-1-ol); IC₅₀ (concentration at 50%inhibition); IPA (isopropanol); IPAc (isopropyl acetate); IPE(isopropylether); LDA (lithium diisopropylamide); LiHMDS (lithiumbis(trimethylsilyl)amide); mCPBA (m-chloroperoxybenzoic acid); Me(methyl); MeOH (methanol); MTBE (methyl tert-butyl ether); MOI(multiplicity of infection); mp (melting point); NaOt-Bu (sodiumtertiary butoxide); NBS (N-bromosuccinimide); NCS(N-chlorosuccinimide);NIS (N-iodosuccinimide); PE (petroleum ether); Ph (phenyl); pIC₅₀(−log₁₀(IC₅₀), where IC₅₀ is given in molar (M) units); Pr (propyl);i-Pr (isopropyl); PTFE (polytetrafluoroethylene); RT (room temperature,approximately 20° C. to 25° C.); SYK (spleen tyrosine kinase); TCEP(tris(2-carboxyethyl)phosphine); TFA (trifluoroacetic acid); TFAA(2,2,2-trifluoroacetic anhydride); THF (tetrahydrofuran); and Trisbuffer (2-amino-2-hydroxymethyl-propane-1,3-diol buffer).

This disclosure concerns compounds of Formula 1, which includescompounds specifically named above, and their pharmaceuticallyacceptable complexes, salts, solvates and hydrates. This disclosure alsoconcerns materials and methods for preparing compounds of Formula 1,pharmaceutical compositions containing them, and their use for treatingdisorders, diseases, and conditions involving the immune system andinflammation, including rheumatoid arthritis, hematologicalmalignancies, epithelial cancers (i.e., carcinomas), and otherdisorders, diseases, and conditions for which inhibition of SYK isindicated.

Compounds of Formula 1 include those in which L¹ is a bond and L² is—NH—; L¹ is —NH— and L² is a bond; L¹ and L² are both bonds; or L¹ andL² are both —NH—.

Compounds of Formula 1 also include those in which R¹ is hydrogen and R²is C₁₋₃ alkyl, in particular, methyl or ethyl; R¹ and R² are both C₁₋₃alkyl groups, in particular methyl; R¹ and R², together with the carbonatom to which they are attached, form a cyclopropyl group; or R¹ and R²are both hydrogen atoms.

Compounds of Formula 1 include those in which L¹ is —NH— and L² is —NH—or a bond; G is N; R¹ and R² are both hydrogen; and R³ is a 2-amino-C₃₋₈cycloalk-1-yl, or more particularly 2-amino-cyclohex-1-yl, optionallysubstituted with from one to four substituents independently selectedfrom halo, oxo, —NO₂, —CN, R⁶, and R⁷.

Compounds of Formula 1 also include those in which L¹ is —NH— and L² is—NH— or a bond; G is N; R¹ and R² are both hydrogen; and R³ is a2-amino-C₂₋₆ alk-1-yl, or more particularly 2-aminoethan-1-yl or2-amino-2-oxoethan-1-yl, optionally substituted with from one to five,from one to four or from one to two substituents, respectively,independently selected from halo, oxo, —NO₂, —CN, R⁶, and R⁷.

Compounds of Formula 1 further include those in which L¹ is —NH— and L²is —NH— or a bond; G is N; R¹ and R² are both hydrogen; and R³ is a C₂₋₅heterocyclyl, or more particularly an amino-C₂₋₅ heterocyclyl such as3-aminotetrahydro-2H-pyran-4-yl, optionally substituted with from one tofive or from one to four substituents, respectively, independentlyselected from halo, oxo, —NO₂, —CN, R⁶, and R⁷, wherein the heterocyclylmoiety has 5 or 6 ring atoms.

Compounds of Formula 1 include those in which L¹ is —NH— and L² is —NH—or a bond; G is N; R¹ and R² are both hydrogen; and R⁴ is a C₆₋₁₄ aryl,or more particularly phenyl, optionally substituted with from one tofive substituents independently selected from halo, oxo, —CN, R⁶, andR⁷.

Compounds of Formula 1 also include those in which L¹ is —NH— and L² is—NH— or a bond; G is N; R¹ and R² are both hydrogen; and R⁴ is a C₁₋₉heteroaryl, or more particularly a monocyclic C₂₋₄ heteroaryl,optionally substituted with from one to five or from one to foursubstituents, respectively, independently selected from halo, oxo, —CN,R⁶, and R⁷.

Compounds of Formula 1 also include those in which L¹ is —NH— and L² is—NH— or a bond; G is N; R¹ and R² are both hydrogen; and R⁴ is amonocyclic C₂₋₄ heteroaryl selected from pyrrolyl, furanyl, thiopheneyl,pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, isothiazoly, and thiazolyl,or more particularly from thiopheneyl, pyrazolyl, isothiazoly, andthiazolyl, each optionally substituted with from one to threesubstituents independently selected from halo, —CN, R⁶, and R⁷.

Compounds of Formula 1 further include those in which L¹ is —NH— and L²is —NH— or a bond; G is N; R¹ and R² are both hydrogen; and R⁴ is apyrazole moiety (e.g., pyrazol-4-yl) optionally substituted with fromone to three substituents independently selected from halo, —CN, R⁶, andR⁷.

Compounds of Formula 1 include those in which L¹ is —NH— and L² is —NH—or a bond; G is C(R⁵); R¹ and R² are both hydrogen; and R⁵ is a C₁₋₅heteroaryl optionally substituted with from one to four substituentsindependently selected from halo, —NO₂, —CN, C₁₋₄ alkyl, C₂₋₄ alkenyl,C₂₋₄ alkynyl, C₁₋₄ haloalkyl, and R¹⁰.

Compounds of Formula 1 also include those in which L¹ is —NH— and L² is—NH— or a bond; G is C(R⁵); R¹ and R² are both hydrogen; and R⁵ ishydrogen or halo, or more particularly, chloro or fluoro.

Compounds of Formula 1 include those in which L¹ is —NH— and L² is —NH—or a bond; G is C(R⁵); R¹ and R² are both hydrogen; and R³ is a2-amino-C₃₋₈ cycloalk-1-yl, or more particularly 2-amino-cyclohex-1-yl,optionally substituted with from one to four substituents independentlyselected from halo, oxo, —NO₂, —CN, R⁶, and R⁷.

Compounds of Formula 1 also include those in which L¹ is —NH— and L² is—NH— or a bond; G is C(R⁵); R¹ and R² are both hydrogen; and R³ is a2-amino-C₂₋₆ alk-1-yl, or more particularly 2-aminoethan-1-yl or2-amino-2-oxoethan-1-yl, optionally substituted with from one to five,from one to four or from one to two substituents, respectively,independently selected from halo, oxo, —NO₂, —CN, R⁶, and R⁷.

Compounds of Formula 1 further include those in which L¹ is —NH— and L²is —NH— or a bond; G is C(R⁵); R¹ and R² are both hydrogen; and R³ is aC₂₋₅ heterocyclyl, or more particularly an amino-C₂₋₅ heterocyclyl suchas 3-aminotetrahydro-2H-pyran-4-yl, optionally substituted with from oneto five or from one to four substituents, respectively, independentlyselected from halo, oxo, —NO₂, —CN, R⁶, and R⁷, wherein the heterocyclylmoiety has 5 or 6 ring atoms.

Compounds of Formula 1 include those in which L¹ is —NH— and L² is —NH—or a bond; G is C(R⁵); R¹ and R² are both hydrogen; and R⁴ is a C₆₋₁₄aryl, or more particularly phenyl, optionally substituted with from oneto five substituents independently selected from halo, oxo, —CN, R⁶, andR⁷.

Compounds of Formula 1 also include those in which L¹ is —NH— and L² is—NH— or a bond; G is C(R⁵); R¹ and R² are both hydrogen, and R⁴ is aC₁₋₉ heteroaryl, or more particularly a monocyclic C₂₋₄ heteroaryl,optionally substituted with from one to five or from one to foursubstituents, respectively, independently selected from halo, oxo, —CN,R⁶, and R⁷.

Compounds of Formula 1 also include those in which L¹ is —NH— and L² is—NH— or a bond; G is C(R⁵); R¹ and R² are both hydrogen; and R⁴ is amonocyclic C₂₋₄ heteroaryl selected from pyrrolyl, furanyl, thiopheneyl,pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, isothiazoly, and thiazolyl,or more particularly from thiopheneyl, pyrazolyl, isothiazoly, andthiazolyl, each optionally substituted with from one to threesubstituents independently selected from halo, —CN, R⁶, and R⁷.

Compounds of Formula 1 further include those in which L¹ is —NH— and L²is —NH— or a bond; G is C(R⁵); R¹ and R² are both hydrogen; and R⁴ ispyrazole moiety (e.g., pyrazol-4-yl) optionally substituted with fromone to three substituents independently selected from halo, —CN, R⁶, andR⁷.

Compounds of Formula 1 include those in which L¹ is —NH— and L² is —NH—or a bond; G is N; R¹ and R² are both hydrogen; R³ is a 2-amino-C₃₋₈cycloalk-1-yl, or more particularly 2-amino-cyclohex-1-yl, optionallysubstituted with from one to four substituents independently selectedfrom halo, oxo, —NO₂, —CN, R⁶, and R⁷; and R⁴ is a C₆₋₁₄ aryl, or moreparticularly phenyl, optionally substituted with from one to fivesubstituents independently selected from halo, oxo, —CN, R⁶, and R⁷.

Compounds of Formula 1 also include those in which L¹ is —NH— and L² is—NH— or a bond; G is N; R¹ and R² are both hydrogen; R³ is a2-amino-C₃₋₈ cycloalk-1-yl, or more particularly 2-amino-cyclohex-1-yl,optionally substituted with from one to four substituents independentlyselected from halo, oxo, —NO₂, —CN, R⁶, and R⁷; and R⁴ is a C₁₋₉heteroaryl, or more particularly a monocyclic C₂₋₄ heteroaryl,optionally substituted with from one to five or from one to foursubstituents, respectively, independently selected from halo, oxo, —CN,R⁶, and R⁷.

Compounds of Formula 1 include those in which L¹ is —NH— and L² is —NH—or a bond; G is N; R¹ and R² are both hydrogen; R³ is a 2-amino-C₃₋₈cycloalk-1-yl, or more particularly 2-amino-cyclohex-1-yl, optionallysubstituted with from one to four substituents independently selectedfrom halo, oxo, —NO₂, —CN, R⁶, and R⁷; and R⁴ is a monocyclic C₂₋₄heteroaryl selected from pyrrolyl, furanyl, thiopheneyl, pyrazolyl,imidazolyl, isoxazolyl, oxazolyl, isothiazoly, and thiazolyl, or moreparticularly from thiopheneyl, pyrazolyl, isothiazoly, and thiazolyl,each optionally substituted with from one to three substituentsindependently selected from halo, —CN, R⁶, and R⁷.

Compounds of Formula 1 further include those in which L¹ is —NH— and L²is —NH— or a bond; G is N; R¹ and R² are both hydrogen; R³ is a2-amino-C₃₋₈ cycloalk-1-yl, or more particularly 2-amino-cyclohex-1-yl,optionally substituted with from one to four substituents independentlyselected from halo, oxo, —NO₂, —CN, R⁶, and R⁷; and R⁴ is a pyrazolemoiety (e.g., pyrazol-4-yl) optionally substituted with from one tothree substituents independently selected from halo, —CN, R⁶, and R⁷.

Compounds of Formula 1 include those in which L¹ is —NH— and L² is —NH—or a bond; G is C(R⁵); R¹ and R² are both hydrogen; R³ is a 2-amino-C₃₋₈cycloalk-1-yl, or more particularly 2-amino-cyclohex-1-yl, optionallysubstituted with from one to four substituents independently selectedfrom halo, oxo, —NO₂, —CN, R⁶, and R⁷; and R⁴ is a C₆₋₁₄ aryl, or moreparticularly phenyl, optionally substituted with from one to fivesubstituents independently selected from halo, oxo, —CN, R⁶, and R⁷.

Compounds of Formula 1 also include those in which L¹ is —NH— and L² is—NH— or a bond; G is C(R⁵); R¹ and R² are both hydrogen; R³ is a2-amino-C₃₋₈ cycloalk-1-yl, or more particularly 2-amino-cyclohex-1-yl,optionally substituted with from one to four substituents independentlyselected from halo, oxo, —NO₂, —CN, R⁶, and R⁷; and R⁴ is a C₁₋₉heteroaryl, or more particularly a monocyclic C₂₋₄ heteroaryl,optionally substituted with from one to five or from one to foursubstituents, respectively, independently selected from halo, oxo, —CN,R⁶, and R⁷.

Compounds of Formula 1 include those in which L¹ is —NH— and L² is —NH—or a bond; G is C(R⁵); R¹ and R² are both hydrogen; R³ is a 2-amino-C₃₋₈cycloalk-1-yl, or more particularly 2-amino-cyclohex-1-yl, optionallysubstituted with from one to four substituents independently selectedfrom halo, oxo, —NO₂, —CN, R⁶, and R⁷; and R⁴ is a monocyclic C₂₋₄heteroaryl selected from pyrrolyl, furanyl, thiopheneyl, pyrazolyl,imidazolyl, isoxazolyl, oxazolyl, isothiazoly, and thiazolyl, or moreparticularly from thiopheneyl, pyrazolyl, isothiazoly, and thiazolyl,each optionally substituted with from one to three substituentsindependently selected from halo, —CN, R⁶, and R⁷.

Compounds of Formula 1 further include those in which L¹ is —NH— and L²is —NH— or a bond; G is C(R⁵); R¹ and R² are both hydrogen; R³ is a2-amino-C₃₋₈ cycloalk-1-yl, or more particularly 2-amino-cyclohex-1-yl,optionally substituted with from one to four substituents independentlyselected from halo, oxo, —NO₂, —CN, R⁶, and R⁷; and R⁴ is a pyrazolemoiety (e.g., pyrazol-4-yl) optionally substituted with from one tothree substituents independently selected from halo, —CN, R⁶, and R⁷.

Compounds of Formula 1 include any of the aforementioned embodiments inwhich L¹ is —NH— and L² is a bond.

Thus, compounds of Formula 1 include those in which L¹ is —NH—; L² is abond; G is C(R⁵); R¹ and R² are both hydrogen; R⁵ is hydrogen or halo,or more particularly, chloro or fluoro; and R³ is a 2-amino-C₃₋₈cycloalk-1-yl, or more particularly 2-amino-cyclohex-1-yl, optionallysubstituted with from one to four substituents independently selectedfrom halo, oxo, —NO₂, —CN, R⁶, and R⁷.

Compounds of Formula 1 include those in which L¹ is —NH—; L² is a bond;G is C(R⁵); R¹ and R² are both hydrogen; R⁵ is hydrogen or halo, or moreparticularly, chloro or fluoro; and R³ is a 2-amino-C₂₋₆ alk-1-yl, ormore particularly 2-aminoethan-1-yl or 2-amino-2-oxoethan-1-yl,optionally substituted with from one to five, from one to four or fromtwo to two substituents, respectively, independently selected from halo,oxo, —NO₂, —CN, R⁶, and R⁷.

Compounds of Formula 1 include those in which L¹ is —NH—; L² is a bond;G is C(R⁵); R¹ and R² are both hydrogen; R⁵ is hydrogen or halo, or moreparticularly, chloro or fluoro; and R³ is a C₂₋₅ heterocyclyl, or moreparticularly an amino-C₂₋₅ heterocyclyl such as3-aminotetrahydro-2H-pyran-4-yl, optionally substituted with from one tofive or from one to four substituents, respectively, independentlyselected from halo, oxo, —NO₂, —CN, R⁶, and R⁷, wherein the heterocyclylmoiety has 5 or 6 ring atoms.

Compounds of Formula 1 include those in which L¹ is —NH—; L² is a bond;G is C(R⁵); R¹ and R² are both hydrogen; R⁵ is hydrogen or halo, or moreparticularly, chloro or fluoro; and R⁴ is a C₆₋₁₄ aryl, or moreparticularly phenyl, optionally substituted with from one to fivesubstituents independently selected from halo, oxo, —CN, R⁶, and R⁷.

Compounds of Formula 1 also include those in which L¹ is —NH—; L² is abond; G is C(R⁵); R¹ and R² are both hydrogen; R⁵ is hydrogen or halo,or more particularly, chloro or fluoro; and R⁴ is a C₁₋₉ heteroaryl, ormore particularly a monocyclic C₂₋₄ heteroaryl, optionally substitutedwith from one to five or from one to four substituents, respectively,independently selected from halo, oxo, —CN, R⁶, and R⁷.

Compounds of Formula 1 include those in which L¹ is —NH—; L² is a bond;G is C(R⁵); R¹ and R² are both hydrogen; R⁵ is hydrogen or halo, or moreparticularly, chloro or fluoro; and R⁴ is a monocyclic C₂₋₄ heteroarylselected from pyrrolyl, furanyl, thiopheneyl, pyrazolyl, imidazolyl,isoxazolyl, oxazolyl, isothiazoly, and thiazolyl, or more particularlyfrom thiopheneyl, pyrazolyl, isothiazoly, and thiazolyl, each optionallysubstituted with from one to three substituents independently selectedfrom halo, —CN, R⁶, and R⁷.

Compounds of Formula 1 include those in which L¹ is —NH—; L² is a bond;G is C(R⁵); R¹ and R² are both hydrogen; R⁵ is hydrogen or halo, or moreparticularly, chloro or fluoro; and R⁴ is a pyrazole moiety (e.g.,pyrazol-4-yl) optionally substituted with from one to three substituentsindependently selected from halo, —CN, R⁶, and R⁷.

Compounds of Formula 1 include those in which L¹ is —NH—; L² is a bond;G is C(R⁵); R¹ and R² are both hydrogen; R⁵ is hydrogen or halo, or moreparticularly, chloro or fluoro; R³ is a 2-amino-C₃₋₈ cycloalk-1-yl, ormore particularly 2-amino-cyclohex-1-yl, optionally substituted withfrom one to four substituents independently selected from halo, oxo,—NO₂, —CN, R⁶, and R⁷; and R⁴ is a C₆₋₁₄ aryl, or more particularlyphenyl, optionally substituted with from one to five substituentsindependently selected from halo, oxo, —CN, R⁶, and R⁷.

Compounds of Formula 1 include those in which L¹ is —NH—; L² is a bond;G is C(R⁵); R¹ and R² are both hydrogen; R⁵ is hydrogen or halo, or moreparticularly, chloro or fluoro; R³ is a 2-amino-C₃₋₈ cycloalk-1-yl, ormore particularly 2-amino-cyclohex-1-yl, optionally substituted withfrom one to four substituents independently selected from halo, oxo,—NO₂, —CN, R⁶, and R⁷; and R⁴ is a C₁₋₉ heteroaryl, or more particularlya monocyclic C₂₋₄ heteroaryl, optionally substituted with from one tofive or from one to four substituents, respectively, independentlyselected from halo, oxo, —CN, R⁶, and R⁷.

Compounds of Formula 1 include those in which L¹ is —NH—; L² is a bond;G is C(R⁵); R¹ and R² are both hydrogen; R⁵ is hydrogen or halo, or moreparticularly, chloro or fluoro; R³ is a 2-amino-C₃₋₈ cycloalk-1-yl, ormore particularly 2-amino-cyclohex-1-yl, optionally substituted withfrom one to four substituents independently selected from halo, oxo,—NO₂, —CN, R⁶, and R⁷; and R⁴ is a monocyclic C₂₋₄ heteroaryl selectedfrom pyrrolyl, furanyl, thiopheneyl, pyrazolyl, imidazolyl, isoxazolyl,oxazolyl, isothiazoly, and thiazolyl, or more particularly fromthiopheneyl, pyrazolyl, isothiazoly, and thiazolyl, each optionallysubstituted with from one to three substituents independently selectedfrom halo, —CN, R⁶, and R⁷.

Compounds of Formula 1 include those in which L¹ is —NH—; L² is a bond;G is C(R⁵); R¹ and R² are both hydrogen; R⁵ is hydrogen or halo, or moreparticularly, chloro or fluoro; R³ is a 2-amino-C₃₋₈ cycloalk-1-yl, ormore particularly 2-amino-cyclohex-1-yl, optionally substituted withfrom one to four substituents independently selected from halo, oxo,—NO₂, —CN, R⁶, and R⁷; and R⁴ is a pyrazole moiety (e.g., pyrazol-4-yl)optionally substituted with from one to three substituents independentlyselected from halo, —CN, R⁶, and R⁷.

Compounds of Formula 1 also include any of the above embodiments inwhich one or more of the R³, R⁴, R⁵, R⁷, R⁸, and R⁹ substituents have nooptional substituents.

All references to compounds, including compounds of Formula 1 andcompounds named in the specification, generally include all complexes,salts, solvates, hydrates, and liquid crystals of the compounds.Likewise, all references to compounds include all complexes, solvates,hydrates, and liquid crystals of the salts of the compounds.

Compounds of Formula 1, which include compounds specifically namedabove, may form pharmaceutically acceptable complexes, salts, solvatesand hydrates. These salts include acid addition salts (includingdi-acids) and base salts. Pharmaceutically acceptable acid additionsalts include nontoxic salts derived from inorganic acids such ashydrochloric acid, nitric acid, phosphoric acid, sulfuric acid,hydrobromic acid, hydroiodic acid, hydrofluoric acid, and phosphorousacids, as well nontoxic salts derived from organic acids, such asaliphatic mono- and dicarboxylic acids, phenyl-substituted alkanoicacids, hydroxy alkanoic acids, alkanedioic acids, aromatic acids,aliphatic and aromatic sulfonic acids, etc. Such salts include acetate,adipate, aspartate, benzoate, besylate, bicarbonate, carbonate,bisulfate, sulfate, borate, camsylate, citrate, cyclamate, edisylate,esylate, formate, fumarate, gluceptate, gluconate, glucuronate,hexafluorophosphate, hibenzate, hydrochloride/chloride,hydrobromide/bromide, hydroiodide/iodide, isethionate, lactate, malate,maleate, malonate, mesylate, methylsulfate, naphthylate, 2-napsylate,nicotinate, nitrate, orotate, oxalate, palmitate, pamoate, phosphate,hydrogen phosphate, dihydrogen phosphate, pyroglutamate, saccharate,stearate, succinate, tannate, tartrate, tosylate, trifluoroacetate andxinofoate salts.

Pharmaceutically acceptable base salts include nontoxic salts derivedfrom bases, including metal cations, such as an alkali or alkaline earthmetal cation, as well as amines. Examples of suitable metal cationsinclude sodium (Na⁺), potassium (K⁺), magnesium (Mg²⁺), calcium (Ca²⁺),zinc (Zn²⁺), and aluminum (Al³⁺). Examples of suitable amines includearginine, N,N′-dibenzylethylenediamine, chloroprocaine, choline,diethylamine, diethanolamine, dicyclohexylamine, ethylenediamine,glycine, lysine, N-methylglucamine, olamine,2-amino-2-hydroxymethyl-propane-1,3-diol, and procaine. For a discussionof useful acid addition and base salts, see S. M. Berge et al., J.Pharm. Sci. (1977) 66:1-19; see also Stahl and Wermuth, Handbook ofPharmaceutical Salts: Properties, Selection, and Use (2002).

Pharmaceutically acceptable salts may be prepared using various methods.For example, one may react a compound of Formula 1 with an appropriateacid or base to give the desired salt. One may also react a precursor ofthe compound of Formula 1 with an acid or base to remove an acid- orbase-labile protecting group or to open a lactone or lactam group of theprecursor. Additionally, one may convert a salt of the compound ofFormula 1 to another salt through treatment with an appropriate acid orbase or through contact with an ion exchange resin. Following reaction,one may then isolate the salt by filtration if it precipitates fromsolution, or by evaporation to recover the salt. The degree ofionization of the salt may vary from completely ionized to almostnon-ionized.

Compounds of Formula 1 may exist in a continuum of solid states rangingfrom fully amorphous to fully crystalline. The term “amorphous” refersto a state in which the material lacks long range order at the molecularlevel and, depending upon temperature, may exhibit the physicalproperties of a solid or a liquid. Typically such materials do not givedistinctive X-ray diffraction patterns and, while exhibiting theproperties of a solid, are more formally described as a liquid. Uponheating, a change from solid to liquid properties occurs which ischaracterized by a change of state, typically second order (“glasstransition”). The term “crystalline” refers to a solid phase in whichthe material has a regular ordered internal structure at the molecularlevel and gives a distinctive X-ray diffraction pattern with definedpeaks. Such materials when heated sufficiently will also exhibit theproperties of a liquid, but the change from solid to liquid ischaracterized by a phase change, typically first order (“meltingpoint”).

Compounds of Formula 1 may also exist in unsolvated and solvated forms.The term “solvate” describes a molecular complex comprising the compoundand one or more pharmaceutically acceptable solvent molecules (e.g.,EtOH). The term “hydrate” is a solvate in which the solvent is water.Pharmaceutically acceptable solvates include those in which the solventmay be isotopically substituted (e.g., D₂O, acetone-d₆, DMSO-d₆).

A currently accepted classification system for solvates and hydrates oforganic compounds is one that distinguishes between isolated site,channel, and metal-ion coordinated solvates and hydrates. See, e.g., K.R. Morris (H. G. Brittain ed.) Polymorphism in Pharmaceutical Solids(1995). Isolated site solvates and hydrates are ones in which thesolvent (e.g., water) molecules are isolated from direct contact witheach other by intervening molecules of the organic compound. In channelsolvates, the solvent molecules lie in lattice channels where they arenext to other solvent molecules. In metal-ion coordinated solvates, thesolvent molecules are bonded to the metal ion.

When the solvent or water is tightly bound, the complex will have awell-defined stoichiometry independent of humidity. When, however, thesolvent or water is weakly bound, as in channel solvates and inhygroscopic compounds, the water or solvent content will depend onhumidity and drying conditions. In such cases, non-stoichiometry willtypically be observed.

Compounds of Formula 1 may also exist as multi-component complexes(other than salts and solvates) in which the compound (drug) and atleast one other component are present in stoichiometric ornon-stoichiometric amounts. Complexes of this type include clathrates(drug-host inclusion complexes) and co-crystals. The latter aretypically defined as crystalline complexes of neutral molecularconstituents which are bound together through non-covalent interactions,but could also be a complex of a neutral molecule with a salt.Co-crystals may be prepared by melt crystallization, byrecrystallization from solvents, or by physically grinding thecomponents together. See, e.g., O. Almarsson and M. J. Zaworotko, Chem.Commun. (2004) 17:1889-1896. For a general review of multi-componentcomplexes, see J. K. Haleblian, J. Pharm. Sci. (1975) 64(8):1269-88.

When subjected to suitable conditions, compounds of Formula 1 may existin a mesomorphic state (mesophase or liquid crystal). The mesomorphicstate lies between the true crystalline state and the true liquid state(either melt or solution). Mesomorphism arising as the result of achange in temperature is described as “thermotropic” and mesomorphismresulting from the addition of a second component, such as water oranother solvent, is described as “lyotropic.” Compounds that have thepotential to form lyotropic mesophases are described as “amphiphilic”and include molecules which possess a polar ionic moiety (e.g.,—COO⁻Na⁺, —COO⁻K⁺, —SO₃ ⁻Na⁺) or polar non-ionic moiety (such as—N⁻N⁺(CH₃)₃). See, e.g., N. H. Hartshorne and A. Stuart, Crystals andthe Polarizing Microscope (4th ed, 1970).

All references to compounds, including compounds of Formula 1 andcompounds named in the specification, generally include all polymorphsand crystal habits, prodrugs, metabolites, stereoisomers, and tautomersthereof, as well as all isotopically-labeled compounds thereof.

“Prodrugs” refer to compounds having little or no pharmacologicalactivity that can, when metabolized in vivo, undergo conversion tocompounds having desired pharmacological activity. Prodrugs may beprepared by replacing appropriate functionalities present inpharmacologically active compounds with “pro-moieties” as described, forexample, in H. Bundgaar, Design of Prodrugs (1985). Examples of prodrugsinclude ester, ether or amide derivatives of compounds of Formula 1having carboxylic acid, hydroxy, or amino functional groups,respectively. For further discussions of prodrugs, see e.g., T. Higuchiand V. Stella “Pro-drugs as Novel Delivery Systems,” ACS SymposiumSeries 14 (1975) and E. B. Roche ed., Bioreversible Carriers in DrugDesign (1987).

“Metabolites” refer to compounds formed in vivo upon administration ofpharmacologically active compounds. Examples include hydroxymethyl,hydroxy, secondary amino, primary amino, phenol, and carboxylic acidderivatives of compounds of Formula 1 having methyl, alkoxy, tertiaryamino, secondary amino, phenyl, and amide groups, respectively.

Certain compounds described herein may have stereoisomers. Thesecompounds may exist as single enantiomers (enantiopure compounds) ormixtures of enantiomers (enriched and racemic samples), which dependingon the relative excess of one enantiomer over another in a sample, mayexhibit optical activity. Such stereoisomers, which arenon-superimposable mirror images, possess a stereogenic axis or one ormore stereogenic centers (i.e., chirality). Other compounds may bestereoisomers that are not mirror images. Such stereoisomers, which areknown as diastereoisomers, may be chiral or achiral (contain nostereogenic centers). They include molecules containing an alkenyl orcyclic group, so that cis/trans (or Z/E) stereoisomers are possible, ormolecules containing two or more stereogenic centers, in which inversionof a single stereogenic center generates a correspondingdiastereoisomer. Unless stated or otherwise clear (e.g., through use ofstereobonds, stereocenter descriptors, etc.) the scope of the inventionand disclosure generally includes the reference compound and itsstereoisomers, whether they are each pure (e.g., enantiopure) ormixtures (e.g., enantiomerically enriched or racemic).

Geometrical (cis/trans) isomers may be separated by conventionaltechniques such as chromatography and fractional crystallization.

Individual enantiomers of compounds may be prepared via chiral synthesisfrom a suitable optically pure precursor or isolated via resolution ofthe racemate (or the racemate of a salt or derivative) using, forexample, chiral HPLC. Alternatively, the racemate (or a racemicprecursor) may be reacted with a suitable enantiomerically pure compound(e.g., acid or base) to yield a pair of diastereoisomers, each composedof a single enantiomer, which are separated via, say, fractionalrecrystallization or chromatography. The desired enantiomer issubsequently regenerated from the appropriate diastereoisomer. Often,the desired enantiomer may be further enriched by recrystallization in asuitable solvent (e.g., ACN) when it is it available in sufficientquantity (e.g., typically not much less than about 85% ee, and in somecases, not much less than about 90% ee). For a further discussion oftechniques for separating stereoisomers, see E. L. Eliel and S. H.Wilen, Stereochemistry of Organic Compounds (1994).

“Tautomers” refer to structural isomers that are interconvertible via alow energy barrier. Tautomeric isomerism (tautomerism) may take the formof proton tautomerism in which the compound contains, for example, animino, keto, or oxime group, or valence tautomerism in which thecompound contains an aromatic moiety.

Compounds described herein also include all pharmaceutically acceptableisotopic variations, in which at least one atom is replaced by an atomhaving the same atomic number, but an atomic mass different from theatomic mass usually found in nature. Isotopes suitable for inclusion incompounds of Formula 1 include, for example, isotopes of hydrogen, suchas ²H and ³H; isotopes of carbon, such as ¹¹C, ¹³C and ¹⁴C; isotopes ofnitrogen, such as ¹³N and ¹⁵N; isotopes of oxygen, such as ¹⁵O, ¹⁷O and¹⁸O; isotopes of sulfur, such as ³⁵S; isotopes of fluorine, such as ¹⁸F;isotopes of chlorine, such as ³⁶Cl, and isotopes of iodine, such as ¹²³Iand ¹²⁵I. Use of isotopic variations (e.g., deuterium, ²H) may affordcertain therapeutic advantages resulting from greater metabolicstability, for example, increased in vivo half-life or reduced dosagerequirements. Additionally, certain isotopic variations of the disclosedcompounds may incorporate a radioactive isotope (e.g., tritium, ³H, or¹⁴C), which may be useful in drug and/or substrate tissue distributionstudies. Substitution with positron emitting isotopes, such as ¹¹C, ¹⁸F,¹⁵O and ¹³N, may be useful in Positron Emission Topography (PET) studiesfor examining substrate receptor occupancy. Isotopically-labeledcompounds may be prepared by processes analogous to those describedelsewhere in the disclosure using an appropriate isotopically-labeledreagent in place of a non-labeled reagent.

The compounds of Formula 1 may be prepared using the techniquesdescribed below. Some of the schemes and examples may omit details ofcommon reactions, including oxidations, reductions, and so on,separation techniques (extraction, evaporation, precipitation,chromatography, filtration, trituration, crystallization, and the like),and analytical procedures, which are known to persons of ordinary skillin the art of organic chemistry. The details of such reactions andtechniques can be found in a number of treatises, including RichardLarock, Comprehensive Organic Transformations (1999), and themulti-volume series edited by Michael B. Smith and others, Compendium ofOrganic Synthetic Methods (1974 et seq.). Starting materials andreagents may be obtained from commercial sources or may be preparedusing literature methods. Some of the reaction schemes may omit minorproducts resulting from chemical transformations (e.g., an alcohol fromthe hydrolysis of an ester, CO₂ from the decarboxylation of a diacid,etc.). In addition, in some instances, reaction intermediates may beused in subsequent steps without isolation or purification (i.e., insitu).

In some of the reaction schemes and examples below, certain compoundscan be prepared using protecting groups, which prevent undesirablechemical reaction at otherwise reactive sites. Protecting groups mayalso be used to enhance solubility or otherwise modify physicalproperties of a compound. For a discussion of protecting groupstrategies, a description of materials and methods for installing andremoving protecting groups, and a compilation of useful protectinggroups for common functional groups, including amines, carboxylic acids,alcohols, ketones, aldehydes, and so on, see T. W. Greene and P. G.Wuts, Protecting Groups in Organic Chemistry (1999) and P. Kocienski,Protective Groups (2000).

Generally, the chemical transformations described throughout thespecification may be carried out using substantially stoichiometricamounts of reactants, though certain reactions may benefit from using anexcess of one or more of the reactants. Additionally, many of thereactions disclosed throughout the specification may be carried out atabout room temperature (RT) and ambient pressure, but depending onreaction kinetics, yields, and so on, some reactions may be run atelevated pressures or employ higher temperatures (e.g., refluxconditions) or lower temperatures (e.g., −78° C. to 0° C.). Anyreference in the disclosure to a stoichiometric range, a temperaturerange, a pH range, etc., whether or not expressly using the word“range,” also includes the indicated endpoints.

Many of the chemical transformations may also employ one or morecompatible solvents, which may influence the reaction rate and yield.Depending on the nature of the reactants, the one or more solvents maybe polar protic solvents (including water), polar aprotic solvents,non-polar solvents, or some combination. Representative solvents includesaturated aliphatic hydrocarbons (e.g., n-pentane, n-hexane, n-heptane,n-octane); aromatic hydrocarbons (e.g., benzene, toluene, xylenes);halogenated hydrocarbons (e.g., methylene chloride, chloroform, carbontetrachloride); aliphatic alcohols (e.g., methanol, ethanol,propan-1-ol, propan-2-ol, butan-1-ol, 2-methyl-propan-1-ol, butan-2-ol,2-methyl-propan-2-ol, pentan-1-ol, 3-methyl-butan-1-ol, hexan-1-ol,2-methoxy-ethanol, 2-ethoxy-ethanol, 2-butoxy-ethanol,2-(2-methoxy-ethoxy)-ethanol, 2-(2-ethoxy-ethoxy)-ethanol,2-(2-butoxy-ethoxy)-ethanol); ethers (e.g., diethyl ether, di-isopropylether, dibutyl ether, 1,2-dimethoxy-ethane, 1,2-diethoxy-ethane,1-methoxy-2-(2-methoxy-ethoxy)-ethane,1-ethoxy-2-(2-ethoxy-ethoxy)-ethane, tetrahydrofuran, 1,4-dioxane);ketones (e.g., acetone, methyl ethyl ketone); esters (methyl acetate,ethyl acetate); nitrogen-containing solvents (e.g., formamide,N,N-dimethylformamide, acetonitrile, N-methyl-pyrrolidone, pyridine,quinoline, nitrobenzene); sulfur-containing solvents (e.g., carbondisulfide, dimethyl sulfoxide, tetrahydro-thiophene-1,1,-dioxide); andphosphorus-containing solvents (e.g., hexamethylphosphoric triamide).

In the schemes, below, substituent identifiers (e.g., R¹, R³, R⁴, R⁵,R⁷, R⁸, R⁹, L¹ and L²) are as defined above for Formula 1. As mentionedearlier, however, some of the starting materials and intermediates mayinclude protecting groups, which are removed prior to the final product.In such cases, the substituent identifier refers to moieties defined inFormula 1 and to those moieties with appropriate protecting groups. Forexample, a starting material or intermediate in the schemes may includean R³ that is a moiety having a potentially reactive amine. In suchcases, R³ would include the moiety with or without, say, a Boc or Cbzgroup attached to the amine.

Scheme 1 illustrates a method for preparing compound 1-5. Startingmaterial 1-0 (e.g., methyl6-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate) ischlorinated at elevated temperature (e.g., 95-105° C.) using phosphoryltrichloride as a reactive solvent, in the presence of a catalytic amountof N,N-dimethyl aniline to give a methylpyrimidine carboxylate 1-1. The2-chloro and 4-chloro groups of intermediate 1-1 are subsequentlydisplaced via treatment with an appropriately-substituted amine. Asdepicted in Scheme 1, the 2-chloro group is reacted with R⁴—NH₂ (e.g.substituted aniline) in a polar aprotic organic solvent (e.g., ACN orTHF) and in the presence of a hindered base such as Et₃N or DIPEA (2 eq)to give intermediate 1-2. The reaction may be carried out at elevatedtemperatures (e.g. 90° C. or reflux conditions). In a similar manner,the 4-chloro group is displaced with R³—NH₂ to give intermediate 1-3.The second displacement is carried out at elevated temperatures (e.g.,90° C. or reflux conditions) in a polar aprotic organic solvent (e.g.,DMA or DMF) in the presence of a hindered base (e.g., Et₃N or DIPEA).

Scheme 1 shows two methods for cyclizing intermediate 1-3. In onemethod, intermediate 1-3 is oxidized with SeO₂ (2-4 eq) in an organicsolvent, such as 1,4-dioxane, under reflux conditions (e.g., about 100°C.) to give a ketone (or aldehyde) intermediate (not shown). Subsequentreaction with 2,4-dimethoxybenzylamine in the presence of a mildreducing agent, such as sodium cyanoborohydride (1.5 eq) or sodiumtriacetoxy-borohydride in MeOH, gives via reductive amination, an aminointermediate which cyclizes to 1-4, either immediately or upon heatingto about 50° C. The dimethoxybenzyl group can be removed by treatingintermediate 1-4 with an acid (e.g., TFA) at about 60° C., which givesthe desired compound 1-5. In a second method, intermediate 1-3 istreated with a bromination reagent such as NBS in the presence of aninitiator (e.g., dibenzoyl peroxide or AIBN) in CCl₄. Refluxing thereaction mixture gives intermediate 1-6, which is treated with a sourceof ammonia (e.g., ammonium hydroxide) in THF to give 1-5.

Scheme 2 provides a method for preparing compound 2-8. Starting material2-0 (2-(1,3-dioxoisoindolin-2-yl)acetic acid) is reacted with2,2-dimethyl-1,3-dioxane-4,6-dione (1-1.5 eq) and4-dimethylaminopyridine (1-1.5 eq) in the presence of DCC (1-1.5 eq) andan organic solvent such as dichloromethane to give intermediate 2-1.Subsequent treatment of 2-1 with 2,4-dimethoxybenzylamine (1 eq) in EtOHat about 50° C. gives an imine 2-2, which is isolated, re-dissolved inan organic solvent (e.g., THF) and treated with an activatedcarbonylisocyanate (e.g., carbonisocyanatidic chloride, 1 eq) at about80° C. to give intermediate 2-3. Treating 2-3 with an acid (e.g., TFA atRT to 60° C.) removes the dimethoxybenzyl group to give intermediate2-4, which is subsequently reacted with a chlorinating agent (e.g.,POCl₃) under refluxing conditions (e.g., about 100° C.) to giveintermediate 2-5. Stepwise displacement of the two chloro groups withappropriately-substituted amines (R⁴—NH₂ and R³—NH₂) gives intermediates2-6 and 2-7. Treatment of intermediate 2-7 with hydrazine hydrate (4-5eq) in EtOH with heating (e.g., at about 65° C.) gives compound 2-8.

Scheme 3 provides another method for preparing compound 2-8. Startingmaterial 3-0 (2,4,6-trichloropyrimidine) is treated with a strong basesuch as LDA (made freshly from diisopropyl amine and n-BuLi orpurchased) at −78° C. in dry THF, followed by quenching with dry ice.Warming the mixture to RT and stirring gives intermediate 3-1.Displacement of a chloro group via treatment with anappropriately-substituted amine (R⁴—NH₂, 1 eq) in the presence of ahindered base (e.g., Et₃N or DIPEA, 2 eq) and a polar aprotic organicsolvent (e.g., DMF) gives intermediate 3-2. Subsequent treatment of 3-2with MeI (1-1.5 eq) and a base (e.g. sodium bicarbonate, 1.5-3 eq)yields an ester 3-3, which may proceed to compound 2-8 through twodifferent routes. In one route, intermediate 3-3 undergoes treatmentwith an appropriately-substituted amine (R³—NH₂, 1-1.1 eq) in thepresence of a hindered base (e.g., DIPEA) and a polar aprotic organicsolvent (e.g., THF) to give intermediate 3-4 and an isomer. Followingisolation, intermediate 3-4 is reacted with zinc cyanide (0.5-1 eq) anda catalytic amount (10%) of tetrakis (triphenylphosphine) palladium(0)in DMF at about 90° C. to give nitrile 3-5. Reduction of the nitrilegroup to an amine via hydrogenation using Pd on carbon (5-10%) in EtOHand a catalytic amount of HCl gives, upon treatment with sodiumbicarbonate, 2-8.

In an alternative route, intermediate 3-3 is first converted to nitrile3-6 via palladium-catalyzed cyanation by heating a mixture of 3-3, zinccyanide (0.5-1 eq), tetrakis(triphenyl phosphine)palladium(0) (0.1 eq),and a polar aprotic solvent (e.g., DMF) in a microwave oven at about120° C. for about 1 hour. Following isolation, intermediate 3-6 isconverted at RT to 3-5 via reaction with an appropriately-substitutedamine (R³—NH₂, 1-1.5 eq) in a polar aprotic solvent (e.g., DMF) and inthe presence of a hindered base (e.g., DIPEA). As described above,reduction of the nitrile group of 3-5 and subsequent cyclization givescompound 2-8.

Scheme 4 shows a method for preparing compound 4-6. Lithiation ofstarting material 4-0 (2,6-di-halo-3-iodopyridine) via directedortho-lithiation by LDA in THF at −78° C., followed by quenching withdry ice, gives 4-1, which is subsequently esterified at RT using MeI anda base (e.g., potassium carbonate). As in Scheme 3, the iodo group ofintermediate 4-2 is converted to a nitrile group via palladium-catalyzedcyanation to give 4-3. Stepwise displacement of the two chloro groupswith appropriately-substituted amines (R⁴—NH₂ and R³—NH₂) givesintermediates 4-4 and 4-5. As in the ring-closure step depicted inScheme 3, hydrogenation followed by cyclization gives compound 4-6.

Scheme 5 depicts a method for preparing compound 5-4. Starting material1-1 (methyl 2,4-dichloro-6-methylpyrimidine-5-carboxylate) is reactedwith an aromatic boronic acid or borate (e.g., R⁴—B(OR¹³)₂, where R⁴ isC₆₋₁₄ aryl or C₁₋₉ heteroaryl, and e.g., each R¹³ is H or C₁₋₄ alkyl) inthe presence of a palladium catalyst (e.g., Pd(PPh₃)₄, (PPh₃)₂PdCl₂,etc.), a base (e.g., KF or Na₂CO₃), and an organic solvent (e.g.,dioxane, DMF, etc.). The Suzuki-type coupling is carried out at elevatedtemperature (e.g., about 90° C.) and gives intermediate 5-1.Displacement of the chloro group with an appropriately-substituted amine(R³—NH₂) gives intermediate 5-2. As in Scheme 1, the methyl group onpyrimidine is oxidized with SeO₂ (2-4 eq) in an organic solvent (e.g.,1,4-dioxane) under reflux conditions to give an aldehyde intermediate,which is subsequently reacted with 2,4-dimethoxybenzylamine in thepresence of a mild reducing agent (e.g., about 1.5 eq of NaCNBH₃ orNaBH(OAc)₃) in MeOH, to give, via reductive amination, an aminointermediate which cyclizes to 5-3, either immediately or upon heatingto about 50° C. Treating intermediate 5-3 with an acid (e.g., TFA) atabout 60° C. gives compound 5-4.

Scheme 6 depicts a method for preparing compound 6-3. Starting material6-0, which may be prepared from methyl2,4-dichloro-6-methylpyrimidine-5-carboxylate using the methodsdescribed above, is reacted with an aromatic boronic acid or borate(e.g., R³—B(OR¹³)₂, where R³ is C₆₋₁₄ aryl or C₁₋₉ heteroaryl and e.g.,R¹³ is H or C₁₋₄ alkyl) in the presence of a palladium catalyst (e.g.,Pd(PPh₃)₄, (PPh₃)₂PdCl₂, etc.), a base (e.g., KF or Na₂CO₃), and anorganic solvent (e.g., dioxane, DMF, DME, etc.). The Suzuki-typecoupling is carried out at elevated temperature (e.g., about 90° C.) andgives intermediate 6-1. The methyl group on pyrimidine is oxidized withSeO₂ (2-4 eq) in an organic solvent (e.g., 1,4-dioxane) under refluxconditions to give an aldehyde intermediate, which is subsequentlyreacted with 2,4-dimethoxybenzylamine in the presence of a mild reducingagent (e.g., about 1.5 eq of NaCNBH₃ or NaBH(OAc)₃) in MeOH, to giveintermediate 6-2. Treating 6-2 with an acid (e.g., TFA) at about 60° C.yields compound 6-3.

Scheme 7 illustrates methods for preparing compounds 7-2,7-3, 7-4, 7-5,and 7-6. Starting material 7-0, which may be prepared using the methodsdescribed above, may be reacted with NBS or NIS to give halo-pyridineintermediate 7-1 (Y¹ is Br or I). As in Scheme 3, the halo group of 7-1may be converted to a nitrile group via palladium-catalyzed cyanation togive 7-2. Compound 7-2 is subsequently reacted with a Grignard reagent(R⁷—MgBr) to give an imine intermediate (not shown), which upon acidhydrolysis, yields compound 7-3. Alternatively, halo-pyridineintermediate 7-1 may be reacted with NHR⁸R⁹ in the presence of apalladium (II) catalyst (e.g., PdCl₂(dppf)), a stoichiometric amount ofbase (e.g., NaOt-Bu), and an organic solvent (e.g., dioxane, toluene,etc.), at elevated temperature (e.g., about 100° C.). TheBuchwald-Hartwig coupling gives heteroaryl amine 7-4. In addition, 7-1may be reacted with a terminal alkyne (HC≡R¹³, e.g., R¹³ is H or C₁₋₄alkyl) in the presence of a palladium(II) catalyst (e.g., (PPh₃)₂PdCl₂),a copper(I) co-catalyst (e.g., CuI), and an amine base (e.g. Et₃N), atRT. Following the Sonogashira coupling, reduction of the alkyne moietyyields compound 7-5 with R⁵ being, e.g., C₁₋₅ alkyl. Compound 7-1 may bereacted with an aromatic boronic acid or borate (e.g., R⁵—B(OR¹³)₂,where R⁵ is C₁₋₉ heteroaryl and e.g., R¹³ is H or C₁₋₄ alkyl) in thepresence of a palladium catalyst (e.g., Pd(PPh₃)₄, (PPh₃)₂PdCl₂, etc.),a base (e.g., KF or Na₂CO₃), and an organic solvent (e.g., dioxane, DMF,etc.). The Suzuki-type coupling is carried out at elevated temperature(e.g., about 90° C.) and gives compound 7-5 with R⁵ being C₁₋₉heteroaryl.

As shown in Scheme 7, compound 7-0 may alternatively be treated with afluorinating agent, such as SELECTFLUOR®(1-(chloromethyl)-4-fluoro-1,4-diazoniabicyclo[2.2.2]octaneditetrafluoroborate), in an organic solvent (e.g., DCM) or a mixture oforganic solvents (e.g., DCM and MeOH), to give a fluoro-pyridinederivative 7-6 (Y² is F). Similarly, 7-0 may be treated with achlorinating agent, such as NCS, in an aprotic solvent (e.g., DCM) togive a chloro-pyridine derivative 7-6 (Y² is Cl).

Scheme 8 shows an alternative method for preparing compound 4-6.Starting material 8-0 (2-chloro-3-iodopyridine) undergoes ortho-directedlithiation via treatment with LDA in THF at −78° C. Quenching with dryice gives 8-1, which is subsequently esterified at RT using iodomethaneand a base (e.g., potassium carbonate). As in Scheme 4, the iodo groupof intermediate 8-2 is converted to a nitrile group viapalladium-catalyzed cyanation or through treatment with cyanocopper orzinc cyanide in a suitable solvent (e.g., DMF, DMA, etc.) at elevatedtemperature. The R⁴ substituent is installed on 8-3 using a Suzukireaction, which gives intermediate 8-4. N-oxidation of the pyridinemoiety via treatment with hydrogen peroxide/urea complex gives anactivated intermediate 8-5, which is chlorinated through reaction withphosphorus oxychloride at an elevated temperature (e.g., 90-100° C.).Displacement of the chloro group on 8-6 via reaction with anappropriately-substituted amine (R³—NH₂) gives intermediate 8-7.Subsequent reduction through palladium-catalyzed hydrogenation andcyclization gives compound 4-6.

Scheme 9 depicts the synthesis of compound 9-5. Starting material 9-0(2,6-dichloro-5-fluoronicotinic acid) is lithiated via treatment withLDA in THF at −78° C. Quenching with DMF gives an aldehyde intermediate9-1, which undergoes reductive amination through reaction with an amine(e.g., 2,4-dimethoxyphenyl)methanamine) and reducing agent (e.g.,NaBH(OAc)₃). The resulting amino acid (not shown) is cyclized via amidecoupling, which employs a suitable coupling agent (e.g., EDCI, DCC,etc.), catalyst (HOBt, DMAP, etc.), and solvent (e.g., DMF, DMSO, ACN,THF, DCM, etc.). As in previous schemes, displacement of the chlorogroup of compound 9-2 with an appropriate amine (R³—NH₂) givesintermediate 9-3, which is subsequently reacted with an aromatic boronicacid or borate (e.g., R⁴—B(OR¹³)₂ in the presence of a palladiumcatalyst (e.g., Pd(PPh₃)₄, (PPh₃)₂PdCl₂, etc.), base (e.g., KF orNa₂CO₃), and organic solvent (e.g., dioxane, DMF, etc.) at elevatedtemperature (e.g., about 90° C.) to give 9-4. Following the Suzukicoupling, treatment of 9-4 with TFA at elevated temperature (e.g.,40-60° C.) generates 9-5.

Scheme 10 shows another method for preparing compound 1-5. The chlorogroup of compound 1-2 is first displaced with sodium methanethiolate togive 10-1. As in Scheme 1, intermediate 10-1 is oxidized with SeO₂ togive a ketone (or aldehyde) intermediate (not shown), which is reactedwith 2,4-dimethoxybenzylamine in the presence of a reducing agent togive, via reductive amination, an amino acid intermediate which cyclizesto 10-2. The methylthio group is converted to methylsulfonyl using mCPBA(m-chloroperoxybenzoic acid), which is displaced with an appropriateamine (R³—NH₂) to give intermediate 10-4. Treatment of 10-4 with an acid(e.g., TFA) at elevated temperature (e.g., 40-60° C.) gives compound1-5.

Scheme 11 depicts an alternate synthesis of compound 9-5. Startingmaterial 11-0 (2,6-dichloro-5-fluoronicotinonitrile) is hydrolyzed bytreatment with concentrated sulfuric acid at elevated temperature (e.g.,about 65° C.) to give amide 11-1, which is lithiated via treatment withLiHMDS at about 0° C. or reaction with LDA in THF at −78° C. Quenchingwith DMF gives aldehyde intermediate 11-2, which is reduced to lactam11-3 by treatment with a reducing agent (e.g., triethyl silane) and anacid (e.g., TFA) in an organic solvent (e.g., DCM). Followinginstallation of a Boc protecting group on lactam 11-3, displacement of achloro group on compound 11-4 via reaction with an appropriate amine(R³—NH₂) gives intermediate 11-5. The intermediate is subsequentlyreacted with an aromatic boronic acid or borate (e.g., R⁴—B(OR¹³)₂ inthe presence of a palladium catalyst (e.g., Pd(PPh₃)₄, (PPh₃)₂PdCl₂,Pd₂(dba)₃, etc.), an optional ligand (e.g.,2-(dicyclohexylphosphino)biphenyl), a base (e.g., KF or Na₂CO₃), and anorganic solvent (e.g., dioxane, DMF, etc.) to give compound 11-6. TheSuzuki reaction is carried out at elevated temperature (e.g., 90-160°C.), either by conventional heating or via microwave irradiation.Alternatively, compound 11-5 may be reacted with an aromatic tin reagent(e.g., R⁴—Sn(n-Bu)₃) in the presence of a palladium catalyst (e.g.,Pd(PPh₃)₄) and an organic solvent (e.g., toluene) at elevatedtemperature (e.g., about 100° C.). Following the Suzuki or Stillecoupling, treatment of 11-6 with an acid (e.g., TFA or HCl) at RT orabove (e.g., about 20-60° C.) generates 9-5.

Compounds of Formula 1, which include compounds named above, and theirpharmaceutically acceptable complexes, salts, solvates and hydrates,should be assessed for their biopharmaceutical properties, such assolubility and solution stability across pH, permeability, and the like,to select an appropriate dosage form and route of administration.Compounds that are intended for pharmaceutical use may be administeredas crystalline or amorphous products, and may be obtained, for example,as solid plugs, powders, or films by methods such as precipitation,crystallization, freeze drying, spray drying, evaporative drying,microwave drying, or radio frequency drying.

Compounds of Formula 1 may be administered alone or in combination withone another or with one or more pharmacologically active compounds whichare different than the compounds of Formula 1. Generally, one or morethese compounds are administered as a pharmaceutical composition (aformulation) in association with one or more pharmaceutically acceptableexcipients. The choice of excipients depends on the particular mode ofadministration, the effect of the excipient on solubility and stability,and the nature of the dosage form, among other things. Usefulpharmaceutical compositions and methods for their preparation may befound, for example, in A. R. Gennaro (ed.), Remington: The Science andPractice of Pharmacy (20th ed., 2000).

Compounds of Formula 1 may be administered orally. Oral administrationmay involve swallowing in which case the compound enters the bloodstreamvia the gastrointestinal tract. Alternatively or additionally, oraladministration may involve mucosal administration (e.g., buccal,sublingual, supralingual administration) such that the compound entersthe bloodstream through the oral mucosa.

Formulations suitable for oral administration include solid, semi-solidand liquid systems such as tablets; soft or hard capsules containingmulti- or nano-particulates, liquids, or powders; lozenges which may beliquid-filled; chews; gels; fast dispersing dosage forms; films; ovules;sprays; and buccal or mucoadhesive patches. Liquid formulations includesuspensions, solutions, syrups and elixirs. Such formulations may beemployed as fillers in soft or hard capsules (made, e.g., from gelatinor hydroxypropylmethylcellulose) and typically comprise a carrier (e.g.,water, ethanol, polyethylene glycol, propylene glycol, methylcellulose,or a suitable oil) and one or more emulsifying agents, suspending agentsor both. Liquid formulations may also be prepared by the reconstitutionof a solid (e.g., from a sachet).

Compounds of Formula 1 may also be used in fast-dissolving,fast-disintegrating dosage forms such as those described in Liang andChen, Expert Opinion in Therapeutic Patents (2001) 11(6):981-986.

For tablet dosage forms, depending on dose, the active pharmaceuticalingredient (API) may comprise from about 1 wt % to about 80 wt % of thedosage form or more typically from about 5 wt % to about 60 wt % of thedosage form. In addition to the API, tablets may include one or moredisintegrants, binders, diluents, surfactants, glidants, lubricants,anti-oxidants, colorants, flavoring agents, preservatives, andtaste-masking agents. Examples of disintegrants include sodium starchglycolate, sodium carboxymethyl cellulose, calcium carboxymethylcellulose, croscarmellose sodium, crospovidone, polyvinylpyrrolidone,methyl cellulose, microcrystalline cellulose, C₁₋₆ alkyl-substitutedhydroxypropylcellulose, starch, pregelatinized starch, and sodiumalginate. Generally, the disintegrant will comprise from about 1 wt % toabout 25 wt % or from about 5 wt % to about 20 wt % of the dosage form.

Binders are generally used to impart cohesive qualities to a tabletformulation. Suitable binders include microcrystalline cellulose,gelatin, sugars, polyethylene glycol, natural and synthetic gums,polyvinylpyrrolidone, pregelatinized starch, hydroxypropylcellulose andhydroxypropylmethylcellulose. Tablets may also contain diluents, such aslactose (monohydrate, spray-dried monohydrate, anhydrous), mannitol,xylitol, dextrose, sucrose, sorbitol, microcrystalline cellulose, starchand dibasic calcium phosphate dihydrate.

Tablets may also include surface active agents, such as sodium laurylsulfate and polysorbate 80, and glidants such as silicon dioxide andtalc. When present, surface active agents may comprise from about 0.2 wt% to about 5 wt % of the tablet, and glidants may comprise from about0.2 wt % to about 1 wt % of the tablet.

Tablets may also contain lubricants such as magnesium stearate, calciumstearate, zinc stearate, sodium stearyl fumarate, and mixtures ofmagnesium stearate with sodium lauryl sulfate. Lubricants may comprisefrom about 0.25 wt % to about 10 wt % or from about 0.5 wt % to about 3wt % of the tablet.

Tablet blends may be compressed directly or by roller compaction to formtablets. Tablet blends or portions of blends may alternatively be wet-,dry-, or melt-granulated, melt congealed, or extruded before tableting.If desired, prior to blending one or more of the components may be sizedby screening or milling or both. The final dosage form may comprise oneor more layers and may be coated, uncoated, or encapsulated. Exemplarytablets may contain up to about 80 wt % of API, from about 10 wt % toabout 90 wt % of binder, from about 0 wt % to about 85 wt % of diluent,from about 2 wt % to about 10 wt % of disintegrant, and from about 0.25wt % to about 10 wt % of lubricant. For a discussion of blending,granulation, milling, screening, tableting, coating, as well as adescription of alternative techniques for preparing drug products, seeA. R. Gennaro (ed.), Remington: The Science and Practice of Pharmacy(20th ed., 2000); H. A. Lieberman et al. (ed.), Pharmaceutical DosageForms: Tablets, Vol. 1-3 (2d ed., 1990); and D. K. Parikh & C. K.Parikh, Handbook of Pharmaceutical Granulation Technology, Vol. 81(1997).

Consumable oral films for human or veterinary use are pliablewater-soluble or water-swellable thin film dosage forms which may berapidly dissolving or mucoadhesive. In addition to the API, a typicalfilm includes one or more film-forming polymers, binders, solvents,humectants, plasticizers, stabilizers or emulsifiers,viscosity-modifying agents, and solvents. Other film ingredients mayinclude anti-oxidants, colorants, flavorants and flavor enhancers,preservatives, salivary stimulating agents, cooling agents, co-solvents(including oils), emollients, bulking agents, anti-foaming agents,surfactants, and taste-masking agents. Some components of theformulation may perform more than one function.

In addition to dosing requirements, the amount of API in the film maydepend on its solubility. If water soluble, the API would typicallycomprise from about 1 wt % to about 80 wt % of the non-solventcomponents (solutes) in the film or from about 20 wt % to about 50 wt %of the solutes in the film. A less soluble API may comprise a greaterproportion of the composition, typically up to about 88 wt % of thenon-solvent components in the film.

The film-forming polymer may be selected from natural polysaccharides,proteins, or synthetic hydrocolloids and typically comprises from about0.01 wt % to about 99 wt % or from about 30 wt % to about 80 wt % of thefilm.

Film dosage forms are typically prepared by evaporative drying of thinaqueous films coated onto a peelable backing support or paper, which maycarried out in a drying oven or tunnel (e.g., in a combinedcoating-drying apparatus), in lyophilization equipment, or in a vacuumoven.

Useful solid formulations for oral administration may include immediaterelease formulations and modified release formulations. Modified releaseformulations include delayed-, sustained-, pulsed-, controlled-,targeted-, and programmed-release. For a general description of suitablemodified release formulations, see U.S. Pat. No. 6,106,864. For detailsof other useful release technologies, such as high energy dispersionsand osmotic and coated particles, see Verma et al, PharmaceuticalTechnology On-line (2001) 25(2):1-14.

Compounds of Formula 1 may also be administered directly into the bloodstream, muscle, or an internal organ of the subject. Suitable techniquesfor parenteral administration include intravenous, intraarterial,intraperitoneal, intrathecal, intraventricular, intraurethral,intrasternal, intracranial, intramuscular, intrasynovial, andsubcutaneous administration. Suitable devices for parenteraladministration include needle injectors, including microneedleinjectors, needle-free injectors, and infusion devices.

Parenteral formulations are typically aqueous solutions which maycontain excipients such as salts, carbohydrates and buffering agents(e.g., pH of from about 3 to about 9). For some applications, however,compounds of Formula 1 may be more suitably formulated as a sterilenon-aqueous solution or as a dried form to be used in conjunction with asuitable vehicle such as sterile, pyrogen-free water. The preparation ofparenteral formulations under sterile conditions (e.g., bylyophilization) may be readily accomplished using standardpharmaceutical techniques.

The solubility of compounds which are used in the preparation ofparenteral solutions may be increased through appropriate formulationtechniques, such as the incorporation of solubility-enhancing agents.Formulations for parenteral administration may be formulated to beimmediate or modified release. Modified release formulations includedelayed, sustained, pulsed, controlled, targeted, and programmedrelease. Thus, compounds of Formula 1 may be formulated as a suspension,a solid, a semi-solid, or a thixotropic liquid for administration as animplanted depot providing modified release of the active compound.Examples of such formulations include drug-coated stents and semi-solidsand suspensions comprising drug-loaded poly(DL-lactic-coglycolic)acid(PGLA) microspheres.

Compounds of Formula 1 may also be administered topically,intradermally, or transdermally to the skin or mucosa. Typicalformulations for this purpose include gels, hydrogels, lotions,solutions, creams, ointments, dusting powders, dressings, foams, films,skin patches, wafers, implants, sponges, fibers, bandages andmicroemulsions. Liposomes may also be used. Typical carriers may includealcohol, water, mineral oil, liquid petrolatum, white petrolatum,glycerin, polyethylene glycol and propylene glycol. Topical formulationsmay also include penetration enhancers. See, e.g., Finnin and Morgan, J.Pharm. Sci. 88(10):955-958 (1999).

Other means of topical administration include delivery byelectroporation, iontophoresis, phonophoresis, sonophoresis andmicroneedle or needle-free (e.g. Powderject™ and Bioject™) injection.Formulations for topical administration may be formulated to beimmediate or modified release as described above.

Compounds of Formula 1 may also be administered intranasally or byinhalation, typically in the form of a dry powder, an aerosol spray, ornasal drops. An inhaler may be used to administer the dry powder, whichcomprises the API alone, a powder blend of the API and a diluent, suchas lactose, or a mixed component particle that includes the API and aphospholipid, such as phosphatidylcholine. For intranasal use, thepowder may include a bioadhesive agent, e.g., chitosan or cyclodextrin.A pressurized container, pump, sprayer, atomizer, or nebulizer, may beused to generate the aerosol spray from a solution or suspensioncomprising the API, one or more agents for dispersing, solubilizing, orextending the release of the API (e.g., EtOH with or without water), oneor more solvents (e.g., 1,1,1,2-tetrafluoroethane or1,1,1,2,3,3,3-heptafluoropropane) which serve as a propellant, and anoptional surfactant, such as sorbitan trioleate, oleic acid, or anoligolactic acid. An atomizer using electrohydrodynamics may be used toproduce a fine mist.

Prior to use in a dry powder or suspension formulation, the drug productis usually comminuted to a particle size suitable for delivery byinhalation (typically 90% of the particles, based on volume, having alargest dimension less than 5 microns). This may be achieved by anyappropriate size reduction method, such as spiral jet milling, fluid bedjet milling, supercritical fluid processing, high pressurehomogenization, or spray drying.

Capsules, blisters and cartridges (made, for example, from gelatin orhydroxypropylmethyl cellulose) for use in an inhaler or insufflator maybe formulated to contain a powder mixture of the active compound, asuitable powder base such as lactose or starch, and a performancemodifier such as L-leucine, mannitol, or magnesium stearate. The lactosemay be anhydrous or monohydrated. Other suitable excipients includedextran, glucose, maltose, sorbitol, xylitol, fructose, sucrose, andtrehalose.

A suitable solution formulation for use in an atomizer usingelectrohydrodynamics to produce a fine mist may contain from about 1 μgto about 20 mg of the API per actuation and the actuation volume mayvary from about 1 μL to about 100 μL. A typical formulation may compriseone or more compounds of Formula 1, propylene glycol, sterile water,EtOH, and NaCl. Alternative solvents, which may be used instead ofpropylene glycol, include glycerol and polyethylene glycol.

Formulations for inhaled administration, intranasal administration, orboth, may be formulated to be immediate or modified release using, forexample, PGLA. Suitable flavors, such as menthol and levomenthol, orsweeteners, such as saccharin or sodium saccharin, may be added toformulations intended for inhaled/intranasal administration.

In the case of dry powder inhalers and aerosols, the dosage unit isdetermined by means of a valve that delivers a metered amount. Units aretypically arranged to administer a metered dose or “puff” containingfrom about 10 μg to about 1000 μg of the API. The overall daily dosewill typically range from about 100 μg to about 10 mg which may beadministered in a single dose or, more usually, as divided dosesthroughout the day.

The active compounds may be administered rectally or vaginally, e.g., inthe form of a suppository, pessary, or enema. Cocoa butter is atraditional suppository base, but various alternatives may be used asappropriate. Formulations for rectal or vaginal administration may beformulated to be immediate or modified release as described above.

Compounds of Formula 1 may also be administered directly to the eye orear, typically in the form of drops of a micronized suspension orsolution in isotonic, pH-adjusted, sterile saline. Other formulationssuitable for ocular and aural administration include ointments, gels,biodegradable implants (e.g. absorbable gel sponges, collagen),non-biodegradable implants (e.g. silicone), wafers, lenses, andparticulate or vesicular systems, such as niosomes or liposomes. Theformulation may include one or more polymers and a preservative, such asbenzalkonium chloride. Typical polymers include crossed-linkedpolyacrylic acid, polyvinylalcohol, hyaluronic acid, cellulosic polymers(e.g., hydroxypropylmethylcellulose, hydroxyethylcellulose, methylcellulose), and heteropolysaccharide polymers (e.g., gelan gum). Suchformulations may also be delivered by iontophoresis. Formulations forocular or aural administration may be formulated to be immediate ormodified release as described above.

To improve their solubility, dissolution rate, taste-masking,bioavailability, or stability, compounds of Formula 1 may be combinedwith soluble macromolecular entities, including cyclodextrin and itsderivatives and polyethylene glycol-containing polymers. For example,API-cyclodextrin complexes are generally useful for most dosage formsand routes of administration. Both inclusion and non-inclusion complexesmay be used. As an alternative to direct complexation with the API, thecyclodextrin may be used as an auxiliary additive, i.e. as a carrier,diluent, or solubilizer. Alpha-, beta- and gamma-cyclodextrins arecommonly used for these purposes. See, e.g., WO 91/11172, WO 94/02518,and WO 98/55148.

As noted above, one or more compounds of Formula 1, including compoundsspecifically named above, and their pharmaceutically active complexes,salts, solvates and hydrates, may be combined with each other or withone or more other active pharmaceutically active compounds to treatvarious diseases, conditions and disorders. In such cases, the activecompounds may be combined in a single dosage form as described above ormay be provided in the form of a kit which is suitable forcoadministration of the compositions. The kit comprises (1) two or moredifferent pharmaceutical compositions, at least one of which contains acompound of Formula 1; and (2) a device for separately retaining the twopharmaceutical compositions, such as a divided bottle or a divided foilpacket. An example of such a kit is the familiar blister pack used forthe packaging of tablets or capsules. The kit is suitable foradministering different types of dosage forms (e.g., oral andparenteral) or for administering different pharmaceutical compositionsat separate dosing intervals, or for titrating the differentpharmaceutical compositions against one another. To assist with patientcompliance, the kit typically comprises directions for administrationand may be provided with a memory aid.

For administration to human patients, the total daily dose of theclaimed and disclosed compounds is typically in the range of about 0.1mg to about 3000 mg depending on the route of administration. Forexample, oral administration may require a total daily dose of fromabout 1 mg to about 3000 mg, while an intravenous dose may only requirea total daily dose of from about 0.1 mg to about 300 mg. The total dailydose may be administered in single or divided doses and, at thephysician's discretion, may fall outside of the typical ranges givenabove. Although these dosages are based on an average human subjecthaving a mass of about 60 kg to about 70 kg, the physician will be ableto determine the appropriate dose for a patient (e.g., an infant) whosemass falls outside of this weight range.

As noted above, the compounds of Formula 1 may be used to treatdisorders, diseases, and conditions for which inhibition of SYK isindicated. Such disorders, diseases, and conditions generally relate toany unhealthy or abnormal state in a subject for which the inhibition ofSYK provides a therapeutic benefit. More particularly, such disorders,diseases, and conditions may involve the immune system and inflammation,including Type I hypersensitivity (allergic) reactions (allergicrhinitis, allergic asthma, and atopic dermatitis); autoimmune diseases(rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus,psoriasis, and immune thrombocytopenic purpura); inflammation of thelung (chronic obstructive pulmonary disease) and thrombosis. Thecompounds of Formula 1 may also be used to treat disorders, diseases,and conditions related to abnormal cell growth, including hematologicalmalignancies, such as acute myeloid leukemia, B-cell chronic lymphocyticleukemia, B-cell lymphoma (e.g., mantle cell lymphoma), and T-celllymphoma (e.g., peripheral T-cell lymphoma), as well as epithelialcancers (i.e., carcinomas), such as lung cancer (small cell lung cancerand non-small cell lung cancer), pancreatic cancer, and colon cancer.

In addition to the hematological malignancies and epithelial cancersnoted above, the compounds of Formula 1 may also be used to treat othertypes of cancer, including leukemia (chronic myelogenous leukemia andchronic lymphocytic leukemia); breast cancer, genitourinary cancer, skincancer, bone cancer, prostate cancer, and liver cancer; brain cancer;cancer of the larynx, gall bladder, rectum, parathyroid, thyroid,adrenal, neural tissue, bladder, head, neck, stomach, bronchi, andkidneys; basal cell carcinoma, squamous cell carcinoma, metastatic skincarcinoma, osteosarcoma, Ewing's sarcoma, veticulum cell sarcoma, andKaposi's sarcoma; myeloma, giant cell tumor, islet cell tumor, acute andchronic lymphocytic and granulocytic tumors, hairy-cell tumor, adenoma,medullary carcinoma, pheochromocytoma, mucosal neuromas, intestinalganglioneuromas, hyperplastic corneal nerve tumor, marfanoid habitustumor, Wilms' tumor, seminoma, ovarian tumor, leiomyomater tumor,cervical dysplasia, neuroblastoma, retinoblastoma, myelodysplasticsyndrome, rhabdomyosarcoma, astrocytoma, non-Hodgkin's lymphoma,malignant hypercalcemia, polycythermia vera, adenocarcinoma,glioblastoma multiforma, glioma, lymphomas, and malignant melanomas,among others.

In addition to cancer, the compounds of Formula 1 may also be used totreat other diseases related to abnormal cell growth, includingnon-malignant proliferative diseases such as benign prostatichypertrophy, restinosis, hyperplasia, synovial proliferation disorder,retinopathy or other neovascular disorders of the eye, among others.

The compounds of Formula 1 may also be used to treat autoimmunedisorders in addition to those listed above. Such disorders, diseases,and conditions include Crohns disease, dermatomyositis, diabetesmellitus type 1, Goodpasture's syndrome, Graves' disease, Guillain-Barrésyndrome, Hashimoto's disease, mixed connective tissue damage,myasthenia gravis, narcolepsy, pemphigus vulgaris, pernicious anemia,polymyositis, primary biliary cirrhosis, Sjögren's syndrome, temporalarteritis, ulcerative colitis, vasculitis, and Wegener's granulomatosis,among others.

Furthermore, compounds of Formula 1 may be used to treat inflammatorydisorders including asthma, chronic inflammation, chronic prostatitis,glomerulonephritis, hypersensitivities, inflammatory bowel diseases(ulcerative colitis in addition to Crohn's disease), pelvic inflammatorydisease, reperfusion injury, transplant rejection, vasculitis, andsystemic inflammatory response syndrome.

The compounds of Formula 1 may also be used to treat specific diseasesthat may fall within one or more general disorders described above,including arthritis. In addition to rheumatoid arthritis, Sjögren'ssyndrome, systemic lupus erythematosus, SLE in children and adolescents,compounds of Formula 1 may also be used to treat other arthritisdiseases, including ankylosing spondylitis, avascular necrosis, Bechet'sdisease, bursitis, calcium pyrophosphate dihyrate crystal depositiondisease (pseudo gout), carpal tunnel syndrome, Ehlers-Danlos syndrome,fibromyalgia, Fifth disease, giant cell arteritis, gout, juveniledermatomyositis, juvenile rheumatoid arthritis, juvenilespondyloarthopathy, Lyme disease, Marfan syndrome, myositis,osteoarthritis, osteogenesis imperfect, osteoporosis, Paget's disease,psoriatic arthritis, Raynaud's phenomenon, reactive arthritis, reflexsympathetic dystrophy syndrome, scleroderma, spinal stenosis, Still'sdisease, and tendinitis, among others.

The claimed and disclosed compounds may be combined with one or moreother pharmacologically active compounds or therapies for the treatmentof one or more disorders, diseases or conditions for which SYK isindicated, including disorders, diseases, and conditions involving theimmune system, inflammation, and abnormal cell growth. For example,compounds of Formula 1, which include compounds specifically namedabove, and their pharmaceutically acceptable complexes, salts, solvatesand hydrates, may be administered simultaneously, sequentially orseparately in combination with one or more compounds or therapies fortreating arthritis, including rheumatoid arthritis and osteoarthritis,or for treating cancer, including hematological malignancies, such asacute myeloid leukemia, B-cell chronic lymphocytic leukemia, B-celllymphoma, and T-cell lymphoma, and carcinomas, such as lung cancer,pancreatic cancer, and colon cancer. Such combinations may offersignificant therapeutic advantages, including fewer side effects,improved ability to treat underserved patient populations, orsynergistic activity.

For example, when used to treat arthritis, the compounds of Formula 1may be combined with one or more nonsteroidal anti-inflamatory drugs(NSAIDs), analgesics, corticosteroids, biological response modifiers,and protein-A immunoadsorption therapy. Alternatively or additionally,when treating rheumatoid arthritis, the compounds of Formula 1 may becombined with one or more disease modifying antirheumatic drugs(DMARDs), and when treating osteoarthritis, the compounds of Formula 1may be combined with one or more osteoporosis agents.

Representative NSAIDs include apazone, aspirin, celecoxib, diclofenac(with and without misoprostol), diflunisal, etodolac, fenoprofen,flurbiprofen, ibuprofen, indomethacin, ketoprofen, meclofenamate sodium,mefenamic acid, meloxicam, nabumetone, naproxen, oxaprozin,phenylbutazone, piroxicam, choline and magnesium salicylates, salsalate,and sulindac. Representative analgesics include acetaminophen andmorphine sulfate, as well as codeine, hydrocodone, oxycodone,propoxyphene, and tramadol, all with or without acetaminophen.Representative corticosteroids include betamethasone, cortisone acetate,dexamethasone, hydrocortisone, methylprednisolone, prednisolone, andprednisone. Representative biological response modifiers include TNF-αinhibitors, such as adalimumab, etanercept, and infliximab; selectiveB-cell inhibitors, such as rituximab; IL-1 inhibitors, such as anakinra,and selective costimulation modulators, such as abatacept.

Representative DMARDs include auranofin (oral gold), azathioprine,chlorambucil, cyclophosamide, cyclosporine, gold sodium thiomalate(injectable gold), hydroxychloroquine, leflunomide, methotrexate,minocycline, myophenolate mofetil, penicillamine, and sulfasalazine.Representative osteoporosis agents include bisphosphonates, such asalendronate, ibandronate, risedronate, and zoledronic acid; selectiveestrogen receptor modulators, such as droloxifene, lasofoxifene, andraloxifene; hormones, such as calcitonin, estrogens, and parathyroidhormone; and immunosuppressant agents such as azathioprine,cyclosporine, and rapamycin.

Particularly useful combinations for treating rheumatoid arthritisinclude a compound of Formula 1 and methotrexate; a compound of Formula1 and one or more biological response modifiers, such as lefluonomide,etanercept, adalimumab, and infliximab; or a compound of Formula 1,methotrexate, and one or more biological response modifiers, such aslefluonomide, etanercept, adalimumab, and infliximab.

For the treatment of thrombis and restensosis, the compounds of Formula1 may be combined with one or more cardiovascular agents such as calciumchannel blockers, statins, fibrates, beta-blockers, ACE inhibitors, andplatelet aggregation inhibitors.

The compounds of Formula 1 may also be combined with one or morecompounds or therapies for treating cancer. These includechemotherapeutic agents (i.e., cytotoxic or antineoplastic agents) suchas alkylating agents, antibiotics, antimetabolic agents, plant-derivedagents, and topoisomerase inhibitors, as well as molecularly targeteddrugs which block the growth and spread of cancer by interfering withspecific molecules involved in tumor growth and progression. Molecularlytargeted drugs include both small molecules and biologics.

Representative alkylating agents include bischloroethylamines (nitrogenmustards, e.g., chlorambucil, cyclophosphamide, ifosfamide,mechlorethamine, melphalan, and uracil mustard); aziridines (e.g.,thiotepa); alkyl alkone sulfonates (e.g., busulfan); nitrosoureas (e.g.,carmustine, lomustine, and streptozocin); nonclassical alkylating agents(e.g., altretamine, dacarbazine, and procarbazine); and platinumcompounds (e.g., carboplatin, cisplatin, nedaplatin, oxaliplatin,satraplatin, and triplatin tetranitrate).

Representative antibiotic agents include anthracyclines (e.g.,aclarubicin, amrubicin, daunorubicin, doxorubicin, epirubicin,idarubicin, pirarubicin, valrubicin, and zorubicin); anthracenediones(e.g., mitoxantrone and pixantrone); and streptomyces (e.g.,actinomycin, bleomycin, dactinomycin, mitomycin C, and plicamycin).

Representative antimetabolic agents include dihydrofolate reductaseinhibitors (e.g., aminopterin, methotrexate, and pemetrexed); hymidylatesynthase inhibitors (e.g., raltitrexed and pemetrexed); folinic acid(e.g., leucovorin); adenosine deaminase inhibitors (e.g., pentostatin);halogenated/ribonucleotide reductase inhibitors (e.g., cladribine,clofarabine, and fludarabine); thiopurines (e.g, thioguanine andmercaptopurine); thymidylate synthase inhibitors (e.g., fluorouracil,capecitabine, tegafur, carmofur, and floxuridine); DNA polymeraseinhibitors (e.g., cytarabine); ribonucleotide reductase inhibitors(e.g., gemcitabine); hypomethylating agent (e.g., azacitidine anddecitabine); and ribonucleotide reductase inhibitor (e.g., hydroxyurea);and an asparagine depleter (e.g., asparaginase)

Representative plant-derived agents include vinca alkaloids (e.g.,vincristine, vinblastine, vindesine, vinzolidine, and vinorelbine),podophyllotoxins (e.g., etoposide and teniposide), and taxanes (e.g.,docetaxel, larotaxel, ortataxel, paclitaxel, and tesetaxel).

Representative type I topoisomerase inhibitors include camptothecins,such as belotecan, irinotecan, rubitecan, and topotecan. Representativetype II topoisomerase inhibitors include amsacrine, etoposide, etoposidephosphate, and teniposide, which are derivatives of epipodophyllotoxins.

Molecularly targeted therapies include biologic agents such as cytokinesand other immune-regulating agents. Useful cytokines includeinterleukin-2 (IL-2, aldesleukin), interleukin 4 (IL-4), interleukin 12(IL-12), and interferon, which includes more than 23 related subtypes.Other cytokines include granulocyte colony stimulating factor (CSF)(filgrastim) and granulocyte macrophage CSF (sargramostim). Otherimmuno-modulating agents include bacillus Calmette-Guerin, levamisole,and octreotide; monoclonal antibodies against tumor antigens, such astrastruzumab and rituximab; and cancer vaccines, which induce an immuneresponse to tumors.

In addition, molecularly targeted drugs that interfere with specificmolecules involved in tumor growth and progression include inhibitors ofepidermal growth factor (EGF), transforming growth factor-alpha(TGF_(α)), TGF_(β), heregulin, insulin-like growth factor (IGF),fibroblast growth factor (FGF), keratinocyte growth factor (KGF), colonystimulating factor (CSF), erythropoietin (EPO), interleukin-2 (IL-2),nerve growth factor (NGF), platelet-derived growth factor (PDGF),hetaptocyte growth factor (HGF), vascular endothelial growth factor(VEGF), angiopoietin, epidermal growth factor receptor (EGFR), humanepidermal growth factor receptor 2 (HER2), HER4, insulin-like growthfactor 1 receptor (IGF1R), IGF2R, fibroblast growth factor 1 receptor(FGF1R), FGF2R, FGF3R, FGF4R, vascular endothelial growth factorreceptor (VEGFR), tyrosine kinase with immunoglobulin-like and epidermalgrowth factor-like domains 2 (Tie-2), platelet-derived growth factorreceptor (PDGFR), Abl, Bcr-Abl, Raf, FMS-like tyrosine kinase 3 (FLT3),c-Kit, Src, protein kinase c (PKC), tropomyosin receptor kinase (Trk),Ret, mammalian target of rapamycin (mTOR), Aurora kinase, polo-likekinase (PLK), mitogen activated protein kinase (MAPK),mesenchymal-epithelial transition factor (c-MET), cyclin-dependantkinase (CDK), Akt, extracellular signal-regulated kinases (ERK),poly(ADP) ribose polymerase (PARP), and the like.

Specific molecularly targeted drugs include selective estrogen receptormodulators, such as tamoxifen, toremifene, fulvestrant, and raloxifene;antiandrogens, such as bicalutamide, nilutamide, megestrol, andflutamide; and aromatase inhibitors, such as exemestane, anastrozole,and letrozole. Other specific molecularly targeted drugs include agentswhich inhibit signal transduction, such as imatinib, dasatinib,nilotinib, trastuzumab, gefitinib, erlotinib, cetuximab, lapatinib,panitumumab, and temsirolimus; agents that induce apoptosis, such asbortezomib; agents that block angiogensis, such as bevacizumab,sorafenib, and sunitinib; agents that help the immune system destroycancel cells, such as rituximab and alemtuzumab; and monoclonalantibodies which deliver toxic molecules to cancer cells, such asgemtuzumab ozogamicin, tositumomab, 131I-tositumoab, and ibritumomabtiuxetan.

Biological Activity: SYK Inhibition

The ability of compounds to inhibit SYK activity may be assessed using avariety of methods, including in vitro and in vivo assays. The followingin vitro assay measures a test compound's ability to inhibitSYK-mediated phosphorylation of a FAM-labeled SYK-specific substrate(5FAM-KKKKEEIYFFFG-NH₂).

SYK protein is prepared from cDNA encoding human spleen tyrosine kinaseand is expressed in insect cells using a baculovirus expression vector.The cDNA (IMAGE: 3542895) is purchased from Open Biosystems. The SYKkinase domain (residues 356-635) is amplified via PCR and cloned intoplasmid pFastBac1 (Invitrogen) at BamHI/XbaI sites. Recombinant plasmidencoding Met-Ala-Lys-SYK(356-635)-HHHHHH is sequenced and transformedinto E. coli DH10Bac strain. The recombinant bacmid DNA is isolated andtransfected into Sf9 insect cells. Recombinant virus is harvested 72 hafter transfection. High titer viral stock is prepared by infecting Sf9cells at a multiplicity of infection (MOI) of approximately 0.01. Asuspension of Sf9 cells (10 L) is infected with recombinant virus(MOI=5) and is incubated in a Wave Bioreactor (GE-Healthcare) for 48 h.The cells are harvested and stored at −80° C.

To purify the expressed protein, the frozen Sf9 cells (10 L) are brokeninto small (<1 cm) particles and suspended in a lysis buffer (300 mL)containing 20 mM Tris (pH 7.6), 0.25 mM TCEP, 100 mM NaCl, 5% glyceroland a protease inhibitor. The suspension is stirred at RT untilcompletely thawed, lysed an additional 2-4 min on a rotary bladehomogenizer, and then centrifuged at 4200 g for 1 h. Followingcentrifugation, the supernatant is poured through cheese cloth andcombined with a nickel chelating resin (Probond Resin™, Invitrogen)which is pre-equilibrated in a wash buffer containing 10 mM Tris (pH7.6), 0.25 mM TCEP, 300 mM NaCl, 5% glycerol, and 20 mM imidazole. Themixture is agitated for 3 h in a cold room and then centrifuged at 900 gfor 10 min. The resin is dispersed in wash buffer (50 mL), centrifugedfor 10 min at 900 g, re-dispersed in a small amount of wash buffer (5mL), and then pour into a disposable Poly-Prep chromatography column,through which wash buffer is passed by gravity until no protein isobserved in coomassie buffer (about 120 mL of wash buffer). An elutionbuffer (30 mL) containing 10 mM HEPES (pH 7.4), 150 mM NaCl, 10%glycerol, 5 mM DTT, and 400 mM imidazole is used to elute the SYKprotein from the resin. The eluate is concentrated (5 mL) and furtherpurified on a Superdex 200 column (1.2 mL/min for 160 min, 10 mM HEPES(pH 7.4), 10 mM NaCl, 10 mM MgCl, 0.1 mM EDTA, and 0.25 mM TCEP). Thechromatographed fractions are run on SDS-PAGE and the requisitefractions are pooled and concentrated. Final delivery buffer is 10 mMHEPES (pH 7.4), 10 mM Methione, 150 mM NaCl, 10% glycerol, 5 mM DTT.

SYK inhibition is determined using a black 384 well plate format inbuffer containing 50 mM HEPES, 10 mM NaCl, 10 mM MgCl₂, 0.2 mM EDTA,0.01% EDA (Brij 35), 1 mM DTT, and 0.1 mg/ml BSA at pH 7.3. Each testcompound is prepared in DMSO using 2-fold serial dilutions for 11 datapoints, which are added to the buffer so that each dilution contains 3%DMSO. To each well is added 2 μL of 3 μM 5FAM-KKKKEEIYFFFG-NH₂ (inbuffer), 2 μL of diluted test compound (3% DMSO in buffer), and 2 μL of2.4 nM SYK and 45 μM ATP (in buffer). The reaction mixture is incubatedat RT for 60 min, and quenched by adding 50 mM Hepes, 30 mM EDTA, 0.1%Triton X-100 (pH 7.3). To quantify the fluorescent-labeled substrate andproduct following reaction, the test plate is loaded on a CaliperLC-3000, which measures percent of conversion by microfluidic-basedseparation. Corresponding IC₅₀ values are calculated by non-linear curvefitting of the compound concentrations and percent of inhibition to thestandard IC₅₀ equation and reported as pIC₅₀, i.e., −log(IC₅₀), whereIC₅₀ is molar concentration.

EXAMPLES

The following examples are intended to be illustrative and non-limiting,and represent specific embodiments of the present invention.

¹H Nuclear magnetic resonance (NMR) spectra were obtained for many ofthe compounds in the following examples. Characteristic chemical shifts(δ) are given in parts-per-million downfield from tetramethylsilaneusing conventional abbreviations for designation of major peaks,including s (singlet), d (doublet), t (triplet), q (quartet), m(multiplet), spt (septet) and br (broad). The mass spectra (m/z) wererecorded using either electrospray ionization (ESI) or atmosphericpressure chemical ionization (APCI). The following abbreviations areused for common solvents: CDCl₃ (deuterochloroform), DMSO-d₆(deuterodimethylsulfoxide), CD₃OD (deuteromethanol), and THF-d₈(deuterotetrahydrofuran). “Ammonia” refers to a concentrated solution ofammonia in water possessing a specific gravity of 0.88.

Where indicated, products of certain preparations and examples arepurified by mass-triggered HPLC (e.g., Pump: Waters™ 2525; MS: ZQ™;Software: MassLynx™), flash chromatography or preparative thin layerchromatography (TLC). Preparative HPLC is carried out using eitheracidic or basic conditions. Acid conditions are typically gradients inSolvent A (water with 0.05% TFA) and Solvent B (acetonitrile with 0.035%TFA); basic conditions are typically gradients in Solvent A (10 mMNH₄HCO₃ in water) and Solvent B (10 mM NH₄HCO₃ in 20/80 (v/v)water/acetonitrile). The mentioned preparative HPLC conditions useacidic conditions unless indicated as basic. Preparative TLC istypically carried out on silica gel 60 F₂₅₄ plates. After isolation bychromatography, the solvent is removed and the product is obtained bydrying in a centrifugal evaporator (e.g., GeneVac™), rotary evaporator,evacuated flask, lyophilizer, etc. Reactions in an inert (e.g.,nitrogen) or reactive (e.g., H₂) atmosphere are typically carried out ata pressure of about 1 atmosphere (14.7 psi) or greater.

Preparation 1: Methyl 2,4-dichloro-6-methylpyrimidine-5-carboxylate

To a suspension of methyl6-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (1 g, 5.43mmol) in POCl₃ (10 mL) was added 10 drops of N,N-dimethylaniline. Thereaction mixture was heated at 105° C. for 6 h until it became a clearsolution. It was then cooled, concentrated under reduced pressure,poured over ice, and extracted with EtOAc. The organic extract waswashed with water and brine, dried and concentrated under reducedpressure to give the title compound as greenish-yellow solid (940 mg,78%). [M+H] calc'd for C₇H₆Cl₂N₂O₂, 222; found, 221, 223.

Preparation 2: Methyl2-chloro-4-methyl-6-(m-tolylamino)pyrimidine-5-carboxylate

A mixture of methyl 2,4-dichloro-6-methylpyrimidine-5-carboxylate (940mg, 4.25 mmol), m-toluidine (0.461 mL, 4.25 mmol) andN-ethyldiisopropylamine (1.481 mL, 8.51 mmol) in CH₃CN (30 mL) washeated under reflux for 3 h. The mixture was diluted with EtOAc, and waswashed with brine and water. The organic extract was dried andconcentrated under reduced pressure to give the title compound as alight yellow solid (1.2 g, 97%). [M+H] calc'd for C₁₄H₁₄N₃ClO₂, 292;found, 292.

Example 12-((1R,2S)-2-Aminocyclohexylamino)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one

A. Methyl2-((1R,2S)-2-(tert-butoxycarbonylamino)cyclohexylamino)-4-methyl-6-(m-tolylamino)pyrimidine-5-carboxylate

A solution of methyl2-chloro-4-methyl-6-(m-tolylamino)pyrimidine-5-carboxylate (1.2 g, 4.11mmol), tert-butyl (1S,2R)-2-aminocyclohexylcarbamate (0.882 g, 4.11mmol) and triethylamine (1.720 mL, 12.34 mmol) in DMA (10 mL) was heatedat 90° C. for 4 h. The solution was then diluted with EtOAc, washed withbrine and water. The organic extract was dried and concentrated underreduced pressure to give a light yellow residue; white crystals wereformed upon triturating with ACN (5 mL). The resultant solid wasfiltered, washed with ACN, and dried to give the title compound as whitesolid (1.2 g, 62%). [M+H] calc'd for C₂₅H₃₅N₅O₄, 470; found, 470.

B. tert-Butyl(1S,2R)-2-(6-(2,4-dimethoxybenzyl)-5-oxo-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-ylamino)cyclohexylcarbamate

A mixture of methyl2-((1R,2S)-2-(tert-butoxycarbonylamino)cyclohexylamino)-4-methyl-6-(m-tolylamino)pyrimidine-5-carboxylate(500 mg, 1.065 mmol) and selenium dioxide (236 mg, 2.130 mmol) indioxane (10 mL) was heated at 100° C. for 24 h. The solution wassubsequently cooled and filtered. The filtrate was concentrated underreduced pressure and dried to give a brown foam (534 mg; dihydroxyl formwas observed via mass spectroscopy), which was used directly in the nextstep without further purification. A mixture of the unpurifiedintermediate (534 mg, 1.065 mmol) and (2,4-dimethoxyphenyl)methanamine(0.160 mL, 1.065 mmol) in MeOH (10 mL) was stirred at RT for 10 min,after which sodium cyanoborohydride (100 mg, 1.597 mmol) was added, andthe reaction mixture was stirred at RT for 20 h. The reaction mixturewas warmed to 50° C. and stirred for an additional 2 h to complete thereaction. The mixture was cooled to RT and the solid filtered and washedwith MeOH to give the title compound as a pinkish solid (237 mg, 37%).[M+H] calc'd for C₃₃H₄₂N₆O₅, 603; found, 603.

C.2-((1R,2S)-2-Aminocyclohexylamino)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one

A mixture of crude tert-butyl(1S,2R)-2-(6-(2,4-dimethoxybenzyl)-5-oxo-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-ylamino)cyclohexylcarbamate(235 mg, 0.390 mmol) in TFA (5 mL) was stirred at 60° C. for 2 h and wasthen purified by reverse phase preparative HPLC. The fractions werecollected, concentrated under reduced pressure, diluted in EtOAc, andbasified with an aqueous saturated solution of NaHCO₃. The organicextract was dried and concentrated under reduced pressure to give thetitle compound as a white solid (60 mg, 44%). ¹H NMR (400 MHz, DMSO-d₆)δ ppm 1.33-1.60 (m, 10H), 2.32 (s, 3H), 3.16 (m, 2H), 3.92 (br s, 1H),4.14 (s, 2H), 6.88 (d, J=7.07 Hz, 1H), 7.13 (br s, 1H), 7.22 (t, J=7.45Hz, 1H), 7.34-7.55 (m, 1H), 7.70 (br s, 1H), 8.01 (br s, 1H), 8.58 (brs, 1H). [M+H] calc'd for C₁₉H₂₄N₆O, 353; found, 353.

Example 22-((1R,2S)-2-Aminocyclohexylamino)-4-(3-fluorophenylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one

The title compound was prepared in a manner similar to EXAMPLE 1 byreacting methyl 2,4-dichloro-6-methylpyrimidine-5-carboxylate with3-fluoroaniline instead of m-toluidine. The final product was purifiedvia reverse phase preparative HPLC. Lyophilization gave a TFA salt ofthe title compound as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ ppm1.29-1.56 (m, 2H), 1.56-1.73 (m, 4H), 1.77-1.85 (br s, 2H), 4.22 (br s,4H), 6.90 (br s, 1H), 7.25-7.44 (m, 2H), 7.48 (br s, 1H), 7.77 (br s,3H), 8.20 (d, J=13.64 Hz, 1H), 8.83 (d, J=14.40 Hz, 1H). [M+H] calc'dfor C₁₈H₂₁FN₆O, 357; found, 357.

Example 32-((1R,2S)-2-Aminocyclohexylamino)-4-(3-chlorophenylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one

The title compound was prepared in a manner similar to EXAMPLE 1 byreacting methyl 2,4-dichloro-6-methylpyrimidine-5-carboxylate with3-chloroaniline instead of m-toluidine. The final product was purifiedvia reverse phase preparative HPLC. Lyophilization gave a TFA salt ofthe title compound as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ ppm1.43 (br s, 2H), 1.67-1.96 (m, 6H), 4.20 (br s, 3H), 7.13 (d, J=7.33 Hz,1H), 7.36 (t, J=8.08 Hz, 1H), 7.48 (br s, 1H), 7.75 (br s, 2H), 8.16 (brs, 1H), 8.82 (br s, 1H). [M+H] calc'd for C₁₈H₂₁ClN₆O, 373; found, 373.

Example 44-(1H-Indazol-6-ylamino)-2-((1R,2S)-2-aminocyclohexylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one

The title compound was prepared in a manner similar to EXAMPLE 1 byreacting methyl 2,4-dichloro-6-methylpyrimidine-5-carboxylate with1H-indazol-6-amine instead of m-toluidine. The final product waspurified via reverse phase preparative HPLC. Lyophilization gave a TFAsalt of the title compound as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δppm 1.43-1.92 (br s, 8H), 2.33 (s, 1H), 3.57 (m, 1H), 4.21 (br s, 2H),6.94 (s, 1H), 7.07 (s, 1H), 7.14-7.31 (m, 1H), 7.43 (m, 1H), 7.71 (d,J=8.59 Hz, 2H), 8.01 (s, 1H), 8.14 (br s, 1H), 8.84 (s, 1H), 12.99 (brs, 1H). [M+H] calc'd for C₁₉H₂₂N₈O, 379; found, 379.

Example 52-((1R,2S)-2-Aminocyclohexylamino)-4-(3-(trifluoromethyl)phenylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one

A. Methyl4-(bromomethyl)-2-((1R,2S)-2-(tert-butoxycarbonylamino)cyclohexyl-amino)-6-(3-(trifluoromethyl)phenylamino)pyrimidine-5-carboxylate

Methyl2-((1R,2S)-2-(tert-butoxycarbonylamino)cyclohexylamino)-4-methyl-6-(3-(trifluoromethyl)phenylamino)pyrimidine-5-carboxylate(104 mg, 0.199 mmol), which was prepared in a manner similar to methyl2-((1R,2S)-2-(tert-butoxycarbonylamino)cyclohexyl-amino)-4-methyl-6-(m-tolylamino)pyrimidine-5-carboxylatein step B of EXAMPLE 1 using 3-(trifluoromethyl)aniline in place ofm-toluidine in step A of the example, was combined with1-bromopyrrolidine-2,5-dione (53.0 mg, 0.298 mmol) and benzoicperoxyanhydride (48.1 mg, 0.199 mmol) in CCl₄ (10 mL), and the resultingmixture was stirred at 70° C. for 18 h. The reaction was stopped. Themixture was concentrated under reduced pressure, separated between waterand EtOAc. The organic extract was dried and concentrated under reducedpressure to give the title compound, which was used in the next stepwithout further purification. [M+H] calc'd for C₂₅H₃₁BrN₅O₄, 603; found,604.

B.2-((1R,2S)-2-Aminocyclohexylamino)-4-(3-(trifluoromethyl)phenylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one

A mixture of methyl4-(bromomethyl)-2-((1R,2S)-2-(tert-butoxycarbonyl-amino)cyclohexylamino)-6-(3-(trifluoromethyl)phenylamino)pyrimidine-5-carboxylate(120 mg, 0.199 mmol) in THF was treated with ammonium hydroxide. Thereaction mixture was stirred at RT overnight, and subsequently worked upand purified by reverse phase preparative HPLC. The fractions werecollected and concentrated under reduced pressure to give a residue,which was treated with TFA/DCM. The final product was purified again bypreparative HPLC. Lyophilization gave a TFA salt of the title compoundas a white solid (2.6 mg, 3%). [M+H] calc'd for C₁₉H₂₁F₃N₆O, 407; found,407.

Example 6cis-2-(2-Aminocyclohexylamino)-4-(3-(trifluoromethyl)phenylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one

The title compound was prepared in a manner similar to EXAMPLE 5 usingmethylcis-2-(2-(tert-butoxycarbonylamino)cyclohexylamino)-4-methyl-6-(3-(trifluoromethyl)phenylamino)pyrimidine-5-carboxylatein place of methyl2-((1R,2S)-2-(tert-butoxycarbonylamino)cyclohexylamino)-4-methyl-6-(3-(trifluoromethyl)phenylamino)pyrimidine-5-carboxylate.The final product was purified via reverse phase preparative HPLC.Lyophilization gave a TFA salt of the title compound as a white solid.[M+H] calc'd for C₁₉H₂₁F₃N₆O, 407; found, 407.

Example 72-(1-Methyl-1H-pyrazol-4-yl)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one

A TFA salt of the title compound was prepared in a manner similar toEXAMPLE 1 using1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole inplace of tert-butyl (1S,2R)-2-aminocyclohexylcarbamate. ¹H NMR (500 MHz,DMSO-d₆) δ ppm 2.37 (s, 3H), 3.93 (s, 3H), 4.39 (s, 2H), 6.95 (d, J=7.32Hz, 1H), 7.32 (t, J=7.81 Hz, 1H), 7.62 (s, 1H), 7.77 (d, J=8.30 Hz, 1H),8.03 (s, 1H), 8.37 (s, 1H), 8.65 (s, 1H), 8.82 (s, 1H). [M+H] calc'd forC₁₇H₁₆N₆O, 321; found, 321.

Preparation 3: Ethyl2,4-dichloro-6-((1,3-dioxoisoindolin-2-yl)methyl)pyrimidine-5-carboxylate

A. Ethyl 4-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-oxobutanoate

To a solution of 2-(1,3-dioxoisoindolin-2-yl)acetic acid (3.01 g, 14.67mmol), 2,2-dimethyl-1,3-dioxane-4,6-dione (2.23 g, 15.47 mmol) and4-dimethylaminopyridine (2.73 g, 22.35 mmol) in dichloromethane (150 mL)was added a solution of DCC (3.36 g, 16.28 mmol) in DCM (50 mL) at 0° C.The mixture was stirred at RT for 16 h. The insoluble materials werefiltered off, and the filtrate was washed with 5% NaHSO₄ aqueoussolution. The organic phase was dried over anhydrous Na₂SO₄, filteredand the filtrate was concentrated under reduced pressure. The residuewas treated with EtOH (200 mL) and the resulting mixture was stirred at70° C. for 4 h and then concentrated under reduced pressure. Water wasadded to the residue and the mixture was extracted with EtOAc. Theorganic layers were washed with water and brine, dried over anhydrousMgSO₄, and filtered. The filtrate was concentrated under reducedpressure and the residue was washed with IPE to give the title compoundas a colorless solid (3.43 g, 85%). ¹H NMR (400 MHz, CDCl₃) δ ppm 1.31(t, J=6.8 Hz, 3H), 3.58 (s, 2H), 4.24 (q, J=6.8 Hz, 2H), 4.67 (s, 2H),7.73-7.78 (m, 2H), 7.86-7.91 (m, 2H).

B. Ethyl1-(2,4-dimethoxybenzyl)-6-((1,3-dioxoisoindolin-2-yl)methyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate

A mixture of ethyl4-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-oxobutanoate (249.8 mg,0.908 mmol) and (2,4-dimethoxyphenyl)methanamine (152 mg, 0.908 mmol) inEtOH (4 mL) was stirred at 50° C. for 16 h. The obtained solid wasisolated by filtration to give a colorless solid (51.7 mg). To asuspension of the solid in THF (4 mL) was added carbonisocyanatidicchloride (96 mg, 0.908 mmol) and the mixture was stirred at 80° C. for 1h. After cooling to RT, water (10 mL) was added and the mixture wasextracted with EtOAc. The organic layers were washed with brine, driedover anhydrous Na₂SO₄, and filtered. The filtrate was concentrated underreduced pressure and the residue was purified by column chromatography(SiO₂, hexane/EtOAc=1/1) to give the title compound (56.2 mg, 13%). ¹HNMR (400 MHz, CDCl₃) δ ppm 1.28 (t, J=7.2 Hz, 3H), 3.63 (s, 3H), 3.81(s, 3H), 4.22 (q, J=7.2 Hz, 2H), 4.95 (s, 2H), 5.12 (s, 2H), 6.18 (dd,J=8.4, 6.4 Hz, 1H), 6.23 (d, J=6.4 Hz, 1H), 6.75 (d, J=8.4 Hz, 1H),7.63-7.72 (m, 4H), 8.23 (br s, 1H).

C. Ethyl6-((1,3-dioxoisoindolin-2-yl)methyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate

To trifluoroacetic acid (2 mL, 26.0 mmol) was added ethyl1-(2,4-dimethoxybenzyl)-6-((1,3-dioxoisoindolin-2-yl)methyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate(198.9 mg, 0.403 mmol) at 0° C. The mixture was stirred at 0° C. for 1h, then at RT for 6 h. The mixture was concentrated under reducedpressure, and the residue was washed with IPE (5 mL) to give the titlecompound (183.3 mg). ¹H NMR (400 MHz, CDCl₃) δ ppm 1.42 (t, J=7.2 Hz,3H), 4.45 (q, J=7.2 Hz, 2H), 4.98 (s, 2H), 7.78-7.81 (m, 2H), 7.91-7.93(m, 2H), 8.19 (br s, 1H), 8.96 (br s, 1H).

D. Ethyl2,4-dichloro-6-((1,3-dioxoisoindolin-2-yl)methyl)pyrimidine-5-carboxylate

A mixture of ethyl6-((1,3-dioxoisoindolin-2-yl)methyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate(96.1 mg, 0.280 mmol) and phosphorus oxychloride (1 mL, 10.92 mmol) wasstirred at 100° C. for 12 h and allowed to cool. The mixture wasconcentrated under reduced pressure to remove excess POCl₃. The residuewas treated with saturated aq NaHCO₃ and extracted with EtOAc. Theorganic phase was washed with saturated aqueous NaHCO₃, water, andbrine, was dried over anhydrous Na₂SO₄, and then filtered through SiO₂.The filtrate was concentrated under reduced pressure and the residue waspurified by column chromatography (SiO₂, hexanes/EtOAc=4/1) to give thetitle compound (46.0 mg, 43%). ¹H NMR (400 MHz, CDCl₃) δ ppm 1.42 (t,J=7.2 Hz, 3H), 4.45 (q, J=7.2 Hz, 2H), 5.05 (s, 2H), 7.76-7.80 (m, 2H),7.89-7.93 (m, 2H).

Example 82-((1R,2S)-2-Aminocyclohexylamino)-4-(3-(trifluoromethyl)phenylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one(free base)

A. Ethyl2-chloro-4-((1,3-dioxoisoindolin-2-yl)methyl)-6-(m-tolylamino)pyrimidine-5-carboxylate

To a solution of ethyl2,4-dichloro-6-((1,3-dioxoisoindolin-2-yl)methyl)pyrimidine-5-carboxylate(45.3 mg, 0.119 mmol) in MeCN (1 mL) was added m-toluidine (0.020 mL,0.187 mmol) and N,N-diisopropylethylamine (0.037 mL, 0.212 mmol). Themixture was stirred at RT for 12 h. Saturated aq NaHCO₃ was added to themixture, which was subsequently extracted with EtOAc. The organic layerswere washed again with saturated aq NaHCO₃, water, and brine, were driedover anhydrous Na₂SO₄, and then filtered through SiO₂. The filtrate wasconcentrated under reduced pressure and the residue was washed with IPEto give the title compound as a pale brown solid (37.1 mg, 69%). ¹H NMR(400 MHz, CDCl₃) δ ppm 1.50 (t, J=7.2 Hz, 3H), 2.36 (s, 3H), 4.52 (q,J=7.2 Hz, 2H), 5.20 (s, 2H), 6.97-6.98 (m, 1H), 7.23-7.27 (m, 1H), 7.33(br s, 1H), 7.45-7.47 (m, 1H), 7.73-7.78 (m, 2H), 7.89-7.94 (m, 2H),10.67 (br s, 1H).

B. Ethyl2-((1R,2S)-2-(tert-butoxycarbonylamino)cyclohexylamino)-4-((1,3-dioxoisoindolin-2-yl)methyl)-6-(m-tolylamino)pyrimidine-5-carboxylate

A mixture of ethyl2-chloro-4-((1,3-dioxoisoindolin-2-yl)methyl)-6-(m-tolylamino)pyrimidine-5-carboxylate(96.3 mg, 0.214 mmol), tert-butyl (1S,2R)-2-aminocyclohexylcarbamate(58.14 mg, 0.271 mmol) and Et₃N (0.030 mL, 0.214 mmol) in DMA (2 mL) wasstirred at 80° C. for 3 h. Saturated aq NaHCO₃ was added to the mixture,which was extracted with EtOAc. The combined organic layers were washedwith aqueous NaHCO₃, water, and brine, were dried over anhydrous Na₂SO₄,and then filtered through SiO₂. The filtrate was concentrated underreduced pressure and the residue was purified by column chromatography(SiO₂, hexanes/EtOAc=3/1) to give the title compound as a yellow oil(123.8 mg, 92%). ¹H NMR (400 MHz, CDCl₃) δ ppm 1.12-1.71 (m, 20H), 2.33(s, 3H), 3.39-3.57 (m, 1H), 3.84-3.99 (m, 1H), 4.42 (q, J=7.2 Hz, 2H),4.55-4.79 (m, 1H), 5.16 (s, 2H), 5.41 (br s, 1H), 6.87-6.89 (m, 1H),7.16-7.49 (m, 3H), 7.74-7.75 (m, 2H), 7.90-7.91 (m, 2H), 10.68-10.81 (m,1H). [M+H] calc'd for C₃₄H₄₁N₆O₆, 629; found, 629.

C. tert-Butyl(1S,2R)-2-(5-oxo-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-ylamino)cyclohexylcarbamate

A mixture of ethyl2-((1R,2S)-2-(tert-butoxycarbonylamino)cyclohexylamino)-4-((1,3-dioxoisoindolin-2-yl)methyl)-6-(m-tolylamino)pyrimidine-5-carboxylate(109 mg, 0.174 mmol) and hydrazine hydrate (36.5 mg, 0.729 mmol) in EtOH(2 mL) was stirred at 65° C. for 12 h. After cooling, the mixture wasconcentrated under reduced pressure and the residue was treated withwater and extracted with EtOAc. The combined organic layers were washedwith aqueous NaHCO₃, water, and brine, were filtered through SiO₂, andthe filtrate was concentrated under reduced pressure. The residue wasrecrystallized from EtOAc/hexanes and filtered to give the titlecompound (34.8 mg). The filtrate was concentrated and triturated withIPE to give a second batch (20.3 mg) of the title compound (total 65.1mg, 83%). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.24-1.79 (m, 17H), 2.32 (s,3H), 3.84 (br s, 1H), 4.06 (br s, 1H), 4.14 (s, 2H), 6.55-6.70 (m, 1H),6.87-7.04 (m, 2H), 7.20-7.24 (m, 1H), 7.40-7.48 (m, 1H), 7.68-7.80 (m,1H), 8.01-8.06 (m, 1H), 8.56-8.59 (m, 1H). [M+H] calc'd for C₂₄H₃₃N₆O₃,453; found, 453.

D.2-((1R,2S)-2-Aminocyclohexylamino)-4-(3-(trifluoromethyl)phenylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one

To a solution of tert-butyl(1S,2R)-2-(5-oxo-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-ylamino)cyclohexylcarbamate(50.4 mg, 0.111 mmol) in HOAc (2 mL) was added hydrochloric acid (0.5mL, 16.46 mmol). The mixture was stirred at RT for 30 min and thenconcentrated under reduced pressure. The residue was treated withsaturated aq NaHCO₃ and extracted with EtOAc. The organic layers werewashed with saturated aq NaHCO₃, water, and brine, were dried overanhydrous Na₂SO₄, and then filtered. The filtrate was concentrated underreduced pressure and the residue was purified by column chromatography(SiO₂, EtOAc/MeOH=20/1) to give the title compound as a white powder(11.3 mg, 29%). ¹H NMR (400 MHz, CDCl₃) δ ppm 1.48-1.80 (m, 10H), 2.37(s, 3H), 3.24 (br s, 1H), 4.07 (br s, 1H), 4.20 (s, 2H), 5.55 (br s,1H), 5.89 (br s, 1H), 6.89-6.91 (m, 1H), 7.22-7.24 (m, 1H), 7.53-7.63(m, 2H), 8.49 (br s, 1H). [M+H] calc'd for C₁₉H₂₅N₆O, 353; found, 353.

Preparation 4: Methyl2,4-dichloro-6-(m-tolylamino)pyrimidine-5-carboxylate

A. 2,4,6-Trichloropyrimidine-5-carboxylic acid

To a solution of diisopropylamine (23.42 mL, 164 mmol) in THF (200 mL)was slowly added butyllithium (100 mL, 160 mmol) at −78° C. The mixturewas stirred at −78° C. for 15 min. To this mixture was slowly added asolution of 2,4,6-trichloropyrimidine (20.06 g, 109 mmol) in THF (50 mL)at −78° C. The mixture was stirred for 1 h. Dry ice was added and themixture was stirred at RT for 1 h. To the mixture was added 1N HCl,which was subsequently extracted with EtOAc. The organic layers werebasified with aqueous NaHCO₃, and washed with EtOAc. The aqueous layerwas then acidified with 1N HCl, and extracted with EtOAc. The organiclayers were washed with 1N HCl, water, and brine, were dried overanhydrous MgSO₄, and then filtered. The filtrate was concentrated underreduced pressure. The residue was washed with hexane to give the desiredproduct as a pale brown solid (12.28 g, 49%). ¹H NMR (500 MHz, CDCl₃) δppm 7.65 (br s, 1H).

B. 2,4-Dichloro-6-(m-tolylamino)pyrimidine-5-carboxylic acid

To a solution of 2,4,6-trichloropyrimidine-5-carboxylic acid (5.69 g,25.02 mmol) in DMF (60 mL) was added Et₃N (8 mL, 57.4 mmol) andm-toluidine (3.2 mL, 29.5 mmol) at 0° C. The mixture was stirred at RTfor 12 h. To the mixture was added 1N HCl. The mixture was extractedwith EtOAc. The organic layers were basified with saturated aq NaHCO₃and the aqueous layers were washed with EtOAc. The washed aqueous layerwas acidified with 1N HCl and extracted with EtOAc. The combined organiclayers were washed with 1N HCl, water, and brine, were dried overanhydrous Na₂SO₄, and then filtered. The filtrate was concentrated underreduced pressure, triturated with hexane, and filtered to give a firstbatch of the title compound (4.36 g). The filtrate was concentrated,triturated with hexane, and filtered to give a second batch (0.36 g) ofthe title compound (total 4.72 g, 63%). ¹H NMR (500 MHz, DMSO-d₆) δ ppm2.30 (s, 3H), 7.00-7.02 (m, 1H), 7.25-7.28 (m, 2H), 7.33-7.35 (m, 2H),10.13 (s, 1H), 1H not detected. [M+H] calc'd for C₁₂H₁₀Cl₂N₃O₂, 298;found, 298.

C. Methyl 2,4-dichloro-6-(m-tolylamino)pyrimidine-5-carboxylate

To a solution of 2,4-dichloro-6-(m-tolylamino)pyrimidine-5-carboxylicacid (7.67 g, 25.7 mmol) in DMF (80 mL) was added NaHCO₃ (3.30 g, 39.3mmol) and iodomethane (1.605 mL, 25.7 mmol) at 0° C. The mixture wasstirred at RT for 14 h, after which saturated aq NaHCO₃ was added. Themixture was extracted with EtOAc. The organic layers were washed withaqueous NaHOC₃, water, and brine, were dried over anhydrous Na₂SO₄, andthen filtered through SiO₂. The filtrate was concentrated under reducedpressure. The residue was triturated with isopropyl ether and filteredto give a first batch (5.28 g) of the title compound. The filtrate wasconcentrated, triturated with IPE, and filtered to give a second batch(0.66 g) of the title compound as a yellow solid (total 5.94 g, 74%). ¹HNMR (500 MHz, CDCl₃) δ ppm 2.38 (s, 3H), 4.00 (s, 3H), 7.02-7.03 (m,1H), 7.27-7.33 (m, 2H), 7.44-7.46 (m, 1H), 10.30 (br s, 1H). [M+H]calc'd for C₁₃H₁₂Cl₂N₃O₂, 312; found, 312.

Example 92-(4-Ethylpiperazin-1-yl)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one

A. Methyl4-chloro-2-(4-ethylpiperazin-1-yl)-6-(m-tolylamino)pyrimidine-5-carboxylate

A mixture of methyl2,4-dichloro-6-(m-tolylamino)pyrimidine-5-carboxylate (502.6 mg, 1.610mmol), N-ethyldiisopropylamine (0.3 mL, 1.718 mmol) andN-ethylpiperazine (0.21 mL, 1.653 mmol) in THF (8 mL) was stirred at RTfor 12 h. Saturated aq NaHCO₃ was added and the resulting mixture wasextracted with EtOAc. The organic layers were washed with saturated aqNaHCO₃, water, and brine, were dried over anhydrous Na₂SO₄, and thenfiltered through SiO₂. The filtrate was concentrated under reducedpressure and the residue was purified by column chromatography (SiO₂,hexanes/EtOAc=4/1) to give the title compound (152.6 mg, 24%). ¹H NMR(500 MHz, CDCl₃) δ ppm 1.12 (t, J=6.5 Hz, 3H), 2.35 (s, 3H), 2.48 (br s,6H), 3.82-3.97 (m, 7H), 6.92-6.93 (m, 1H), 7.21-7.22 (m, 1H), 7.37-7.42(m, 2H), 10.45 (s, 1H). [M+H] calc'd for C₁₉H₂₅ClN₅O₂, 390; found, 390.

B. Methyl4-cyano-2-(4-ethylpiperazin-1-yl)-6-(m-tolylamino)pyrimidine-5-carboxylate

A mixture of methyl4-chloro-2-(4-ethylpiperazin-1-yl)-6-(m-tolylamino)pyrimidine-5-carboxylate(152.6 mg, 0.391 mmol), tetrakis(triphenylphosphine)palladium (40.8 mg,0.035 mmol) and zinc(II) cyanide (25.2 mg, 0.215 mmol) in DMF (3 mL) wasstirred at 90° C. for 3 h. Water was added and the resulting mixture wasextracted with EtOAc. The organic layers were washed with aq NaHCO₃,water, and brine, were dried over anhydrous Na₂SO₄, and then filteredthrough SiO₂. The filtrate was concentrated under reduced pressure andthe residue was purified by column chromatography (SiO₂hexanes/EtOAc=5/1) to give the title compound as a yellow oil (51.1 mg,34%). ¹H NMR (500 MHz, CDCl₃) δ ppm 1.12 (t, J=7.5 Hz, 3H), 2.35 (s,3H), 2.44-2.49 (m, 6H), 3.81-3.98 (m, 7H), 6.95-6.96 (m, 1H), 7.23-7.26(m, 1H), 7.37-7.47 (m, 2H), 10.46 (s, 1H). [M+H] calc'd for C₂₀H₂₅N₆O₂,381; found, 381.

C.2-(4-Ethylpiperazin-1-yl)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one

A mixture of methyl4-cyano-2-(4-ethylpiperazin-1-yl)-6-(m-tolylamino)pyrimidine-5-carboxylate(49.8 mg, 0.131 mmol) and palladium on carbon (10.1 mg) in EtOH (3 mL)and 1N HCl (3 mL) was stirred at RT for 2 h under a hydrogen atmosphere.The insoluble materials were filtered off, and the filtrate wasconcentrated under reduced pressure. The residue was treated withsaturated aq NaHCO₃ and EtOAc for 3 h. The mixture was extracted withEtOAc. The organic layers were washed with aq NaHCO₃, water, and brine,were dried over anhydrous Na₂SO₄, and then filtered. The filtrate wasconcentrated under reduced pressure and the residue was purified bycolumn chromatography twice (SiO₂, EtOAc then DM1020 EtOAc/MeOH=20/1) togive the title compound as a white solid (19.8 mg, 43%). ¹H NMR (500MHz, CDCl₃) δ ppm 1.19 (br s, 3H), 2.36 (s, 3H), 2.5 (br s, 6H), 4.08(br s, 4H), 4.23 (s, 2H), 5.50 (s, 1H), 6.91-6.92 (m, 1H), 7.22-7.26 (m,1H), 7.49-7.54 (m, 2H), 8.44 (s, 1H). [M+H] calc'd for C₁₉H₂₅N₆O, 353;found, 353.

Example 102-(Cyclohexylamino)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one

A. Methyl 2,4-dicyano-6-(m-tolylamino)pyrimidine-5-carboxylate

A mixture of methyl2,4-dichloro-6-(m-tolylamino)pyrimidine-5-carboxylate (500.5 mg, 1.603mmol), zinc(II) cyanide (100.7 mg, 0.857 mmol) andtetrakis(triphenylphosphine)palladium (187.3 mg, 0.162 mmol) in DMF (5mL) was stirred at 120° C. for 1 h in a microwave oven. After cooling,saturated aq NaHCO₃ was added and the mixture was extracted with EtOAc.The organic layers were washed with aq NaHCO₃, water, and brine, weredried over anhydrous Na₂SO₄, and then filtered through SiO₂. Thefiltrate was concentrated under reduced pressure and the residue waspurified by column chromatography (SiO₂, hexanes/EtOAc=4/1) to afford ayellow solid (182.5 mg), which was washed with IPE to give the titlecompound (117.5 mg). ¹H NMR (500 MHz, CDCl₃) δ ppm 2.41 (s, 3H), 4.12(s, 3H), 7.10-7.12 (m, 1H), 7.31-7.35 (m, 2H), 7.42-7.43 (m, 1H), 10.65(br s, 1H). [M+H] calc'd for C₁₅H₁₂N₅O₂, 294; found, 294.

B. Methyl4-cyano-2-(cyclohexylamino)-6-(m-tolylamino)pyrimidine-5-carboxylate

A mixture of methyl 2,4-dicyano-6-(m-tolylamino)pyrimidine-5-carboxylate(102.3 mg, 0.349 mmol), N,N-diisopropylethylamine (0.075 mL, 0.429 mmol)and cyclohexylamine (0.05 mL, 0.437 mmol) in DMF (2 mL) was stirred atRT for 14 h. Saturated aq NaHCO₃ was added and the mixture was extractedwith EtOAc. The organic layers were washed with aq NaHCO₃, water, andbrine, and were filtered through SiO₂. The filtrate was concentratedunder reduced pressure and the residue was purified by columnchromatography (SiO₂, hexanes/EtOAc=4/1) to give the title compound as ayellow oil (114.7 mg, 90%). ¹H NMR (500 MHz, CDCl₃) δ ppm 1.19-1.45 (m,5H), 1.64-1.67 (m, 1H), 1.73-1.80 (m, 2H), 2.00-2.05 (m, 2H), 2.38 (s,3H), 3.75-3.82 (m, 1H), 3.98 (s, 3H), 5.57-5.58 (br d, J=7.9 Hz, 1H),6.97-6.98 (m, 1H), 7.27-7.29 (m, 1H), 7.46-7.51 (m, 2H), 10.62 (br s,1H). [M+H] calc'd for C₂₀H₂₄N₅O₂, 366; found, 366.

C.2-(Cyclohexylamino)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one

A mixture of methyl4-cyano-2-(cyclohexylamino)-6-(m-tolylamino)pyrimidine-5-carboxylate(112.6 mg, 0.308 mmol) and palladium on carbon (26.4 mg, 0.248 mmol) inMeOH (2 mL) and HCl (1N, 2 mL) was stirred at RT for 4 h under ahydrogen atmosphere. Saturated aq NaHCO₃ was added and the mixture wasstirred for 12 h. The mixture was filtered and the filtrate wasconcentrated under reduced pressure. The residue was extracted withEtOAc. The organic layers were washed with aq NaHCO₃, water, and brine,were dried over anhydrous Na₂SO₄, and then filtered through SiO₂. Thefiltrate was concentrated under reduced pressure and the residue waspurified by column chromatography (SiO₂, EtOAc) to give a white solid(72.2 mg, 69%). The white solid was recrystallized from EtOH gave thetitle compound (35.2 mg). ¹H NMR (500 MHz, DMSO-d₆) δ ppm 1.14-1.17 (m,1H), 1.24-1.34 (m, 4H), 1.62-1.63 (m, 1H), 1.73-1.78 (m, 2H), 1.89-1.97(m, 2H), 2.33 (s, 3H), 3.74-3.83 (m, 1H), 4.12-4.17 (m, 2H), 6.86-6.88(m, 1H), 7.20-7.23 (m, 1H), 7.42-7.52 (m, 2H), 7.76 (s, 1H), 8.00-8.05(m, 1H), 8.53-8.57 (m, 1H). [M+H] calc'd for C₁₉H₂₄N₅O, 338; found, 338.

Example 11cis-2-(2-Hydroxycyclohexylamino)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one

The above compound was prepared in a manner similar to EXAMPLE 10 usingcis-2-aminocyclohexanol in place of cyclohexylamine. ¹H NMR (500 MHz,DMSO-d₆) δ ppm 1.31-1.37 (m, 2H), 1.46-1.78 (m, 6H), 2.32 (s, 3H),3.82-3.96 (m, 2H), 4.13-4.17 (m, 2H), 4.66-4.71 (m, 1H), 6.86-6.92 (m,2H), 7.20-7.23 (m, 1H), 7.46-7.50 (m, 1H), 7.71-7.77 (m, 1H), 8.03-8.08(m, 1H), 8.58-8.59 (m, 1H). [M+H] calc'd for C₁₉H₂₄N₅O₂, 354; found,354.

Example 122-(3-Aminopiperidin-1-yl)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one

The above compound was prepared in a manner similar to EXAMPLE 10 usingtert-butyl piperidin-3-ylcarbamate in place of cyclohexylamine.Following cyclization, tert-butyl1-(5-oxo-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-yl)piperidin-3-ylcarbamate(20.00 mg, 0.046 mmol) was treated with 4M HCl in dioxane (2 mL, 8.00mmol) at RT for 5 h to deprotect the Boc group. The mixture wassubsequently basified with 2N NaOH, extracted with EtOAc, washed withbrine, dried over MgSO₄, and evaporated. The residue was purified byrecrystallization (EtOH-Hexane) to give the title compound as whitesolid (10 mg, 64.8% yield). ¹H NMR (500 MHz, DMSO-d₆) δ ppm 0.99-2.03(m, 4H), 2.30 (s, 3H), 2.57-3.07 (m, 3H), 4.16 (s, 2H), 4.26-4.86 (m,2H), 6.88 (d, J=5.6 Hz, 1H), 7.23 (s, 1H), 7.42-7.55 (m, 1H), 7.59 (s,1H), 8.08 (s, 1H), 8.55 (s, 1H). [M+H] calc'd for C₁₈H₂₂N₆O, 339; found,339.

Preparation 5: Methyl 2,6-dichloro-4-cyanonicotinate

A. Methyl 2,6-dichloro-4-iodonicotinate

A solution of n-butyllithium in hexane (1.6M, 120 mL, 192 mmol) wasadded dropwise to a solution of diisopropylamine (31.2 mL, 219 mmol) inTHF (200 mL) at −78° C. and the mixture was stirred for 30 min. Asolution of 2,6-dichloro-3-iodopyridine (50.0 g, 183 mmol) in THF (100mL) was added dropwise to the reaction mixture at −78° C. and theresulting mixture was stirred at −78° C. for 2 h. After adding dry iceto the reaction mixture, the mixture was warmed to RT and stirredovernight. The resulting mixture was quenched with H₂O and the organicphase was washed with H₂O. The combined aqueous phase was acidified withHCl and extracted with CHCl₃ (3×). The organic phases were combined,washed with brine, dried over MgSO₄, and evaporated. After the residuewas dissolved into DMF (500 mL), K₂CO₃ (39.2 g, 284 mmol) and CH₃I(17.73 mL, 284 mmol) were added. The reaction mixture was stirred at RTfor 3 h. To the resulting mixture was added 1N HCl and Et₂O. The aqueousphase was extracted with Et₂O and the combined organic layers werewashed with H₂O and brine, dried over MgSO₄ and evaporated. The residuewas purified by chromatography on SiO₂ to give the title compound as awhite solid (7.24 g, 11%). ¹H NMR (500 MHz, CDCl₃) δ ppm 3.99 (s, 3H),7.77 (s, 1H). [M+H] calc'd for C₇H₄Cl₁NO₂, 332; found, 332.

B. Methyl 2,6-dichloro-4-cyanonicotinate

A mixture of tetrakis(triphenylphosphine)palladium (34.8 mg, 0.03 mmol),methyl 2,6-dichloro-4-iodonicotinate (100 mg, 0.301 mmol) anddicyanozinc (38.9 mg, 0.331 mmol) in DMF (2 mL) was stirred at 100° C.overnight under N₂ atmosphere. To the resulting mixture were added H₂Oand EtOAc. The aqueous phase was extracted with EtOAc, and the combinedorganic layers were washed with H₂O and brine, dried over MgSO₄ andevaporated. The residue was purified by chromatography on SiO₂ to givethe title compound as a white solid (28 mg, 40%). ¹H NMR (500 MHz,DMSO-d₆) δ ppm 3.99 (s, 3H), 8.44 (s, 1H).

Preparation 6: Methyl 6-chloro-4-cyano-2-(m-tolylamino)nicotinate

A solution of methyl 2,6-dichloro-4-cyanonicotinate (455 mg, 1.97 mmol),triethylamine (0.549 mL, 3.94 mmol) and m-toluidine (0.32 mL, 2.95 mmol)in THF (10 mL) was stirred at RT for 3 days. Water was added to theresulting mixture, and the aqueous phase was extracted with EtOAc. Theorganic phases were combined, washed with H₂O and brine, dried overMgSO₄, and evaporated. The residue was purified by chromatography onSiO₂ to give the title compound as a yellow solid (198 mg, 33.3%). ¹HNMR (500 MHz, CDCl₃) δ ppm 2.40 (s, 3H), 3.99 (s, 3H), 6.92 (s, 1H),7.05-7.14 (m, 4H), 7.33 (t, J=7.81 Hz, 1H).

Preparation 7: tert-Butyl(1S,2R)-2-(3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate

A. Methyl6-((1R,2S)-2-(tert-butoxycarbonylamino)cyclohexylamino)-4-cyano-2-(m-tolylamino)nicotinate

A solution of methyl 6-chloro-4-cyano-2-(m-tolylamino)nicotinate (198mg, 0.656 mmol), tert-butyl (1S,2R)-2-aminocyclohexylcarbamate (562 mg,2.62 mmol) and Et₃N (0.402 mL, 2.89 mmol) was stirred at refluxovernight. To the resulting mixture were added H₂O and EtOAc. Theaqueous phase was extracted with EtOAc. The organic layers werecombined, washed with brine, dried over MgSO₄, and evaporated. Theresidue was triturated with EtOAc. The resulting solid was filtered,rinsed with EtOAc, and dried to give the title compound as a yellowsolid (250 mg, 79%). ¹H NMR (500 MHz, CDCl₃) δ ppm 1.23-1.77 (m, 17H),2.34 (s, 3H), 3.94 (br s, 3H), 3.98 (br s, 1H), 4.80 (s, 1H), 6.15 (s,1H), 6.91 (d, J=5.37 Hz, 1H), 7.21 (t, J=7.81 Hz, 1H), 7.29 (s, 1H),7.47-7.55 (m, 1H), 10.64 (br s, 1H).

B. tert-Butyl(1S,2R)-2-(3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate

Methyl6-((1R,2S)-2-(tert-butoxycarbonylamino)cyclohexylamino)-4-cyano-2-(m-tolylamino)nicotinate(100 mg, 0.209 mmol) was dissolved into DMF (5 mL). To the solution wasadded palladium on carbon (22.19 mg, 0.209 mmol) and the resultingmixture was stirred at 80° C. overnight under H₂ atmosphere. The mixturewas filtered, the filtrate was evaporated, and the residue was dilutedwith H₂O and EtOAc. The aqueous phase was extracted with EtOAc. Theorganic phases were combined, washed with H₂O and brine, dried overMgSO₄, and evaporated. The residue was purified by recrystallization(EtOH-Hexane) to give the title compound as a white solid (70 mg,74.3%). ¹H NMR (500 MHz, CDCl₃) δ ppm 1.03-2.10 (m, 17H), 2.34 (s, 3H),3.81-4.29 (m, 4H), 5.03 (s, 1H), 5.32 (s, 1H), 5.81 (s, 1H), 6.20 (s,1H), 6.81 (s, 1H), 7.18 (s, 1H), 7.49 (s, 1H), 7.64 (s, 1H), 8.77 (s,1H). [M+H] calc'd for C₂₅H₃₃N₅O₃, 452; found, 452.

Example 136-((1R,2S)-2-Aminocyclohexylamino)-4-(m-tolylamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A mixture of tert-butyl(1S,2R)-2-(3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate(50.0 mg, 0.111 mmol) and 4N HCl in dioxane (2 mL, 8.00 mmol) wasstirred at RT for 2 h. The reaction mixture was concentrated underreduced pressure, the residue was purified by reverse phase preparativeHPLC. The fractions were collected, concentrated, diluted with EtOAc,and basified with saturated aq NaHCO₃ solution. The organic extract wasdried and evaporated to give the title compound as a white solid (10 mg,25.7%). ¹H NMR (500 MHz, CDCl₃) δ ppm 1.19-1.77 (m, 8H), 2.29 (s, 3H),3.20 (br s, 1H), 3.99 (br s, 1H), 4.19 (s, 2H), 6.06 (s, 1H), 6.75 (d,J=7.32 Hz, 2H), 7.14 (t, J=7.81 Hz, 1H), 7.48 (d, J=7.32 Hz, 1H), 7.60(s, 1H), 7.90 (s, 1H), 8.87 (s, 1H). [M+H] calc'd for C₂₀H₂₅N₅O, 352;found, 352.

Example 142-((1R,2S)-2-Aminocyclohexylamino)-4-(1-methyl-1H-pyrazol-4-yl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one

A. Methyl2-chloro-4-methyl-6-(1-methyl-1H-pyrazol-4-yl)pyrimidine-5-carboxylate

A mixture of methyl 2,4-dichloro-6-methylpyrimidine-5-carboxylate (0.79g, 3.57 mmol),1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole(0.595 g, 2.86 mmol) and bis(triphenylphosphine)palladium chloride(0.050 g, 0.071 mmol) in dioxane (5 mL) was stirred at RT for 10 min,after which potassium fluoride (1.038 g, 17.87 mmol) was added. Themixture was stirred under a nitrogen atmosphere and heated at 90° C. for12 h. The reaction mixture was filtered through a bed of Celite 545,rinsed with DCM and a small amount of MeOH. Following solvent removal,the residue was dispersed in DMSO/MeOH (1/1) and purified via reversephase preparative HPLC to give the title compound (237 mg, 25%). [M+H]calc'd for C₁₁H₁₁ClN₄O₂, 267; found, 267.

B. Methyl2-((1R,2S)-2-(tert-butoxycarbonylamino)cyclohexylamino)-4-methyl-6-(1-methyl-1H-pyrazol-4-yl)pyrimidine-5-carboxylate

To a mixture of methyl2-chloro-4-methyl-6-(1-methyl-1H-pyrazol-4-yl)pyrimidine-5-carboxylate(0.227 g, 0.851 mmol) and tert-butyl (1S,2R)-2-aminocyclohexylcarbamate(0.182 g, 0.851 mmol) in DMA (3 mL) was added Et₃N (0.356 mL, 2.55mmol). The reaction mixture was heated at 90° C. for 4 h. The reactionmixture was cooled to RT and poured onto ice. The solid was filtered anddried under high vacuum to yield the title compound as an off-white foam(170 mg). [M+H] calc'd for C₂₂H₃₂N₆O₄, 445; found, 445.

C. Methyl2-((1R,2S)-2-(tert-butoxycarbonylamino)cyclohexylamino)-4-formyl-6-(1-methyl-1H-pyrazol-4-yl)pyrimidine-5-carboxylate

To a 25 mL round bottom flask was added methyl2-((1R,2S)-2-(tert-butoxycarbonylamino)cyclohexylamino)-4-methyl-6-(1-methyl-1H-pyrazol-4-yl)pyrimidine-5-carboxylate(0.17 g, 0.382 mmol), selenium dioxide (0.085 g, 0.765 mmol) anddioxane. The reaction mixture was heated at 100° C. overnight, cooled toRT, and filtered through a bed of Celite 545, which was rinsed withMeOH. The solvent was removed to give the title compound asyellowish-brown foam, which was used in the next step without furtherpurification (245 mg).

D. tert-Butyl(1S,2R)-2-(6-(2,4-dimethoxybenzyl)-4-(1-methyl-1H-pyrazol-4-yl)-5-oxo-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-ylamino)cyclohexylcarbamate

Methyl2-((1R,2S)-2-(tert-butoxycarbonylamino)cyclohexylamino)-4-formyl-6-(1-methyl-1H-pyrazol-4-yl)pyrimidine-5-carboxylate(0.175 g, 0.382 mmol) was dissolved in DCM (2 mL) and MeOH (1 mL). Tothis mixture was added (2,4-dimethoxyphenyl)methanamine (0.057 mL, 0.382mmol) and sodium acetate (0.094 g, 1.145 mmol). The mixture was stirredin a capped 20 mL vial for 1 h, after which sodium cyanoborohydride(0.060 g, 0.954 mmol) was added. The reaction mixture was stirred at RTovernight. After the solvent was removed under reduced pressure, theresidue was dissolved in DMSO/MeOH (1/1) solution. An off-white solidprecipitate was initially formed, which was isolated by vacuumfiltration, rinsed with MeOH, and air dried to give a first batch of thetitle compound (6.7 mg). The mother liquor was purified via preparativeHPLC. The fractions were concentrated under reduced pressure until anoff-white solid precipitate was formed, which was collected by vacuumfiltration and air dried to give a second batch (46 mg) of the titlecompound (total 62.5 mg, 28%). [M+H] calc'd for C₃₀H₃₉N₇O₅, 578; found,578.

E.2-((1R,2S)-2-Aminocyclohexylamino)-4-(1-methyl-1H-pyrazol-4-yl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one

tert-Butyl(1S,2R)-2-(6-(2,4-dimethoxybenzyl)-4-(1-methyl-1H-pyrazol-4-yl)-5-oxo-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-ylamino)cyclohexylcarbamate(0.0625 g, 0.108 mmol) was dissolved in TFA (2 mL) and heated at 70° C.for 1 h. The solvent was removed under reduced pressure and theresulting residue was dispersed in DMSO/MeOH (1/1) solution. A palepurple precipitate was formed and was separated by filtration. Thefiltrate, which contained the product, was purified via reverse phasepreparative HPLC. Lyophilized fractions gave a TFA salt of the titlecompound as a white solid (21 mg, 59%). ¹H NMR (500 MHz, DMSO-d₆) δ ppm1.28-1.52 (m, 2H) 1.51-1.94 (m, 6H) 3.93 (s, 3H) 4.14-4.30 (m, 2H)4.29-4.58 (m, 1H) 7.51 (d, J=6.83 Hz, 1H) 7.71 (br s, 2H) 8.29 (s, 1H)8.34-8.69 (m, 1H) 9.11 (d, J=17.09 Hz, 1H). [M+H] calc'd for C₁₆H₂₁N₇O,328; found, 328.

Example 152-((1R,2S)-2-Aminocyclohexylamino)-4-(1-isobutyl-1H-pyrazol-4-yl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one

A TFA salt of the title compound was prepared in a manner similar toEXAMPLE 14 using1-isobutyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazolein place of1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole. ¹HNMR (500 MHz, CD₃OD) δ ppm 0.92 (d, J=1.00 Hz, 6H), 0.87-1.00 (m, 6H),1.45-1.70 (m, 2H), 1.46-1.70 (m, 2H), 1.70-2.00 (m, 6H), 2.22 (spt,J=13.70 Hz, 1H), 3.64 (br s, 1H), 4.02 (d, J=6.83 Hz, 2H), 4.30 (s, 2H),4.63 (d, J=3.91 Hz, 1H), 8.54 (s, 1H), 9.12 (br s, 1H). [M+H] calc'd forC₁₉H₂₇N₇O, 370; found, 370.

Example 162-((1R,2S)-2-Aminocyclohexylamino)-4-phenyl-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one

The title compound was prepared in a manner similar to EXAMPLE 14 usingphenylboronic acid in place of1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole.The final product was purified via reverse phase preparative HPLC. Thefractions were collected, concentrated, neutralized with saturated aqNaHCO₃, and extracted into EtOAc. The organic phase was dried overanhydrous Na₂SO₄ and the solvent removed in vacuo to give the titlecompound as an off-white film. ¹H NMR (400 MHz, CD₃OD) δ ppm 1.40-1.95(m, 8H), 3.27 (br s, 1H), 4.18-4.54 (m, 3H), 7.35-7.59 (m, 3H), 8.12 (brs, 2H). [M+H] calc'd for C₁₈H₂₁N₅O, 324; found, 324.

Example 172-((1R,2S)-2-Aminocyclohexylamino)-4-(benzo[b]thiophen-3-yl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one

A TFA salt of the title compound was prepared in a manner similar toEXAMPLE 14 using benzo[b]thiophen-3-ylboronic acid in place of1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole. ¹HNMR (400 MHz, CD₃OD) δ ppm 1.44-2.02 (m, 8H), 3.53-3.84 (m, 1H),4.25-4.43 (m, 2H), 4.54-4.72 (m, 1H), 7.32-7.55 (m, 2H), 7.84-8.03 (m,1H), 8.40-8.88 (m, 1H), 8.86-9.10 (m, 1H). [M+H] calc'd for C₂₀H₂₁N₅OS,380; found, 380.

Example 182-((1R,2S)-2-Aminocyclohexylamino)-4-(1-ethyl-1H-pyrazol-4-yl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one

A TFA salt of the title compound was prepared in a manner similar toEXAMPLE 14 using1-ethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole inplace of1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole. ¹HNMR (400 MHz, CD₃OD) δ ppm 1.47-1.55 (m, 3H), 1.54-1.99 (m, 8H), 3.64(br s, 1H), 4.26 (q, J=7.32 Hz, 2H), 4.30 (s, 2H), 4.63 (br s, 1H), 8.54(br s, 1H), 9.14 (s, 1H). [M+H] calc'd for C₁₇H₂₃N₇O, 342; found, 342.

Example 192-((1R,2S)-2-Aminocyclohexylamino)-4-(1-benzyl-1H-pyrazol-4-yl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one

A TFA salt of the title compound was prepared in a manner similar toEXAMPLE 14 using1-benzyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole inplace of1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole. ¹HNMR (400 MHz, CD₃OD) δ ppm 1.45-1.69 (m, 2H), 1.69-2.00 (m, 6H), 3.63(br s, 1H), 4.29 (s, 2H), 4.61 (br s, 1H), 5.40 (s, 2H), 7.22-7.41 (m,5H), 8.58 (s, 1H), 9.16 (br s, 1H). [M+H] calc'd for C₂₂H₂₅N₇O, 404;found, 404.

Example 202-((1R,2S)-2-Aminocyclohexylamino)-4-(imidazo[1,2-a]pyridin-3-yl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one

A TFA salt of the title compound was prepared in a manner similar toEXAMPLE 14 using imidazo[1,2-a]pyridin-3-ylboronic acid in place of1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole. ¹HNMR (500 MHz, CD₃OD) δ ppm 1.47-1.73 (m, 2H), 1.74-2.03 (m, 6H), 3.68(br s, 1H), 4.27-4.54 (m, 2H), 4.58-4.75 (m, 1H), 7.52-7.79 (m, 1H),8.00-8.12 (m, 1H), 8.14 (t, J=7.57 Hz, 1H), 10.23 (br s, 1H), 10.81 (d,J=5.86 Hz, 1H). [M+H] calc'd for C₁₉H₂₁N₇O, 364; found, 364.

Example 212-((1R,2S)-2-Aminocyclohexylamino)-4-(1-propyl-1H-pyrazol-4-yl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one

A TFA salt of the title compound was prepared in a manner similar toEXAMPLE 14 using1-propyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole inplace of1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole. ¹HNMR (500 MHz, CD₃OD) δ ppm 0.92 (t, J=1.00 Hz, 3H), 1.43-1.70 (m, 2H),1.69-2.14 (m, 8H), 3.62 (br s, 1H), 4.18 (t, J=6.83 Hz, 2H), 4.24-4.41(m, 2H), 4.63 (br s, 1H), 8.56 (br s, 1H), 9.13 (br s, 1H). [M+H] calc'dfor C₁₈H₂₅N₇O, 356; found, 356.

Example 222-((1R,2S)-2-Aminocyclohexylamino)-4-(1-(2-methoxyethyl)-1H-pyrazol-4-yl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one

A TFA salt of the title compound was prepared in a manner similar toEXAMPLE 14 using1-(2-methoxyethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazolein place of1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole. ¹HNMR (500 MHz, CD₃OD) δ ppm 1.45-1.70 (m, 2H), 1.70-2.05 (m, 6H),3.33-3.35 (m, 3H), 3.63 (br s, 1H), 3.73-3.90 (m, 2H), 4.30 (s, 2H),4.33-4.47 (m, 2H), 4.63 (br s, 1H), 8.58 (br s, 1H), 9.13 (br s, 1H).[M+H] calc'd for C₁₈H₂₅N₇O₂, 372; found, 372.

Example 234-(1H-Indazol-6-ylamino)-6-((1R,2S)-2-aminocyclohexylamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A. Methyl 2-(1H-indazol-6-ylamino)-6-chloro-4-cyanonicotinate

A mixture of methyl 2,6-dichloro-4-cyanonicotinate (250 mg, 1.082 mmol),1H-indazol-6-amine (173 mg, 1.299 mmol) and Et₃N (0.226 mL, 1.623 mmol)in THF (10 mL) was stirred at 80° C. overnight. Water and EtOAc wereadded to the mixture. The organic phase was washed with H₂O and brine,dried over MgSO₄, and evaporated. The residue was purified bychromatography on SiO₂(Hexane/EtOAc=5/1) to give the title compound as ayellow solid (120 mg, 38.5%).

B. Methyl2-(1H-indazol-6-ylamino)-6-((1R,2S)-2-(tert-butoxycarbonylamino)cyclohexylamino)-4-cyanonicotinate

A solution of methyl 2-(1H-indazol-6-ylamino)-6-chloro-4-cyanonicotinate(115 mg, 0.351 mmol), tert-butyl (1S,2R)-2-aminocyclohexylcarbamate (90mg, 0.421 mmol) and Et₃N (0.073 mL, 0.526 mmol) in THF (1 mL) wasstirred at reflux overnight. Water and EtOAc were added to the mixture.The aqueous phase was extracted with EtOAc. The organic phases werecombined, washed with H₂O and brine, dried over MgSO₄, and evaporated.The residue was rinsed with EtOAc to give the title compound as yellowsolid (110 mg, 62.0%). ¹H NMR (500 MHz, CDCl₃) δ ppm 1.00-1.86 (m, 17H),3.84 (s, 3H), 3.91 (br s, 1H), 4.12 (br s, 1H), 6.51 (s, 1H), 6.63 (d,J=8.79 Hz, 1H), 7.13 (d, J=8.30 Hz, 1H), 7.97 (s, 1H), 8.03 (br s, 1H),10.71 (br s, 1H), 12.87 (br s, 1H).

C. Methyl2-(1H-indazol-6-ylamino)-6-((1R,2S)-2-aminocyclohexylamino)-4-cyanonicotinate

A solution of methyl2-(1H-indazol-6-ylamino)-6-((1R,2S)-2-(tert-butoxycarbonylamino)cyclohexylamino)-4-cyanonicotinate(110 mg, 0.218 mmol) and TFA (2 mL, 26.9 mmol) in DCM (1 mL) was stirredat room temperature for 3 h. Following reaction, the mixture wasconcentrated in vacuo to give the title compound, which was used in thenext step without further purification.

D.4-(1H-Indazol-6-ylamino)-6-((1R,2S)-2-aminocyclohexylamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

To a solution of methyl2-(1H-indazol-6-ylamino)-6-((1R,2S)-2-aminocyclohexylamino)-4-cyanonicotinate(88 mg, 218 mmol) in MeOH (2 mL) was added palladium on carbon, and theresulting mixture was stirred at room temperature overnight under H₂atmosphere. The mixture was subsequently filtered to remove the catalystand the filtrate was evaporated. The residue was diluted with saturatedaq NaHCO₃ and MeOH, and the mixture was stirred at RT for 30 min. Theresulting suspension was filtered and the precipitate was washed withEtOAc and dried to give the title compound as a white solid (15 mg,18.2%). ¹H NMR (500 MHz, DMSO-d₆) δ ppm 1.22-1.74 (m, 8H), 3.13 (br s,1H), 3.94-4.07 (m, 1H), 4.21 (s, 2H), 6.02-6.14 (m, 1H), 6.70 (br s,1H), 7.13 (d, J=8.30 Hz, 1H), 7.63 (d, J=8.30 Hz, 1H), 7.94 (d, J=2.93Hz, 2H), 8.23 (s, 1H), 9.08 (s, 1H), 12.84 (br s, 1H). [M+H] calc'd forC₂₀H₂₃N₇O, 378; found, 378.

Example 246-((1R,2S)-2-Aminocyclohexylamino)-4-(4-fluoro-3-methylphenylamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A. Methyl 6-chloro-4-cyano-2-(4-fluoro-3-ethylphenylamino)nicotinate

A solution of methyl 2,6-dichloro-4-cyanonicotinate (500 mg, 2.164mmol), 4-fluoro-3-methylaniline (325 mg, 2.60 mmol) and Et₃N (0.452 mL,3.25 mmol) in ACN (5 mL) was stirred at 50° C. for 24 h. Water and EtOAcwere added to the mixture and the aqueous phase was extracted withEtOAc. The organic phases were combined, washed with H₂O and brine,dried over MgSO₄, and evaporated. The residue was purified bychromatography on SiO₂ to give the title compound, which contains somestarting material and was used without further purification (390 mg).[M+H] calc'd for C₁₅H₁₁ClFN₃O₂, 320; found, 320.

B. Methyl6-((1R,2S)-2-(tert-butoxycarbonylamino)cyclohexylamino)-4-cyano-2-(4-fluoro-3-methylphenylamino)nicotinate

A mixture of methyl6-chloro-4-cyano-2-(4-fluoro-3-methylphenylamino)nicotinate (390 mg,1.220 mmol), Et₃N (0.204 mL, 1.464 mmol) and tert-butyl(1S,2R)-2-aminocyclohexylcarbamate (392 mg, 1.830 mmol) in THF (5 mL)was stirred at 80° C. overnight. Water and EtOAc were subsequently addedto the mixture and the aqueous phase was extracted with EtOAc. Theorganic phases were combined, washed with H₂O and brine, dried overMgSO₄, and evaporated. The residue was diluted with EtOAc and filteredto give the title compound as a yellow solid (75 mg, 12.36%). ¹H NMR(500 MHz, DMSO-d₆) δ ppm 1.03-1.71 (m, 17H), 2.22 (d, J=0.98 Hz, 3H),3.80-3.82 (m, 3H), 3.83 (br s, 1H), 4.01-4.09 (m, 1H), 6.48 (s, 1H),6.62 (d, J=7.81 Hz, 1H), 7.06 (t, J=9.03, 1H), 7.39 (d, J=4.39 Hz, 1H),7.50-7.68 (m, 1H), 10.41 (br s, 1H).

C. tert-Butyl(1S,2R)-2-(4-(4-fluoro-3-methylphenylamino)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate

A mixture of methyl6-((1R,2S)-2-(tert-butoxycarbonylamino)cyclohexylamino)-4-cyano-2-(4-fluoro-3-methylphenylamino)nicotinate(75 mg, 0.151 mmol) and platinum oxide (34.2 mg, 0.151 mmol) in DCM (2mL) and HOAc (0.5 mL) was stirred at RT under H₂ atmosphere. The mixturewas subsequently filtered through Celite. The filtrate was concentratedand the residue was purified by preparative HPLC to give the titlecompound (50 mg, 70.6%). [M+H] calc'd for C₂₅H₃₂FN₅O₃, 470; found, 470.

D.6-((1R,2S)-2-Aminocyclohexylamino)-4-(4-fluoro-3-methylphenylamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A solution of tert-butyl(1S,2R)-2-(4-(4-fluoro-3-methylphenylamino)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate(50.0 mg, 0.106 mmol) and TFA (1 mL, 12.98 mmol) in DCM (0.5 mL) wasstirred at RT for 1 hr. The resulting mixture was concentrated and theresidue was purified by preparative HPLC to give the title compound as awhite solid (1 mg, 2.54%). ¹H NMR (500 MHz, CD₃OD) δ ppm 1.14-1.95 (m,8H), 2.28 (s, 3H), 3.73 (br s, 1H), 4.30 (s, 2H), 4.38 (s, 1H), 6.17 (s,1H), 7.00 (t, J=9.03 Hz, 1H), 7.41-7.54 (m, 2H).

Example 256-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-4-(m-tolylamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A. tert-Butyl(1S,2R)-2-(7-fluoro-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate

A solution of tert-butyl(1S,2R)-2-(3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate(94 mg, 0.208 mmol) and SELECTFLUOR® (73.7 mg, 0.208 mmol) was stirredat 0° C. for 5 h and at RT for 1 h. The mixture was filtered and thefiltrate was purified by preparative HPLC. The fractions were collectedand concentrated. The residue was washed with saturated aq NaHCO₃solution, extracted with EtOAc, washed with brine, dried over MgSO₄, andevaporated to give the title compound as yellow solid (45 mg, 46.0%).[M+H] calc'd for C₂₅H₃₂FN₅O₃, 470; found, 470.

B.6-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-4-(m-tolylamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A solution of tert-butyl(1S,2R)-2-(7-fluoro-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate(40.0 mg, 0.085 mmol) and TFA (2 mL, 26.0 mmol) in DCM (1 mL) wasstirred at RT for 1 h. The mixture was concentrated and the resultingresidue was purified by preparative HPLC to give the title compound as awhite solid (20 mg, 63.5%). ¹H NMR (500 MHz, DMSO-d₆) δ ppm 1.36-1.97(m, 8H), 2.30 (s, 3H), 3.70 (br s, 1H), 4.27 (br s, 1H), 4.33-4.46 (m,2H), 6.73 (d, J=6.35 Hz, 1H), 6.79 (d, J=7.32 Hz, 1H), 7.17 (t, J=7.57Hz, 1H), 7.43 (d, J=7.81 Hz, 1H), 7.46 (s, 1H), 7.76 (br s, 2H), 8.29(s, 1H), 8.79 (s, 1H). [M+H] calc'd for C₂₀H₂₄FN₅O, 370; found, 370.

Preparation 8: Methyl 2-chloro-4-cyanonicotinate

A. Methyl 2-chloro-4-iodonicotinate

Butyllithium in hexane solution (1.6 M, 13.70 mL, 21.93 mmol) was addeddrop wise to a solution of diisopropylamine (3.57 mL, 25.06 mmol) in THF(100 mL) at −78° C. and the mixture was stirred for 30 min. A solutionof 2-chloro-3-iodopyridine (5.00 g, 20.88 mmol) in THF (50 mL) was addeddrop wise to the reaction mixture at −78° C. and the resulting mixturewas stirred at −78° C. for 2 h. Dry ice was added to the reactionmixture, which was warmed to room temperature and stirred overnight. Theresulting mixture was quenched with H₂O and the organic phase was washedwith H₂O. The combined aqueous phase was acidified with concentrated HCland extracted with EtOAc. The organic phases were combined, washed withbrine, dried over MgSO₄, and evaporated to yield crude2-chloro-4-iodonicotinic acid, which was combined with potassiumcarbonate (5.77 g, 41.8 mmol) and iodomethane (1.567 mL, 25.06 mmol) inDMF (70 mL). The mixture was stirred at room temperature for 1 h, whichwas followed by the addition of Et₂O and H₂O. The organic phase waswashed with H₂O and brine, dried over MgSO₄, and evaporated. The residuewas purified by chromatography on SiO₂ to give the title compound as awhite solid (3.23 g, 52.0%). ¹H NMR (500 MHz, CDCl₃) δ ppm 4.01 (s, 3H),7.68-7.76 (m, 1H), 7.97-8.11 (m, 1H). [M+H] calc'd for C₇H₅ClINO₂, 298;found, 298.

B. Methyl 2-chloro-4-cyanonicotinate

A solution of methyl 2-chloro-4-iodonicotinate (3.20 g, 10.76 mmol) andcyanocopper (0.963 g, 10.76 mmol) in DMA (40 mL) was stirred at 140° C.overnight. Following reaction, the mixture was filtered through Celiteand the filtrate was diluted with H₂O and EtOAc. The aqueous phase wasextracted with EtOAc. The organic phases were combined, washed with H₂Oand brine, dried over MgSO₄, and evaporated. The residue was purified bychromatography on SiO₂ (Hexane/EtOAc=10/1) to give the title compound asa white solid (730 mg, 34.5%). ¹H NMR (500 MHz, CDCl₃) δ ppm 4.07 (s,3H), 7.57 (d, J=5.37 Hz, 1H), 8.66 (d, J=4.88 Hz, 1H).

Preparation 9: Methyl6-chloro-4-cyano-2-(1-methyl-1H-pyrazol-4-yl)nicotinate

A. Methyl 4-cyano-2-(1-methyl-1H-pyrazol-4-yl)nicotinate

A mixture of methyl 2-chloro-4-cyanonicotinate (730 mg, 3.71 mmol),1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole(927 mg, 4.46 mmol), trans-dichlorobis(triphenylphosphine)palladium (261mg, 0.371 mmol) and potassium fluoride (2697 mg, 14.85 mmol) in DME (15mL) was stirred at 120° C. for 1 h under microwave irradiation. Themixture was filtered through Celite, and the filtrate was diluted withH₂O and EtOAc. The organic phase was washed with H₂O and brine, driedover MgSO₄, and evaporated. The residue was purified by chromatographyon SiO₂ to give the title compound as a pale yellow solid (470 mg,52.3%). ¹H NMR (500 MHz, CDCl₃) δ ppm 3.97 (s, 3H), 4.03 (s, 3H), 7.41(d, J=4.88 Hz, 1H), 7.82 (s, 1H), 7.91 (s, 1H), 8.79 (d, J=4.88 Hz, 1H).[M+H] calc'd for C₁₂H₁₀N₄O₂, 243; found, 243.

B. Methyl 6-chloro-4-cyano-2-(1-methyl-1H-pyrazol-4-yl)nicotinate

To a mixture of methyl 4-cyano-2-(1-methyl-1H-pyrazol-4-yl)nicotinate(470 mg, 1.940 mmol) in DCM (10 mL) was added urea-hydrogen peroxidecompound (1/1, 913 mg, 9.70 mmol), and 2,2,2-trifluoroacetic anhydride(1.370 mL, 9.70 mmol) at 0° C. The mixture was stirred at roomtemperature for 4 h. More urea-hydrogen peroxide compound (1/1, 400 mg)was added and the mixture was stirred at RT for an additional 3 h afterwhich was added saturated aq NaHCO₃ solution and CHCl₃. The aqueousphase was extracted with CHCl₃ (3×), and the combined organic layerswere washed with brine, dried over MgSO₄, and evaporated to obtain crude4-cyano-3-(methoxycarbonyl)-2-(1-methyl-1H-pyrazol-4-yl)pyridine1-oxide, which was combined with phosphorus oxychloride (2 mL, 21.46mmol). The resulting mixture was stirred at 80° C. for 5 h and thenconcentrated to a residue, which was neutralized with 2N NaOH. Theorganic phase was washed with brine, dried over MgSO₄, and evaporated.The residue was purified by chromatography on SiO₂(Hexane/EtOAc=1/1) togive the title compound as a white solid (155 mg, 41.3%). ¹H NMR (500MHz, CDCl₃) δ ppm 3.96 (s, 3H), 4.03 (s, 3H), 7.41 (s, 1H), 7.81 (s,1H), 7.94 (s, 1H). [M+H] calc'd for C₁₂H₉ClN₄O₂, 277; found, 277.

Preparation 10: tert-Butyl(1S,2R)-2-(4-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate

A. Methyl6-((1R,2S)-2-(tert-butoxycarbonylamino)cyclohexylamino)-4-cyano-2-(1-methyl-1H-pyrazol-4-yl)nicotinate

A mixture of methyl6-chloro-4-cyano-2-(1-methyl-1H-pyrazol-4-yl)nicotinate (155 mg, 0.560mmol) and tert-butyl (1S,2R)-2-aminocyclohexylcarbamate (144 mg, 0.672mmol) in DMA (2 mL) was stirred at 150° C. for 1 h under microwaveirradiation. To the resulting mixture were added H₂O and EtOAc. Theorganic phase was washed with H₂O (3×) and brine, dried over MgSO₄, andevaporated. The residue was purified by chromatography on SiO₂ to givethe title compound as a yellow oil (100 mg, 39.3%). ¹H NMR (500 MHz,CDCl₃) δ ppm 1.34-1.95 (m, 17H), 3.92 (s, 3H), 3.93 (s, 3H), 4.87 (br s,1H), 5.66 (br s, 1H), 6.52 (s, 1H), 7.78-7.83 (m, 2H). [M+H] calc'd forC₂₃H₃₀N₆O₄, 455; found, 455.

B. tert-Butyl(1S,2R)-2-(4-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate

A solution of methyl6-((1R,2S)-2-(tert-butoxycarbonylamino)cyclohexylamino)-4-cyano-2-(1-methyl-1H-pyrazol-4-yl)nicotinate(110 mg, 0.242 mmol) and palladium on carbon (2.58 mg, 0.024 mmol) inMeOH (5 mL) and HOAc (1 mL) was stirred at RT overnight under H₂atmosphere. After reaction, the mixture was filtered through Celite, thefiltrate was evaporated, and the residue was diluted with MeOH and sataq NaHCO₃. The mixture was stirred at RT for 30 min and extracted withEtOAc. The organic phase was washed with brine, dried over MgSO₄, andevaporated. The residue was purified by chromatography on SiO₂ andpreparative HPLC to give the title compound (60 mg, 58.1%). ¹H NMR (500MHz, CDCl₃) δ ppm 1.26-1.87 (m, 17H), 3.91 (s, 3H), 4.25 (br s, 2H),5.16-5.49 (m 2H), 6.23 (br s, 1H), 6.75 (br s, 1H), 8.18-8.44 (m, 1H),8.76-9.05 (m, 1H).

Example 266-((1R,2S)-2-Aminocyclohexylamino)-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A mixture of tert-butyl(1S,2R)-2-(4-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate(94 mg, 0.22 mmol) and TFA (1 mL, 12.98 mmol) in DCM (1 mL) was stirredat RT for 2 h. The mixture was subsequently concentrated. The residuewas purified by preparative HPLC (01-25; 5.45 min) and basified to givethe title compound as a yellow solid (10 mg, 14%). ¹H NMR (500 MHz,DMSO-d₆) δ ppm 122-1.61 (m, 8H), 3.63 (s, 3H), 4.19 (s, 2H), 6.46 (br s,1H), 7.98 (s, 1H), 8.29 (s, 1H), 8.85 (s, 1H). [M+H] calc'd forC₁₇H₂₂N₆O, 327; found, 327.

Preparation 11: (3R,4R)-Tetrahydro-2H-pyran-3,4-diamine

A. (3R,4S)-Tetrahydro-2H-pyran-3,4-diyl diacetate

A mixture of (3R,4S)-3,4-dihydro-2H-pyran-3,4-diyl diacetate (8 g, 40mmol) and Pd/C (10%, 5.0 g) in MeOH was stirred at RT for 12 h under H₂atmosphere (50 psi). After filtration, the residue was concentrated togive the title compound, which was used without further purification(7.5 g). ¹H NMR (400 MHz, CDCl₃) δ ppm 2.06 (s, 6H), 3.95-4.03 (m, 2H),4.84 (t, J=4.0 Hz, 1H), 5.15-5.20 (m, 1H), 5.43 (t, J=4.0 Hz, 1H), 6.49(d, J=4.0 Hz, 1H).

B. (3R,4S)-Tetrahydro-2H-pyran-3,4-diol

(3R,4S)-Tetrahydro-2H-pyran-3,4-diyl diacetate (7.5 g, 0.4 mmol) andsodium methylate (8.64 g, 0.16 mol) in MeOH was stirred overnight at RT.The reaction mixture was subsequently quenched with 6 N HCl in an icebath. The mixture was concentrated to dryness. The residue was treatedwith EtOAc (500 mL) and vigorously stirred at 45° C. for 30 min. Afterfiltration, the filtrate was concentrated to give the title compound,which was used without further purification (4.4 g). ¹H NMR (400 MHz,CDCl₃) δ ppm 1.79-1.84 (m, 1H), 2.00 (s, 6H), 3.56-3.67 (m, 2H),3.88-3.97 (m, 2H), 5.09-5.14 (m, 2H).

C. (3R,4R)-3,4-Diazidotetrahydro-2H-pyran

(3R,4S)-Tetrahydro-2H-pyran-3,4-diol (5.0 g, 42.4 mmol) was dissolved inDCM (50 mL). To the mixture was added pyridine (2.5 eq), and in an icebath, trifluoromethane-sulfonic anhydride (21.5 g, 94.3 mmol). Thereaction was complete in 15 min. To the mixture was added DMF (50 mL)and hexamethylphosphoramide (1 mL), followed by sodium azide (25.0 g,385.0 mmol). The reaction mixture was stirred at 50° C. for 3 h. DCM wasremoved under reduced pressure. Water was added and the mixture wasextracted with EtOAc (3×30 mL). The organic layer was washed with water,dried over Na₂SO₄, and concentrated to give the title compound, whichwas used without further purification (1.88 g). ¹H NMR (400 MHz, CDCl₃)δ ppm 1.85-1.90 (m, 1H), 2.05-2.09 (m, 1H), 3.54-3.60 (m, 1H), 3.65-3.72(m, 1H), 3.81-3.89 (m, 1H), 3.91-3.95 (m, 1H).

D. (3R,4R)-Tetrahydro-2H-pyran-3,4-diamine

A mixture of (3R,4R)-3,4-diazidotetrahydro-2H-pyran (1.0 g, 5.9 mmol),di-tert-butyl pyrocarbonate (2.8 g, 12.9 mmol) and Pd/C (10%, 1.0 g) inMeOH was stirred at RT for 12 h under H₂ atmosphere (50 psi). Afterfiltration, the residue was concentrated and purified by columnchromatography eluting with EtOAc and petroleum ether (EtOAc/PE=1/3) togive the intermediate di-tert-butylN,N-((3R,4R)-tetrahydro-2H-pyran-3,4-diyl)-biscarbamate (1.2 g). Theintermediate was dissolved in 1 M HCl-EtOAc and stirred at RT overnightto give the title compound (400 mg, 58%). ¹H NMR (400 MHz, CDCl₃) δ ppm1.93-1.97 (m, 1H), 2.12-2.22 (m, 1H), 3.60-3.66 (m, 1H), 3.76-3.79 (m,2H), 3.86-3.92 (m, 1H), 4.04-4.15 (m, 1H). [M+H] calc'd for C₅H₁₂N₂O,117; found, 117.

Example 276-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A TFA salt of the title compound was prepared in a manner similar toEXAMPLE 26 using (3R,4R)-tetrahydro-2H-pyran-3,4-diamine in place oftert-butyl (1S,2R)-2-aminocyclohexylcarbamate. The desired stereoisomerwas isolated using preparative HPLC. ¹H NMR (500 MHz, DMSO-d₆) δ ppm3.52 (m, 2H), 3.78-4.01 (m & s, 10H), 4.21-4.42 (m & s, 3H), 6.50 (s,1H), 7.91 (br s, 2H), 8.29-8.39 (m, 1H), 8.88-8.96 (m, 1H). [M+H] calc'dfor C₁₆H₂₀N₆O₂, 329; found, 329.

Example 286-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A. tert-Butyl(1S,2R)-2-(7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate

A solution of tert-butyl(1S,2R)-2-(4-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate(150 mg, 0.352 mmol) and SELECTFLUOR® (150 mg, 0.422 mmol) in DCM (1 mL)and MeOH (1 mL) was stirred at RT overnight. Water was subsequentlyadded and the mixture was extracted with CHCl₃ (3×). The organic phaseswere combined, washed with brine, dried over MgSO₄, and evaporated. Theresidue was purified by preparative HPLC to give the title compound (15mg, 9.60%). [M+H] calc'd for C₂₂H₂₉FN₆O₃, 445; found, 445.

B.6-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A solution of tert-butyl(1S,2R)-2-(7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate(15 mg, 0.034 mmol) and TFA (0.5 mL, 6.49 mmol) in DCM (0.5 mL) wasstirred at RT for 30 min. The reaction mixture was concentrated and theresulting residue was purified by preparative HPLC to give a TFA salt ofthe title compound (7 mg, 60.2%). ¹H NMR (500 MHz, DMSO-d₆) δ ppm1.37-2.01 (m, 8H), 3.67 (br s, 1H), 3.89 (s, 3H), 4.32-4.43 (m, 2H),4.45 (br s, 1H), 6.77 (d, J=6.35 Hz, 1H), 7.93 (br s, 3H), 8.30 (s, 1H),8.36 (s, 1H), 8.84 (s, 1H). [M+H] calc'd for C₁₇H₂₁FN₆O, 345; found,345.

Example 296-((1R,2S)-2-Aminocyclohexylamino)-7-chloro-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A. tert-Butyl(1S,2R)-2-(7-chloro-4-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate

A solution of tert-butyl(1S,2R)-2-(4-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate(30 mg, 0.070 mmol) and N-chlorosuccinimide (9.86 mg, 0.074 mmol) in DCM(1 mL) was stirred at RT overnight. Additional N-chlorosuccinimide (1eq) was added and the mixture was stirred at RT for 3 h. Water and CHCl₃were added to the mixture and the organic phase was washed with brine,dried over MgSO₄, and evaporated. The residue was purified bypreparative HPLC to give the title compound (20 mg, 61.7%). ¹H NMR (500MHz, CDCl₃) δ ppm 1.18-2.09 (m, 17H), 4.02 (s, 3H), 4.28-4.45 (m, 2H),5.80 (br s, 1H), 8.39 (br s, 1H), 9.03 (br s, 1H). [M+H] calc'd forC₂₂H₂₉ClN₆O₃, 461; found, 461.

B.6-((1R,2S)-2-Aminocyclohexylamino)-7-chloro-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A solution of tert-butyl(1S,2R)-2-(7-chloro-4-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate(10.00 mg, 0.022 mmol) in HCl (0.5 mL, 16.46 mmol) and HOAc (1 mL) wasstirred at RT for 30 min. The reaction mixture was concentrated and theresulting residue was washed with IPE to give the HCl salt of the titlecompound (5 mg, 63.9%). ¹H NMR (500 MHz, DMSO-d₆) δ ppm 1.48-1.97 (m,8H), 3.72-3.78 (m, 1H), 3.96 (br s, 3H), 4.35 (d, J=4.88 Hz, 2H), 4.57(br s, 1H), 6.29 (d, J=6.83 Hz, 1H), 7.93 (br s, 2H), 8.40-8.45 (m, 1H),8.49 (s, 1H), 8.98 (s, 1H). [M+H] calc'd for C₁₇H₂₁ClN₆O, 361; found,361.

Preparation 12:4,6-Dichloro-2-(2,4-dimethoxybenzyl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A. 4,6-Dichloro-7-fluoro-1-hydroxyfuro[3,4-c]pyridin-3(1H)-one

To a butyllithium-hexane solution (100 mL, 160 mmol) in THF (200 mL) wasslowly added diisopropylamine (27.4 mL, 192 mmol) in THF (15 mL) at −78°C. The mixture was stirred at the same temperature for 15 min. Asolution of 2,6-dichloro-5-fluoronicotinic acid (14.98 g, 71.4 mmol) inTHF (15 mL) was added and the mixture was stirred for 2 h. Next, DMF(29.3 mL, 378 mmol) was added and the mixture was stirred for 1 h.Hydrochloric acid (1N, 400 mL) was added and the mixture wassubsequently extracted with EtOAc (2×300 mL). The organic phase wasbasified with saturated aq NaHCO₃ solution and the aqueous phase wasseparated. The aqueous phase was re-acidified with 1N HCl (300 mL) andextracted with EtOAc (2×300 mL). The organic phase was washed with H₂O(200 mL) and brine (200 mL), dried over MgSO₄, and evaporated. Theresidue was washed with Hexane/EtOAc (1/8) to give the title compound asa white solid (11.5 g, 67.7%). ¹H NMR (500 MHz, DMSO-d₆) δ ppm 6.85 (brs, 1H), 8.82 (br s, 1H).

B.4,6-Dichloro-2-(2,4-dimethoxybenzyl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A mixture of 4,6-dichloro-7-fluoro-1-hydroxyfuro[3,4-c]pyridin-3(1H)-one(25.8 g, 108 mmol) and (2,4-dimethoxyphenyl)methanamine (34.2 mL, 228mmol) in MeOH (400 mL) was stirred at RT for 2 h. Sodiumtriacetoxyhydroborate (22.98 g, 108 mmol) was added to the mixture,which was stirred at RT for 2 h. Next, HCl (2N, 120 mL) was added andthe resulting solid (17.3 g) was isolated by filtration. A mixture ofthe solid, N1-((ethylimino)methylene)-N3,N3-dimethylpropane-1,3-diaminehydrochloride (10.35 g, 54 mmol) and 1H-benzo[d][1,2,3]triazol-1-olhydrate (8.27 g, 54 mmol) in DMF (200 mL) was stirred at roomtemperature for 2 h. Next, water was added and the mixture was extractedwith EtOAc (2×300 mL). The organic phases were combined, washed withsaturated aq NaHCO₃ solution (300 mL), H₂O (300 mL), and brine (300 mL),dried over anhydrous Na₂SO₄, and filtered. The filtrate was concentratedunder reduced pressure and the residue was washed with EtOAc to give thetitle compound as a pale yellow solid (6.7 g, 16.7%). [M+H] calc'd forC₁₆H₁₃Cl₂FN₂O₃, 371; found, 371.

Preparation 13: tert-Butyl(1S,2R)-2-(4-chloro-2-(2,4-dimethoxybenzyl)-7-fluoro-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate

A mixture of4,6-dichloro-2-(2,4-dimethoxybenzyl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one(4.8 g, 12.93 mmol) and tert-butyl (1S,2R)-2-aminocyclohexylcarbamate(4.16 g, 19.40 mmol) and diisopropylethylamine (3.39 mL, 19.40 mmol) inACN (20 mL) was stirred at 100° C. for 3 days. Water and EtOAc wereadded and the aqueous phase was extracted with EtOAc. The organic phaseswere combined, washed with brine, dried over MgSO₄, and evaporated. Theresidue was purified by chromatography on SiO₂ (Hexane/EtOAc=1/1) togive the title compound as a brown amorphous solid (3.31 g, 46.6%). ¹HNMR (500 MHz, CDCl₃) δ ppm 1.35-2.02 (m, 17H), 3.80 (s, 3H), 3.84 (s,3H), 4.01 (br s, 1H), 4.20 (s, 2H), 4.23 (br s, 1H), 4.66 (s, 2H), 4.91(br s, 1H), 6.40-6.52 (m, 2H), 7.20-7.28 (m, 1H). [M+H] calc'd forC₂₇H₃₄ClFN₄O₅, 549; found, 549.

Example 306-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one(HCl salt)

A. tert-Butyl(1S,2R)-2-(2-(2,4-dimethoxybenzyl)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate

A mixture of tert-butyl(1S,2R)-2-(4-chloro-2-(2,4-dimethoxybenzyl)-7-fluoro-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate(200 mg, 0.364 mmol), sodium carbonate (77 mg, 0.729 mmol),1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (91mg, 0.437 mmol) and bis(triphenylphosphine)palladium chloride (25.6 mg,0.036 mmol) in DME (2 mL) and H₂O (0.667 mL) was stirred at 85° C. for 2h. To the resulting mixture was added EtOAc. The aqueous phase wasextracted with EtOAc. The organic phases were combined, washed withbrine, dried over MgSO₄, and evaporated. The residue was purified bychromatography on SiO₂(Hexane/EtOAc=2/3) to give the title compound as ayellow oil (88 mg, 40.6%). ¹H NMR (500 MHz, CDCl₃) δ ppm 1.28-2.01 (m,17H), 3.80 (d, J=2.93 Hz, 3H), 3.85 (s, 3H), 3.91-4.01 (m, 4H), 4.23 (brs, 2H), 4.41 (br s, 1H), 4.68 (d, J=1.95 Hz, 2H), 5.36 (br s, 1H),6.36-6.54 (m, 2H), 7.15-7.21 (m, 1H), 8.26 (br s, 1H), 9.02 (br s, 1H).[M+H] calc'd for C₃₁H₃₉FN₆O₅, 595; found, 595.

B.6-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A solution of tert-butyl(1S,2R)-2-(2-(2,4-dimethoxybenzyl)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate(2.4 g, 4.04 mmol) and TFA (5 mL, 64.9 mmol) was stirred at 80° C. for30 min. The resulting suspension was diluted with EtOAc (5 mL) andfiltered. The filtrate was evaporated in vacuo. The residue was dilutedwith H₂O (300 mL) and EtOAc (100 mL) and filtered. The precipitate waswashed with EtOAc and dried to give the title compound as a TFA salt(900 mg). The filtrate was extracted with EtOAc (200 mL). The aqueousphase was neutralized with saturated aq NaHCO₃ solution and extractedwith EtOAc (2×400 mL) and THF (2×200 mL). The organic phases werecombined, dried over MgSO₄, and evaporated. The residue was washed withEtOAc to give a first crop (400 mg) of the title compound as the freebase. The TFA salt obtained above was diluted with saturated aq NaHCO₃solution (20 mL) and stirred at RT overnight. The resulting suspensionwas filtered and the solids were washed with EtOAc to give a second crop(700 mg) of the title compound as the free base (1.1 g, 79%).

C.6-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one(HCl salt)

To a solution of6-((1R,2S)-2-aminocyclohexylamino)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one(2.300 g, 6.68 mmol) in THF (300 mL) was added 1N HCl in EtOAc (20 mL,20.0 mmol) dropwise and the mixture was stirred at room temperature for30 min. The resulting suspension was filtered and the precipitate wascollected and washed with EtOAc (10 mL) to afford crude HCl salt of thetitle compound (2.55 g). The crude compound was recrystallized from EtOH(60 mL) and H₂O (16 mL) to give the HCl salt of the title compound as awhite solid (1.5 g, 59.0%). ¹H NMR (500 MHz, DMSO-d₆) δ ppm 1.34-1.99(m, 8H), 3.67 (br s, 3H), 3.89 (br s, 3H), 4.32-4.43 (m, 2H), 4.45 (brs, 1H), 6.76 (d, J=5.86 Hz, 1H), 7.88 (br s, 3H), 8.29 (d, J=4.88 Hz,1H), 8.36 (s, 1H), 8.84 (s, 1H). [M+H] calc'd for C₁₇H₂₁FN₆O, 345;found, 345.

Example 316-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-4-(pyrazolo[1,5-a]pyridin-3-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A. tert-butyl(1S,2R)-2-(2-(2,4-dimethoxybenzyl)-7-fluoro-3-oxo-4-(pyrazolo[1,5-a]pyridin-3-yl)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate

A mixture of tert-butyl(1S,2R)-2-(4-chloro-2-(2,4-dimethoxybenzyl)-7-fluoro-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate(100 mg, 0.182 mmol),3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazolo[1,5-a]pyridine(53.4 mg, 0.219 mmol), sodium carbonate (48.3 mg, 0.455 mmol) andtetrakis(triphenylphosphine)palladium (21.05 mg, 0.018 mmol) in DME (1mL) and H₂O (0.333 mL) was stirred at 85° C. for 3 h. Followingreaction, the mixture was filtered and the filtrate was diluted withEtOAc and H₂O. The aqueous phase was extracted with EtOAc. The organicphases were combined, washed with brine, dried over MgSO₄, andevaporated. The residue was purified by chromatography on SiO₂ to givethe title compound (53 mg, 46.1%). ¹H NMR (500 MHz, CDCl₃) δ ppm1.17-2.03 (m, 17H), 3.74-3.81 (m, 3H), 3.84-3.89 (m, 3H), 4.04 (br s,1H), 4.26 (br s, 2H), 4.46 (br s, 1H), 4.71 (br s, 2H), 6.36-6.55 (m,2H), 6.83 (d, J=5.86 Hz, 1H), 7.18-7.31 (m, 2H), 8.42 (br s, 1H),8.47-8.57 (m, 1H), 9.42 (br s, 1H).

B.6-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-4-(pyrazolo[1,5-a]pyridin-3-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A mixture of tert-butyl(1S,2R)-2-(2-(2,4-dimethoxybenzyl)-7-fluoro-3-oxo-4-(pyrazolo[1,5-a]pyridin-3-yl)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate(52 mg, 0.082 mmol) and TFA (1 mL, 12.98 mmol) was stirred at 65° C. for30 min. The mixture was concentrated and the residue was purified bypreparative HPLC to give the title compound as a white solid (15 mg,47.8%). ¹H NMR (500 MHz, DMSO-d₆) δ ppm 1.21-2.07 (m, 8H), 3.31 (br s,1H), 4.18-4.26 (m, 1H), 4.46 (br s, 2H), 6.61 (br s, 1H), 7.09 (d,J=6.35 Hz, 1H), 7.49 (d, J=7.32, 1H), 8.36 (br s, 1H), 8.59 (d, J=7.81Hz, 1H), 8.83 (d, J=6.83 Hz, 1H), 9.56 (br s, 1H). [M+H] calc'd forC₂₀H₂₁FN₆O, 381; found, 381.

Example 322-(2-(Aminomethyl)piperidin-1-yl)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one

A. Methyl2-(2-((tert-butoxycarbonylamino)methyl)piperidin-1-yl)-4-chloro-6-(m-tolylamino)pyrimidine-5-carboxylate

A mixture of methyl2,4-dichloro-6-(m-tolylamino)pyrimidine-5-carboxylate (600.6 mg, 1.924mmol), tert-butyl piperidin-2-ylmethylcarbamate (500.9 mg, 2.337 mmol)and N-ethyl-N-isopropylpropan-2-amine (0.4 mL, 2.296 mmol) in DMF (10mL) was stirred at 0° C. for 3 h. Water (50 mL) was added to themixture, which was extracted with EtOAc (2×40 mL). The organic layerswere washed with saturated aq NaHCO₃ (20 mL), water (20 mL) and brine(20 mL), were dried over anhydrous Na₂SO₄, and then filtered (DM1020).The filtrate was concentrated under reduced pressure and the residue waspurified by column chromatography (SiO₂, hexanes/EtOAc=4/1) to give thetitle compound as a clear oil (310.5 mg). ¹H NMR (500 MHz, CDCl₃) δ ppm1.34-1.74 (m, 15H), 2.35-2.37 (m, 3H), 3.03-3.21 (m, 2H), 3.60-3.71 (m,1H), 3.90 (s, 3H), 4.43-5.04 (m, 3H), 6.94-6.98 (m, 1H), 7.23-7.46 (m,3H), 10.13-10.43 (m, 1H). [M+H] calc'd for C₂₄H₃₃ClN₅O₄, 490; found,490.

B. Methyl2-(2-((tert-butoxycarbonylamino)methyl)piperidin-1-yl)-4-cyano-6-(m-tolylamino)pyrimidine-5-carboxylate

A mixture of methyl2-(2-((tert-butoxycarbonylamino)methyl)piperidin-1-yl)-4-chloro-6-(m-tolylamino)pyrimidine-5-carboxylate(399.7 mg, 0.816 mmol), tetrakis(triphenylphosphine)palladium(0) (96.3mg, 0.083 mmol), and zinc cyanide (53.2 mg, 0.453 mmol) in DMF (5 mL)was stirred at 120° C. for 1 h under microwave irradiation. Water (50mL) was added and the mixture was extracted with EtOAc (2×100 mL). Theorganic layers were washed with saturated aq NaHCO₃ (50 mL), water (50mL), and brine (50 mL), were dried over anhydrous Na₂SO₄, and thenfiltered (DM1020). The filtrate was concentrated under reduced pressureand was purified by column chromatography (SiO₂, hexanes/EtOAc=4/1) togive the title compound as a colorless oil (315.0 mg, 80%). ¹H NMR (500MHz, CDCl₃) δ ppm 1.34-1.77 (m, 15H), 2.36-2.39 (m, 3H), 3.00-3.21 (m,2H), 3.49-3.69 (m, 1H), 3.97 (s, 3H), 4.49-5.10 (m, 3H), 6.96-7.02 (m,1H), 7.24-7.41 (m, 3H), 10.14-10.45 (m, 1H). [M+H] calc'd forC₂₅H₃₃N₆O₄, 481; found, 481.

C. tert-Butyl(1-(5-oxo-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-yl)piperidin-2-yl)methylcarbamate

A mixture of methyl2-(2-((tert-butoxycarbonylamino)methyl)piperidin-1-yl)-4-cyano-6-(m-tolylamino)pyrimidine-5-carboxylate(310.1 mg, 0.645 mmol), palladium on carbon (72.4 mg, 0.680 mmol) inEtOH (8 mL), and 1N HCl (4 mL) was stirred at RT for 16 h. The mixturewas filtered to remove the catalyst. The filtrate was treated withsaturated aq NaHCO₃ (20 mL) for 3 h. The mixture was concentrated underreduced pressure and the residue was extracted with EtOAc (2×40 mL). Theorganic layers were washed with saturated aq NaHCO₃ (20 mL), water (20mL), and brine (20 mL), were dried over anhydrous Na₂SO₄, and thenfiltered through SiO₂. The filtrate was concentrated under reducedpressure to give the title compound as a colorless solid (213.4 mg,73%). ¹H-NMR (DMSO-d₆) δ ppm 1.28 (s, 9H), 1.35 (br s, 1H), 1.49-1.56(m, 2H), 1.67-1.69 (m, 3H), 2.31 (s, 3H), 3.06 (br s, 1H), 3.24 (br s,2H), 4.16 (s, 2H), 4.67 (br s, 1H), 5.08 (br s, 1H), 6.77 (br s, 1H),6.87 (d, 1H, J=7.0 Hz), 7.23-7.25 (m, 1H), 7.53 (br s, 2h), 8.07 (s,1H), 8.55 (s, 1H). [M+H] calc'd for C₂₄H₃₃N₆O₃, 453; found, 453.5.

D.2-(2-(Aminomethyl)piperidin-1-yl)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one

To a solution of tert-butyl(1-(5-oxo-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-yl)piperidin-2-yl)methylcarbamate(207.1 mg, 0.458 mmol) in HOAc (3 mL) was added HCl (1 mL, 32.9 mmol).The mixture was stirred at RT for 1 h and then concentrated underreduced pressure. The residue was treated with saturated aq NaHCO₃ (50mL) and was extracted with EtOAc-THF (1/1, 2×40 mL). The organic layerswere washed with saturated aq NaHCO3 (20 mL), water (20 mL), and brine(20 mL), were dried over anhydrous Na₂SO₄, and then filtered. Thefiltrate was concentrated under reduced pressure and the residue waswashed with EtOH to give the title compound as a pale yellow solid (27.4mg, 17%). ¹H-NMR (DMSO-d₆) δ ppm 1.32-1.70 (m, 7H), 1.89-1.92 (m, 1H),2.31 (s, 3H), 2.74-2.87 (m, 1H), 2.81-2.85 (m, 1H), 2.94 (br s, 1H),4.17 (s, 2H), 4.68-4.79 (m, 2H), 6.88 (d, 1H, J=7.5 Hz), 7.22-7.25 (m,1H), 7.49-7.50 (m, 1H), 7.60 (s, 1H), 8.06 (s, 1H), 8.58 (s, 1H). [M+H]calc'd for C₁₉H₂₅N₆O, 353; found, 353.5.

Preparation 14: Methyl6-chloro-4-cyano-2-(3-(methylsulfonyl)phenylamino)nicotinate

A. Methyl 6-chloro-4-cyano-2-(3-(methylthio)phenylamino)nicotinate

A mixture of methyl 2,6-dichloro-4-cyanonicotinate (340.8 mg, 1.475mmol), DIPEA (0.3 mL, 1.718 mmol) and 3-(methylthio)aniline (234.8 mg,1.687 mmol) in CH₃CN (5 mL) was stirred at 60° C. for 2 days. After themixture was cooled, saturated aq NaHCO₃ (30 mL) was added and themixture was extracted with EtOAc (2×30 mL). The organic layers werewashed with saturated aq NaHCO₃ (20 mL), water (20 mL) and brine (20mL), were dried over anhydrous Na₂SO₄, and then filtered through SiO₂.The filtrate was concentrated under reduced pressure and the residue waswashed with IPE and filtered to give the title compound as a yellowsolid (157.8 mg). The filtrate was purified by column chromatography(SiO₂, hexanes/EtOAc=8/1) to give another crop (135.5 mg) of the titlecompound as a yellow oil of (total 293 mg, 60%). ¹H-NMR (CDCl₃) δ ppm2.52 (s, 3H), 4.05 (s, 3H), 7.00 (s, 1H), 7.03-7.05 (m, 1H), 7.25-7.32(m, 2H), 7.66-7.67 (m, 1H), 10.51 (br s, 1H). [M+H] calc'd forC₁₅H₁₃ClN₃O₂S, 334; found, 334.

B. Methyl 6-chloro-4-cyano-2-(3-(methylsulfonyl)phenylamino)nicotinate

To a solution of methyl6-chloro-4-cyano-2-(3-(methylthio)phenylamino)nicotinate (291.1 mg,0.872 mmol) in DMF (10 mL) was added m-chloroperoxybenzoic acid (538.9mg, 2.405 mmol) at 0° C. The mixture was stirred at RT for 16 h. AqueousNa₂S₂O₃ (30 mL) was added and the mixture was extracted with EtOAc (2×30mL). The organic layers were washed with saturated aq NaHCO₃ (20 mL),water (20 mL) and brine (20 mL), were dried over anhydrous Na₂SO₄, andthen filtered (DM1020). The filtrate was concentrated under reducedpressure and the residue was washed with IPE to give the title compoundas a yellow solid (158.2 mg, 50%). ¹H-NMR (CDCl₃) δ ppm 3.11 (s, 3H),4.07 (s, 3H), 7.10 (s, 1H), 7.57-7.60 (m, 1H), 7.70-7.72 (m, 1H),7.91-7.93 (m, 1H), 8.25-8.26 (m, 1H), 10.73 (s, 1H).

Example 336-((1R,2S)-2-Aminocyclohexylamino)-4-(3-(methylsulfonyl)phenylamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A. Methyl6-((1R,2S)-2-(tert-butoxycarbonylamino)cyclohexylamino)-4-cyano-2-(3-(methylsulfonyl)phenylamino)nicotinate

A mixture of methyl6-chloro-4-cyano-2-(3-(methylsulfonyl)phenylamino)nicotinate (162.8 mg,0.445 mmol), tert-butyl (1S,2R)-2-aminocyclohexylcarbamate (111.6 mg,0.521 mmol) and Et₃N (0.1 mL, 0.717 mmol) in THF (6 mL) and DMF (6.00mL) was stirred at 60° C. for 12 h. After the mixture was cooled,saturated aq NaHCO₃ (30 mL) was added and the mixture was extracted withEtOAc (2×30 mL). The organic layers were washed with saturated aq NaHCO₃(15 mL), water (15 mL) and brine (15 mL), were dried over anhydrousNa₂SO₄, and filtered through SiO₂. The filtrate was concentrated underreduced pressure and the residue was washed with IPE to give the titlecompound as a yellow solid (182.2 mg, 75%). ¹H-NMR (CDCl₃) δ ppm1.42-1.67 (m, 15H), 1.84-1.91 (m, 2H), 3.07 (s, 3H), 3.95-3.97 (m, 4H),4.16-4.17 (m, 1H), 4.77 (s, 1H), 6.24 (s, 1H), 7.48-7.51 (m, 1H),7.58-7.61 (m, 1H), 7.77-7.78 (m, 1H), 8.41 (s, 1H), 10.99 (s, 1H), 1Hnot detected.

B. Methyl6-((1R,2S)-2-aminocyclohexylamino)-4-cyano-2-(3-(methylsulfonyl)phenylamino)nicotinate

To a solution of methyl6-((1R,2S)-2-(tert-butoxycarbonylamino)cyclohexylamino)-4-cyano-2-(3-(methylsulfonyl)phenylamino)nicotinate(178.3 mg, 0.328 mmol) in HOAc (4 mL) was added HCl (4 mL, 132 mmol).The mixture was stirred at RT for 4 h and then concentrated underreduced pressure. Water (15 mL) and 1M HCl (15 mL) were added to theconcentrate and the aqueous layer was washed with EtOAc (10 mL). Thewashed aqueous layer was basified with saturated aqueous NaHCO₃ (50 mL)and extracted with EtOAc (2×30 mL). The organic layers were combined,washed with saturated aq NaHCO₃ (20 mL), water (20 mL) and brine (20mL), dried over anhydrous Na₂SO₄, and filtered. The filtrate wasconcentrated under reduced pressure to give the title compound as abrown solid (123.2 mg, 85%). ¹H-NMR (CDCl₃) δ ppm 1.45-16.4 (m, 6H),1.77-1.79 (m, 4H), 3.06 (s, 3H), 3.17-3.18 (m, 1H), 3.94 (s, 3H),4.10-4.14 (m, 1H), 6.03-6.05 (m, 1H), 6.29 (s, 1H), 7.48-7.51 (m, 1H),7.58-7.60 (m, 1H), 7.71-7.72 (m, 1H), 8.53 (s, 1H), 11.01 (s, 1H).

C.6-((1R,2S)-2-Aminocyclohexylamino)-4-(3-(methylsulfonyl)phenylamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A mixture of methyl6-((1R,2S)-2-aminocyclohexylamino)-4-cyano-2-(3-(methylsulfonyl)phenylamino)nicotinate(117.3 mg, 0.264 mmol) and palladium on carbon (23.6 mg, 0.222 mmol) inMeOH (4 mL) and 1N HCl (4 mL) was stirred at RT for 16 h under ahydrogen atmosphere. The mixture was filtered to remove the catalyst andthe filtrate was treated with saturated aq NaHCO₃ (20 mL) and stirred atRT for 20 h. The mixture was concentrated under reduced pressure and theresidue was extracted with EtOAc/THF (2/1, 2×30 mL). The organic layerswere washed with saturated aq NaHCO₃ (15 mL), water (15 mL) and brine(15 mL), were dried over anhydrous Na₂SO₄, and then filtered. Thefiltrate was concentrated under reduced pressure and the residue waspurified by column chromatography (DM1020, EtOAc/MeOH=20/1) to give thedesired product (37.2 mg, 34%). The product was recrystallized from EtOHto give the title compound as a colorless solid (13.2 mg, 12%). ¹H-NMR(DMSO-d₆) δ ppm 1.31-1.41 (m, 4H), 1.55-1.68 (m, 6H), 3.05 (s, 1H), 3.21(s, 3H), 4.08 (s, 1H), 4.23 (s, 2H), 6.17 (s, 1H), 6.78-6.79 (m, 1H),7.46-7.47 (m, 1H), 7.53-7.56 (m, 1H), 7.96-7.99 (m, 2H), 8.49 (s, 1H),9.18 (s, 1H).

Example 346-((1R,2S)-2-Aminocyclopentylamino)-4-(3-(methylsulfonyl)phenylamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one(HCl salt)

A. Methyl6-((1R,2S)-2-(tert-butoxycarbonylamino)cyclopentylamino)-4-cyano-2-(3-(methylsulfonyl)phenylamino)nicotinate

A mixture of methyl6-chloro-4-cyano-2-(3-(methylsulfonyl)phenylamino)nicotinate (165.0 mg,0.451 mmol), Et₃N (0.15 mL, 1.076 mmol), and tert-butyl(1S,2R)-2-aminocyclopentylcarbamate (142.0 mg, 0.709 mmol) in DMF (6 mL)was stirred at 60° C. for 12 h. Saturated aq NaHCO₃ (20 mL) was added tothe mixture, which was subsequently extracted with EtOAc (2×30 mL). Theorganic layers were washed with saturated aq NaHCO₃ (20 mL), water (20mL) and brine (20 mL), were dried over anhydrous Na₂SO₄, and filtered(DM1020). The filtrate was concentrated under reduced pressure. Theresidue was purified by column chromatography (SiO₂, hexanes/EtOAc=1/1)and then triturated with IPE to provide the title compound (147 mg).

B. tert-Butyl(1S,2R)-2-(4-(3-(methylsulfonyl)phenylamino)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclopentylcarbamate

A mixture of methyl6-((1R,2S)-2-(tert-butoxycarbonylamino)cyclopentylamino)-4-cyano-2-(3-(methylsulfonyl)phenylamino)nicotinate(141.1 mg, 0.266 mmol) and palladium hydroxide on carbon (43.2 mg, 0.308mmol) in MeOH (10 mL) and HOAc (10 mL) was stirred at RT for 12 h undera hydrogen atmosphere. The mixture was filtered to remove the catalystand the filtrate was concentrated under reduced pressure. The residuewas treated with saturated aq NaHCO₃ (20 mL) and MeOH (20 mL). Themixture was stirred at RT for 6 h and then concentrated under reducedpressure. The residue was treated with saturated aq NaHCO₃ (30 mL) andextracted with EtOAc (2×50 mL). The organic layers were washed withsaturated aq NaHCO₃ (20 mL), water (20 mL) and brine (20 mL), were driedover anhydrous Na₂SO₄, and filtered. The filtrate was concentrated underreduced pressure and the residue was purified by column chromatography(DM1020, EtOAc) to give the desired product (46.5 mg). The product waswashed with IPE/EtOAc to give the title compound as a pale brown solid(34.7 mg, 26%).

C.6-((1R,2S)-2-Aminocyclopentylamino)-4-(3-(methylsulfonyl)phenylamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one(HCl salt)

A mixture of tert-butyl(1S,2R)-2-(4-(3-(methylsulfonyl)phenylamino)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclopentylcarbamate(16.5 mg, 0.329 mmol) and HCl (1 mL, 32.9 mmol) in HOAc (2 mL) wasstirred at RT for 3 h. The mixture was concentrated under reducedpressure and the residue was recrystallized from EtOH—H₂O to give thetitle compound (9.6 mg, 67%). ¹H-NMR (DMSO-d₆) δ ppm 1.63-1.79 (m, 4H),20.3-2.06 (m, 1H), 2.19-2.20 (m, 1H), 3.32 (s, 3H), 3.74 (br s, 1H),4.23-4.28 (m, 2H), 4.45 (br s, 1H), 6.22 (s, 1H), 7.34-7.35 (m, 1H),7.51-7.58 (m, 3H), 7.73 (br s, 3H), 8.13 (s, 1H), 8.82 (s, 1H), 9.26 (s,1H).

Example 35(R)-4-Methyl-2-(4-(3-(methylsulfonyl)phenylamino)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)pentanamide

A. (R)-Methyl6-(1-amino-4-methyl-1-oxopentan-2-ylamino)-4-cyano-2-(3-(methylsulfonyl)phenylamino)nicotinate

A mixture of methyl6-chloro-4-cyano-2-(3-(methylsulfonyl)phenylamino)nicotinate (120.7 mg,0.330 mmol), (R)-2-amino-4-methylpentanamide (67.1 mg, 0.515 mmol), andEt₃N (0.1 mL, 0.717 mmol) in DMF (4 mL) was stirred at 60° C. for 14 h.Saturated aq NaHCO₃ (20 mL) was added to the mixture, which wassubsequently extracted with EtOAc (2×30 mL). The organic layers werewashed with saturated aq NaHCO₃ (20 mL), water (20 mL) and brine (20mL), were dried over anhydrous Na₂SO₄, and filtered (DM1020). Thefiltrate was concentrated under reduced pressure. The residue waspurified by column chromatography (SiO₂, hexanes/EtOAc=1/2) and thentriturated with IPE to give the title compound (76 mg, 50%).

B.(R)-4-Methyl-2-(4-(3-(methylsulfonyl)phenylamino)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)pentanamide

A mixture of (R)-methyl6-(1-amino-4-methyl-1-oxopentan-2-ylamino)-4-cyano-2-(3-(methylsulfonyl)phenylamino)nicotinate(73.2 mg, 0.159 mmol) and palladium hydroxide on carbon (23.2 mg, 0.165mmol) in MeOH (6 mL) and HOAc (3 mL) was stirred at RT for 12 h under ahydrogen atmosphere. The mixture was filtered to remove the catalyst andthe filtrate was concentrated under reduced pressure. The residue wastreated with saturated aq NaHCO₃ (20 mL) and MeOH (20 mL). The resultingmixture was stirred at RT for 16 h and then concentrated under reducedpressure. The residue was treated with saturated aq NaHCO₃ (30 mL) andextracted with EtOAc (2×50 mL). The organic layers were washed withsaturated aq NaHCO₃ (20 mL), water (20 mL) and brine (20 mL), were driedover anhydrous Na₂SO₄, and filtered. The filtrate was concentrated underreduced pressure and the residue was recrystallized from EtOH to givethe title compound as a white solid (18.8 mg, 27%). ¹H-NMR (DMSO-d₆) δppm 0.87-0.94 (m, 6H), 1.54-1.63 (m, 2H), 1.76 (br s, 1H), 3.32 (s, 3H),4.24 (s, 2H), 4.50 (br s, 1H), 6.17 (s, 1H), 7.00-7.04 (m, 2H), 7.22 (brs, 1H), 7.47-7.57 (m, 2H), 8.01 (br s, 1H), 8.06 (s, 1H), 8.45 (br s,1H), 9.23 (s, 1H). [M+H] calc'd for C₂₀H₂₆N₅O₄S, 432; found, 432.5.

Example 36(R)-4-Methyl-2-(4-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)pentanamide

A. (R)-Methyl6-(1-amino-4-methyl-1-oxopentan-2-ylamino)-4-cyano-2-(1-methyl-1H-pyrazol-4-yl)nicotinate

A mixture of methyl6-chloro-4-cyano-2-(1-methyl-1H-pyrazol-4-yl)nicotinate (82.9 mg, 0.300mmol) and (R)-2-amino-4-methylpentanamide (39.0 mg, 0.300 mmol) in DMA(2 mL) was stirred at 150° C. for 12 h. Water was subsequently added andthe mixture was extracted with EtOAc. The organic layers were washedwith saturated aq NaHCO₃, water, and brine, were dried over anhydrousNa₂SO₄, and filtered. The filtrate was concentrated under reducedpressure. The residue was purified by column chromatography (SiO₂,EtOAc) to give the title compound as a yellow oil (11.7 mg, 11%).

B.(R)-4-Methyl-2-(4-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)pentanamide

A mixture of (R)-methyl6-(1-amino-4-methyl-1-oxopentan-2-ylamino)-4-cyano-2-(1-methyl-1H-pyrazol-4-yl)nicotinate(20.3 mg, 0.055 mmol) and palladium hydroxide (10 mg, 0.094 mmol) inMeOH (2 mL) and HOAc (2 mL) was stirred at RT for 3 h under a hydrogenatmosphere. The mixture was filtered to remove the catalyst and thefiltrate was concentrated under reduced pressure. The residue wastreated with saturated aq NaHCO₃ (20 mL) and EtOAc (20 mL) for 12 h. Themixture was extracted with EtOAc (2×20 mL). The organic layers werewashed with saturated aq NaHCO₃ (20 mL), water (20 mL) and brine (20mL), were dried over anhydrous Na₂SO₄, and filtered. The filtrate wasconcentrated under reduced pressure and the residue was purified bycolumn chromatography (DM1020, EtOAc/MeOH=15/1-10/1) to give the titlecompound as a white solid (10.2 mg, 54%). ¹H-NMR (DMSO-d₆) δ ppm0.88-0.95 (m, 6H), 1.52-1.60 (m, 2H), 1.73-1.76 (m, 1H), 3.88 (s, 3H),4.21 (s, 2H), 4.48 (br s, 1H), 6.43 (s, 1H), 6.90 (s, 1H), 7.03 (br s,1H), 7.42 (s, 1H), 8.01 (s, 1H), 8.41 (s, 1H), 8.92 (s, 1H). [M+H]calc'd for C₁₇H₂₃N₆O₂, 343; found, 343.

Example 372-((1R,2S)-2-(Dimethylamino)cyclohexylamino)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one

A solution of2-((1R,2S)-2-aminocyclohexylamino)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one(10 mg, 0.028 mmol), paraformaldehyde (0.852 mg, 0.028 mmol) in MeOH (2mL) was stirred at RT for 10 min. Sodium cyanotrihydroborate (1.783 mg,0.028 mmol) was added and the reaction mixture was stirred at RTovernight. The mixture was purified by reverse phase preparative HPLC togive the TFA salt of the title compound (5 mg, 46%). ¹H NMR (400 MHz,DMSO-d₆) δ ppm 1.44-1.57 (m, 4H), 1.85 (br s, 4H), 2.32 (s, 3H),2.64-2.87 (2s, 6H), 4.20 (d, J=4.55 Hz, 2H), 6.91 (d, J=7.07 Hz, 1H),7.00 (s, 1H), 7.13 (s, 1H), 7.17-7.34 (m, 2H), 8.19 (br s, 1H), 8.68 (brs, 1H). [M+H] calc'd for C₂₁H₂₈N₆O, 381; found, 381.

Example 382-((1R,2S)-2-(Methylamino)cyclohexylamino)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one

A solution of2-((1R,2S)-2-Aminocyclohexylamino)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one(17.7 mg, 0.050 mmol), paraformaldehyde (1.508 mg, 0.050 mmol) in MeOH(2 mL) was stirred at RT for 10 min. Sodium cyanotrihydroborate (3.16mg, 0.050 mmol) was added and the reaction mixture was stirred at RT for4 h. The reaction was stopped and the mixture was purified by reversephase preparative HPLC to give the TFA salt of the title compound (5 mg,27%). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.35-1.79 (m, 8H), 2.32 (s, 3H),4.20 (br s, 2H), 6.52 (br s, 2H), 6.91 (d, J=7.33 Hz, 1H), 7.24 (t,J=7.71 Hz, 2H), 8.03 (br s, 1H), 8.16 (br s, 2H), 8.40 (br s, 1H), 8.66(br s, 1H). [M+H] calc'd for C₂₀H₂₆N₆O, 367; found, 367.

Example 392′-((1R,2S)-2-Aminocyclohexylamino)-4′-(m-tolylamino)spiro[cyclopropane-1,7′-pyrrolo[3,4-d]pyrimidin]-5′(6′H)-one

A. tert-Butyl(1S,2R)-2-(5′-oxo-4′-(m-tolylamino)-5′,6′-dihydrospiro[cyclopropane-1,7′-pyrrolo[3,4-d]pyrimidine]-2′-ylamino)cyclohexylcarbamate

Ethylmagnesium bromide (0.069 mL, 0.208 mmol) was added at RT to asolution of methyl2-((1R,2S)-2-(tert-butoxycarbonylamino)cyclohexylamino)-4-cyano-6-(m-tolylamino)pyrimidine-5-carboxylate(50 mg, 0.104 mmol) and tetraisopropylorthotitanate (0.091 mL, 0.312mmol) in Et₂O (5 mL). The reaction mixture was stirred at RT for 20 hand was subsequently diluted with EtOAc. The organic phase was washedwith saturated aq NaHCO₃, brine and water, was dried then concentratedto give a pink residue, which was purified by reverse phase preparativeHPLC. The fractions were collected and concentrated to a residue, whichwas used in next step. [M+H] calc'd for C₂₆H₃₄N₆O₃, 479; found, 479.

B.2′-((1R,2S)-2-Aminocyclohexylamino)-4′-(m-tolylamino)spiro[cyclopropane-1,7′-pyrrolo[3,4-d]pyrimidin]-5′(6′H)-one

A solution of tert-Butyl(1S,2R)-2-(5′-oxo-4′-(m-tolylamino)-5′,6′-dihydrospiro[cyclopropane-1,7′-pyrrolo[3,4-d]pyrimidine]-2′-ylamino)cyclohexylcarbamate(50 mg, 0.104 mmol) in DCM (5 mL) was treated with TFA (2 mL) for 1 hand was purified by reverse phase preparative HPLC. The collectedfractions were lyophilized to give the TFA salt of the title compound (4mg, 10% in two steps). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.12-1.31 (m,1H), 1.42 (m, 6H), 1.63 (m, 3H), 1.86 (m, 2H), 2.33 (s, 3H), 3.62 (br s,1H), 4.18 (br s, 1H), 6.91 (d, J=7.33 Hz, 1H), 7.24 (t, J=7.71 Hz, 1H),7.36-7.56 (m, 1H), 7.60 (br s, 1H), 7.73 (br s, 2H), 8.33 (br s, 1H),8.65 (br s, 1H). [M+H] calc'd for C₂₁H₂₆N₆O, 379; found, 379.

Example 402-(2-Aminoethylamino)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one

A. Methyl4-methyl-2-(methylthio)-6-(m-tolylamino)pyrimidine-5-carboxylate

Methyl 2-chloro-4-methyl-6-(m-tolylamino)pyrimidine-5-carboxylate (0.078g, 0.267 mmol) was dissolved in DMF (3 mL). Sodium thiomethoxide (0.019g, 0.267 mmol) was added and the reaction mixture was allowed to stir atRT for 1 h. The reaction mixture was poured onto ice. The pH wasadjusted to 7 with 1 N HCl. The title compound was isolated as a yellowsolid by vacuum filtration (72.8 mg, 90%). [M+H] calc'd for C₁₅H₁₇N₃O₂S,304; found, 304.

B.6-(2,4-Dimethoxybenzyl)-2-(methylthio)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one

A mixture methyl4-methyl-2-(methylthio)-6-(m-tolylamino)pyrimidine-5-carboxylate (0.44g, 1.45 mmol) and selenium dioxide (0.32 g, 2.89 mmol) in dioxane (12mL) was heated at 100° C. for 24 h. The reaction mixture wassubsequently cooled and filtered. The filtrate was concentrated anddried to give a brown foam (0.459 g) which was dispersed in(2,4-dimethoxyphenyl)methanamine (0.217 mL, 1.446 mmol) in DCM (6 mL)and MeOH (3 mL). The resulting mixture was stirred at RT for 30 min.Sodium cyanoborohydride (0.227 g, 3.62 mmol) was added and the reactionmixture was stirred at RT for 20 h. The solid phase was filtered andwashed with MeOH to give the title compound as a yellow solid (0.537 g,85%). [M+H] calc'd for C₂₃H₂₄N₄O₃S, 437; found, 437.

C.6-(2,4-dimethoxybenzyl)-2-(methylsulfonyl)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one

6-(2,4-Dimethoxybenzyl)-2-(methylthio)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one(0.432 g, 0.990 mmol) was dissolved in DCM (10 mL). The solution waschilled in an ice bath and m-chloroperoxybenzoic acid (0.256 g, 1.484mmol) was added. The reaction was allowed to warm to RT with stirringfor 3 h. A second aliquot of m-chloroperoxybenzoic acid (0.170 g, 0.990mmol) was added to the reaction mixture, which was stirred for 1 h. Athird aliquot of m-chloroperoxybenzoic acid (0.100 g, 0.579 mmol) wasadded. The reaction mixture was stirred for 30 min, diluted with DCM (20mL), and quenched with saturated aq NaHCO₃ (20 mL). The organic phasewas washed with saturated aq NaHCO₃ (20 mL) and brine (20 mL), and wasdried over anhydrous Na₂SO₄. The solvent was removed in vacuo to givethe title compound as a light brown glassy solid (330 mg, 71%). [M+H]calc'd for C₂₃H₂₄N₄O₅S, 469; found, 469.

D. tert-Butyl2-(6-(2,4-dimethoxybenzyl)-5-oxo-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-ylamino)ethylcarbamate

A mixture of6-(2,4-dimethoxybenzyl)-2-(methylsulfonyl)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one(0.07 g, 0.149 mmol), tert-butyl 2-aminoethylcarbamate (0.024 g, 0.149mmol), and Et₃N (0.104 mL, 0.747 mmol) in DMA (2 mL) was heated in asealed tube at 90° C. for 4 h. The reaction mixture was poured slowlyonto ice and its pH adjusted to about 7 through addition of 1 N HCl,resulting in precipitation of a tan solid. The solid was isolated byvacuum filtration, washed with water, and dried under vacuum to give thetitle compound as a tan brown solid (55 mg, 67%). [M+H] calc'd forC₂₉H₃₆N₆O₅, 549; found, 549.

E.2-(2-Aminoethylamino)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one

A mixture of tert-butyl2-(6-(2,4-dimethoxybenzyl)-5-oxo-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-ylamino)ethylcarbamate(0.055 g, 0.100 mmol) in TFA (2 mL) was stirred at 70° C. for 1.5 h.Following reaction, the solvent was removed and the resulting residuewas dispersed into a solution of DMSO and MeOH (1/1). The mixture wasfiltered and the filtrate was purified by preparative HPLC. Thefractions were collected and dried in vacuo to give a TFA salt of thetitle compound as an off-white solid (28 mg, 93%). ¹H NMR (500 MHz,DMSO-d₆) δ ppm 2.21-2.40 (m, 3H) 2.90-3.21 (m, 2H) 3.57 (q, J=5.86 Hz,2H) 4.19 (br s, 2H) 6.90 (br s, 1H) 7.13-7.34 (m, 1H) 7.54 (br s, 1H)7.56-7.74 (m, 2H) 7.80 (br s, 2H) 8.18 (d, J=13.67 Hz, 1H) 8.54-8.82 (m,1H). [M+H] calc'd for C₁₅H₁₈N₆O, 299; found, 299.

Example 412-(2-Amino-2-methylpropylamino)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one

A TFA salt of the title compound was prepared in a manner similar toEXAMPLE 40 using tert-butyl 1-amino-2-methylpropan-2-ylcarbamate inplace of tert-butyl 2-aminoethylcarbamate. ¹H NMR (500 MHz, CD₃OD) δ ppm1.14-1.53 (m, 6H), 2.37 (br s, 3H), 3.62 (br s, 2H), 4.12-4.47 (m, 2H),6.77-7.15 (m, 1H), 7.13-7.40 (m, 1H), 7.40-7.79 (m, 2H). [M+H] calc'dfor C₁₇H₂₂N₆O, 327; found, 327.

Example 422-(5-Oxo-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-ylamino)acetamide

The title compound was prepared in a manner similar to EXAMPLE 40 usingglycinamide hydrochloride in place of tert-butyl 2-aminoethylcarbamate.¹H NMR (500 MHz, CD₃OD) δ ppm 2.38 (s, 3H), 4.11 (br s, 2H), 4.41 (br s,2H), 7.02 (br s, 1H), 7.27 (br s, 1H), 7.51 (br s, 2H). [M+H] calc'd forC₁₅H₁₆N₆O₂, 313; found, 313.

Example 432-((2-Aminoethyl)(methyl)amino)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one

A TFA salt of the title compound was prepared in a manner similar toEXAMPLE 40 using tert-butyl 2-(methylamino)ethylcarbamate hydrochloridein place of tert-butyl 2-aminoethylcarbamate. ¹H NMR (500 MHz, CD₃OD) δppm 2.35 (s, 3H), 3.26 (t, J=5.86 Hz, 2H), 3.30 (s, 3H), 3.89-4.04 (m,2H), 4.24 (s, 2H), 6.94 (d, J=7.32 Hz, 1H), 7.23 (t, J=7.81 Hz, 1H),7.55 (d, J=7.81 Hz, 2H). [M+H] calc'd for C₁₆H₂₀N₆O, 313; found, 313.

Example 442-(Pyrrolidin-2-ylmethylamino)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one

A TFA salt of the title compound was prepared in a manner similar toEXAMPLE 40 using tert-butyl 2-(aminomethyl)pyrrolidine-1-carboxylate inplace of tert-butyl 2-aminoethylcarbamate. ¹H NMR (500 MHz, CD₃OD) δ ppm1.80 (br s, 1H), 1.91-2.26 (m, 3H), 2.38 (br s, 3H), 3.19 (br s, 1H),3.63 (d, J=7.32 Hz, 1H), 3.71-4.03 (m, 2H), 4.15-4.51 (m, 2H), 6.74-7.16(m, 1H), 7.13-7.76 (m, 3H). [M+H] calc'd for C₁₈H₂₂N₆O, 339; found, 339.

Example 452-(3-Aminopyrrolidin-1-yl)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one

A TFA salt of the title compound was prepared in a manner similar toEXAMPLE 40 using tert-butyl pyrrolidin-3-ylcarbamate in place oftert-butyl 2-aminoethylcarbamate. ¹H NMR (500 MHz, CD₃OD) δ ppm2.13-2.28 (m, 1H), 2.35 (s, 3H), 2.51 (dd, J=13.42, 6.10 Hz, 1H),3.69-4.12 (m, 5H), 4.22 (d, J=18.06 Hz, 2H), 6.93 (d, J=7.32 Hz, 1H),7.21 (t, J=7.81 Hz, 1H), 7.46-7.69 (m, 2H). [M+H] calc'd for C₁₇H₂₀N₆O,325; found, 325.

Preparation 15: Ethyl4-chloro-6-methyl-2-(methylthio)pyrimidine-5-carboxylate

Ethyl 4-hydroxy-6-methyl-2-(methylthio)pyrimidine-5-carboxylate (0.2 g,0.876 mmol), tetraethylammonium chloride (0.145 g, 0.876 mmol), andN,N-dimethylaniline (0.112 mL, 0.876 mmol) were dispersed inacetonitrile (10 mL). The reaction mixture was stirred briefly followedby the addition of phosphorous oxychloride (0.204 mL, 2.190 mmol). Thereaction was heated at 100° C. for 4 h. The solvent was subsequentlyremoved in vacuo. The residue was poured onto ice to give an off-whiteoil, which was extracted with DCM (2×15 mL), and dried over anhydrousNa₂SO₄. The solvent was removed in vacuo to give the title compound as ayellowish-green oil (0.179 g, 83%). [M+H] calc'd for C₉H₁₁ClN₂O₂S, 247;found, 247.

Example 462-((1R,2S)-2-Aminocyclohexylamino)-4-(1,5-dimethyl-1H-pyrazol-4-yl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one

A. Ethyl4-(1,5-dimethyl-1H-pyrazol-4-yl)-6-methyl-2-(methylthio)pyrimidine-5-carboxylate

Ethyl 4-chloro-6-methyl-2-(methylthio)pyrimidine-5-carboxylate (0.179 g,0.726 mmol),1,5-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole(0.242 g, 1.088 mmol), and PdCl₂(dppf) (0.106 g, 0.145 mmol) weredispersed in DMA (2 mL). After 10 min, 2 N sodium carbonate (1.814 mL,3.63 mmol) was added to the reaction mixture. The reaction mixture waspurged with nitrogen, sealed in a vial, and then heated at 80° C. for 5h. The mixture was subsequently filtered through a pad of Celite, rinsedwith MeOH, and the filtrate was purified via reverse phase preparativeHPLC. The fractions were concentrated in vacuo to give the titlecompound as tan needles (0.159 g, 71%). [M+H] calc'd for C₁₄H₁₈N₄O₂S,307; found, 307.

B. Ethyl4-(1,5-dimethyl-1H-pyrazol-4-yl)-6-methyl-2-(methylsulfonyl)pyrimidine-5-carboxylate

Ethyl4-(1,5-dimethyl-1H-pyrazol-4-yl)-6-methyl-2-(methylthio)pyrimidine-5-carboxylate(0.159 g, 0.519 mmol) was dissolved in DCM (10 mL). The solution waschilled in an ice bath and m-chloroperoxybenzoic acid (0.134 g, 0.778mmol) was added. The reaction was allowed to warm to RT over a 30 minperiod with stirring. Another aliquot of m-chloroperoxybenzoic acid(0.159 g, 0.519 mmol) was added to the reaction mixture and it wasstirred for an additional 45 min. The reaction mixture was subsequentlydiluted with DCM (10 mL) and was quenched with saturated aq NaHCO₃ (10mL). The organic phase was washed with saturated aq NaHCO₃ (5 mL) andbrine (5 mL) and was dried over anhydrous Na₂SO₄. The solvents wereremoved in vacuo to give the title compound as a yellow oil (173 mg,98%). [M+H] calc'd for C₁₄H₁₈N₄O₄S, 339; found, 339.

C. Ethyl2-((1R,2S)-2-(tert-butoxycarbonylamino)cyclohexylamino)-4-(1,5-dimethyl-1H-pyrazol-4-yl)-6-methylpyrimidine-5-carboxylate

A solution of ethyl4-(1,5-dimethyl-1H-pyrazol-4-yl)-6-methyl-2-(methylsulfonyl)pyrimidine-5-carboxylate(0.07 g, 0.207 mmol), tert-butyl (1S,2R)-2-aminocyclohexylcarbamate(0.089 g, 0.414 mmol) and Et₃N (0.115 mL, 0.827 mmol) in DMA (3 mL) washeated in a sealed tube at 90° C. for 8 h. The reaction mixture waspoured slowly onto ice to yield a pale yellow precipitate, which wasisolated by vacuum filtration, washed with water, and dried under vacuumto give the title compound. [M+H] calc'd for C₂₄H₃₆N₆O₄, 473; found,473.

D. tert-Butyl(1S,2R)-2-(6-(2,4-dimethoxybenzyl)-4-(1,5-dimethyl-1H-pyrazol-4-yl)-5-oxo-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-ylamino)cyclohexylcarbamate

A mixture ethyl2-((1R,2S)-2-(tert-butoxycarbonylamino)cyclohexylamino)-4-(1,5-dimethyl-1H-pyrazol-4-yl)-6-methylpyrimidine-5-carboxylate(0.098 g, 0.207 mmol) and selenium dioxide (0.046 g, 0.415 mmol) indioxane (2 mL) was heated at 100° C. for 24 h. The mixture wassubsequently cooled and filtered. The filtrate was concentrated anddried to give a brown foam (0.1 g, 0.206 mmol) which was combined withsodium acetate (0.051 g, 0.617 mmol) and(2,4-dimethoxyphenyl)methanamine (0.031 mL, 0.206 mmol) in DCM (2 mL)and MeOH (1 mL). The mixture was stirred at RT for 30 min, after whichsodium cyanoborohydride (0.032 g, 0.514 mmol) was added. The reactionmixture was stirred at RT for 20 h, and then filtered through a pad ofCelite, which was rinsed with MeOH. The filtrate was purified by reversephase preparative HPLC and the fractions concentrated in vacuo to givethe title compound as a tan solid. [M+H] calc'd for C₃₁H₄₁N₇O₅, 592;found, 592.

E.2-((1R,2S)-2-Aminocyclohexylamino)-4-(1,5-dimethyl-1H-pyrazol-4-yl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one

A mixture of tert-butyl(1S,2R)-2-(6-(2,4-dimethoxybenzyl)-4-(1,5-dimethyl-1H-pyrazol-4-yl)-5-oxo-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-ylamino)cyclohexylcarbamateobtained above in TFA (2 mL) was stirred at 70° C. for 2 h. The mixturewas subsequently purified by reverse phase preparative HPLC. Thefractions were collected and concentrated to give a TFA salt of thetitle compound as a white solid (0.5 mg). ¹H NMR (500 MHz, CD₃OD) δ ppm1.59 (br s, 2H), 1.67-2.02 (m, 6H), 2.66-2.72 (m, 3H), 3.67 (br s, 1H),3.85 (s, 3H), 4.29 (s, 2H), 4.50-4.64 (m, 1H), 8.64 (br s, 1H). [M+H]calc'd for C₁₇H₂₃N₇O, 342; found, 342.

Example 472-((1R,2S)-2-Aminocyclohexylamino)-4-(1H-indol-2-yl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one

A TFA salt of the title compound was prepared in a manner similar toEXAMPLE 46 using 1-(tert-butoxycarbonyl)-1H-indol-2-ylboronic acid inplace of1,5-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole.¹H NMR (500 MHz, CD₃OD) δ ppm 1.46-1.72 (m, 2H), 1.72-2.06 (m, 6H),3.56-3.89 (m, 1H), 4.36 (s, 2H), 4.52-4.77 (m, 1H), 7.08 (t, J=7.57 Hz,1H), 7.25 (t, J=7.57 Hz, 1H), 7.47 (d, J=8.30 Hz, 1H), 7.58-7.79 (m,2H). [M+H] calc'd for C₂₀H₂₂N₆O, 363; found, 363.

Example 482-((1R,2S)-2-Aminocyclohexylamino)-4-(1H-pyrazol-5-yl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one

A TFA salt of the title compound was prepared in a manner similar toEXAMPLE 46 using tert-butyl5-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)-1H-pyrazole-1-carboxylate inplace of1,5-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole.¹H NMR (500 MHz, CD₃OD) δ ppm 1.44-1.69 (m, 2H), 1.68-1.94 (m, 6H), 3.64(br s, 1H), 4.41 (s, 2H), 4.65 (br s, 1H), 7.11-7.55 (m, 1H), 7.69 (d,J=1.77 Hz, 1H). [M+H] calc'd for C₁₅H₁₉N₇O, 314; found, 314.

Example 492-(3-Aminopropyl)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one

A. Methyl2-(3-(tert-butoxycarbonylamino)prop-1-ynyl)-4-methyl-6-(m-tolylamino)pyrimidine-5-carboxylate

Methyl 2-chloro-4-methyl-6-(m-tolylamino)pyrimidine-5-carboxylate (0.4g, 1.371 mmol), tert-butyl prop-2-ynylcarbamate (0.426 g, 2.74 mmol),tetrakis(triphenylphosphine)palladium (0.032 g, 0.027 mmol), and copper(I) iodide (0.026 g, 0.137 mmol) was dispersed in DMA (5 mL).Triethylamine (0.382 mL, 2.74 mmol) was added and the mixture wasdegassed with nitrogen for 5 min. The reaction mixture was placed in asealed tube and heated at 90° C. for 4 h, after which it was filteredthrough a pad of Celite, which was rinsed with MeOH. The filtrate waspurified via reverse phase preparative HPLC and the fractions wereconcentrated in vacuo to give the title compound as a brown oil (0.190g, 34%). [M+H] calc'd for C₂₂H₂₆N₄O₄, 411; found, 411.

B. Methyl2-(3-(tert-butoxycarbonylamino)propyl)-4-methyl-6-(m-tolylamino)pyrimidine-5-carboxylate

Methyl2-(3-(tert-butoxycarbonylamino)prop-1-ynyl)-4-methyl-6-(m-tolylamino)pyrimidine-5-carboxylate(0.190 g, 0.463 mmol) was dissolved in EtOH (4 mL). To this solution wasadded palladium on carbon (0.049 g, 0.046 mmol) and the resultingmixture was stirred overnight at RT under H₂ atmosphere. The mixture wasfiltered through a pad of Celite, and the filtrate was evaporated togive the title compound as a brown oil, which was used in next stepwithout further purification. [M+H] calc'd for C₂₂H₃₀N₄O₄, 415; found,415.

C. tert-Butyl3-(6-(2,4-dimethoxybenzyl)-5-oxo-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-yl)propylcarbamate

A mixture methyl2-(3-(tert-butoxycarbonylamino)propyl)-4-methyl-6-(m-tolylamino)pyrimidine-5-carboxylate(0.124 g, 0.299 mmol) and selenium dioxide (0.033 g, 0.299 mmol) indioxane (2 mL) was heated at 100° C. for 24 h. The reaction mixture wassubsequently cooled and filtered. The filtrate was concentrated anddried to give a brown foam (0.128 g, 0.299 mmol), which was combinedwith (2,4-dimethoxyphenyl)methanamine (0.045 mL, 0.299 mmol), DCM (2 mL)and MeOH (1 mL). The mixture was stirred at RT for 30 min, after whichsodium cyanoborohydride (0.047 g, 0.747 mmol) was added. The reactionmixture was stirred at RT for 20 h, and then filtered through a pad ofCelite, which was rinsed with MeOH. The filtrate was purified viareverse phase preparative HPLC. The fractions were collected andconcentrated in vacuo to yield the title compound as a tan solid (1.7mg, 1%). [M+H] calc'd for C₃₀H₃₇N₅O₅, 548; found, 548.

D.2-(3-Aminopropyl)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one

A mixture of tert-butyl3-(6-(2,4-dimethoxybenzyl)-5-oxo-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-yl)propylcarbamate(1.7 mg, 0.003 mmol) in TFA (2 mL) was stirred at 70° C. for 2 h. Themixture was purified by reverse phase preparative HPLC. The fractionswere collected and concentrated to give a TFA salt of the title compoundas a white solid (0.6 mg, 65%). ¹H NMR (500 MHz, CD₃OD) δ ppm 2.11-2.26(m, 2H), 2.30-2.45 (m, 3H), 2.92-3.09 (m, 4H), 4.39 (s, 2H), 6.98 (d,J=8.34 Hz, 1H), 7.16-7.35 (m, 1H), 7.51 (s, 1H), 7.65 (d, J=8.59 Hz,1H). [M+H] calc'd for C₁₆H₁₉N₅O, 298; found, 298.

Example 506-((1R,2S)-2-Aminocyclohexylamino)-4-(benzofuran-3-yl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A. tert-Butyl(1S,2R)-2-(4-(benzofuran-3-yl)-2-(2,4-dimethoxybenzyl)-7-fluoro-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate

A mixture of tert-butyl(1S,2R)-2-(4-chloro-2-(2,4-dimethoxybenzyl)-7-fluoro-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate(65 mg, 0.118 mmol), aqueous sodium carbonate (2 N, 0.237 mL, 0.474mmol), 2-(benzofuran-3-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (43mg, 0.178 mmol) and bis(triphenylphosphine)palladium chloride (17 mg,0.024 mmol) in DME (2 mL) was placed in a vial. The vial was purged withnitrogen, sealed, and the reaction mixture heated at 120° C. for 1 h.The mixture was filtered through a pad of Celite, which was rinsed withMeOH. The solvent was removed in vacuo and the residue diluted withMeOH, passed through a microfiltration frit, and purified viapreparative HPLC. The fractions were collected and concentrated in vacuoto give the title compound as a tan oil (36.3 mg, 48%). [M+H] calc'd forC₃₅H₃₉FN₄O₆, 632; found, 632.

B.6-((1R,2S)-2-Aminocyclohexylamino)-4-(benzofuran-3-yl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A mixture of tert-butyl(1S,2R)-2-(4-(benzofuran-3-yl)-2-(2,4-dimethoxybenzyl)-7-fluoro-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate(75 mg, 0.119 mmol) and TFA (2 mL) was placed in a vial and heated at125° C. for 3 h. The solvent was subsequently removed in vacuo to give aresidue which was dispersed in DMSO and MeOH (1/1), passed through amicrofiltration frit, and purified via preparative HPLC. The fractionswere collected and the solvent removed in vacuo to give a TFA salt ofthe title compound as a gray solid (9.2 mg, 20%). ¹H NMR (500 MHz,CD₃OD) δ ppm 1.67 (br s, 3H), 1.79-2.05 (m, 5H), 3.98 (br s, 1H), 4.50(s, 2H), 4.69 (br s, 1H), 7.28-7.47 (m, 2H), 7.56 (d, J=7.81 Hz, 1H),8.31 (d, J=6.83 Hz, 1H), 9.08 (s, 1H). [M+H] calc'd for C₂₁H₂₁FN₄O₂,381; found, 381.

Example 516-((1R,2S)-2-aminocyclohexylamino)-7-fluoro-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A TFA salt of the title compound was prepared in a manner similar toEXAMPLE 50 using imidazo[1,2-a]pyridin-3-ylboronic acid in place of2-(benzofuran-3-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane. ¹H NMR (500MHz, CD₃OD) δ ppm 1.50-1.75 (m, 3H), 1.74-1.98 (m, 5H), 3.78 (br s, 1H),4.58 (br s, 3H), 7.57 (t, J=6.35 Hz, 1H), 7.93-8.21 (m, 2H), 8.78 (br s,1H), 9.45 (d, J=6.35 Hz, 1H). [M+H] calc'd for C₂₀H₂₁FN₆O, 381; found,381.

Example 526-((1R,2S)-2-aminocyclohexylamino)-4-(benzo[b]thiophen-3-yl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A TFA salt of the title compound was prepared in a manner similar toEXAMPLE 50 using benzo[b]thiophen-3-ylboronic acid in place of2-(benzofuran-3-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane. ¹H NMR (500MHz, CD₃OD) δ ppm 1.50-1.93 (m, 8H), 3.80 (br s, 1H), 4.42-4.68 (m, 3H),7.38 (m, J=4.40 Hz, 2H), 7.94 (br s, 1H), 8.00-8.20 (m, 2H). [M+H]calc'd for C₂₁H₂₁FN₄OS, 397; found, 397.

Example 536-((1S,2R)-2-Aminocyclohexylamino)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A. tert-Butyl(1R,2S)-2-(4-chloro-2-(2,4-dimethoxybenzyl)-7-fluoro-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate

To a mixture of4,6-dichloro-2-(2,4-dimethoxybenzyl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one(200 mg, 0.539 mmol) and tert-butyl (1R,2S)-2-aminocyclohexylcarbamate(173 mg, 0.808 mmol) in ACN (5 mL) was added N,N-diisopropylethylamine(0.141 mL, 0.808 mmol). The reaction mixture was heated in a sealed vialat 100° C. for several hours after which additional amine (0.5 eq) wasadded. The mixture was heated overnight and the solvent was subsequentlyremoved in vacuo. The residue was dispersed in DMSO and MeOH (1/1) andthe resulting mixture was filtered. The filtrate was purified viapreparative HPLC. The fractions were collected and dried in vacuo togive the title compound as a tan solid (60.7 mg, 21%). [M+H] calc'd forC₂₇H₃₄ClFN₄O₅, 550; found, 550

B. tert-Butyl(1R,2S)-2-(2-(2,4-dimethoxybenzyl)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate

A mixture of tert-butyl(1R,2S)-2-(4-chloro-2-(2,4-dimethoxybenzyl)-7-fluoro-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate(60 mg, 0.109 mmol),1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (34mg, 0.164 mmol) and bis(triphenylphosphine)palladium chloride (15 mg,0.022 mmol) in DME (1 mL) was placed in a vial. The vial was purged withnitrogen and aqueous sodium carbonate (2 N, 0.219 mL, 0.437 mmol) wasadded. The vial was sealed and the reaction mixture heated in an oilbath at 85° C. for 3 h. The reaction mixture was filtered through a padof Celite, which was rinsed with MeOH and DCM. The solvent was removedin vacuo and the residue was diluted with DMSO and MeOH (1/1). Theresulting mixture was filtered to recover a white precipitate (31.3 mg).The mother liquor was purified via preparative HPLC. The fractions werecollected and dried in vacuo to recover an additional white solid (10.2mg). The two crops were combined to give the title compound as a whitesolid (41.5 mg, 64%). [M+H] calc'd for C₃₁H₃₉FN₆O₅, 595; found, 595.

C.6-((1S,2R)-2-Aminocyclohexylamino)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A mixture of tert-butyl(1R,2S)-2-(2-(2,4-dimethoxybenzyl)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate(41.5 mg, 0.070 mmol) and TFA (2 mL) was heated at 65° C. for 3 h.Following reaction, the solvent was removed in vacuo. The residue wasdiluted with DMSO and MeOH (1/1), passed through a microfiltration frit,and purified via preparative HPLC. The fractions were collected anddried in vacuo to give a TFA salt of the title compound as a white solid(22 mg, 92%). ¹H NMR (500 MHz, CD₃OD) δ ppm 1.56-2.01 (m, 8H), 3.85 (brs, 1H), 3.94 (br s, 3H), 4.45 (br s, 2H), 4.67 (br s, 1H), 8.31 (br s,1H), 8.81 (br s, 1H). [M+H] calc'd for C₁₇H₂₁FN₆O, 345; found, 345.

Preparation 16: (R)-tert-Butyl 1-amino-3-ethoxypropan-2-ylcarbamate

A. (S)-2-(tert-Butoxycarbonylamino)-3-ethoxypropanoic acid

To a suspension of sodium hydride (17.73 g, 702 mmol) in THF (600 mL) at0° C. was added MeOH (18 mL) dropwise. The mixture was stirred at RT for1 h to yield a sodium methanolate solution. Iodoethane (25.5 mL, 316mmol) and a portion of the sodium methanolate solution (120 mL) wereadded to a solution of(S)-2-(tert-butoxycarbonylamino)-3-hydroxypropanoic acid (18 g, 88 mmol)in THF (600 mL). After stirring at RT for 1 h, the remaining sodiummethanolate solution (480 mL) was added, followed by additionaliodoethane (9.9 mL, 123 mmol). The mixture was stirred at RT overnight.The mixture was subsequently concentrated and the residue was dissolvedin water. The aqueous layer was washed with ether (250 mL), acidified topH 2 using 1N HCl, and extracted with EtOAc (3×300 mL). The combinedorganic layers were washed with 1M Na₂S₂O₃ (300 mL), dried, andconcentrated. The resulting crude material was reconstituted in MeOH,DCM and DMF (total volume: 50 mL) and purified via reverse phasepreparative HPLC. The fractions were collected and the ACN was removedvia rotary evaporation. The resulting aq solution was neutralized withsaturated aq NaHCO₃, washed with EtOAc (2×200 mL), dried over Na₂SO₄,filtered, and the organic phase stripped to dryness via rotaryevaporation to yield the title compound as a clear oil (1.81 g, 9%).[M+H] calc'd for C₁₀H₁₉NO₅, 234; found, 234.

B. (R)-tert-Butyl 1-ethoxy-3-hydroxypropan-2-ylcarbamate

To a solution of (S)-2-(tert-butoxycarbonylamino)-3-ethoxypropanoic acid(1.81 g, 7.76 mmol) in THF (20 mL) at −15° C. was added isobutylchloroformate (1.015 mL, 7.76 mmol) in THF (5 mL) and 4-methylmorpholine(0.853 mL, 7.76 mmol) in THF (5 mL). After stirring for 10 min at −15°C., the mixture was slowly added to a solution of sodium borohydride(0.881 g, 23.28 mmol) in H₂O (7 mL). The mixture was stirred at −15° C.for 30 min and was diluted with EtOAc. The organic layer was washed withsaturated aq NaHCO₃ and brine and dried. The residue was carried to nextstep without further purification (1.6 g, 94%). [M+H] calc'd forC₁₀H₂₁NO₄, 220; found, 220.

C. (R)-tert-Butyl 1-azido-3-ethoxypropan-2-ylcarbamate

Methanesulfonyl chloride (0.851 mL, 10.95 mmol) in DCM (1 mL) was addedto a solution of (R)-tert-butyl 1-ethoxy-3-hydroxypropan-2-ylcarbamate(1.6 g, 7.30 mmol) and Et₃N (1.538 mL, 10.95 mmol) in DCM (10 mL) at 0°C. After stirring at RT for 1 h, the mixture was diluted with EtOAc. Theorganic layer was washed with saturated aq NaHCO₃ solution, dried, andconcentrated in vacuo. The residue was dissolved in DMF (10.00 mL).Sodium azide (2.372 g, 36.5 mmol) and tetrabutylammonium iodide (0.270g, 0.730 mmol) were added, and the reaction mixture was stirred at 75°C. for 4 h. After cooling to RT, the mixture was diluted with EtOAc. Theorganic layer was washed with saturated aq NaHCO₃, dried, andconcentrated in vacuo to give the title compound (1.2 g, 67%). [M+H]calc'd for C₁₀H₂₀N₄O₃, 245; found, 245.

D. (R)-tert-Butyl 1-amino-3-ethoxypropan-2-ylcarbamate

A mixture of (R)-tert-butyl 1-azido-3-ethoxypropan-2-ylcarbamate (1.2 g,4.91 mmol) in MeOH (10 mL) was added palladium on carbon (0.523 g, 4.91mmol). The mixture was stirred under hydrogen atmosphere overnight atRT. The resulting crude material was reconstituted in MeOH (1.0 mL) andpurified via reverse phase preparative HPLC. The fractions werecollected and solvent was stripped to dryness via rotary evaporation togive the title compound as clear oil (722 mg, 67%). [M+H] calc'd forC₁₀H₂₂N₂O₃, 219; found, 219.

Preparation 17: (R)-tert-Butyl1-ethoxy-3-(3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)propan-2-ylcarbamate

A. (R)-Methyl6-(2-(tert-butoxycarbonylamino)-3-ethoxypropylamino)-4-cyano-2-(m-tolylamino)nicotinate

To a solution of methyl 6-chloro-4-cyano-2-(m-tolylamino)nicotinate (200mg, 0.663 mmol) in DMF (5 mL) was added DIPEA (0.232 mL, 1.326 mmol) and(R)-tert-butyl 1-amino-3-ethoxypropan-2-ylcarbamate (174 mg, 0.795mmol). The reaction mixture was stirred at RT overnight. Additional(R)-tert-butyl 1-amino-3-ethoxypropan-2-ylcarbamate (231.25 mg, 1.061mmol) was added and the mixture was heated at 65° C. for 1 h. Aftercooling to RT, the reaction mixture was diluted with EtOAc (30 mL) andwashed with water (2×20 mL) and brine (20 mL). The combined organiclayers were dried over Na₂SO₄ and concentrated to thick yellow oil. Thecrude product was used in the next step without further purification(415 mg). [M+H] calc'd for C₂₅H₃₃N₅O₅, 484; found, 484.

B. (R)-tert-Butyl1-ethoxy-3-(3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)propan-2-ylcarbamate

In a flask containing (R)-methyl6-(2-(tert-butoxycarbonylamino)-3-ethoxypropylamino)-4-cyano-2-(m-tolylamino)nicotinate(400 mg, 0.827 mmol) in HOAc (0.25 mL) and DCM (1 mL) was addedplatinum(IV) oxide (18.78 mg, 0.083 mmol). The flask was evacuated andfilled with H₂ three times, and the reaction mixture was stirredvigorously at RT under H₂ atmosphere for 3-4 h. The mixture wassubsequently filtered through Celite, and the solvent was removed invacuo. The residue was kept under vacuum overnight to remove excessHOAc. The crude residue was dissolved in anhydrous DCM (20 mL).Potassium carbonate (572 mg, 4.14 mmol) was added, and the mixture wasstirred at RT for 8 h. The mixture was filtered through Celite andconcentrated in vacuo. The residue was reconstituted in a MeOH/DCMsolution (1/1, 5 mL) and purified via reverse phase preparative HPLC.The collected fractions were concentrated in vacuo to give the titlecompound as a TFA salt (109 mg, 28.9%). [M+H] calc'd for C₂₄H₃₃N₅O₄,456; found, 456.

Example 54(R)-6-(2-Amino-3-ethoxypropylamino)-4-(m-tolylamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

To a solution of (R)-tert-butyl1-ethoxy-3-(3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)propan-2-ylcarbamate(109 mg, 0.239 mmol) in DCM (1 mL) was added a TFA/DCM solution (1/1, 10mL). The mixture was stirred at RT for 2 h. After removal of thesolvent, the resulting crude material was reconstituted in a solution ofMeOH/DCM (1/1, 5 mL) and was purified via reverse phase preparativeHPLC. The fractions were collected, and ACN was removed via rotaryevaporation. The resulting aq solution was neutralized with saturated aqNaHCO₃, washed with EtOAc (2×200 mL), dried over Na₂SO₄, and filtered.The organic phase was stripped to dryness via rotary evaporation to givethe title compound (11 mg, 13%). ¹H NMR (400 MHz, DMSO-d₆) δ ppm1.08-1.18 (m, 3H), 1.25-1.44 (m, 4H), 2.26-2.32 (m, 3H), 4.07-4.17 (m,3H), 4.19-4.29 (m, 2H), 6.03 (s, 1H), 6.78 (d, J=7.83 Hz, 1H), 7.06 (brs, 1H), 7.12-7.22 (m, 1H), 7.48 (s, 1H), 7.60 (d, J=7.83 Hz, 1H),7.66-7.75 (m, 2H), 7.99 (s, 1H), 8.83-8.97 (m, 1H). [M+H] calc'd forC₁₉H₂₅N₅O₂, 356; found, 356.

Preparation 18: (R)-tert-Butyl1-ethoxy-3-(7-fluoro-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)propan-2-ylcarbamate

To a chilled solution of (R)-tert-butyl1-ethoxy-3-(3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)propan-2-ylcarbamate(94.7 mg, 0.208 mmol) in CH₂Cl₂ (5 mL) at 0° C. was added SELECTFLUOR®(73.6 mg, 0.208 mmol). The mixture was left stirring in an ice bath andwarmed slowly to RT for 6 h. Afterwards, the mixture was diluted withEtOAc (10 mL) and washed with saturated aq NaHCO₃ (5 mL) followed bywater (5 mL) and brine (5 mL). The organic layers were combined, driedover Na₂SO₄, and concentrated to a brown residue. The resulting crudematerial was reconstituted in MeOH/DCM (5 mL) and purified viapreparative HPLC. The collected fractions were collected and ACN wasremoved via rotary evaporation. The resulting aq solution wasneutralized with saturated aq NaHCO₃ and washed with EtOAc (2×200 mL),dried over Na₂SO₄, filtered, and the organic phase stripped to drynessvia rotary evaporation to yield the title compound. [M+H] calc'd forC₂₄H₃₂FN₅O₄, 474; found, 474.

Example 55(R)-6-(2-Amino-3-ethoxypropylamino)-7-fluoro-4-(m-tolylamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A TFA salt of the title compound was prepared in a manner similar toEXAMPLE 54 using (R)-tert-butyl1-ethoxy-3-(7-fluoro-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)propan-2-ylcarbamatein place of (R)-tert-butyl1-ethoxy-3-(3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)propan-2-ylcarbamate.¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.08-1.19 (m, 3H), 2.25-2.36 (m, 3H),3.38-3.77 (m, 7H), 4.40 (s, 2H), 6.80 (d, J=7.58 Hz, 1H), 7.07-7.25 (m,2H), 7.38 (s, 1H), 7.54 (d, J=7.58 Hz, 1H), 7.92 (br s, 2H), 8.28 (s,1H), 8.83 (s, 1H). [M+H] calc'd for C₁₉H₂₄FN₅O₂, 374; found, 374.

Preparation 19: 3,3,3-Trifluoropropane-1,2-diamine

A. 3,3,3-Trifluoro-1-nitroprop-1-ene

A mixture of 2,2,2-trifluoroethane-1,1-diol (75% aq solution, 20 g, 0.13mol), CH₃NO₂ (24 g, 0.39 mol) and Na₂CO₃ (0.85 g, 8 mmol) was stirredovernight at RT. Water (50 mL) was added and the mixture was extractedwith diethyl ether (3×30 mL) and dried over Na₂SO₄. After concentratingthe organic extract at low temperature and under reduced pressure, P₂O₅(20.0 g, 0.14 mol) was added to the residue oil, which was distilled atatmospheric pressure to give a green-yellow oil (4 g, 50% purity, 10%yield). Boiling point 85-90° C.; ¹H NMR (400 MHz, CDCl₃) δ ppm 7.09-7.17(m, 1H), 7.50 (dd, J=2.0 Hz, 12.0 Hz, 1H).

B. N-Benzyl-1,1,1-trifluoro-3-nitropropan-2-amine

A mixture of 3,3,3-trifluoro-1-nitroprop-1-ene (4 g, 28.4 mmol) andbenzylamine (3.2 g, 30.0 mmol) in toluene (50 mL) was stirred for RT or1 h. The mixture was concentrated and the residue was purified by columnchromatography (EtOAc/PE=1/10) to give the title compound (5.5 g, 78%).¹H NMR (400 MHz, CDCl₃) δ ppm 3.91-3.95 (m, 1H), 4.06-4.14 (m, 1H),4.45-4.51 (m, 1H), 4.63-4.67 (m, 1H), 7.30-7.39 (m, 5H).

C. Di-tert-butyl N,N-(3,3,3-trifluoropropane-1,2-diyl)-biscarbamate

A mixture of N-benzyl-1,1,1-trifluoro-3-nitropropan-2-amine (5.5 g, 22.0mmol) and Pd/C (3.0 g) in MeOH was stirred at RT overnight under H₂atmosphere. The mixture was subsequently filtered and concentrated toafford an oil, which was combined with di-tert-butyl pyrocarbonate (11.0g, 50.0 mmol) and Et₃N (5.0 g, 50.0 mmol) in DCM (100 mL). The mixturewas stirred overnight and then concentrated. The residue was purified bycolumn chromatography (EtOAc/PE=1/7) to give the title compound as awhite solid (5.5 g).

D. 3,3,3-Trifluoropropane-1,2-diamine

A mixture of di-tert-butylN,N-(3,3,3-trifluoropropane-1,2-diyl)-biscarbamate and 1.0 M HCl-EtOAcwas stirred at RT overnight to give the title compound (1.5 g, 54%). ¹HNMR (400 MHz, CD₃OD) δ ppm 3.50-3.55 (m, 1H), 3.61-3.66 (m, 1H),4.58-4.63 (m, 1H). [M+H] calc'd for C₃H₇F₃N₂, 129; found, 129.

Example 566-(2-Amino-3,3,3-trifluoropropylamino)-4-(m-tolylamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

The title compound was prepared in a manner similar to EXAMPLE 54 using3,3,3-trifluoropropane-1,2-diamine in place of (R)-tert-butyl1-amino-3-ethoxypropan-2-ylcarbamate. ¹H NMR (400 MHz, DMSO-d₆) δ ppm1.12-1.39 (m, 2H), 1.91-2.15 (m, 1H), 2.22-2.40 (m, 3H), 3.47-3.66 (m,1H), 3.66-3.86 (m, 1H), 4.14-4.27 (m, 1H), 4.33-4.46 (m, 1H), 4.74-4.89(m, 1H), 5.96-6.13 (m, 1H), 6.71-6.86 (m, 1H), 7.08-7.26 (m, 1H),7.38-7.70 (m, 2H), 8.79-9.07 (m, 1H). [M+H] calc'd for C₁₇H₁₈F₃N₅O, 366;found, 366.

Example 57(R)-4-Methyl-2-(3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)pentanamide

The title compound was prepared in a manner similar to EXAMPLE 54 using(R)-2-amino-4-methylpentanamide (64.7 mg, 0.497 mmol) in place of(R)-tert-butyl 1-amino-3-ethoxypropan-2-ylcarbamate. ¹H NMR (400 MHz,DMSO-d₆) δ ppm 0.82-0.88 (m, 3H), 0.91-0.96 (m, 3H), 1.18-1.32 (m, 1H),1.61 (t, J=7.33 Hz, 2H), 1.69-1.83 (m, 1H), 2.24-2.34 (m, 3H), 4.21 (s,1H), 4.37 (s, 1H), 6.00-6.17 (m, 1H), 6.69-6.80 (m, 1H), 6.96 (br s,1H), 7.04 (d, J=7.83 Hz, 1H), 7.10-7.26 (m, 2H), 7.49 (s, 1H), 7.58 (d,J=7.33 Hz, 1H), 7.95 (s, 1H), 8.82-8.97 (m, 1H). [M+H] calc'd forC₂₀H₂₅N₅O₂, 368; found, 368.

Preparation 20: (3R,4S)-Tetrahydrofuran-3,4-diamine

A. (3R,4S)-tetrahydrofuran-3,4-diyl dimethanesulfonate

Methanesulfonyl chloride (1.642 mL, 21.13 mmol) in DCM (5 mL) was addedto a solution of (3R,4S)-tetrahydrofuran-3,4-diol (0.787 mL, 9.61 mmol)and Et₃N (4.05 mL, 28.8 mmol) in DCM (10 mL) at 0° C. After stirring at0° C. for 1 h, the mixture was diluted with DCM. The organic layer waswashed with saturated aqueous NaHCO₃, dried, and concentrated in vacuoto give the title compound as a yellowish white solid (2.5 g, 100%). ¹HNMR (400 MHz, CDCl₃) δ ppm 3.09-3.20 (m, 6H), 3.90-4.07 (m, 2H),4.10-4.22 (m, 2H), 5.19 (ddd, J=5.31, 3.54, 1.77 Hz, 2H).

B. (3R,4S)-3,4-Diazidotetrahydrofuran

To a solution of (3R,4S)-tetrahydrofuran-3,4-diyl dimethanesulfonate(2.5 g, 9.60 mmol) in DMF (50 mL) was added sodium azide (3.75 g, 57.6mmol) and tetrabutylammonium iodide (0.355 g, 0.960 mmol). The reactionmixture was heated at 100° C. overnight. After cooling to RT, themixture was diluted with EtOAc, and the organic layer was washed withbrine, dried over Na₂SO₄, and concentrated in vacuo. The residue wasdispersed in toluene and the mixture was evaporated in vacuo to removeexcess DMF and to give the title compound as brown oil which was used inthe next step without further purification (2.2 g). ¹H NMR (400 MHz,CDCl₃) δ ppm 3.72-3.87 (m, 2H), 3.94-4.46 (m, 4H).

C. (3R,4S)-Tetrahydrofuran-3,4-diamine

To a mixture of (3R,4S)-3,4-diazidotetrahydrofuran (2.2 g, 14.27 mmol)dispersed in MeOH (10 mL) and DCM (8 mL) was added palladium on carbon(1.519 g, 14.27 mmol). The reaction mixture was stirred under H₂atmosphere overnight. Following hydrogenation, the mixture was filteredthrough Celite and the solvent was removed in vacuo to yield the titlecompound which was used without further purification (1.54 g).

Example 586-(cis-4-Aminotetrahydrofuran-3-ylamino)-4-(m-tolylamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A. Methyl6-(cis-4-Aminotetrahydrofuran-3-ylamino)-4-cyano-2-(m-tolylamino)nicotinate

To a solution of methyl 6-chloro-4-cyano-2-(m-tolylamino)nicotinate (40mg, 0.133 mmol) in DMF (1 mL) was added DIPEA (0.046 mL, 0.265 mmol) and(3R,4S)-tetrahydrofuran-3,4-diamine (13.54 mg, 0.133 mmol). The mixturewas stirred at RT overnight. Additional amine was added and the reactionmixture was stirred at RT for an additional day. The reaction mixturewas diluted in MeOH (10 mL) and purified by reverse phase preparativeHPLC. The fractions were collected and ACN was removed via rotaryevaporation. The resulting aq solution was neutralized with saturated aqNaHCO₃ and washed with EtOAc (2×200 mL), dried over Na₂SO₄, andfiltered. The organic phase was stripped to dryness via rotaryevaporation to yield the title compound (35.5 mg, 73%). [M+H] calc'd forC₁₉H₂₁N₅O₃, 368; found, 368.

B.6-(cis-4-Aminotetrahydrofuran-3-ylamino)-4-(m-tolylamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

To a vessel containing methyl6-(cis-4-aminotetrahydrofuran-3-ylamino)-4-cyano-2-(m-tolylamino)nicotinate(35.5 mg, 0.097 mmol) in MeOH (5 mL) and HOAc (2.5 mL) was addedpalladium on carbon (1.028 mg, 9.66 μmol). The vessel was evacuated andfilled with H₂ three times, and the mixture was then stirred vigorouslyat RT under H₂ atmosphere overnight. The mixture was subsequentlyfiltered through Celite, and the solvent was removed in vacuo. Theresidue was dissolved in DCM (10 mL) and MeOH (5 mL) and potassiumcarbonate (26.7 mg, 0.193 mmol) was added. The mixture was stirred at RTovernight. Additional potassium carbonate (40.1 mg, 0.290 mmol) wasadded and the reaction mixture was stirred for 4 h at RT, and thenheated at 50° C. for 30 min. The mixture was filtered to remove solidK₂CO₃ and the filtrate was diluted with MeOH (10 mL) and purified byreverse phase preparative HPLC. The fractions were collected andconcentrated in vacuo to give a TFA salt of the title compound (4.5 mg,13.7%). ¹H NMR (500 MHz, DMSO-d₆) δ ppm 2.30 (s, 3H), 2.52-2.58 (m, 2H),3.67-3.83 (m, 2H), 3.90 (br s, 1H), 3.98-4.14 (m, 2H), 4.20-4.30 (m,2H), 4.58 (br s, 1H), 6.16 (s, 1H), 6.81 (d, J=7.32 Hz, 1H), 7.11-7.27(m, 2H), 7.46 (d, J=7.32 Hz, 1H), 7.59 (br s, 1H), 8.08 (s, 1H), 8.94(s, 1H). [M+H] calc'd for C₁₈H₂₁N₅O₂, 340; found, 340.

Preparation 21: tert-Butyl(1S,2R)-2-(4-(1-ethyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate

A. Methyl 4-cyano-2-(1-ethyl-1H-pyrazol-4-yl)nicotinate

A mixture of methyl 2-chloro-4-cyanonicotinate (207 mg, 1.053 mmol),1-ethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (201mg, 0.905 mmol) and tetrakis(triphenylphosphine)palladium(0) (122 mg,0.105 mmol) in DME (2 mL), and saturated aq Na₂CO₃ (2 mL) was stirred at80° C. for 3 h under N₂ atmosphere. Water and EtOAc were subsequentlyadded. The organic phase was washed with H₂O and brine, dried overMgSO₄, and evaporated to yield the title compound (265.3 mg, 98%). [M+H]calc'd for C₁₃H₁₂N₄O₂, 257; found, 257.

B. 4-Cyano-2-(1-ethyl-1H-pyrazol-4-yl)-3-(methoxycarbonyl)pyridine1-oxide

To a mixture of methyl 4-cyano-2-(1-ethyl-1H-pyrazol-4-yl)nicotinate(207 mg, 0.808 mmol) in ACN (2 mL) was added urea hydrogen peroxide (380mg, 4.04 mmol) and trifluoroacetic anhydride (0.456 mL, 3.23 mmol) at 0°C. The resulting mixture was stirred at RT overnight. Next, saturated aqNaHCO₃ solution and chloroform were added. The aqueous phase wasextracted with chloroform (3×200 mL). The organic layers were combinedand washed with brine, dried over MgSO₄, and evaporated to give thetitle compound which was used without further purification (210 mg,95%). [M+H] calc'd for C₁₃H₁₂N₄O₃, 273.5; found, 273.5.

C. Methyl 6-chloro-4-cyano-2-(1-ethyl-1H-pyrazol-4-yl)nicotinate

A solution of4-cyano-2-(1-ethyl-1H-pyrazol-4-yl)-3-(methoxycarbonyl)pyridine 1-oxide(210 mg, 0.771 mmol) in POCl₃ (2 mL) was heated at 80° C. for 3-4 h. Themixture was concentrated and purified by flash chromatography (SiO₂,10-100% EtOAc in Hexane). The fractions were collected and the solventwas removed in vacuo to give the title compound (201 mg, 90%).

D. Methyl6-((1R,2S)-2-(tert-butoxycarbonylamino)cyclohexylamino)-4-cyano-2-(1-ethyl-1H-pyrazol-4-yl)nicotinate

To a solution of methyl6-chloro-4-cyano-2-(1-ethyl-1H-pyrazol-4-yl)nicotinate (201 mg, 0.691mmol) in DMF (1 mL) was added DIPEA (0.242 mL, 1.383 mmol) andtert-butyl (1S,2R)-2-aminocyclohexylcarbamate (237 mg, 1.106 mmol). Thereaction mixture was stirred at 100° C. overnight, after which thesolvent was removed, and the resulting crude material was diluted inMeOH (5.0 mL) and purified via reverse phase preparative HPLC. Thecollected fractions were collected and ACN was removed via rotaryevaporation. The resulting aq solution was neutralized with saturated aqNaHCO₃ and washed with EtOAc (2×200 mL), dried over Na₂SO₄, andfiltered. The organic phase was stripped to dryness via rotaryevaporation to yield the title compound (62 mg, 19%). [M+H] calc'd forC₂₄H₃₂N₆O₄, 469; found, 469.

E. tert-Butyl(1S,2R)-2-(4-(1-ethyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate

To a flask containing methyl6-((1R,2S)-2-(tert-butoxycarbonylamino)cyclohexyl-amino)-4-cyano-2-(1-ethyl-1H-pyrazol-4-yl)nicotinate(62 mg, 0.132 mmol) in MeOH (2 mL) was added HOAc (1 mL) to give ayellow solution. Palladium on carbon was added (14.08 mg, 0.132 mmol).The flask was evacuated and filled with H₂ three times, after which themixture was stirred vigorously at RT under a H₂ atmosphere overnight.The mixture was filtered through Celite, and the solvent was removed invacuo to give a residue, which was dissolved in DCM (10 mL) and MeOH (10mL). Potassium carbonate was added and the mixture was stirred for 5 h.The solids were filtered out and the filtrate concentrated to give thetitle compound (50 mg, 86%). [M+H] calc'd for C₂₃H₃₂N₆O₃, 441; found,441.

Example 596-((1R,2S)-2-Aminocyclohexylamino)-4-(1-ethyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

To a solution of tert-butyl(1S,2R)-2-(4-(1-ethyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate(50 mg, 0.113 mmol) in DCM (1 mL) was added DCM/TFA (1/1, 2 mL). Themixture was stirred at RT for 2 h. After removal of solvent, theresulting crude material was reconstituted in MeOH (5.0 mL) and waspurified by preparative HPLC. The fractions were collected and thesolvent stripped to dryness via rotary evaporation to yield the titlecompound as a TFA salt (10.5 mg, 27%). ¹H NMR (500 MHz, DMSO-d₆) δ ppm1.31-1.55 (m, 6H), 1.58-1.86 (m, 8H), 4.20-4.31 (m, 3H), 6.56 (s, 1H),6.84 (d, J=7.32 Hz, 1H), 7.56-7.76 (m, 2H), 8.10 (s, 1H), 8.38 (s, 1H),8.96 (s, 1H). [M+H] calc'd for C₁₈H₂₄N₆O, 341; found, 341.

Example 606-((1R,2S)-2-Aminocyclohexylamino)-4-(1-ethyl-1H-pyrazol-4-yl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A. tert-Butyl(1S,2R)-2-(4-(1-ethyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino

A solution of tert-Butyl(1S,2R)-2-(4-(1-ethyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate(69.7 mg, 0.158 mmol) in DCM (5 mL) was cooled to 0° C. SELECTFLUOR® (84mg, 0.237 mmol) was added. The mixture was left stirring in an ice bathand was allowed to warm slowly to RT with stirring overnight. AdditionalSELECTFLUOR® (2 eq) was added and the reaction was stopped after 2 h.After removal of solvent, the residue was diluted with EtOAc (10 mL) andwashed with saturated aq NaHCO₃ (5 mL), water (5 mL), and brine (5 mL).The organic layers were combined, dried over Na₂SO₄, and concentrated toa brown residue. The resulting crude material was reconstituted inMeOH/DCM (6 mL) and was purified via preparative HPLC. The fractionswere collected and ACN was removed via rotary evaporation. The resultingaq solution was neutralized with saturated aq NaHCO₃, washed with EtOAc(2×200 mL), dried over Na₂SO₄, and filtered. The organic phase wasstripped to dryness via rotary evaporation to yield the title compound(20 mg, 28%). [M+H] calc'd for C₂₃H₃₁FN₆O₃, 459; found, 459.

B.6-((1R,2S)-2-Aminocyclohexylamino)-4-(1-ethyl-1H-pyrazol-4-yl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

To a solution of tert-butyl(1S,2R)-2-(4-(1-ethyl-1H-pyrazol-4-yl)-7-fluoro-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate(20 mg, 0.044 mmol) in DCM (1 mL) was added DCM/TFA (1/1, 2 mL). Themixture was stirred at RT for 2 h. After removal of solvent, theresulting crude material was reconstituted in MeOH (5.0 mL) and waspurified by preparative HPLC. The fractions were collected and solventstripped to dryness via rotary evaporation to yield the title compoundas a TFA salt (7 mg, 45%). ¹H NMR (500 MHz, DMSO-d₆) δ ppm 1.40 (t,J=7.08 Hz, 4H), 1.54-1.72 (m, 2H), 1.75-1.97 (m, 2H), 3.47-3.60 (m, 2H),3.69 (br s, 1H), 4.18 (q, J=7.32 Hz, 2H), 4.33-4.52 (m, 3H), 6.74 (d,J=6.83 Hz, 1H), 7.77 (br s, 3H), 8.26-8.44 (m, 2H), 8.88 (s, 1H). [M+H]calc'd for C₁₈H₂₃FN₆O, 359; found, 359.

Preparation 22:1-Isopropyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole

In a microwave vial, a solution of4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (1 g, 5.15mmol) in DMF (10 mL) was added cesium carbonate (5.04 g, 15.46 mmol) and2-iodopropane (2.58 mL, 25.8 mmol). The mixture was heated at 100° C.overnight. After cooling to RT, H₂O (300 mL) was added and the aqueouslayer was extracted with EtOAC (2×200 mL). The organic extracts werecombined, dried over Na₂SO₄, filtered, and solvent was removed in vacuo.The resulting crude material was reconstituted in MeOH (1.0 mL) andpurified by HPLC. The fractions were collected and stripped to drynessvia rotary evaporation to yield the title compound. [M+H] calc'd forC₁₂H₂₁BN₂O₂, 237; found 237.

Preparation 23:1-Cyclopropyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole

The title compound was prepared in a manner similar to PREPARATION 22using bromocyclopropane in place of iodopropane. [M+H] calc'd forC₁₂H₁₉BN₂O₂, 234; found, 234.

Preparation 24:1-(Difluoromethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole

The title compound was prepared in a manner similar to PREPARATION 22using difluoroiodomethane in place of iodopropane and carrying out thereaction at 90° C. [M+H] calc'd for C₁₀H₁₅BF₂N₂O₂, 245; found, 245.

Example 616-((1R,2S)-2-Aminocyclohexylamino)-4-(1-cyclopropyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A TFA salt of the title compound was prepared in a manner similar toEXAMPLE 59 using1-cyclopropyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazolein place of1-ethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole. ¹HNMR (500 MHz, CD₃OD) δ ppm 1.47-1.67 (m, 4H), 1.69-1.95 (m, 8H),3.63-3.74 (m, 3H), 4.35 (s, 2H), 6.65 (s, 1H), 8.35 (s, 1H), 8.96 (s,1H). [M+H] calc'd for C₁₉H₂₄N₆O, 353; found, 353.

Example 626-((1R,2S)-2-Aminocyclohexylamino)-4-(1-(difluoromethyl)-1H-pyrazol-4-yl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A. tert-Butyl(1S,2R)-2-(4-(1-(difluoromethyl)-1H-pyrazol-4-yl)-2-(2,4-dimethoxybenzyl)-7-fluoro-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate

A solution of tert-butyl(1S,2R)-2-(4-chloro-2-(2,4-dimethoxybenzyl)-7-fluoro-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate(35 mg, 0.064 mmol),1-(difluoromethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole(18.67 mg, 0.076 mmol) and bis(triphenylphosphine)palladium chloride(44.7 mg, 0.064 mmol) in dioxane (500 μL) and saturated aq Na₂CO₃ (500μL) was heated at 85° C. for 2 h. After filtering out the solids, thesolvent was removed and the residue was dissolved in MeOH and DCM andpurified by preparative HPLC. The fractions were collected and ACN wasremoved via rotary evaporation. The resulting aq solution wasneutralized with saturated aq NaHCO₃, washed with EtOAc (2×200 mL),dried over Na₂SO₄, and filtered. The organic phase was stripped todryness via rotary evaporation to yield the title compound (36 mg, 90%).[M+H] calc'd for C₃₁H₃₇F₃N₆O₅, 631; found, 631.

B.6-((1R,2S)-2-Aminocyclohexylamino)-4-(1-(difluoromethyl)-1H-pyrazol-4-yl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A solution of tert-butyl(1S,2R)-2-(4-(1-(difluoromethyl)-1H-pyrazol-4-yl)-2-(2,4-dimethoxybenzyl)-7-fluoro-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate(36 mg, 0.057 mmol) in TFA (2 mL) was heated at 60° C. for 2 h. Afterremoval of the solvent, the residue was diluted in MeOH (2 mL) and waspurified by preparative HPLC. The fractions were collected and strippedto dryness via rotary evaporation to yield the title compound as a TFAsalt (18.7 mg, 86%). ¹H NMR (500 MHz, DMSO-d₆) δ ppm 1.40-1.52 (m, 2H),1.58-1.76 (m, 3H), 1.75-1.94 (m, 3H), 3.67 (br s, 1H), 4.44 (d, J=4.88Hz, 2H), 4.53 (br s, 1H), 6.86 (d, J=6.83 Hz, 1H), 7.71 (br s, 2H),7.79-8.12 (m, 1H), 8.53 (s, 2H), 9.41 (s, 1H). [M+H] calc'd forC₁₇H₁₉F₃N₆O, 381; found, 381.

Example 636-((1R,2S)-2-Aminocyclohexylamino)-4-(1-cyclopropyl-1H-pyrazol-4-yl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A TFA salt of the title compound was prepared in a manner similar toEXAMPLE 62 using1-cyclopropyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazolein place of1-(difluoromethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole.¹H NMR (500 MHz, DMSO-d₆) δ ppm 0.94-1.11 (m, 4H), 1.47 (d, J=6.35 Hz,2H), 1.56-1.97 (m, 6H), 3.60-3.85 (m, 2H), 4.28-4.53 (m, 3H), 6.74 (d,J=6.35 Hz, 1H), 7.70 (br s, 2H), 8.25 (s, 1H), 8.38 (s, 1H), 8.94 (s,1H). [M+H] calc'd for C₁₉H₂₃FN₆O, 371; found, 371.

Example 64cis-6-(2-Aminocyclohexylamino)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A. cis-tert-Butyl2-(4-chloro-2-(2,4-dimethoxybenzyl)-7-fluoro-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate

A mixture of4,6-dichloro-2-(2,4-dimethoxybenzyl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one(316 mg, 0.851 mmol) and cis-tert-butyl 2-aminocyclohexylcarbamate (365mg, 1.703 mmol) and DIPEA (0.743 mL, 4.26 mmol) in ACN (2 mL) wasstirred at 85° C. for 3 d. The resulting crude material wasreconstituted in MeOH (1 mL) and purified by preparative HPLC. Thefractions were collected and stripped to dryness via rotary evaporationto yield the title compound (161 mg, 34%). ¹H NMR (500 MHz, DMSO-d₆) δppm 1.35 (br s, 10H), 1.58 (br s, 2H), 1.76 (br s, 2H), 3.71-3.90 (m,11H), 4.33 (br s, 2H), 4.51 (br s, 2H), 6.43-6.72 (m, 3H), 6.87 (br s,1H), 7.07 (br s, 1H). [M+H] calc'd for C₂₇H₃₄ClFN₄O₅, 549; found, 549.

B. cis-tert-Butyl2-(2-(2,4-dimethoxybenzyl)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate

A solution of cis-tert-butyl2-(4-chloro-2-(2,4-dimethoxybenzyl)-7-fluoro-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate(135.8 mg, 0.247 mmol),1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole(154 mg, 0.742 mmol) and bis(triphenylphosphine)palladium chloride (174mg, 0.247 mmol) in dioxane (2 mL) and saturated aq Na₂CO₃ (2 mL) washeated at 120° C. for 30 min. After filtering out the solids, thesolvent was removed and the residue was dissolved in MeOH and DCM andthe mixture was purified by preparative HPLC. The fractions werecollected and the solvent was stripped to dryness via rotary evaporationto give the title compound (109 mg, 74%). ¹H NMR (500 MHz, DMSO-d₆) δppm 0.97-1.98 (m, 10H), 2.28-2.44 (m, 3H), 2.56-2.72 (m, 4H), 3.63-3.99(m, 11H), 4.36 (d, J=18.06 Hz, 2H), 4.56 (br s, 2H), 6.50 (br s, 1H),6.61 (br s, 1H), 6.65-6.81 (m, 1H), 7.08 (br s, 1H), 7.70 (br s, 1H),8.30 (br s, 1H), 8.75-9.02 (m, 1H). [M+H] calc'd for C₃₁H₃₉FN₆O₅, 595;found, 595.

C.cis-6-(2-Aminocyclohexylamino)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A solution of cis-tert-butyl2-(2-(2,4-dimethoxybenzyl)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate(109 mg, 0.183 mmol) in TFA (5 mL) was heated at 60° C. for 2 h. Afterremoval of the solvent, the residue was diluted in MeOH (2 mL) and waspurified by preparative HPLC. The fractions were collected and strippedto dryness via rotary evaporation to give the title compound as a TFAsalt. ¹H NMR (500 MHz, DMSO-d₆) δ ppm 1.47 (br s, 2H), 1.57-1.75 (m,3H), 1.84 (br s, 2H), 3.12-3.23 (m, 2H), 3.87-3.94 (m, 3H), 4.35-4.50(m, 3H), 6.73 (br s, 1H), 7.71 (br s, 2H), 8.28-8.44 (m, 2H), 8.84 (d,J=3.91 Hz, 1H). [M+H] calc'd for C₁₇H₂₁FN₆O, 345; found, 345.

Example 656-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A TFA salt of the title compound was prepared in a manner similar toEXAMPLE 64 using (3R,4R)-tetrahydro-2H-pyran-3,4-diamine dihydrochloridein place of cis-tert-butyl 2-aminocyclohexylcarbamate. The desiredstereoisomer was isolated using preparative HPLC. ¹H NMR (500 MHz,CD₃OD) δ ppm 1.29 (br s, 2H), 1.86-1.99 (m, 1H), 3.84-3.99 (m, 4H),4.03-4.17 (m, 1H), 4.45 (br s, 2H), 8.29 (br s, 1H), 8.79 (br s, 1H).[M+H] calc'd for C₁₆H₁₉FN₆O₂₀, 347; found, 347.

Preparation 25: cis-4,4-Difluorocyclopentane-1,2-diamine

A. Cyclopenta-1,3-diene

A flask containing dicyclopentadiene was flushed with N₂ for 1 min andwas then heated by oil bath to approximately 180° C. Cyclopentadienedistilled slowly at 40-45° C. The title compound (100 g) was collectedand kept at −70° C. under N₂. ¹H NMR (400 MHz, CDCl₃) δ ppm 3.02 (t,J=1.4 Hz, 2H), 6.49-6.51 (m, 2H), 6.61-6.62 (m, 2H).

B. Cyclopent-3-enol

To cooled alpha-pinene (225.0 g, 1.65 mol) at 0° C. was added dropwiseBH₃-THF (1 M, 750 mL) over a 30 min period under N₂ atmosphere. Thereaction mixture was stirred for 3.5 h at 0° C. Distilledcyclopenta-1,3-diene (99.0 g, 1.50 mol) was added dropwise at 0° C. overa 40 min period. The resulting mixture was slowly warmed to RT andstirred for 20 h. Excess hydride was decomposed by adding water (30 mL)at a temperature below 10° C. Aqueous NaOH (3N, 300 mL) was added at atemperature below 5° C., followed by H₂O₂ (30%, 250 mL). The aqueouslayer was salted out with NaCl, and the organic layer was separated anddried over Na₂SO₄. The product was distilled at 65° C. under a reducedpressure of 20 mm Hg to give the title compound as an oil (30.4 g, 24%).¹H NMR (400 MHz, CDCl₃) δ ppm 2.29 (d, J=17.6 Hz, 2H), 2.61 (dd, J=6.0,16.4 Hz, 2H), 4.82 (s, 1H), 5.68 (s, 2H).

C. ((Cyclopent-3-enyloxy)methyl)benzene

To a cooled solution of cyclopent-3-enol (30.40 g, 0.36 mol) in THF (300mL) at 0° C. was added NaH (18.82 g, 0.47 mol, 60% in mineral oil).After effervescence had ceased, benzyl bromide (80.45 g, 0.47 mol) wasadded dropwise at 0° C. over a 45 min period. The reaction mixture wasallowed to warm to RT over a 6 h period. Excess NaH was quenched withMeOH (120 mL) at a temperature below 5° C. The mixture was warmed to RT,diluted with H₂O, and the two layers were separated. The aqueous layerwas extracted with EtOAc. The organic layers were combined,concentrated, and purified by column chromatography eluting withpetroleum ether and EtOAc (PE/EA=40/1 to 30/1) to give the titlecompound as an oil (45.28 g, 72%). ¹H NMR (400 MHz, CDCl₃) δ ppm2.38-2.41 (m, 2H), 2.49-2.54 (m, 2H), 4.20-4.24 (m, 1H), 4.42 (s, 2H),5.62 (s, 2H), 7.17-7.28 (m, 5H).

D. (1R,3s,5S)-3-(Benzyloxy)-6-oxabicyclo[3.1.0]hexane and(1R,3r,5S)-3-(Benzyloxy)-6-oxabicyclo[3.1.0]hexane

To a cooled solution of ((cyclopent-3-enyloxy)methyl)benzene (45.28 g,260 mmol) in DCM (300 mL) at 0° C. was added m-chloroperoxybenzoic acid(111.9 g, 520 mmol) in one portion. The mixture was stirred at atemperature from 0° C. to RT overnight. The reaction mixture wasfiltered and excess m-chloroperoxybenzoic acid was reduced by theaddition of saturated aq Na₂S₂O₃ until a negative starch iodide test wasobserved. The mixture was neutralized with saturated NaHCO₃ to pH 8-9and filtered. The filtrate was separated with DCM, washed with brine,dried over Na₂SO₄, and purified by column chromatography eluting withpetroleum ether and EtOAc (PE/EtOAc=30/1, 20/1 to 10/1) to give thetitle compounds as oils ((1R,3s,5S): 14.41 g, 76 mmol; ((1R,3r,55):21.38 g, 113 mmol). ¹H NMR of (1R,3s,5S) (400 MHz, CDCl₃) δ ppm 1.69(dd, J=6.8, 14.0 Hz, 2H), 2.49 (dd, J=7.2, 14.0 Hz, 2H), 3.49 (s, 2H),3.85 (quintet J=7.0 Hz, 1H), 4.43 (s, 2H), 7.25-7.34 (m, 5H); ¹H NMR of(1R,3r,5S) (400 MHz, CDCl₃) δ ppm 1.99 (dd, J=7.6, 15.6 Hz, 2H), 2.23(d, J=16.6 Hz, 2H), 3.55 (s, 2H), 4.08 (t, J=7.2 Hz, 1H), 4.49 (s, 2H),7.27-7.35 (m, 5H).

E. (1S,2S,4R)-2-Azido-4-(benzyloxy)cyclopentanol

To a solution of (1R,3s,5S)-3-(benzyloxy)-6-oxabicyclo[3.1.0]hexane(14.41 g, 76 mmol) in EtOH/H₂O (550 mL/160 mL) was added NH₄Cl (15.06 g,284 mmol) and sodium azide (18.47 g, 284 mmol), The mixture was refluxedovernight and then cooled to RT. After removing EtOH, water was addedand the residue was extracted with EtOAc. The organic layer was washedwith brine, dried over Na₂SO₄, and purified by column chromatographyeluting with petroleum ether and EtOAc (PE/EtOAc=20/1, 10/1 to 6/1) togive the title compound as an oil (18.24 g, 78.3 mmol). ¹H NMR (400 MHz,CDCl₃) δ ppm 1.65-1.79 (m, 2H), 2.01-2.07 (m, 1H), 2.30-2.37 (m, 1H),3.49-3.54 (m 1H), 3.97-4.06 (m, 2H), 4.11-4.13 (br, 1H), 4.33-4.40 (m,2H), 7.18-7.27 (m, 5H).

F. (1R,2R,4R)-2-Azido-4-(benzyloxy)cyclopentyl methanesulfonate

To a cooled mixture of Et₃N (9.49 g, 94.0 mmol) and(1S,2S,4R)-2-azido-4-(benzyloxy)cyclopentanol (18.25 g, 78.3 mmol) inDCM (500 mL) was added dropwise methanesulfonyl chloride (9.87 g, 86.2mmol) in DCM (50 mL) at 0° C. The mixture was stirred overnight at atemperature of 0° C. to RT. After complete conversion, aq NaHCO₃ (5%,300 mL) was added. The mixture was extracted with DCM, washed withbrine, and dried over Na₂SO₄ to give the title compound as an oil (23.58g, 75.8 mmol). ¹H NMR (400 MHz, CDCl₃) δ ppm 1.83-1.89 (m, 1H),2.06-2.13 (m, 1H), 2.34-2.49 (m, 2H), 3.04 (s, 3H), 3.94-3.99 (m, 1H),4.08-4.13 (m, 1H), 4.64 (s, 2H), 4.93-4.98 (q, J=5.6/7.0 Hz, 1H),7.25-7.36 (m, 5H).

G. (((1s,3R,4S)-3,4-Diazidocyclopentyloxy)methyl)benzene

To a mixture of (1R,2R,4R)-2-azido-4-(benzyloxy)cyclopentylmethanesulfonate (23.58 g 75.8 mmol), pyridine (25 mL), water (140 mL),and DMA (350 mL) was added NaN₃ (10.84 g, 166.8 mmol). The mixture washeated at 130° C. under N₂ atmosphere overnight. The reaction mixturewas cooled to RT and quenched with cold water (300 mL). The mixture wasextracted with EtOAc, washed with H₂O (several times) and with brine,dried over Na₂SO₄, and purified by column chromatography eluting withpetroleum ether and EtOAc (PE/EA=40/1 to 30/1) to give the titlecompound as an oil (15.35 g, 59.5 mmol). ¹H NMR (400 MHz, CDCl₃) δ ppm1.99-2.08 (m. 2H), 2.23-2.30 (m, 2H), 3.75-3.80 (m, 2H), 3.99-4.04 (m,1H), 4.49 (s, 2H), 7.26-7.35 (m, 5H).

H. Di-tert-butylN,N-((1R,2S,4s)-4-hydroxycyclopentane-1,2-diyl)-biscarbamate

To a solution of (((1s,3R,4S)-3,4-diazidocyclopentyloxy)methyl)benzene(15.35 g, 59.5 mmol) and di-tert-butyl pyrocarbonate (31.69 g, 145.4mmol) in MeOH (200 mL) was added Pd/C (50% wet, 8.0 g) in an autoclave.The autoclave was charged with H₂ to 2.2 MPa. The reaction mixture wasstirred at RT overnight. After conversion, the mixture was filtered andsolvent removed to give the title compound, which was used withoutfurther purification (14.8 g, 46.8 mmol). ¹H NMR (400 MHz, CDCl₃) δ ppm1.45 (s, 18H), 1.72-1.75 (m, 2H), 2.20 (m, 2H), 4.04 (br, 2H), 4.34-4.37(m, 1H), 4.45 (br, 2H), 5.21 (br, 1H).

I. Di-tert-butyl N,N-(cis-4-oxocyclopentane-1,2-diyl)-biscarbamate

To a cooled solution of di-tert-butylN,N-((1R,2S,4s)-4-hydroxycyclopentane-1,2-diyl)-biscarbamate (5.35 g,16.9 mmol) in DCM 90 (mL) at 0° C. was added Dess-Martin periodinanereagent (24.4 g, 57.6 mmol). The mixture was stirred from 0° C. to RTfor 1.5 h. After the reaction was completed, the mixture was filteredand the residue was purified by column chromatography eluting withpetroleum ether and EtOAc (PE/EtOAc=6/1 to 2/1) to give the titlecompound as a solid (5.03 g, 15.9 mmol). ¹H NMR (400 MHz, CDCl₃) δ ppm1.38 (s, 18H), 2.30-2.50 (m, 4H), 4.29 (s, 2H).

J. Di-tert-butylN,N-(cis-4,4-difluorocyclopentane-1,2-diyl)-biscarbamate

To a cooled solution of di-tert-butylN,N-(cis-4-oxocyclopentane-1,2-diyl)-biscarbamate (5.00 g, 15.9 mmol) inDCM (100 mL) was added dropwise a mixture of diethylaminosulfurtrifluoride (12.82 g, 79.6 mmol) in DCM (10 mL) at 0° C. The mixture wasstirred at a temperature of from 0° C. to RT overnight. The mixture wassubsequently cooled to 0° C. and its pH adjusted to 9-10 with saturatedaq K₂CO₃, while maintaining the temperature of the mixture below 5° C.Di-tert-butyl pyrocarbonate (7.60 g, 2.2 eq) was added and the mixturewas stirred at a temperature of from 0° C. to RT for 3 h. After removingDCM, the residue was purified by column chromatography eluting withpetroleum ether and EtOAc (PE/EtOAc=20/1 to 15/1 to 12/1) to give thetitle compound as a solid (2.40 g, 7.10 mmol). ¹H NMR (400 MHz, CDCl₃) δppm 1.45 (br, 18H), 2.15-2.19 (m, 2H), 2.47-2.52 (m, 2H), 4.22 (br, 2H),4.87 (br, 2H).

K. cis-4,4-Difluorocyclopentane-1,2-diamine

To a cooled solution of di-tert-butylN,N-(cis-4,4-difluorocyclopentane-1,2-diyl)-biscarbamate (2.40 g, 7.10mmol) in EtOAc (30 mL) at 0° C. was added 1N HCl-EtOAc (10 mL) whilemaintaining the temperature of the mixture below 5° C. The mixture wasstirred at RT overnight. The mixture was subsequently filtered, washedwith EtOAc several times, and dried in vacuo to give a hydrochloridesalt of the title compound as a solid (0.98 g, 4.7 mmol). ¹H NMR (400MHz, CD₃OD) δ ppm 2.63-2.67 (m, 2H), 2.76-2.86 (m, 2H), 4.15-4.17 (m,2H). [M+H] calc'd for C₅H₁₀F₂N₂, 137; found 137.

Example 666-(cis-2-Amino-4,4-difluorocyclopentylamino)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A TFA salt of the title compound was prepared in a manner similar toEXAMPLE 64 using cis-4,4-difluorocyclopentane-1,2-diamine in place ofcis-tert-butyl 2-aminocyclohexylcarbamate. ¹H NMR (500 MHz, DMSO-d₆) δppm 2.62-2.69 (m, 2H), 2.87 (td, J=16.84, 8.79 Hz, 2H), 3.89 (s, 3H),4.14 (br s, 1H), 4.32-4.48 (m, 2H), 4.79 (d, J=9.76 Hz, 1H), 7.28 (d,J=5.37 Hz, 1H), 7.93 (br s, 2H), 8.41 (d, J=7.32 Hz, 2H), 8.87 (s, 1H).[M+H] calc'd for C₁₆H₁₇F₃N₆O, 367; found, 367.

Preparation 26: cis-3,3-Difluorocyclohexane-1,2-diamine

A. tert-Butyl(cyclohex-2-enyloxy)dimethylsilane

Pyridine (4.74 g, 60 mmol) and tert-butyldimethylsilyl chloride (4.83 g,32 mmol) were added to a solution of cyclohex-2-enol (1.96 g, 20 mmol)in DCM (40 mL). The reaction mixture was stirred at RT overnight. Themixture was concentrated and the residue was dispersed in EtOAc andwater. The organic phase was separated and washed with brine, dried overanhydrous Na₂SO₄, concentrated, and purified by silica flashchromatography eluting with EtOAc and petroleum ether (5-10% EtOAc) togive the title compound as an oil (4.1 g, 97%). ¹H NMR (400 MHz, CDCl₃)δ ppm 0.06-0.09 (m, 6H), 0.92 (s, 9H), 1.50-1.57 (m, 2H), 1.74-1.89 (m,2H), 1.93-2.03 (m, 2H), 4.21-4.23 (m, 1H), 5.61-5.64 (m, 1H), 5.72-5.76(m, 1H).

B. (1S,2S,3S)-3-(tert-Butyldimethylsilyloxy)cyclohexane-1,2-diol and(1R,2R,3R)-3-(tert-butyldimethylsilyloxy)cyclohexane-1,2-diol

tert-Butyl(cyclohex-2-enyloxy)dimethylsilane (12.72 g, 60 mmol) wasdissolved in CH₃CN (100 mL). A solution of N-methylmorpholine-N-oxide(14 g, 120 mmol) in H₂O (20 mL) and OsO₄ (0.5 g) in acetone (5 mL) wasadded, and the mixture was stirred at RT overnight. The mixture was thendiluted with EtOAc (800 mL), washed with brine and saturated aq NaHCO₃,dried over anhydrous Na₂SO₄, concentrated, and purified by silica flashchromatography eluting with EtOAC and petroleum ether (20-40% EtOAc) togive the title compounds as an oil (12.8 g, 87%). ¹H NMR (400 MHz,CDCl₃) δ ppm 0.06-0.09 (m, 6H), 0.90 (s, 9H), 1.25-1.28 (m, 2H),1.44-1.62 (m, 2H), 1.80-1.84 (m, 2H), 2.28 (s, 1H), 2.51 (s, 1H),3.40-3.44 (m, 1H), 3.77-3.82 (m, 1H), 4.08-4.11 (m, 1H).

C. (1S,2R,3S)-3-(tert-Butyldimethylsilyloxy)cyclohexane-1,2-diyldimethanesulfinate and(1R,2S,3R)-3-(tert-Butyldimethylsilyloxy)cyclohexane-1,2-diyldimethanesulfinate

(1S,2S,3S)/(1R,2R,3R)-3-(tert-Butyldimethylsilyloxy)cyclohexane-1,2-diol(1.9 g, 7.7 mmol) was dissolved in DCM (40 mL). The mixture was placedin an ice bath. Pyridine (3.1 mL, 38.5 mmol) and methanesulfonylchloride (1.44 mL, 18.5 mmol) were added and the reaction mixture wasstirred at RT overnight. Next, the mixture was diluted with DCM, washedwith brine, dried over anhydrous Na₂SO₄, concentrated, and purified bysilica flash chromatography eluting with EtOAC and petroleum ether(20-30% EtOAc) to give the title compounds as an oil (2.6 g, 84%). ¹HNMR (400 MHz, CDCl₃) δ ppm 0.06-0.09 (m, 6H), 0.90 (s, 9H), 1.58-1.64(m, 2H), 1.70-1.78 (m, 2H), 1.85-1.90 (m, 2H), 3.12 (s, 6H), 4.08-4.12(m, 1H), 4.51-4.55 (m, 1H), 5.06-5.10 (m, 1H).

D. (1S,2R,6S)-2-Azido-6-(tert-butyldimethylsilyloxy)cyclohexylmethanesulfonate and(1R,2S,6R)-2-Azido-6-(tert-butyldimethylsilyloxy)cyclohexylmethanesulfinate

(1S,2R,3S)/(1R,2S,3R)-3-(tert-Butyldimethylsilyloxy)cyclohexane-1,2-diyldimethanesulfinate (12.0 g, 29.8 mmol) was dissolved in DMF (80 mL) andhexamethylphosphoramide (20 mL). Sodium azide (10.0 g, 154 mmol) wasadded and the mixture was stirred at 75° C. overnight. The mixture wasdiluted with EtOAc, washed with water and brine, dried over anhydrousNa₂SO₄, and concentrated. The solid was washed petroleum ether and driedin vacuo to give the title compounds (7 g, 68%). ¹H NMR (400 MHz, CDCl₃)δ ppm 0.06-0.09 (m, 6H), 0.90 (s, 9H), 1.32-1.47 (m, 3H), 1.76-1.81 (m,1H), 1.97-2.01 (m, 1H), 2.10-2.14 (m, 1H), 3.14 (s, 3H), 3.33-3.39 (m,1H), 3.55-3.61 (m, 1H), 4.23-4.28 (m, 1H).

E. tert-Butyl((1S,2R,3R)-2,3-diazidocyclohexyloxy)dimethylsilane andtert-Butyl((1R,2S,3S)-2,3-diazidocyclohexyloxy)dimethylsilane

(1S,2R,6S)/(1R,2S,6R)-2-Azido-6-(tert-butyldimethylsilyloxy)cyclohexylmethanesulfonate (7 g, 20 mmol) was dissolved in DMF (80 mL) andhexamethylphosphoramide (20 mL). Sodium azide (15.0 g, 230 mmol) wasadded and the mixture was stirred at 120° C. for 24 h. The mixture wasdiluted with EtOAc, washed with water and brine, dried over anhydrousNa₂SO₄, concentrated, and purified by silica flash chromatographyeluting with EtOAc and petroleum ether (3% EtOAc) to give the titlecompounds as an oil (3.52 g, 60%). ¹H NMR (400 MHz, CDCl₃) δ ppm0.06-0.09 (m, 6H), 0.90 (s, 9H), 1.66-1.70 (m, 2H), 1.72-1.76 (m, 2H),1.80-1.85 (m, 2H), 3.16-3.21 (m, 1H), 3.71-3.76 (m, 1H), 3.80-3.85 (m,1H).

F. (1S,2R,3R)-2,3-Diazidocyclohexanol and(1R,2S,3S)-2,3-Diazidocyclohexanol

Tetrabutylammonium fluoride (16.0 g, 61.3 mmol) dissolved in THF wasadded totert-butyl((1S,2R,3R)/(1R,2S,3S)-2,3-diazidocyclohexyloxy)dimethylsilane(12.0 g, 40.5 mmol) in THF (300 mL). The reaction mixture was stirred atRT for 3 h and was then quenched with MeOH. The mixture was concentratedand the residue was purified by column chromatography (EtOAc/PE=4/1) togive the title compounds as an oil (5 g, 68%).

G. (1S,2R,3R)-2,3-Diaminocyclohexanol and(1R,2S,3S)-2,3-Diaminocyclohexanol

A mixture of (1S,2R,3R)/(1R,2S,3S)-2,3-diazidocyclohexanol (5.0 g, 27.5mmol) and Pd/C (2.0 g) in MeOH was stirred at RT overnight under H₂atmosphere. Following reaction, the mixture was filtered andconcentrated to give the title compounds as an oil, which was usedwithout further purification (3.18 g).

H. Dibenzyl N,N-((1R,2R,3S)-3-hydroxycyclohexane-1,2-diyl)-biscarbamateand Dibenzyl N,N-((1S,2S,3R)-3-hydroxycyclohexane-1,2-diyl)-biscarbamate

To a solution of (1S,2R,3R)/(1R,2S,3S)-2,3-diaminocyclohexanol (3.1 g,24.5 mmol) and Et₃N (7.4 g, 73.5 mmol) in DCM (50 mL) at −10° C. wasadded benzyl carbonochloridate (9.6 g, 56.3 mmol). The progress of thereaction was monitored by TLC and LCMS. Following completion of thereaction, the mixture was washed with water, dried over Na₂SO₄, andconcentrated. The residue was purified by column chromatography(EtOAc/PE=2/1) to give the title compounds as an oil (2.2 g, 22%). ¹HNMR (400 MHz, CDCl₃) δ ppm 1.59-1.84 (m, 6H), 3.80 (br, 1H), 4.05-4.16(m, 2H), 5.12 (s, 4H), 5.4 (s, 1H), 6.4 (s, 1H), 7.33-7.37 (m, 10H).

I. Dibenzyl N,N-(cis-3-oxocyclohexane-1,2-diyl)-biscarbamate

To a solution of dibenzylN,N-((1R,2R,3S)/(1S,2S,3R)-3-hydroxycyclohexane-1,2-diyl)-biscarbamate(2.2 g, 5.5 mmol) in DCM (30 mL) at −0° C. was added Dess-Martinperiodinane reagent (5.9 g, 13.8 mmol). The suspension was stirred at RTfor 3 h. The mixture was concentrated and the residue was purified bycolumn chromatography (EtOAc/PE=2/1) to give the title compound as asolid (2.0 g, 93%). ¹H NMR (400 MHz, CDCl₃) δ ppm 1.60-1.70 (m, 3H),2.00-2.04 (m, 1H), 2.35-2.58 (m, 2H), 4.27-4.31 (m, 1H), 5.12 (s, 4H),5.82-5.92 (m, 1H), 7.33-7.38 (m, 10H).

J. Dibenzyl N,N-(cis-3,3-difluorocyclohexane-1,2-diyl)-biscarbamate

To a solution of dibenzylN,N-(cis-3-oxocyclohexane-1,2-diyl)-biscarbamate (2.0 g, 5.1 mmol) inDCM (30 mL) at −0° C. was added diethylaminosulfur trifluoride (4 mL,1.22 g/cm³). The reaction mixture was stirred at −0° C. overnight. Thereaction mixture was neutralized with sodium bicarbonate, concentrated,and the residue was purified by column chromatography (EtOAc/PE=2/1) togive the title compound as a solid (1.0 g, 47%). ¹H NMR (400 MHz, CD₃OD)δ ppm 1.43-2.01 (m, 6H), 3.83-3.84 (m, 1H), 4.23-4.24 (m, 1H), 4.97 (s,4H), 7.16-7.24 (m, 10H).

K. cis-3,3-Difluoro cyclohexane-1,2-diamine

A mixture of dibenzylN,N-(cis-3,3-difluorocyclohexane-1,2-diyl)-biscarbamate (1.0 g, 2.4mmol) and Pd/C (0.9 g) in MeOH was stirred at RT overnight under H₂atmosphere. Following reaction, the mixture was filtered andconcentrated to an oil, which was reacted with EtOAc—HCl to give ahydrochloride salt of the title compound as a white solid (280 mg, 77%).¹H NMR (400 MHz, CD₃OD) δ ppm 1.84-2.31 (m, 6H), 4.01 (m, 1H), 4.20-4.26(m, 1H). [M+H] calc'd for C₆H₁₂F₂N₂, 151; found, 151.

Preparation 27:6-(cis-2-Amino-3,3-difluorocyclohexylamino)-4-chloro-2-(2,4-dimethoxybenzyl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A mixture of4,6-dichloro-2-(2,4-dimethoxybenzyl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one(100 mg, 0.269 mmol) and cis-3,3-difluorocyclohexane-1,2-diaminehydrochloride (75 mg, 0.404 mmol) and DIPEA (118 μL, 0.674 mmol) inacetonitrile (449 μL) was stirred at 100° C. for 3 d. The reactionmixture was concentrated to a brown oil and reconstituted in DMF (1 mL).The residue was purified by preparative HPLC, the appropriate fractionwas collected, and excess acetonitrile was evaporated. The residue wastreated with saturated aq sodium carbonate and extracted with EtOAc(3×20 mL). The organic layers were combined, dried over sodium sulfate,and concentrated to give the title compound as a colorless residue (13.7mg, 10%). [M+H] calc'd for C₂₂H₂₄ClF₃N₄O₃, 485; found, 485.

Example 676-(cis-2-Amino-3,3-difluorocyclohexylamino)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A.6-(cis-2-Amino-3,3-difluorocyclohexylamino)-2-(2,4-dimethoxybenzyl)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A microwave vial was charged with6-(cis-2-amino-3,3-difluorocyclohexylamino)-4-chloro-2-(2,4-dimethoxybenzyl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one(13.7 mg, 0.028 mmol) and1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole(8.82 mg, 0.042 mmol) and bis(triphenylphosphine)palladium chloride(3.97 mg, 5.65 μmol) and placed under an inert environment. DME (283 μL)was added to the mixture and the resulting yellow slurry was degassedfor 5 min. Sodium carbonate was added (56.5 μL, 0.113 mmol) and theslurry degassed for an additional 3 min. The vessel was capped and themixture was heated at 80° C. for 4 h, cooled to ambient temperature,diluted with EtOAc (5 mL), and washed with water (3 mL) and brine (3mL). The organic layer was collected, dried over sodium sulfate, andconcentrated to give the title compound as a dark brown residue whichwas used in the next step without further purification (21 mg). [M+H]calc'd for C₂₆H₂₉F₃N₆O₃, 531; found, 531.

B.6-(cis-2-Amino-3,3-difluorocyclohexylamino)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

To a solution of6-(cis-2-amino-3,3-difluorocyclohexylamino)-2-(2,4-dimethoxybenzyl)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one(21 mg, 0.040 mmol) in DCM (300 μL) was added TFA (500 μL, 6.49 mmol).The reaction mixture was stirred at ambient temperature for 12 h then anadditional 3 h at 50° C. The mixture was subsequently concentrated to adark oil and diluted with DMF (1 mL) which was purified via preparativeHPLC and lyophilized to give a TFA salt of the title compound as afluffy white solid (3.6 mg, 19%). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.89(s, 1H), 8.43 (s, 3H), 8.16 (s, 1H), 6.89 (br s, 1H), 6.54 (br s, 1H),4.65-4.52 (m, 1H), 4.49-4.32 (m, 2H), 4.17 (br s, 1H), 3.89 (s, 3H),2.37-2.03 (m, 2H), 1.84 (br s, 3H), 1.63 (br s, 1H). [M+H] calc'd forC₁₇H₁₉F₃N₆O, 381; found, 381.

Example 686-(cis-2-Amino-3,3-difluorocyclohexylamino)-4-(1-(difluoromethyl)-1H-pyrazol-4-yl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A TFA salt of the title compound was prepared in a manner similar toEXAMPLE 67 using1-(difluoromethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazolein place of1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole. ¹HNMR (400 MHz, DMSO-d₆) δ ppm 1.64 (br s, 1H), 1.83 (br s, 3H), 2.00-2.29(m, 2H), 2.33 (t, J=1.77 Hz, 1H), 2.63-2.72 (m, 1H), 4.11 (br s, 1H),4.40-4.50 (m, 2H), 4.62 (br s, 1H), 6.93 (d, J=5.31 Hz, 1H), 7.74-8.14(m, 1H), 8.45 (s, 1H), 8.56 (s, 1H), 9.40 (s, 1H). [M+H] calc'd forC₁₇H₁₇F₅N₆O, 417; found, 417.

Example 696-(cis-2-amino-3,3-difluorocyclohexylamino)-4-(1-cyclopropyl-1H-pyrazol-4-yl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A TFA salt of the title compound was prepared in a manner similar toEXAMPLE 67 using1-cyclopropyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazolein place of1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole. ¹HNMR (400 MHz, DMSO-d₆) δ ppm 1.63 (br s, 1H), 1.75-1.92 (m, 3H),2.00-2.29 (m, 2H), 2.33 (dt, J=3.73, 1.80 Hz, 1H), 2.62-2.74 (m, 1H),4.34-4.46 (m, 2H), 4.57 (br s, 1H), 4.81 (d, J=5.56 Hz, 2H), 5.08-5.30(m, 2H), 5.93-6.10 (m, 1H), 6.83 (d, J=6.06 Hz, 1H), 8.22 (s, 1H), 8.39(s, 2H), 8.84-9.05 (m, 1H). [M+H] calc'd for C₁₉H₂₁F₃N₆O, 407; found,407.

Preparation 28:(R)-2-(4-Chloro-2-(2,4-dimethoxybenzyl)-7-fluoro-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-4-methylpentanamide

A mixture of4,6-dichloro-2-(2,4-dimethoxybenzyl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one(200 mg, 0.539 mmol), (R)-2-amino-4-methylpentanamide (140 mg, 1.078mmol), and N-isopropyl-N-methylpropan-2-amine (310 mg, 2.69 mmol) inacetonitrile (2 mL) was stirred at 85° C. for 3 d. The resulting crudematerial was reconstituted in MeOH/DCM/DMF (10.0 mL) and purified viapreparative HPLC. The fractions were collected and stripped to drynessvia rotary evaporation to yield the title compound (83 mg, 33%). [M+H]calc'd for C₂₂H₂₆ClFN₄O₄, 465; found, 465.

Example 70(R)-2-(7-Fluoro-4-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-4-methylpentanamide

A.(R)-2-(2-(2,4-dimethoxybenzyl)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-4-methylpentanamide

A solution of(R)-2-(4-chloro-2-(2,4-dimethoxybenzyl)-7-fluoro-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-4-methylpentanamide(83 mg, 0.179 mmol),1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole(111 mg, 0.536 mmol), and bis(triphenylphosphine)palladium chloride(12.53 mg, 0.018 mmol) in dioxane (2 mL) and saturated aq Na₂CO₃ (2 mL)was heated at 120° C. for 30 min. After filtering off the solid, thesolvent was removed, and the residue was dissolved in MeOH and DCM andwas purified by preparative HPLC. The fractions were collected and thesolvent was stripped to dryness via rotary evaporation to yield thetitle compound (40 mg, 44%). [M+H] calc'd for C₂₆H₃₁FN₆O₄, 511; found,511.

B.(R)-2-(7-Fluoro-4-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-4-methylpentanamide

A solution of(R)-2-(2-(2,4-dimethoxybenzyl)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-4-methylpentanamide(39.8 mg, 0.078 mmol) in TFA (5 mL) was heated at 60° C. for 2 h. Afterremoval of solvent, the residue was diluted in MeOH (2 mL) and waspurified by preparative HPLC. The fractions were collected and thesolvent stripped to dryness via rotary evaporation to yield the titlecompound (12.8 mg, 46%). ¹H NMR (500 MHz, DMSO-d₆) δ ppm 0.82-1.00 (m,6H), 1.45-1.60 (m, 1H), 1.67-1.83 (m, 2H), 3.87 (s, 3H), 4.36 (s, 2H),4.50-4.64 (m, 1H), 6.88-7.02 (m, 2H), 7.44 (s, 1H), 8.28 (s, 2H), 8.83(s, 1H). [M+H] calc'd for C₁₇H₂₁FN₆O₂, 361; found, 361.

Example 71(R)-2-(4-(1-(Difluoromethyl)-1H-pyrazol-4-yl)-7-fluoro-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-4-methylpentanamide

The title compound was prepared in a manner similar to EXAMPLE 70 using1-(difluoromethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazolein place of1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole. ¹HNMR (400 MHz, DMSO-d₆) δ ppm 1.63 (br s, 1H), 1.75-1.92 (m, 3H),2.00-2.29 (m, 2H), 2.33 (dt, J=3.73, 1.80 Hz, 1H), 2.62-2.74 (m, 1H),4.34-4.46 (m, 2H), 4.57 (br s, 1H), 4.81 (d, J=5.56 Hz, 2H), 5.08-5.30(m, 2H), 5.93-6.10 (m, 1H), 6.83 (d, J=6.06 Hz, 1H), 8.22 (s, 1H), 8.39(s, 2H), 8.84-9.05 (m, 1H). [M+H] calc'd for C₁₇H₁₉F₃N₆O₂, 397; found,397.

Example 72(R)-2-(4-(1-Cyclopropyl-1H-pyrazol-4-yl)-7-fluoro-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-4-methylpentanamide

The title compound was prepared in a manner similar to EXAMPLE 70 using1-cyclopropyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazolein place of1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole. ¹HNMR (400 MHz, DMSO-d₆) δ ppm 0.70-1.07 (m, 7H), 1.15-1.35 (m, 1H),1.48-1.64 (m, 1H), 1.67-1.93 (m, 2H), 4.25-4.43 (m, 2H), 4.54 (d, J=9.60Hz, 1H), 4.79 (d, J=5.81 Hz, 1H), 5.11-5.31 (m, 1H), 5.91-6.16 (m, 1H),6.80-7.07 (m, 2H), 7.42 (br s, 1H), 8.25 (s, 1H), 8.34-8.43 (m, 1H),8.83-8.97 (m, 1H). [M+H] calc'd for C₁₉H₂₃FN₆O₂, 387; found, 387.

Example 73(R)-2-(4-(Benzofuran-3-yl)-7-fluoro-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-4-methylpentanamide

The title compound was prepared in a manner similar to EXAMPLE 70 using2-(benzofuran-3-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane in place of1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole. ¹HNMR (400 MHz, DMSO-d₆) δ ppm 0.73-0.96 (m, 6H), 1.57-1.91 (m, 3H), 4.42(s, 2H), 4.63-4.77 (m, 1H), 6.99-7.17 (m, 2H), 7.24-7.42 (m, 3H), 7.62(d, J=7.83 Hz, 1H), 8.32-8.48 (m, 2H), 9.28 (s, 1H). [M+H] calc'd forC₂₁H₂₁FN₄O₃, 397; found, 397.

Example 74(R)-2-(7-Fluoro-3-oxo-4-(pyrazolo[1,5-a]pyridin-3-yl)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-4-methylpentanamide

The title compound was prepared in a manner similar to EXAMPLE 70 using3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazolo[1,5-a]pyridinein place of1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole. ¹HNMR (400 MHz, DMSO-d₆) δ ppm 0.77-0.99 (m, 6H), 1.57-1.70 (m, 1H),1.71-1.90 (m, 2H), 4.33-4.45 (m, 2H), 4.56-4.68 (m, 1H), 6.93-7.12 (m,3H), 7.27-7.42 (m, 2H), 8.27 (s, 1H), 8.47 (d, J=8.84 Hz, 1H), 8.72 (d,J=6.82 Hz, 1H), 9.30 (s, 1H). [M+H] calc'd for C₂₀H₂₁FN₆O₂, 397; found,397.

Preparation 29: tert-Butyl(1S,2R)-2-(7-chloro-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate

A vial was charged with tert-butyl(1S,2R)-2-(3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate(63 mg, 0.140 mmol) and N-chlorosuccinimide (18.63 mg, 0.140 mmol) inDCM (1.4 mL) to give a yellow solution. The solution was stirred for 1 hat RT. The crude reaction mixture was diluted with DCM (20 mL) andwashed with saturated aq NaHCO₃ (2×10 mL) followed by water (10 mL) andbrine (10 mL). The organic layers were combined, dried over sodiumsulfate, and concentrated to a residue which was purified by flashcolumn chromatography. The collected fractions were concentrated to abrown residue to give the title compound as a cream colored solid upondrying (38.1 mg, 56%). [M+H] calc'd for C₂₅H₃₂ClN₅O₃, 486; found, 486.

Example 756-((1R,2S)-2-Aminocyclohexylamino)-7-chloro-4-(m-tolylamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

To a solution of tert-butyl(1S,2R)-2-(7-chloro-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate(20 mg, 0.041 mmol) in DCM (0.8 mL) was added trifluoroacetic acid (0.31mL). The reaction mixture was stirred at RT for 1 h, then concentratedto a brown residue which was diluted in MeOH (2 mL) and purified viapreparative HPLC to give a TFA salt of the title compound as a fluffywhite solid (12.3 mg, 61.9%). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.85 (s,1H), 8.36 (s, 1H), 7.83 (br s, 3H), 7.39-7.57 (m, 2H), 7.12-7.32 (m,1H), 6.84 (d, J=7.6 Hz, 1H), 6.22 (d, J=6.8 Hz, 1H), 4.19-4.43 (m, 3H),3.71 (br s, 1H), 2.32 (s, 3H), 1.37-1.99 (m, 8H). [M+H] calc'd forC₂₀H₂₄ClN₅O, 386; found, 386.

Preparation 30: tert-Butyl(1S,2R)-2-(7-iodo-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate

To a screw-top vial was added tert-butyl(1S,2R)-2-(3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate(73 mg, 0.162 mmol) and 1-iodopyrrolidine-2,5-dione (36.4 mg, 0.162mmol) in DCM (1.6 mL) to give a yellow solution. The reaction wasstirred 0.5 h at RT. The reaction mixture was diluted with DCM (10 mL)and washed with saturated aq NaHCO₃ (10 mL), water (10 mL), and brine(10 mL). The collected organic layers were dried with sodium sulfate andconcentrated to give the title compound as a brown solid, which was usedwithout further purification (85.7 mg, 92%). [M+H] calc'd forC₂₅H₃₂₁N₅O₃, 578; found, 578.

Preparation 31: tert-Butyl(1S,2R)-2-(7-cyano-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate

To an oven-dried microwave vial was added tert-butyl(1S,2R)-2-(7-iodo-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate(47.0 mg, 0.081 mmol), dicyanozinc (5.74 mg, 0.049 mmol), zinc powder(0.532 mg, 8.14 μmol), dppf (0.451 mg, 0.814 μmol), and Pd₂(dba)₃ (0.745mg, 0.814 μmol). N,N-Dimethylacetamide (814 μL) was added and theresulting dark brown solution was degassed with nitrogen for 3 min. Thevial was capped and heated at 80° C. with stirring for 1 h. Thetemperature was increased to 110° C., and the mixture was stirred for anadditional 3 h, then cooled to RT, diluted with EtOAc (10 mL), andwashed with water (2×10 mL) and brine (10 mL). The organic phase wasdried with sodium sulfate and concentrated to give the title compound asa brown residue, which was used without further purification (40 mg,103%). [M+H] calc'd for C₂₆H₃₂N₆O₃, 477; found, 477.

Example 766-((1R,2S)-2-Aminocyclohexylamino)-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-7-carbonitrile

A TFA salt of the title compound was prepared in a manner similar toEXAMPLE 75 using tert-butyl(1S,2R)-2-(7-cyano-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamatein place of tert-butyl(1S,2R)-2-(7-chloro-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate.¹H NMR (400 MHz, DMSO-d₆) δ ppm 9.22 (s, 1H), 8.48 (s, 1H), 7.80 (br s,3H), 7.40-7.59 (m, 2H), 7.26 (t, J=7.7 Hz, 1H), 6.91 (dd, J=13.0, 6.9Hz, 2H), 4.43 (s, 2H), 4.26-4.38 (m, 1H), 3.68 (br s, 1H), 2.33 (s, 3H),1.78-1.96 (m, 2H), 1.35-1.79 (m, 6H). [M+H] calc'd for C₂₁H₂₄N₆O, 377;found, 377.

Preparation 32: (R)-tert-Butyl 1-amino-3-methoxypropan-2-ylcarbamate

A. (S)-2-(tert-Butoxycarbonylamino)-3-methoxypropanoic acid

A sodium methanolate (NaOMe) solution was prepared by slowly adding MeOH(50 mL) to a suspension of sodium hydride (60% in mineral oil, 28 g,0.71 mol) in dry THF (1.2 L) at 0° C. The resulting mixture was stirredat RT for 2 h. A portion of the NaOMe solution (320 mL) was added to(S)-2-(tert-butoxycarbonylamino)-3-hydroxypropanoic acid (36 g, 175mmol) in dry THF (1.6 L), and the mixture was stirred at RT for 1 h.Methyl iodine (16 mL) was then added and the mixture was stirred at RTfor 1 h. Another aliquot of NaOMe solution (540 mL) was added and thereaction mixture stirred at RT for 1 h. Additional methyl iodine (38 mL)in THF (200 mL) was added and the reaction mixture was stirred at RT for36 h. Following reaction, the mixture was concentrated and the residuewas dissolved in water and washed with diethyl ether (2×100 mL). Theaqueous layer was acidified to pH 2 by the addition of solid citric acidand was extracted with EtOAc (3×200 mL) and dried over Na₂SO₄. Theorganic phase was concentrated, and the residue was dissolved in waterand extracted with DCM (4×150 mL). The organic layers were combined andconcentrated to give the title compound as an oil, which was usedwithout further purification (10.9 g, 28%).

B. (R)-tert-Butyl 1-hydroxy-3-methoxypropan-2-ylcarbamate

To a mixture of (S)-2-(tert-butoxycarbonylamino)-3-methoxypropanoic acid(10.9 g) and N-methylmorpholine (5.6 g, 55 mmol) in THF (50 mL) wasadded 2-methylpropylchloroformate (7.48 g, 55 mmol) in THF at −15° C.The reaction mixture was stirred −15° C. for 15 min, after which NaBH₄(6.0 g, 159 mmol) in water (10 mL) was added. The reaction mixture wasstirred for 30 min, then diluted with EtOAc, and neutralized with diluteHCl. The organic layer was dried over Na₂SO₄ and concentrated. Theresidue was purified by column chromatography on silica gel eluting withEtOAc and petroleum ether (EtOAc/PE=1.5/1) to give the title compound(6.0 g, 58%). ¹H NMR (400 MHz, CDCl₃) δ ppm 5.23 (s, 1H), 3.80 (d, J=8.0Hz, 2H), 3.72-3.68 (m, 1H), 3.60-3.52 (m, 2H), 3.38 (s, 3H), 2.85 (s,1H), 1.47 (s, 9H).

C. (R)-tert-Butyl 1-azido-3-methoxypropan-2-ylcarbamate

Methanesulfonyl chloride (4.0 g, 35 mmol) in DCM (50 mL) was slowlyadded to a solution of (R)-tert-butyl1-hydroxy-3-methoxypropan-2-ylcarbamate (6.0 g, 29 mmol) and Et₃N (3.64g, 36 mmol) in DCM (150 mL) at 0° C. The reaction mixture was stirred atRT for 2 h. The organic phase was washed with water and saturated aqNaHCO₃, concentrated, and dissolved in DMF. Sodium azide (2.34 g, 36.0mmol) was added, and the reaction mixture was stirred at 75° C. for 4 h.The reaction mixture was diluted by EtOAc and washed with water. Thecrude product was purified by column chromatography on silica geleluting with EtOAc and petroleum ether (EtOAc/PE=2/1) to give the titlecompound (4.3 g, 64%). ¹H NMR (400 MHz, CDCl₃) δ ppm 4.92 (s, 1H), 3.91(m, 1H), 3.53-3.48 (m, 2H), 3.45-3.40 (m, 2H), 3.38 (s, 3H), 1.47 (s,9H).

D. (R)-tert-Butyl 1-amino-3-methoxypropan-2-ylcarbamate

A mixture of (R)-tert-butyl 1-azido-3-methoxypropan-2-ylcarbamate (4.3g, 18.7 mmol) and 10% Pd/C (1.5 g) in MeOH was stirred at RT under H₂atmosphere overnight. After filtration, the crude product was purifiedby amino-protected silica gel chromatography eluting with EtOAc andpetroleum ether (EtOAc/PE=1/1) to give the title compound (740 mg,19.4%). ¹H NMR (400 MHz, CD₃OD) δ ppm 5.00 (s, 1H), 3.67-3.66 (m, 1H),3.51-3.47 (m, 1H), 3.42-3.38 (m, 1H), 3.35 (s, 1H), 2.82-2.78 (m, 2H),1.46 (s, 9H). [M+H] calc'd for C₉H₂₀N₂O₃, 205; found, 205.

Preparation 33: (R)-Methyl6-(2-(tert-butoxycarbonylamino)-3-methoxypropylamino)-4-cyano-2-(m-tolylamino)nicotinate

To a screw-top vial was added methyl6-chloro-4-cyano-2-(m-tolylamino)nicotinate (0.28 g, 0.928 mmol),(R)-tert-Butyl 1-amino-3-methoxypropan-2-ylcarbamate (0.227 g, 1.114mmol), and DIPEA (0.211 mL, 1.206 mmol) in DMF (3 mL). The resultingyellow solution was stirred at RT for 12 h, diluted with EtOAc (30 mL)and washed with water (2×20 mL) and brine (20 mL). The organic phase wasdried with Na₂SO₄ and concentrated to give the title compound as thickyellow oil, which was used without further purification (470 mg). [M+H]calc'd for C₂₄H₃₁N₅O₅, 470; found, 470.

Preparation 34: (R)-tert-Butyl1-methoxy-3-(3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)propan-2-ylcarbamate

To a round-bottomed flask was added (R)-methyl6-(2-(tert-butoxycarbonylamino)-3-methoxypropylamino)-4-cyano-2-(m-tolylamino)nicotinate(84.5 mg, 0.180 mmol) in acetic acid (3 mL) and DCM (10 mL). To theresulting yellow solution was added platinum(IV) oxide (4.09 mg, 0.018mmol). The flask was evacuated and back filled with hydrogen (3×1 atm).The reaction mixture was stirred vigorously at RT for 16 h, subsequentlydiluted with DCM (10 mL), and filtered through Celite. The filtrate wasconcentrated to an oil, which was diluted with DCM (10 mL). Potassiumcarbonate (24.87 mg, 0.180 mmol) was added and the reaction mixture wasstirred at RT for 12 h. The crude reaction was diluted with DCM (10 mL),filtered through Celite, and concentrated to give the title compound asa thick yellow oil, which was used without further purification (26.5mg, 33.4%). [M+H] calc'd for C₂₃H₃₁N₅O₄, 442; found, 442.

Example 77(R)-6-(2-Amino-3-methoxypropylamino)-4-(m-tolylamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A TFA salt of the title compound was prepared in a manner similar toEXAMPLE 75 using (R)-tert-butyl1-methoxy-3-(3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)propan-2-ylcarbamatein place of tert-butyl(1S,2R)-2-(7-chloro-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate.¹H NMR (400 MHz, CD₃OD) δ ppm 7.57 (d, J=8.3 Hz, 1H), 7.36 (s, 1H), 7.22(t, J=7.8 Hz, 1H), 6.87 (d, J=7.3 Hz, 1H), 6.07 (s, 1H), 4.30 (s, 2H),3.70-3.82 (m, 2H), 3.50-3.65 (m, 3H), 3.40 (s, 3H), 2.35 (s, 3H). [M+H]calc'd for C₁₈H₂₃N₅O₂, 342; found, 342.

Preparation 35: (R)-tert-Butyl1-(7-cyano-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-3-methoxypropan-2-ylcarbamate

A. (R)-tert-Butyl1-(7-iodo-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-3-methoxypropan-2-ylcarbamate

The title compound was prepared in a manner similar to PREPARATION 30using (R)-tert-butyl1-methoxy-3-(3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)propan-2-ylcarbamatein place of tert-butyl(1S,2R)-2-(3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate.[M+H] calc'd for C₂₃H₃₀IN₅O₄, 568; found, 568.

B. (R)-tert-Butyl1-(7-cyano-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-3-methoxypropan-2-ylcarbamate

The title compound was prepared in a manner similar to PREPARATION 31using (R)-tert-butyl1-(7-iodo-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-3-methoxypropan-2-ylcarbamatein place of tert-butyl(1S,2R)-2-(7-iodo-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate.[M+H] calc'd for C₂₄H₃₀N₆O₄, 467; found, 467.

Example 78(R)-6-(2-Amino-3-methoxypropylamino)-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-7-carbonitrile

A TFA salt of the title compound was prepared in a manner similar toEXAMPLE 75 using (R)-tert-butyl1-(7-cyano-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-3-methoxypropan-2-ylcarbamatein place of tert-butyl(1S,2R)-2-(7-chloro-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate.¹H NMR (400 MHz, DMSO-d₆) δ ppm 9.25 (s, 1H), 8.47 (s, 1H), 7.93 (br s,3H), 7.58 (d, J=7.8 Hz, 1H), 7.51 (t, J=5.4 Hz, 1H), 7.42 (s, 1H), 7.27(t, J=7.8 Hz, 1H), 6.93 (d, J=7.3 Hz, 1H), 4.43 (s, 2H), 3.71-3.80 (m,1H), 3.60-3.70 (m, 1H), 3.44-3.60 (m, 3H), 3.29 (s, 3H), 2.33 (s, 3H).[M+H] calc'd for C₁₉H₂₂N₆O₂, 367; found, 367.

Preparation 36: (R)-tert-Butyl1-(7-fluoro-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-3-methoxypropan-2-ylcarbamate

To a screw-top vial was added (R)-tert-butyl1-methoxy-3-(3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)propan-2-ylcarbamate(27 mg, 0.061 mmol) in a mixture of DCM and MeOH (1/1, 1.2 mL). Theresulting colorless solution was cooled to 0° C. SELECTFLUOR® (21.66 mg,0.061 mmol) was added and the reaction mixture was stirred at 0° C. for2 h. Next, the reaction mixture was diluted with EtOAc (10 mL) andwashed with saturated aq sodium bicarbonate (5 mL), water (5 mL), andbrine (5 mL). The organic layer was collected, dried over Na₂SO₄, andconcentrated to give the title compound as a brown residue, which wasused without further purification (32 mg, 114%). [M+H] calc'd forC₂₃H₃₀FN₅O₄, 460; found, 460.

Example 79(R)-6-(2-Amino-3-methoxypropylamino)-7-fluoro-4-(m-tolylamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A TFA salt of the title compound was prepared in a manner similar toEXAMPLE 75 using (R)-tert-butyl1-(7-fluoro-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-3-methoxypropan-2-ylcarbamatein place of tert-butyl(1S,2R)-2-(7-chloro-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate.¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.84 (s, 1H), 8.28 (s, 1H), 7.97 (br s,3H), 7.47-7.62 (m, 1H), 7.40 (s, 1H), 7.11-7.29 (m, 2H), 6.80 (d, J=7.6Hz, 1H), 4.40 (s, 2H), 3.62-3.78 (m, 2H), 3.46-3.61 (m, 3H), 3.31 (s,3H), 2.31 (s, 3H). [M+H] calc'd for C₁₈H₂₂FN₅O₂, 360; found, 360.

Preparation 37: tert-Butyl(1S,2R)-2-(7-(3-hydroxyprop-1-ynyl)-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate

To an oven dried glass pressure vessel was added tert-butyl(1S,2R)-2-(7-iodo-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate(25 mg, 0.043 mmol), copper(I) iodide (12.37 mg, 0.065 mmol),bis(triphenylphosphine) palladium(II)chloride (9.12 mg, 0.013 mmol),butylated hydroxytoluene (one granule), THF (866 μL), and Et₃N (121 μL,0.866 mmol). The mixture was degassed 3 min with nitrogen. Propargylalcohol (31 μL, 0.520 mmol) was added and the vessel was capped andheated at 80° C. with stirring for 2 h and then at RT for 12 h. Thereaction mixture was diluted with EtOAc (10 mL) and washed with water (5mL) and brine (5 mL). The organic layer was collected, dried withNa₂SO₄, and concentrated to give the title compound as a brown residue,which was used without further purification (22 mg, 101%). [M+H] calc'dfor C₂₈H₃₅N₅O₄, 506; found, 506.

Example 807-Acryloyl-6-((1R,2S)-2-aminocyclohexylamino)-4-(m-tolylamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A TFA salt of the title compound was prepared in a manner similar toEXAMPLE 75 using tert-butyl(1S,2R)-2-(7-(3-hydroxyprop-1-ynyl)-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamatein place of tert-butyl(1S,2R)-2-(7-chloro-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate.¹H NMR (400 MHz, DMSO-d₆) δ ppm 10.53 (d, J=7.8 Hz, 1H), 9.81 (s, 1H),8.65 (s, 1H), 7.85 (br s, 3H), 7.60 (s, 1H), 7.51 (s, 1H), 7.27 (t,J=7.8 Hz, 1H), 7.08 (dd, J=16.5, 10.5 Hz, 1H), 6.93 (d, J=7.6 Hz, 1H),6.19 (dd, J=16.7, 2.0 Hz, 1H), 5.68-5.90 (m, 1H), 4.50-4.80 (m, 3H),3.65 (br s, 1H), 2.34 (s, 3H), 1.78-2.01 (m, 2H), 1.75 (s, 3H),1.43-1.58 (m, 3H). [M+H] calc'd for C₂₃H₂₇N₅O₂, 406; found, 406.

Example 816-((1R,2S)-2-Aminocyclohexylamino)-7-iodo-4-(m-tolylamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A TFA salt of the title compound was prepared in a manner similar toEXAMPLE 75 using tert-butyl(1S,2R)-2-(7-iodo-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamatein place of tert-butyl(1S,2R)-2-(7-chloro-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate.¹H NMR (400 MHz, CD₃OD) δ ppm 7.48 (d, J=8.1 Hz, 1H), 7.39 (s, 1H), 7.23(t, J=7.8 Hz, 1H), 6.90 (d, J=7.6 Hz, 1H), 4.47 (d, J=9.1 Hz, 1H), 4.18(d, J=3.0 Hz, 2H), 3.80-3.87 (m, 1H), 2.36 (s, 3H), 1.87 (d, J=5.6 Hz,4H), 1.66 (br s, 4H). [M+H] calc'd for C₂₀H₂₄₁N₅O, 478; found, 478.

Preparation 38: tert-Butyl4-(6-((1R,2S)-2-(tert-butoxycarbonylamino)cyclohexylamino)-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-7-yl)-1H-pyrazole-1-carboxylate

To an oven dried vial was added tert-butyl(1S,2R)-2-(7-iodo-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate(40 mg, 0.069 mmol), tert-butyl3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole-1-carboxylate(30.6 mg, 0.104 mmol), and sodium carbonate (0.104 mL, 0.208 mmol) inDMF (1 mL). The resulting tan mixture was degassed 15 min.Bis(triphenylphosphine) palladium(II)chloride (4.86 mg, 6.93 μmol) wasadded and the mixture was degassed an additional 5 min. The vial wascapped and was heated at 80° C. for 12 h. The reaction mixture wasdiluted with EtOAc (10 mL) and washed with water (5 mL) and brine (5mL). The organic layer was collected, dried with Na₂SO₄ and concentratedto give a brown residue, which was used without further purification (55mg). LCMS indicated the desired mass less one of the Boc protectinggroups. [M+H-Boc] calc'd for C₃₃H₄₃N₇O₅, 518; found, 518.

Example 826-((1R,2S)-2-Aminocyclohexylamino)-7-(1H-pyrazol-4-yl)-4-(m-tolylamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A TFA salt of the title compound was prepared in a manner similar toEXAMPLE 75 using tert-Butyl4-(6-((1R,2S)-2-(tert-butoxycarbonylamino)cyclohexylamino)-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-7-yl)-1H-pyrazole-1-carboxylatein place of tert-butyl(1S,2R)-2-(7-chloro-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate.¹H NMR (400 MHz, DMSO-d₆) δ ppm 13.13 (br s, 1H), 8.97 (s, 1H), 8.19 (s,1H), 8.06 (br s, 1H), 7.75 (br s, 4H), 7.42-7.58 (m, 2H), 7.21 (t, J=8.1Hz, 1H), 6.81 (d, J=7.3 Hz, 1H), 5.55 (d, J=6.6 Hz, 1H), 4.25 (s, 3H),3.77 (br s, 1H), 2.32 (s, 3H), 1.63-1.89 (m, 4H), 1.36-1.63 (m, 4H).[M+H] calc'd for C₂₃H₂₇N₇₀, 418; found, 418.

Example 836-(cis-2-Amino-3,3-difluorocyclohexylamino)-4-(m-tolylamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A. Methyl6-(cis-2-Amino-3,3-difluorocyclohexylamino)-4-cyano-2-(m-tolylamino)nicotinate

To a screw-cap vial was added methyl6-chloro-4-cyano-2-(m-tolylamino)nicotinate (200 mg, 0.663 mmol),cis-3,3-difluorocyclohexane-1,2-diamine hydrochloride (148 mg, 0.795mmol), and DIPEA (347 μL, 1.989 mmol) in DMF (3.9 mL). The resultingbrownish-yellow mixture was stirred at RT for 2 h and then at 60° C. for12 h. The reaction mixture was cooled to RT, diluted with EtOAc (30 mL)and washed with water (2×10 mL) and brine (20 mL). The organic layer wascollected, dried over Na₂SO₄, and concentrated to give a thick brownoil, which included the title compound and isomers (328 mg, 119%). Thecrude product was used without further purification. [M+H] calc'd forC₂₁H₂₃F₂N₅O₂, 416; found, 416.

B.6-(cis-2-Amino-3,3-difluorocyclohexylamino)-4-(m-tolylamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A round-bottomed flask was charged with methyl6-(cis-2-amino-3,3-difluorocyclohexylamino)-4-cyano-2-(m-tolylamino)nicotinate(275 mg, 0.662 mmol) in HOAc (2.6 mL) and DCM (10.6 mL). To theresulting brown solution was added platinum(IV) oxide (15.03 mg, 0.066mmol). The flask was evacuated and back filled with hydrogen (3×1 atm).The reaction mixture was stirred vigorously under H₂ atmosphere (1 atm)at RT for 16 h and then filtered through Celite. The filtrate was washedwith DCM (20 mL) and concentrated to a residue, which was diluted inMeOH (3 mL) and purified via preparative HPLC to give a TFA salt of thetitle compound as a light green solid. ¹H NMR (400 MHz, DMSO-d₆) δ ppm8.97 (s, 1H), 8.48 (br s, 3H), 8.09 (s, 1H), 7.62 (d, J=8.8 Hz, 1H),7.32 (s, 1H), 7.14 (t, J=7.8 Hz, 1H), 6.87 (br s, 1H), 6.79 (d, J=7.3Hz, 1H), 6.15 (s, 1H), 4.45 (br s, 1H), 4.24 (d, 2H), 4.15 (br s, 1H),2.29 (s, 3H), 2.01-2.25 (m, 2H), 1.74-1.89 (m, 3H), 1.60 (d, J=10 Hz,1H). [M+H] calc'd for C₂₀H₂₃F₂N₅O, 388; found, 388.

Preparation 39: tert-Butyl(1S,2R)-2-(7-(1-methyl-1H-pyrazol-5-yl)-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate

The title compound was prepared in a manner similar to PREPARATION 36using1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole inplace of tert-butyl3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole-1-carboxylate.[M+H] calc'd for C₂₉H₃₇N₇O₃, 532; found, 532.

Example 846-((1R,2S)-2-Aminocyclohexylamino)-7-(1-methyl-1H-pyrazol-5-yl)-4-(m-tolylamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A TFA salt of the title compound was prepared in a manner similar toEXAMPLE 75 using tert-butyl(1S,2R)-2-(7-(1-methyl-1H-pyrazol-5-yl)-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamatein place of tert-butyl(1S,2R)-2-(7-chloro-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate.¹H NMR (400 MHz, DMSO-d₆) δ ppm 2.33 (d, J=1.26 Hz, 3H), 3.64 (d,J=14.15 Hz, 3H), 3.89-4.00 (m, 1H), 4.02-4.21 (m, 1H), 5.23-5.58 (m,1H), 6.29-6.47 (m, 1H), 6.85 (d, J=7.58 Hz, 1H), 7.23 (td, J=7.77, 4.93Hz, 1H), 7.47-7.56 (m, 2H), 7.58 (dd, J=9.35, 1.77 Hz, 1H), 7.64-7.83(m, 2H), 8.21 (d, J=2.27 Hz, 1H), 9.04 (s, 1H). [M+H] calc'd forC₂₄H₂₉N₇O, 432; found, 432.

Example 856-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-4-(m-tolylamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A. Methyl6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-4-cyano-2-(m-tolylamino)nicotinateand Methyl6-((3R,4R)-4-Aminotetrahydro-2H-pyran-3-ylamino)-4-cyano-2-(m-tolylamino)nicotinate

To a screw-cap vial was added methyl6-chloro-4-cyano-2-(m-tolylamino)nicotinate (500 mg, 1.657 mmol),(3R,4R)-tetrahydro-2H-pyran-3,4-diamine hydrochloride (303.0 mg, 1.989mmol), and DIPEA (868 μL, 4.97 mmol) in DMF (9748 μL). The resultingyellow suspension, which became a solution upon adding base, was stirredat 50° C. for 12 h. The reaction mixture was cooled to RT, diluted withEtOAc (30 mL), and washed with water (20 mL) and brine (20 mL). Theorganic layer was collected, dried with Na₂SO₄, and concentrated to givea yellow oil, which included the title compounds (350 mg, 55.4%). Thecrude product was used in the next step without further purification.[M+H] calc'd for C₂₀H₂₃N₅O₃, 382; found, 382.

B.6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-4-(m-tolylamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

To a 50 mL round-bottomed flask was added a mixture of methyl6-((3R,4R)-3-aminotetrahydro-2H-pyran-4-ylamino)-4-cyano-2-(m-tolylamino)nicotinateand methyl6-((3R,4R)-4-aminotetrahydro-2H-pyran-3-ylamino)-4-cyano-2-(m-tolylamino)nicotinate(100 mg, 0.262 mmol) and platinum(IV) oxide (11.91 mg, 0.052 mmol) inDCM (4195 μL) and HOAc (1049 μL). The vessel was evacuated and backfilled with hydrogen (1 atm) and the mixture was stirred at RT for 12 h.The reaction mixture was diluted with DCM (10 mL) and MeOH (20 mL),filtered through Celite, and concentrated to a residue, which wasdiluted with DCM (50 mL). Potassium carbonate (217 mg, 1.573 mmol) wasadded and the mixture was stirred at RT for 12 h. The mixture wasfiltered through Celite, concentrated to a residue, diluted with amixture of DMF and MeOH (1/1, 3 mL), and purified via preparative HPLC.The appropriate isomer peak was collected and lyophilized to give a TFAsalt of the title compound as a light grey solid (20.3 mg, 21.9%). ¹HNMR (400 MHz, DMSO-d₆) δ ppm 8.92 (s, 1H), 8.05 (s, 1H), 7.95 (br s,3H), 7.50 (d, J=8.1 Hz, 1H), 7.43 (s, 1H), 7.21 (t, J=7.8 Hz, 1H), 7.09(d, J=4.8 Hz, 1H), 6.80 (d, J=7.6 Hz, 1H), 6.11 (s, 1H), 4.20-4.32 (m,3H), 3.91-4.06 (m, 2H), 3.76 (br s, 1H), 3.53-3.72 (m, 2H), 2.31 (s,3H), 1.99 (qd, J=12.6, 4.7 Hz, 1H), 1.70-1.80 (m, 1H). [M+H] calc'd forC₁₉H₂₃N₅O₂, 354; found, 354.

Example 866-((3R,4R)-4-Aminotetrahydro-2H-pyran-3-ylamino)-4-(m-tolylamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A TFA salt of the title compound was prepared in a manner similar toEXAMPLE 85, collecting the fractions corresponding to6-((3R,4R)-4-aminotetrahydro-2H-pyran-3-ylamino)-4-(m-tolylamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-onein place6-((3R,4R)-3-aminotetrahydro-2H-pyran-4-ylamino)-4-(m-tolylamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one.¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.91 (s, 1H), 7.94-8.15 (m, 4H), 7.52(s, 1H), 7.43 (d, J=8.3 Hz, 1H), 7.18 (t, J=7.8 Hz, 1H), 7.03 (d, J=8.3Hz, 1H), 6.79 (d, J=7.6 Hz, 1H), 6.21 (s, 1H), 4.44 (br s, 1H),4.20-4.30 (m, 2H), 3.84-3.95 (m, 2H), 3.67-3.81 (m, 1H), 3.62 (dd,J=11.6, 1.8 Hz, 1H), 3.50 (td, J=11.2, 2.4 Hz, 1H), 2.30 (s, 3H),1.98-2.13 (m, 1H), 1.71-1.82 (m, 1H).

[M+H] calc'd for C₁₉H₂₃N₅O₂, 354; found, 354.

Example 87 tert-Butyl(1S,2R)-2-(3-oxo-7-phenyl-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate

A TFA salt of the title compound was prepared in a manner similar toEXAMPLE 82 using phenylboronic acid in place of tert-butyl3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole-1-carboxylate.¹H NMR (400 MHz, DMSO-d₆) δ ppm 9.03 (s, 1H), 8.15 (s, 1H), 7.72 (br s,3H), 7.51 (d, J=4.5 Hz, 6H), 7.35-7.45 (m, 1H), 7.22 (dd, J=8.7, 7.5 Hz,1H), 6.83 (d, J=7.6 Hz, 1H), 5.33 (d, J=6.8 Hz, 1H), 4.30 (br s, 1H),4.17-4.27 (m, 1H), 4.04 (d, J=17.7 Hz, 1H), 3.76 (br s, 1H), 2.33 (s,3H), 1.59-1.85 (m, 4H), 1.37-1.59 (m, 4H). [M+H] calc'd for C₂₆H₂₉N₅O,428; found, 428.

Preparation 40: tert-Butyl(1S,2R)-2-(7-methyl-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate

To an oven dry flask was added tert-butyl(1S,2R)-2-(7-bromo-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate(40 mg, 0.075 mmol), 2,4,6-trimethyl-1,3,5,2,4,6-trioxatriborinane(20.99 μL, 0.151 mmol), and potassium carbonate (31.3 mg, 0.226 mmol) indioxane (1959 μL) and water (196 μL). The resulting tan solution wasdegassed with nitrogen for 5 min. Palladium chloride (dppf) (5.52 mg,7.54 μmol) was added and the mixture was degassed for an additional 2min. The vessel was capped and the reaction mixture was heated at 100°C. with stirring overnight. The reaction mixture was cooled to RT,diluted with EtOAc (5 mL), and washed with water (5 mL) and brine (5mL). The organic layer was collected, dried over Na₂SO₄ and concentratedto give the title compound as a brown viscous oil, which was usedwithout purification (45 mg). [M+H] calc'd for C₂₆H₃₅N₅O₃, 466; found,466.

Example 886-((1R,2S)-2-Aminocyclohexylamino)-7-methyl-4-(m-tolylamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A TFA salt of the title compound was prepared in a manner similar toEXAMPLE 75 using tert-butyl(1S,2R)-2-(7-methyl-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamatein place of tert-butyl(1S,2R)-2-(7-chloro-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate.¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.79 (s, 1H), 8.10 (s, 1H), 7.73 (br s,3H), 7.48 (d, J=2.0 Hz, 2H), 7.14-7.21 (m, 1H), 6.77 (d, J=7.6 Hz, 1H),5.69 (d, J=6.6 Hz, 1H), 4.36 (br s, 1H), 4.18-4.29 (m, 2H), 3.72 (br s,1H), 2.31 (s, 3H), 2.01 (s, 3H), 1.88 (d, J=9.1 Hz, 2H), 1.55-1.79 (m,4H), 1.39-1.55 (m, 2H). [M+H] calc'd for C₂₁H₂₇N₅O, 366; found, 366.

Preparation 41: tert-Butyl(3R,4R)-4-(7-fluoro-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)tetrahydro-2H-pyran-3-ylcarbamate

A. tert-Butyl(3R,4R)-4-(3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)tetrahydro-2H-pyran-3-ylcarbamate

To a suspension of6-((3R,4R)-3-aminotetrahydro-2H-pyran-4-ylamino)-4-(m-tolylamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one(13.0 mg, 0.037 mmol) in DCM (368 μL) was added Et₃N (6.05 μL, 0.043mmol) and di-tert-butyl dicarbonate (Boc anhydride) (39.0 μL, 0.039mmol). The suspension was sonicated for 5 min and then stirred at RT for12 h. The solution was diluted with DCM (15 mL) and washed with water(10 mL) and brine (10 mL). The organic layer was collected, dried overNa₂SO₄ and concentrated to give the title compound as a light yellowresidue, which was used without further purification (15.2 mg, 91%).[M+H] calc'd for C₂₄H₃₁N₅O₄, 454; found, 454.

B. tert-Butyl(3R,4R)-4-(7-fluoro-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)tetrahydro-2H-pyran-3-ylcarbamate

To a screw-cap vial was added tert-butyl(3R,4R)-4-(3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)tetrahydro-2H-pyran-3-ylcarbamate(15.2 mg, 0.034 mmol) and SELECTFLUOR® (11.87 mg, 0.034 mmol) in DCM(335 μL) and MeOH (335 μL). The reaction mixture was stirred at RT for 2h, diluted with EtOAc (10 mL) and washed with saturated aq NaHCO₃ (5mL), water (5 mL), and brine (5 mL). The organic layer was collected,concentrated to a residue, and purified via preparative HPLC. Theappropriate fractions were collected and concentrated to yield a TFAsalt of the title compound as a colorless residue (4.2 mg, 26.6%). [M+H]calc'd for C₂₄H₃₀FN₅O₄, 472; found, 472.

Example 896-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-7-fluoro-4-(m-tolylamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A solution of tert-butyl(3R,4R)-4-(7-fluoro-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)tetrahydro-2H-pyran-3-ylcarbamate(4.5 mg, 9.54 μmol) in 4 M HCl-dioxane (2 mL) was stirred for 0.5 h atRT. The reaction mixture was concentrated to a residue, which wasdiluted in DMF (1 mL) and purified via preparative HPLC. The appropriatefractions were collected and lyophilized to give a TFA salt of the titlecompound as a white solid (2.6 mg, 73%). ¹H NMR (400 MHz, DMSO-d₆) δ ppm8.81 (s, 1H), 8.25 (s, 1H), 7.57 (s, 1H), 7.40 (d, J=8.1 Hz, 1H),7.04-7.28 (m, 2H), 6.79 (d, J=7.3 Hz, 1H), 6.62-6.76 (m, 2H), 4.26-4.46(m, 3H), 3.85-3.96 (m, 2H), 2.32 (s, 3H), 1.94-2.13 (m, 1H), 1.59-1.70(m, 1H), 1.07-1.28 (m, 4H). [M+H] calc'd for C₁₉H₂₂FN₅O₂, 372; found,372.

Preparation 42: tert-Butyl(1S,2R)-2-(7-bromo-4-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate

To a round bottomed flask was added tert-butyl(1S,2R)-2-(4-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate(124 mg, 0.291 mmol) in DCM (30 mL). The resulting white suspension washeated with a heat gun while stirring until all the starting materialwas dissolved. The solution was cooled to 0° C., and while stirring,1-bromopyrrolidine-2,5-dione (51.7 mg, 0.291 mmol) was added. Thereaction mixture was allowed to warm to RT and was stirred for 30 min.The solution was diluted with DCM (20 mL) and was washed with saturatedaq NaHCO₃ (20 mL), water (20 mL), and brine (20 mL). The organic layerwas collected and concentrated to an orange solid, which was treatedwith Et₂O (5 mL). Solids began to precipitate after the solution wasallowed to sit undisturbed for 5 min. The mixture was allowed to sit for1 h and was then filtered through paper. The solids were washed withEt₂O (5 mL) and collected to give the title compound as a tan solid(137.3 mg, 93%). [M+H] calc'd for C₂₂H₂₉BrN6O₃, 505; found, 505.

Preparation 43: tert-Butyl(1S,2R)-2-(7-methyl-4-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate

The title compound was prepared in a manner similar to PREPARATION 40using tert-butyl(1S,2R)-2-(7-bromo-4-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamatein place of tert-butyl(1S,2R)-2-(7-bromo-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate.[M+H] calc'd for C₂₃H₃₂N₆O₃, 441; found, 441.

Example 906-((1R,2S)-2-Aminocyclohexylamino)-7-methyl-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A TFA salt of the title compound was prepared in a manner similar toEXAMPLE 89 using tert-butyl(1S,2R)-2-(7-methyl-4-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamatein place of tert-butyl(3R,4R)-4-(7-fluoro-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)tetrahydro-2H-pyran-3-ylcarbamate.¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.87 (s, 1H), 8.30 (s, 1H), 8.17 (s,1H), 7.71 (br s, 3H), 5.71 (d, J=6.3 Hz, 1H), 4.49 (d, J=2.8 Hz, 1H),4.24 (s, 2H), 3.91 (br s, 3H), 3.71 (br s, 1H), 2.08 (s, 3H), 1.77-1.93(m, 3H), 1.69 (d, J=8.6 Hz, 3H), 1.40-1.53 (m, 2H).

[M+H] calc'd for C₁₈H₂₄N₆O, 341; found, 341.

Preparation 44: (R)-Methyl6-(2-(tert-butoxycarbonylamino)-3-methoxypropylamino)-4-cyano-2-(1-methyl-1H-pyrazol-4-yl)nicotinate

To a screw-top vial was added methyl6-chloro-4-cyano-2-(1-methyl-1H-pyrazol-4-yl)nicotinate (115 mg, 0.416mmol), (R)-tert-butyl 1-amino-3-methoxypropan-2-ylcarbamate (93 mg,0.457 mmol), and DIPEA (87 μL, 0.499 mmol) in DMF (308 μL). Theresulting yellow solution was stirred for 12 h at 45° C. and then at 50°C. for 6 h. The reaction mixture was diluted with EtOAc (20 mL) and waswashed with water (10 mL) and brine (20 mL). The organic layer wascollected and dried over Na₂SO₄ and was concentrated to a yellow oil.The concentrate was purified via standard phase column chromatographyeluting with EtOAc and hexanes (50-100% EtOAc gradient) to give thetitle compound as a light yellow residue (36.5 mg, 20%). [M+H] calc'dfor C₂₁H₂₈N₆O₅, 445; found, 445.

Preparation 45: (R)-tert-Butyl1-methoxy-3-(4-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)propan-2-ylcarbamate

The title compound was prepared in a manner similar to PREPARATION 34using (R)-methyl6-(2-(tert-butoxycarbonylamino)-3-methoxypropylamino)-4-cyano-2-(1-methyl-1H-pyrazol-4-yl)nicotinatein place of (R)-methyl6-(2-(tert-butoxycarbonylamino)-3-methoxypropylamino)-4-cyano-2-(m-tolylamino)nicotinate(84.5 mg, 0.180 mmol). [M+H] calc'd for C₂₀H₂₈N₆O₄, 417; found, 417.

Example 91(R)-6-(2-Amino-3-methoxypropylamino)-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A TFA salt of the title compound was prepared in a manner similar toEXAMPLE 89 using (R)-tert-butyl1-methoxy-3-(4-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)propan-2-ylcarbamatein place of tert-butyl(3R,4R)-4-(7-fluoro-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)tetrahydro-2H-pyran-3-ylcarbamate.¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.97 (s, 1H), 8.40 (s, 1H), 8.09 (s,1H), 8.00 (br s, 3H), 7.17-7.26 (m, 1H), 6.42 (s, 1H), 4.24 (s, 2H),3.89 (s, 3H), 3.54-3.60 (m, 5H), 3.33 (s, 3H). [M+H] calc'd forC₁₅H₂₀N₆O₂, 317; found, 317.

Preparation 46:6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-4-chloro-2-(2,4-dimethoxybenzyl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A mixture of4,6-dichloro-2-(2,4-dimethoxybenzyl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one(2.5 g, 6.74 mmol), (3R,4R)-tetrahydro-2H-pyran-3,4-diamine (0.711 g,6.12 mmol), and DIPEA (5.35 mL, 30.6 mmol) in ACN (30 mL) was stirred at85° C. for 3 d in a sealed tube. Additional(3R,4R)-tetrahydro-2H-pyran-3,4-diamine (0.356 g, 3.06 mmol) and DIPEA(2.14 mL, 12.2 mmol) were added and the mixture was heated at 100° C.overnight. The mixture was concentrated and purified via preparativeHPLC. The fractions corresponding to the desired regioisomer werecollected to give the title compound (265 mg, 9.60%). ¹H NMR (400 MHz,DMSO-d₆) δ ppm 1.64-1.65 (m, 1H), 1.80-1.82 (s, 1H), 3.40 (td, J=11.47,2.44 Hz, 1H), 3.53 (dd, J=11.23, 1.95 Hz, 1H), 3.67 (dd, J=11.47, 2.20Hz, 1H), 3.71-3.73 (m, 1H), 3.75 (s, 3H), 3.77-3.79 (m, 1H), 3.81 (s,3H), 4.09-4.11 (m, 1H), 4.33 (s, 2H), 4.50 (s, 2H), 6.48 (dd, J=8.30,2.44 Hz, 1H), 6.58 (d, J=2.44, 1H), 6.90 (br s, 1H), 7.06 (d, J=8.30 Hz,1H). [M+H] calc'd for C₂₁H₂₄ClFN₄O₄, 451; found, 451.

Example 926-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-7-fluoro-4-(pyrazolo[1,5-a]pyridin-3-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A.6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-2-(2,4-dimethoxybenzyl)-7-fluoro-4-(pyrazolo[1,5-a]pyridin-3-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

To a 5 mL microwave vial with a stir bar was addedbis(triphenylphosphine)palladium chloride (11.68 mg, 0.017 mmol),6-((3R,4R)-3-aminotetrahydro-2H-pyran-4-ylamino)-4-chloro-2-(2,4-dimethoxybenzyl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one(75 mg, 0.166 mmol), pyrazolo[1,5-a]pyridin-3-ylboronic acid (135 mg,0.832 mmol) in dioxane (2 mL), and saturated aq NaHCO₃ (2 mL). Themixture was heated in a Biotage Initiator microwave at 120° C. for 30min. The mixture was concentrated and purified via preparative HPLC togive the title compound (89 mg, 100%). ¹H NMR (400 MHz, DMSO-d₆) δ ppm1.82-1.84 (m, 1H), 2.10-2.12 (m, 1H), 3.68-3.72 (m, 3H), 3.75 (s, 3H),3.82 (s, 3H), 3.92-3.95 (m, 1H), 4.01-4.02 (m, 1H), 4.39 (s, 2H),4.55-4.58 (m, 1H), 4.59 (s, 2H), 6.50 (dd, J=8.30, 1.95 Hz, 1H), 6.60(d, J=2.44, 1H), 7.04-7.08 (m, 2H), 7.16 (d, J=5.86 Hz, 1H), 7.48-7.51(m, 1H), 7.93 (br s, 1H), 8.37 (d, J=9.27 Hz, 1H), 8.79 (d, J=6.83 Hz,1H), 9.36 (s, 1H). [M+H] calc'd for C₂₈H₂₉FN₆O₄, 533; found, 533.

B.6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-7-fluoro-4-(pyrazolo[1,5-a]pyridin-3-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

To a 25 mL round bottom flask with a stir bar was added6-((3R,4R)-3-aminotetrahydro-2H-pyran-4-ylamino)-2-(2,4-dimethoxybenzyl)-7-fluoro-4-(pyrazolo[1,5-a]pyridin-3-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one(85 mg, 0.160 mmol) in TFA (5 mL). The mixture was heated at 60° C. for1.5 h and then cooled to RT. The mixture was concentrated and purifiedvia preparative HPLC to give a TFA salt of the title compound as a whitesolid (27 mg, 44.2%). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.83-1.85 (m, 1H),2.12-2.14 (m, 1H), 3.65-3.73 (m, 2H), 3.81-3.82 (m, 1H), 3.93-3.95 (m,1H), 4.01-4.03 (m, 1H), 4.43 (s, 2H), 4.53-4.55 (m, 1H), 7.04 (t, J=6.83Hz, 1H), 7.13 (d, J=4.88 Hz, 1H), 7.49 (t, J=8.05 Hz, 1H), 7.94 (br s,1H), 8.36-8.42 (m, 2H), 8.78 (d, J=6.83 Hz, 1H), 9.33 (s, 1H). [M+H]calc'd for C₁₉H₁₉FN₆O₂, 383; found, 383.

Example 936-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-4-(1-(difluoromethyl)-1H-pyrazol-4-yl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A TFA salt of the title compound was prepared in a manner similar toEXAMPLE 92 using 1-(difluoromethyl)-1H-pyrazol-4-ylboronic acid in placeof pyrazolo[1,5-a]pyridin-3-ylboronic acid. ¹H NMR (400 MHz, DMSO-d₆) δppm 1.75-1.77 (m, 1H), 2.09-2.12 (m, 1H), 3.60-3.63 (m, 1H), 3.76-3.77(m, 1H), 3.88-3.98 (m, 3H), 4.44 (d, J=6.35 Hz, 2H), 4.54-4.55 (m, 1H),7.17 (d, J=5.86 Hz, 1H), 7.89 (br s, 1H), 8.54 (s, 1H), 8.58 (s, 1H),9.43 (s, 1H).

[M+H] calc'd for C₁₆H₁₇F₃N₆O₂, 383; found, 383.

Example 946-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-4-(benzofuran-3-yl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A TFA salt of the title compound was prepared in a manner similar toEXAMPLE 92 using benzofuran-3-ylboronic acid in place ofpyrazolo[1,5-a]pyridin-3-ylboronic acid. ¹H NMR (400 MHz, DMSO-d₆) δ ppm1.84-1.88 (m, 2H), 3.68-3.73 (m, 1H), 3.76-4.02 (m, 4H), 4.47 (s, 2H),4.58-4.59 (m, 1H), 7.25 (d, J=6.35 Hz, 1H), 7.40-7.42 (m, 2H), 7.67-7.69(m, 1H), 7.93 (br s, 1H), 8.33 (d, J=9.76 Hz, 1H), 8.56 (s, 1H), 9.38(s, 1H). [M+H] calc'd for C₂₀H₁₉FN₄O₃, 383; found, 383.

Example 95(S)-6-(3-Aminopyrrolidin-1-yl)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A. (S)-tert-Butyl1-(4-chloro-2-(2,4-dimethoxybenzyl)-7-fluoro-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-yl)pyrrolidin-3-ylcarbamate

A tube containing4,6-dichloro-2-(2,4-dimethoxybenzyl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one(300 mg, 0.808 mmol) and (S)-tert-butyl pyrrolidin-3-ylcarbamate (301mg, 1.616 mmol) dissolved in ACN (4 mL) was sealed and heated at 100° C.for 2 d. The reaction mixture was concentrated and dissolved in EtOAc(20 mL) and washed with saturated aq NaHCO₃ (10 mL) and brine (10 mL).The organic extracts were dried over Na₂SO₄ and evaporated to give acrude product, which was purified via preparative HPLC. Pure fractionswere collected and evaporated to give the title compound (235 mg,55.8%). [M+H] calc'd for C₂₅H₃₀ClFN₄O₅, 521; found, 521.

B.(S)-6-(3-Aminopyrrolidin-1-yl)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

To a 30 mL tube charged with (S)-tert-butyl1-(4-chloro-2-(2,4-dimethoxybenzyl)-7-fluoro-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-yl)pyrrolidin-3-ylcarbamate(225 mg, 0.43 mmol)1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole(145 mg, 0.695 mmol), and PdCl₂(PPh₃) dispersed in dioxane (5 mL) wasadded 2 N Na₂CO₃ (0.5 mL). The tube was sealed and the reaction mixturewas heated at 85° C. for 4 h. The mixture was diluted with water (5 mL)and extracted into EtOAc (2×30 mL). The organic layer was dried overNa₂SO₄ and evaporated to afford a residue, which was treated with TFA (1mL) and heated at 85° C. for 1 h to remove the protecting groups. TFAwas evaporated and the mixture was dissolved in DMSO (8 mL) and purifiedvia preparative HPLC. Pure fractions were collected, evaporated to aminimal volume, and lyophilized to give a TFA salt of the title compoundas a pale yellow solid (46 mg, 27.2%). ¹H NMR (400 MHz, DMSO-d₆) δ ppm2.05-2.39 (m, 3H), 3.75-4.04 (m, 6H), 3.89 (s, 3H), 4.38 (s, 2H), 8.02(br s, 2H), 8.26 (d, J=0.51 Hz, 1H), 8.39 (s, 1H), 8.85 (s, 1H);). [M+H]calc'd for C₁₅H₁₇FN₆O, 317; found, 317.

Example 96(S)-6-(3-Aminopiperidin-1-yl)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A TFA salt of the title compound was prepared in a manner similar toEXAMPLE 95 using (S)-tert-butyl piperidin-3-ylcarbamate in place of(S)-tert-butyl pyrrolidin-3-ylcarbamate. ¹H NMR (400 MHz, DMSO-d₆) δ ppm1.61 (m, 2H), 1.83 (d, J=8.34 Hz, 1H), 2.03 (br s, 1H), 2.53-2.55 (m,2H), 3.16-3.35 (m, 3H), 3.90 (s, 3H), 3.92 (m, 1H), 4.33 (m, 1H), 4.39(s, 2H), 8.04 (br s, 3H), 8.36 (s, 1H), 8.51 (s, 1H), 8.90 (s, 1H).[M+H] calc'd for C₁₆H₁₉FN₆O, 331; found, 331.

Example 976-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-4-(1-isopropyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A TFA salt of the title compound was prepared in a manner similar toEXAMPLE 62 using1-isopropyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazolein place of1-(difluoromethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole.¹H NMR (500 MHz, CDCl₃) δ ppm 1.14-1.33 (m, 6H), 1.47-1.64 (m, 8H), 1.76(br. s., 2H), 1.94-2.01 (m, 2H), 3.86 (br. s., 1H), 4.36 (s, 2H), 4.53(d, J=6.83 Hz, 2H), 8.15 (s, 1H), 8.88 (s, 1H).

[M+H] calc'd for C₁₉H₂₅FN₆O, 373; found, 373.

Preparation 47: tert-Butyl4,6-dichloro-7-fluoro-3-oxo-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxylate

A. 2,6-Dichloro-5-fluoronicotinamide

A 12-L 3-neck round bottom flask equipped with overhead stirrer,refluxing condenser, and N₂ inlet/outlet was charged with2,6-dichloro-5-fluoronicotinonitrile (2.0 kg, 1.0 eq). Concentratedsulfuric acid (4.93 L) was added and the mixture was stirred at RT untilmost of the brown solids had dissolved. Next, the reaction mixture wasstirred at 65° C. for 1 h. The dark-brown solution was cooled to atemperature<10° C. using an ice bath. The reaction mixture was added toa 50-L round bottom flask, which contained de-ionized water (24.7 L)that had been cooled to a temperature<10° C., using a peristaltic pump.The reaction mixture was added to the water quench over a 2.3 h period,which kept the internal temperature of the mixture below 21° C. Theresulting slurry was filtered through a Buchner funnel fitted with aSharkskin filter paper. The 50-L RBF was rinsed with water (3×4 L) andthe rinses were used to wash the filter cake. The filter cake wasconditioned for 50 min, transferred to a drying tray, and was driedunder high vacuum at 40-50° C. for 24 h and then at 20-25° C. for 18 hto give the title compound as a beige solid (896.4 g, 82%). ¹H NMR (500MHz, DMSO-d₆) δ ppm 7.94 (s, 1H), 8.10 (s, 1H), 8.24 (d, 1H). [M+H]calc'd for C₆H₃Cl₂FN₂O, 209; found, 209.

B. 4,6-Dichloro-7-fluoro-1-hydroxy-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A 22-L multi-neck RBF equipped with an overhead stirrer, temperatureprobe, and N₂ inlet/outlet was charged with LiHMDS (10.65 L, 2.5 eq) byN₂ pressure. The orange solution was cooled to <0° C. using an ice/brinebath. A separate 12-L RBF was sequentially charged with2,6-dichloro-5-fluoronicotinamide (890 g, 1.0 eq), anhydrous THF (6.0L), and anhydrous DMF (1.0 L, 3.0 eq). The resulting solution was addedto the LiHMDS solution via a peristaltic pump over a 1 h period, whichkept the internal temperature below 5° C. The 12-L flask was rinsed withTHF (1.6 L), and the rinse was transferred to the reaction mixture. Themixture was stirred at a temperature<5° C. for 1 h, and the reaction wasadded to a pre-cooled 2N HCl aq solution via a peristaltic pump at arate that kept the temperature of the mixture below 22° C. Following thequench, IPAc (14 L) was added and the mixture was stirred for 10 min.The biphasic mixture was separated and the organic layer was stored in acarboy at RT overnight. The organic layer was subsequently washed withwater (8.9 L) and was concentrated under reduced pressure to a volume ofabout 4.5 L. The distillation was continued the next day. Isopropylacetate (16 L) was added to the slurry and the distillation wascontinued until about 4.5 L of material remained. The off-white slurrywas transferred into a 50-L multi-neck RBF to which was charged heptanes(18 L) via a peristaltic pump over a 45 min period. The resultant slurrywas stirred at RT overnight and then filtered through a Buchner funnelwith a Sharkskin filter paper. The filter cake was washed with heptanes(2×4.5 L) and then dried under high vacuum at RT for 24 h to affordtitle compound (913.0 g, 90%). ¹H NMR (300 MHz, DMSO-d₆) δ ppm 6.11 (dd,J=9.3 Hz, 1.5 Hz, 1H), 6.95 (d, J=9.3 Hz, 1H), 9.54 (s, 1H). [M+H]calc'd for C₇H₃Cl₂FN₂O₂, 237; found, 237.

C. 4,6-Dichloro-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A 22-L 3-neck RBF equipped with overhead stirrer, refluxing condenser,and N₂ inlet/outlet, and having all glass or PTFE-coated parts, wassequentially charged with4,6-dichloro-7-fluoro-1-hydroxy-1H-pyrrolo[3,4-c]pyridin-3(2H)-one (908g), DCM (4.55 L), and TFA (3.46 L, 11.76 eq). Agitation was started andEt₃SiH (3.05 L, 4.97 eq) was added. The cloudy mixture was heated toreflux, resulting in a clear solution that was stirred at refluxingconditions for 24 h. The mixture was cooled to RT and stirred overnight.The orange solution was cooled to <10° C. using an ice bath. Methyltert-butyl ether (14.0 L) was added via a peristaltic pump within a 1 hperiod. The resultant slurry was stirred at <10° C. for 1 h and thenfiltered through a coarse fitted glass funnel. The filter cake waswashed with MTBE (2×4 L). The solid was dried under high vacuum at RTfor 19 h to afford the title compound (802 g, 94%). ¹H NMR (500 MHz,DMSO-d₆) δ ppm 4.55 (s, 2H), 9.15 (s, 1H). [M+H] calc'd for C₇H₃Cl₂FN₂O,221; found, 221.

D. tert-Butyl4,6-dichloro-7-fluoro-3-oxo-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxylate

A 12 L 3-neck RBF was charged with4,6-dichloro-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one (745.0 g, 1.0eq), DCM (3.0 L), Et₃N (940 mL, 2.0 eq), and DMAP (20.59 g, 0.05 eq). Toa separate 2-L flask containing di-tert-butyl dicarbonate (882.8 g, 1.2eq) was added DCM (0.75 L), and the resulting clear solution was addeddropwise to the reaction mixture over a 20 min period via a peristalticpump. The 2-L flask was rinsed with DCM (0.75 L) and the rinse was addedto the reaction mixture, which was stirred at RT for 28 min. Ethanol(7.5 L) was added and the mixture was concentrated under reducedpressure to a volume of about 4.5 L. A second volume of EtOH (7.5 L) wasadded to the mixture and distillation was continued until about 4.5 L ofthe material remained. The resultant slurry was stirred at 15-20° C. for10 min and was then filtered through a Buchner funnel. The filter cakewas washed with EtOH (3×1.5 L) and dried under high vacuum at RTovernight to give the title compound as a pink solid (873 g, 81% yield).¹H (300 MHz, CDCl₃) δ ppm 1.61 (s, 9H), 4.82 (d, J=0.9 Hz, 2H), ¹⁹F NMR(282 MHz, CDCl₃) δ ppm −128.36. [M−H] calc'd for C₁₂H₁₁C₁₂FN₂O₃, 319;found, 319.

Example 987-Fluoro-4,6-bis(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A mixture of tert-butyl4,6-dichloro-7-fluoro-3-oxo-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxylate(30.0 mg, 0.093 mmol),1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole(19.4 mg, 0.093 mmol), tris(dibenzylideneacetone)dipalladium (3.42 mg,0.003 mmol), tricyclohexylphosphine (3.90 mg, 0.001 mmol) and potassiumphosphate (35.7 mg, 0.168 mmol) in dioxane (1 mL) and deionized water(0.3 mL) were heated at 120° C. in a microwave for 20 min. The mixturewas concentrated and purified via preparative HPLC to give a TFA salt ofthe title compound as a pale yellow solid (4.1 mg, 14%). ¹H NMR (400MHz, DMSO-d₆) δ ppm 3.92 (s, 3H), 3.96 (s, 3H), 4.53 (s, 2H), 8.17 (s,1H), 8.49 (s, 1H), 8.50 (s, 1H), 8.81 (s, 1H), 8.92 (s, 1H). [M+H]calc'd for C₁₅H₁₃FN₆O, 313; found, 313.

Example 996-((1R,2S)-2-Aminocyclohexylamino)-7-bromo-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A solution of tert-butyl(1S,2R)-2-(7-bromo-4-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate(10 mg, 0.020 mmol) in HCl-dioxane (999 μL, 4.00 mmol) was stirred at RTfor 2 h. The mixture was concentrated to a residue, diluted with Et₂O (3mL), and sonicated to yield a white precipitate, which was filtered anddried overnight in a lyophilizer to give an HCl salt of the titlecompound as a white solid (1.8 mg, 21%). [M+H] calc'd for C₁₇H₂₁BrN₆O,406; found, 406.

Example 1002-((1R,2S)-2-Aminocyclohexylamino)-4-(1-(4-fluorophenyl)-1H-pyrazol-4-yl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one

A TFA salt of the title compound was prepared in a manner similar toEXAMPLE 14 using 1-(4-fluorophenyl)-1H-pyrazol-4-ylboronic acid in placeof 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole.¹H NMR (500 MHz, DMSO-d₆) δ ppm 1.43 (br s, 2H), 1.55-1.98 (m, 6H),4.10-4.35 (m, 2H), 4.34-4.70 (m, 1H), 7.43 (t, J=8.79 Hz, 2H), 7.65 (d,J=7.81 Hz, 1H), 7.68-7.83 (m, 3H), 7.87 (br s, 2H), 8.39 (s, 1H),8.58-9.00 (m, 1H), 9.62-9.86 (m, 1H). [M+H] calc'd for C₂₁H₂₂FN₇O, 408;found, 408.

Example 101(R)-6-(2-Amino-3-methoxypropylamino)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2M-one

To a 20 mL round-bottomed flask was added (R)-tert-butyl1-methoxy-3-(4-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)propan-2-ylcarbamate(19.7 mg, 0.047 mmol) and SELECTFLUOR® (21.78 mg, 0.061 mmol) in DCM(473 μL) and MeOH (473 μL). The resulting yellow solution was stirred atRT for 3 h and concentrated to a residue, which was dissolved in 4 NHCl-dioxane (2 mL) and stirred at RT for 2 h. The mixture wasconcentrated, dissolved in DMF (1 mL) and purified via preparative HPLCto give a TFA salt of the title compound. [M+H] calc'd for C₁₅H₁₉FN₆O₂,335; found, 335.

Preparation 48: cis-tert-butyl 2-aminocyclohexylcarbamate

A. trans-tert-Butyl 2-hydroxycyclohexylcarbamate

To a stirred slurry of trans-2-aminohexanol hydrochloride (15.0 g, 98.92mmol) in EtOAc (75 mL) was added a solution of NaOH (9.1 g, 0.227 mol)in water (150 mL). A solution of di-tert-butyl dicarbonate (25.9 g,118.70 mmol) in EtOAc (75 mL) was added in one portion and the mixturewas heated to 45° C. and stirred for 16 h. The phases were separated andthe aqueous phase was extracted with EtOAc (60 mL). The combined organicextracts were washed with water (45 mL) and phase separated. The organicphase was distilled at atmospheric pressure until approximately 75 mL ofsolution remained. Heptane (90 mL) was added and the solution wasdistilled until approximately 75 mL of solution remained. Heptane (150mL) was added and the mixture was heated to 98-100° C. The heat wasswitched off and the mixture was allowed to cool to RT. Seeds of pureproduct were added at 70° C. and crystallization occurred at about 65°C. Once the slurry reached RT, the mixture was cooled to about 5° C. andwas stirred for 30 min. The solids were filtered, washed with heptane(2×45 mL), and dried to give the title compound as a white crystallinesolid (19.6 g, 92%).

B. cis-tert-Butyl 2-(1,3-dioxoisoindolin-2-yl)cyclohexylcarbamate

To a stirred slurry of trans-tert-butyl 2-hydroxycyclohexylcarbamate(1.00 g, 4.64 mmol), PPh₃ (1.34 g, 5.10 mmol) and phthalimide (1.50 g,10.20 mmol) in a 2:1 mixture of toluene and THF (15 mL) was addeddiisopropyl azodicarboxylate (1.0 mL, 5.10 mmol) dropwise over a periodof 1 h. Once the addition was complete, the mixture was stirred at about0° C. for 7 h and was then warmed slowly to 7° C. over a period of 14 h.The mixture was filtered, and the filtrate was concentrated underreduced pressure to give the title compound as a yellow oil (3.90 g).The crude product was used in the next step without furtherpurification.

C. cis-tert-Butyl 2-aminocyclohexylcarbamate

Crude cis-tert-butyl 2-(1,3-dioxoisoindolin-2-yl)cyclohexylcarbamate(3.90 g) was dissolved in toluene (20 mL) and charged to a round bottomflask. Hydrazine hydrate (0.70 mL) was added and the mixture was heatedto 80° C. for 2 h whereupon TLC analysis indicated the reaction wascomplete. The reaction was cooled to RT and the solids were filtered andwashed with toluene (2×5 mL). The filtrates were washed with 2 N NaOH aq(10 mL) and phase separated. The aqueous phase was extracted withtoluene (2×5 mL) and the combined organic extracts were washed with 10%HOAc aq (2×10 mL). The combined aqueous washes were basified with 2 NNaOH aq (13 mL). The product was extracted with IPAc (2×10 mL) and thecombined organic extracts were washed with water (5 mL). The organicphase was concentrated to dryness to give 0.78 g of crude product. Theoil was re-dissolved in IPAc (12 mL), heated to about 75° C., and maleicacid (423 mg) was added. Precipitation of solids occurred immediatelyand the thick mixture was diluted with IPAc (5 mL). The slurry wascooled to RT and allowed to stand for 20 min. The solids were filtered,washed with IPAc (10 mL), and dried to give a maleic acid salt of thetitle compound as white crystalline solid (730 mg, 44%). ¹H NMR (300MHz, DMSO-d₆) δ ppm 1.34-1.42 (m, 2H), 1.50 (s, 9H), 1.50-1.64 (m, 6H),3.22 (m, 1H), 3.83 (br s, 1H), 6.02 (s, 2H), 6.86 (d, J=7.5 Hz, 1H),7.68 (br s, 3H).

Preparation 49: tert-Butyl (1S,2R)-2-aminocyclohexylcarbamate,(S)-mandelic acid salt

A. cis-N-(2-Aminocyclohexyl)-2,2,2-trifluoroacetamide

cis-Cyclohexane-1,2-diamine (5.00 g, 43.9 mmol, 1.00 eq) was charged toa 250 mL three-neck round bottom flask equipped with an overhead stirrerand a thermocouple. Ethanol (50 mL) was added and the solution wascooled to <0° C. using an ice-brine bath. A solution of ethyltrifluoroacetate (6.23 g, 1.00 eq) in EtOH (25 mL) was added via asyringe pump over a one hour period. Once the addition was complete, thecooling bath was removed and the solution was slowly warmed to RT andstirred for 3.5 hours to afford the title compound in EtOH. Half (41 mL,about 21.9 mmol) of the total solution (about 82 mL) was carried intothe next step.

B. cis-tert-Butyl 2-(2,2,2-trifluoroacetamido)cyclohexylcarbamate

Triethylamine (3.1 mL, 22.05 mmol, 1.0 eq) was added to a solution ofcis-N-(2-aminocyclohexyl)-2,2,2-trifluoroacetamide in EtOH (41 mL, 21.9mmol). Di-tert-butyl dicarbonate (5.74 g, 26.3 mmol, 1.2 eq) was addedin one portion at RT. An ice bath was used to control a modest exothermand the internal reaction temperature was maintained at <25° C. Once theexotherm subsided the ice bath was removed, and the mixture was stirredat RT for 16 h to give the title compound in EtOH.

C. cis-tert-Butyl 2-aminocyclohexylcarbamate

Aqueous sodium hydroxide (50%, 10 g, 0.125 mole, 5.7 eq) was added to asolution of cis-tert-butyl2-(2,2,2-trifluoroacetamido)cyclohexylcarbamate in EtOH (about 21.9mmol). An exotherm from 20 to 37° C. was observed and a fine whiteslurry formed. The reaction mixture was stirred overnight, during whichfurther solids precipitated out of solution. The solvent volume wasconcentrated under reduced pressure to about 10 to 15 mL and then IPAc(40 mL) and water (30 mL) were added to form a clean bi-phasic solution.Following phase separation the aqueous phase was extracted with IPAc (15mL) and the organic extracts were combined and washed with water (15 mL)to give the title compound as a crude racemic product in IPAc.

D. tert-Butyl (1S,2R)-2-aminocyclohexylcarbamate

Crude cis-tert-butyl 2-aminocyclohexylcarbamate in IPAc (70 mL, about21.9 mmol) was charged to a 100 mL three-neck RBF equipped with ashort-path distillation unit, thermocouple, and stir bar. Vacuum wasapplied and the solution was heated and the solvent volume was distilledat 43-44° C. until the volume reached about 45 mL (10 volumes relativeto theoretical crude yield of racemic product). Karl Fisher analysisindicated a water content of 4.9%. The vacuum was released and thesolution was heated to 60° C. The solution was then slowly cooled to RTand seeds of tert-butyl (1S,2R)-2-aminocyclohexylcarbamate, (S)-mandelicacid salt (from small scale resolution experiments) were added at 5° C.intervals. All the seeds dissolved while cooling, but remained when RTwas reached. The solution was cooled in an ice-brine bath (−15° C.) for30 min. The solution was reheated, and following the addition of IPAc(40 mL), was redistilled under vacuum at 45-46° C. to about 45 mL ofvolume. The reaction was cooled to RT and stirred overnight. The solidswere filtered, washed with IPAc (2×12.5 mL) and dried to afford an(S)-mandelic acid salt of the title compound as a white solid (2.21 g,28%, 98% ee). ¹H NMR (500 MHz, DMSO-d₆) δ ppm 1.24-1.30 (m, 2H), 1.35(s, 9H), 1.35-1.64 (m, 6H), 3.15 (m, 1H), 3.71 (br s, 1H), 4.55 (s, 1H),6.85-7.11 (br s, 3H), 6.95 (br d, 1H, J=7.5 Hz), 7.15 (m 1H), 7.23 (m,2H), 7.37 (m, 2H).

Example 1026-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one(HCl salt)

A. tert-Butyl6-((1R,2S)-2-(tert-butoxycarbonylamino)cyclohexylamino)-4-chloro-7-fluoro-3-oxo-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxylate

To a stirred suspension of tert-butyl4,6-dichloro-7-fluoro-3-oxo-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxylate(12.5 g, 38.9 mmol) in 2-propanol (72 mL) was added a solution oftert-butyl (1S,2R)-2-aminocyclohexylcarbamate (10.01 g, 46.7 mmol) inDMSO (12.00 mL) and DIPEA (8.84 mL, 50.6 mmol). The reaction mixture washeated to 90° C. for 16 h at which point it was cooled to 50° C. andwater (50 mL) was added dropwise to give a precipitate. The suspensionwas stirred at 50° C. for 1 h then cooled to RT. The suspension wasreheated to 50° C. for 15 min and cooled to RT for two more cycles. Thesolids were subsequently filtered and washed with isopropanol (20 mL)and dried on a filter to give the title compound (9.538 g, 49%). ¹H NMR(400 MHz, DMSO-d₆) δ ppm 1.18-1.76 (br m, 26H), 3.83 (br s, 1H), 4.12(br s, 1H), 4.72 (s, 2H), 6.71 (d, J=7.58 Hz, 1H), 7.22 (d, J=6.32 Hz,1H).

B. tert-Butyl6-((1R,2S)-2-(tert-butoxycarbonylamino)cyclohexylamino)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-3-oxo-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxylate

A 50 mL, 2-neck round bottom flask was charged with tert-butyl6-((1R,2S)-2-(tert-butoxycarbonylamino)cyclohexylamino)-4-chloro-7-fluoro-3-oxo-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxylate(520 mg, 1.042 mmol),1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole(282 mg, 1.355 mmol), potassium carbonate (504 mg, 3.65 mmol), and DMA(3 mL). The reaction flask was degassed followed by addition of1,1-bis(di-tert-butylphosphino)ferrocene palladium chloride (21 mg,0.032 mmol). Under N₂ atmosphere, the reaction mixture was heated in anoil bath at 80° C. for 2.5 h and then allowed to cool to RT. In aseparate 50 mL recovery flask was added de-ionized H₂O (12 mL) and thevessel was cooled in an ice/water bath. When the internal temperature ofthe water reached 2° C., the reaction mixture was transferred to therecovery flask at a rate which kept the internal temperature below 10°C. Following the addition, the reaction vessel was rinsed with DMA (1mL). The rinse was added to the recovery flask and the resulting aqueousslurry was stirred in an ice bath for 10 min and was then allowed towarm to RT with stirring. When the internal temperature reached 22° C.,the mixture was filtered. The filter cake was rinsed with de-ionized H₂O(2×5 mL) and air-dried under suction. The solids were re-suspended inglacial acetic acid (3 mL) and stirred at RT for 1 h. Isopropanol (1 mL)was added and the mixture was stirred at RT. De-ionized water (3.4 mL)was added to induce crystallization. Precipitation occurred, but somesolids were sticky, so the mixture was heated in a 40° C. oil bath, withstirring, for 20 min. The mixture was allowed to cool to RT withstirring and then filtered. The filter cake was rinsed with a 3:3:1mixture of HOAc/H₂O/IPA (2.1 mL), briefly air-dried under suction, andthen dried in a vacuum oven at 60° C. to give the title compound as atan solid (352 mg, 62%). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.35 (s, 9H),1.53 (s, 9H), 1.65 (m, 3H), 1.76 (m, 3H), 3.94 (s, 3H), 4.03 (br s, 1H),4.38 (br s, 1H), 4.67 (s, 2H), 5.12 (br s, 1H), 5.77 (br s, 1H), 8.25(br s, 1H), 8.96 (br s, 1H). [M+H] calc'd for C₂₇H₃₇FN₆O₅, 545; found,545.

C.6-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A suspension of tert-butyl6-((1R,2S)-2-(tert-butoxycarbonylamino)cyclohexyl-amino)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-3-oxo-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxylate(2.148 g, 3.94 mmol) in IPA (21 mL) was heated to 70° C. at which point2M HCl aq (9.86 mL, 19.72 mmol) was added. The reaction mixture washeated at 65° C. for approximately 3 h, cooled in an ice water bath for1 h, and then filtered. The solids were rinsed with cold IPA (15 mL) andthen dried in a 50° C. vacuum oven overnight to give an HCL salt of thetitle compound as a light yellow solid (1.404 g, 3.37 mmol) having 1.5-2eq of associated water (by ¹H NMR). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.46(d, J=7.07 Hz, 2H), 1.57-1.76 (m, 3H), 1.76-2.04 (m, 3H), 3.31 (s, 3H),3.67 (br s, 1H), 3.90 (s, 3H), 4.39 (d, J=2.53 Hz, 2H), 4.41-4.60 (m,1H), 6.75 (d, J=6.57 Hz, 1H), 7.96 (br s, 3H), 8.22-8.31 (m, 1H), 8.34(s, 1H), 8.84 (s, 1H). [M+H] calc'd for C₁₇H₂₁FN₆O, 345; found 345.

Example 1036-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-7-fluoro-4-(thiophen-3-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A TFA salt of the title compound was prepared in a manner similar toEXAMPLE 92 using thiophene-3-boronic acid in place ofpyrazolo[1,5-a]pyridin-3-ylboronic acid. ¹H NMR (400 MHz, DMSO-d₆) δ ppm3.16-3.17 (m, 2H), 3.61-3.63 (m, 1H), 3.77-3.79 (m, 2H), 3.81-3.83 (m,2H), 4.41-4.43 (m, 2H), 4.49-5.10 (m, 1H), 7.12-7.13 (m, 1H), 7.52-7.54(m, 1H), 7.90-7.97 (m, 3H), 8.48 (s, 1H), 8.88 (s, 1H). [M+H] calc'd forC₁₆H₁₇FN₄O₂S, 349; found, 349.

Example 1046-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-7-fluoro-4-(4-methylthiophen-2-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A TFA salt of the title compound was prepared in a manner similar toEXAMPLE 92 using 4-methylthiophene-2-boronic acid in place ofpyrazolo[1,5-a]pyridin-3-ylboronic acid. ¹H NMR (400 MHz, DMSO-d₆) δ ppm2.24 (s, 3H), 3.17 (d, J=4.04 Hz, 2H), 3.35-3.39 (m, 1H), 3.62-3.64 (m,1H), 3.74-3.75 (m, 2H), 4.00-4.03 (m, 2H), 4.42 (d, J=11.62 Hz, 2H),6.46 (s, 1H), 7.20-7.22 (m, 3H), 8.46 (s, 1H), 8.85 (s, 1H). [M+H]calc'd for C₁₇H₁₉FN₄O₂S, 363; found, 363.

Example 1056-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-4-(4-methylthiophen-2-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A TFA salt of the title compound was prepared in a manner similar toEXAMPLE 62 using4,4,5,5-tetramethyl-2-(4-methylthiophen-2-yl)-1,3,2-dioxaborolane inplace of1-(difluoromethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole.¹H NMR (500 MHz, DMSO-d₆) δ ppm 1.31-2.04 (m, 8H), 2.24 (s, 3H), 3.83(br s, 1H), 4.22 (br s, 1H), 4.36-4.49 (m, 2H), 6.98 (d, J=5.37 Hz, 1H),7.22 (s, 1H), 7.75 (br s, 2H), 8.47 (s, 1H), 8.85 (s, 1H). [M+H] calc'dfor C₁₈H₂₁FN₄OS, 361; found, 361.

Example 1066-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-4-(thiophen-3-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A TFA salt of the title compound was prepared in a manner similar toEXAMPLE 62 using4,4,5,5-tetramethyl-2-(thiophen-3-yl)-1,3,2-dioxaborolane in place of1-(difluoromethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole.¹H NMR (500 MHz, DMSO-d₆) δ ppm 1.31-2.05 (m, 8H), 3.84 (br s, 1H), 4.25(d, J=3.42 Hz, 1H), 4.36-4.50 (m, 2H), 7.01 (d, J=5.86 Hz, 1H), 7.15(dd, J=5.37, 3.91 Hz, 1H), 7.64 (dd, J=4.88, 0.98 Hz, 1H), 7.75 (br s,2H), 8.50 (s, 1H), 8.95-9.07 (m, 1H). [M+H] calc'd for C₁₇H₁₉FN₄OS, 347;found, 347.

Example 107(R)-2-(7-Fluoro-4-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-N,4-dimethylpentanamide

A. (R)-Methyl2-(4-chloro-2-(2,4-dimethoxybenzyl)-7-fluoro-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-4-methylpentanoate

A mixture of4,6-dichloro-2-(2,4-dimethoxybenzyl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one(3 g, 8.08 mmol), (5)-methyl 2-amino-4-methylpentanoate hydrochloride(2.94 g, 16.16 mmol), and N-isopropyl-N-methylpropan-2-amine (3.76 mL,24.25 mmol) in ACN (50 mL) was stirred at 100° C. for 3 d. The solventwas removed and the resulting residue was used in the next step withoutfurther purification. [M+H] calc'd for C₂₃H₂₇ClFN₃O₅, 480; found, 480.

B.(R)-2-(4-Chloro-2-(2,4-dimethoxybenzyl)-7-fluoro-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-4-methylpentanoicacid

A mixture of (R)-methyl2-(4-chloro-2-(2,4-dimethoxybenzyl)-7-fluoro-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-4-methylpentanoate(2.9 g, 6.04 mmol) in MeOH (10 mL) and 1N NaOH (40.0 mL) was stirred at50° C. for 2 h. UPLC showed 30% starting material remained. Additionalsaturated NaOH solution (5 mL) was added and the reaction mixture wasstirred for 3 h at 50° C. The solvent was removed and the resultingresidue was dispersed in H₂O (100 mL) and acidified to pH 3 using HCl.After stirring at RT for 2 h, the solid was filtered to give the titlecompound. [M+H] calc'd for C₂₂H₂₅ClFN₃O₅, 466; found, 466.

C.(R)-2-(2-(2,4-Dimethoxybenzyl)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-4-methylpentanoicacid

A solution of(R)-2-(4-chloro-2-(2,4-dimethoxybenzyl)-7-fluoro-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-4-methylpentanoicacid (1.1 g, 2.361 mmol),1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole(2.456 g, 11.81 mmol) and bis(triphenylphosphine)palladium chloride(1.657 g, 2.361 mmol) in dioxane (10 mL) and saturated aq Na₂CO₃ (10.00mL) was heated to 120° C. for 30 min. After filtering out the solids,the solvent was removed from the filtrate. The resulting residue wasdissolved in MeOH and DCM and was purified via preparative HPLC elutingwith water (0.05% TFA) and ACN (40-70% gradient, 0.035% TFA). Thecollected fractions were combined and the solvent stripped to drynessvia rotary evaporation to yield the title compound. [M+H] calc'd forC₂₆H₃₀FN₅O₅, 512; found, 512.

D.(R)-2-(2-(2,4-Dimethoxybenzyl)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-N,4-dimethylpentanamide

A solution of(R)-2-(2-(2,4-dimethoxybenzyl)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-4-methylpentanoicacid (48 mg, 0.094 mmol), methylamine hydrochloride (31.7 mg, 0.469mmol) and DIPEA (49.2 μL, 0.281 mmol) in DMF (1 mL) was stirred at RTfor 10 min. HATU (71.4 mg, 0.188 mmol) was added and the mixture wasstirred at RT for 1 h, after which UPLC showed about 80% startingmaterial remained. Additional methylamine (58.4 μL, 0.469 mmol, 33% inEtOH) was added, which resulted in little conversion of the startingmaterial. The solvent was stripped off and the residue was dissolved inDMF (1 mL). To this solution was added EDCI hydrochloride (54.0 mg,0.281 mmol), HOBT monohydrate (43.1 mg, 0.281 mmol), and methylaminehydrochloride (31.7 mg, 0.469 mmol). The reaction mixture was heated to60° C. for 4 h. UPLC subsequently showed the reaction mixture contained95% of desired product. The reaction mixture was allowed to cool to RT.Water (50 mL) was added and the mixture was extracted with DCM (3×50mL). The organic layers were collected, dried over Na₂SO₄, filtered, andthe solvent was stripped to dryness via rotary evaporation to yield thetitle compound, which was used without further purification. [M+H]calc'd for C₂₇H₃₃FN₆O₄, 525; found, 525.

E.(R)-2-(7-Fluoro-4-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-N,4-dimethylpentanamide

A solution of(R)-2-(2-(2,4-dimethoxybenzyl)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-N,4-dimethylpentanamide(38 mg, 0.072 mmol) in TFA (5 mL) was heated to 65° C. for 4 h. Afterremoval of the solvent, the residue was diluted in MeOH (2 mL) and waspurified by preparative HPLC eluting with water (0.05% TFA) and ACN(25-30%, gradient, 0.035% TFA). The collected fractions were stripped todryness to give the title compound. ¹H NMR (500 MHz, DMSO-d₆) δ ppm0.84-0.93 (m, 6H), 1.63-1.81 (m, 2H), 2.57 (d, J=4.39 Hz, 3H), 3.88 (s,3H), 4.04-4.19 (m, 2H), 4.36 (s, 2H), 6.99 (d, J=7.32 Hz, 1H), 7.61-7.76(m, 1H), 7.93 (d, J=4.39 Hz, 1H), 8.30 (s, 1H), 8.83 (s, 1H). [M+H]calc'd for C₁₈H₂₃FN₆O₂, 375; found, 375.

Example 1086-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-4-(5-methylthiophen-2-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A TFA salt of the title compound was prepared in a manner similar toEXAMPLE 62 using4,4,5,5-tetramethyl-2-(5-methylthiophen-2-yl)-1,3,2-dioxaborolane inplace of1-(difluoromethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole.¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.31-2.01 (m, 8H), 2.46 (d, J=0.51 Hz,3H), 3.80 (br s, 1H), 4.25 (d, J=4.55 Hz, 1H), 4.36-4.50 (m, 2H), 6.83(dd, J=3.79, 1.01 Hz, 1H), 6.91 (d, J=6.06 Hz, 1H), 7.73 (br s, 2H),8.43 (s, 1H), 8.82 (d, J=3.54 Hz, 1H). [M+H] calc'd for C₁₈H₂₁FN₄OS,361; found, 361.

Example 109(R)-2-(7-Fluoro-4-(4-methylthiophen-2-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-4-methylpentanamide

The title compound was prepared in a manner similar to EXAMPLE 70 using4,4,5,5-tetramethyl-2-(4-methylthiophen-2-yl)-1,3,2-dioxaborolane inplace of1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole. ¹HNMR (400 MHz, DMSO-d₆) δ ppm 0.82-0.95 (m, 6H), 1.20-1.32 (m, 2H), 2.23(s, 3H), 4.38 (s, 2H), 4.59-4.72 (m, 2H), 6.94-6.99 (m, 1H), 7.02-7.08(m, 1H), 7.15-7.23 (m, 1H), 7.27-7.34 (m, 1H), 8.35 (s, 1H), 8.78 (d,J=1.26 Hz, 1H). [M+H] calc'd for C₁₈H₂₁FN₄O₂S, 377; found, 377.

Example 110(R)-2-(7-Fluoro-3-oxo-4-(thiophen-3-yl)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-4-methylpentanamide

The title compound was prepared in a manner similar to EXAMPLE 70 using4,4,5,5-tetramethyl-2-(thiophen-3-yl)-1,3,2-dioxaborolane in place of1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole. ¹HNMR (400 MHz, DMSO-d₆) δ ppm 0.75-1.00 (m, 6H), 1.50-1.63 (m, 1H),1.69-1.83 (m, 2H), 4.39 (s, 2H), 4.52-4.61 (m, 1H), 6.93 (br s, 1H),7.01 (d, J=7.58 Hz, 1H), 7.38 (br s, 1H), 7.49 (dd, J=5.05, 3.03 Hz,1H), 8.04 (dd, J=5.05, 1.26 Hz, 1H), 8.36 (s, 1H), 8.94 (dd, J=3.03,1.01 Hz, 1H). [M+H] calc'd for C₁₇H₁₉FN₄O₂S, 363; found, 363.

Example 111(R)-2-(7-Fluoro-4-(5-methylthiophen-2-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-4-methylpentanamide

The title compound was prepared in a manner similar to EXAMPLE 70 using4,4,5,5-tetramethyl-2-(5-methylthiophen-2-yl)-1,3,2-dioxaborolane inplace of1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole. ¹HNMR (400 MHz, DMSO-d₆) δ ppm 0.71-0.96 (m, 6H), 1.52-1.85 (m, 3H), 2.45(s, 3H), 4.38 (s, 2H), 4.56-4.74 (m, 1H), 6.80 (dd, J=3.66, 1.14 Hz,1H), 6.93-7.10 (m, 2H), 7.30 (br s, 1H), 8.32 (s, 1H), 8.78 (d, J=3.79Hz, 1H). [M+H] calc'd for C₁₈H₂₁FN₄O₂S, 377; found, 377.

Example 1126-((1R,2S)-2-Aminocyclohexylamino)-4-(2-aminothiazol-5-yl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A. tert-Butyl(5-(6-(((1R,2S)-2-((tert-butoxycarbonyl)amino)cyclohexyl)amino)-2-(2,4-dimethoxybenzyl)-7-fluoro-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-4-yl)-1,3-thiazol-2-yl)carbamate

A solution of tert-butyl(1S,2R)-2-(4-chloro-2-(2,4-dimethoxybenzyl)-7-fluoro-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate(50 mg, 0.091 mmol), tert-butyl 5-(tributylstannyl)thiazol-2-ylcarbamate(53.5 mg, 0.109 mmol), and tetrakis(triphenylphosphine)palladium(0) (105mg, 0.091 mmol) in toluene (1 mL) was heated to 102° C. for 24 h. Afterremoval of the solvent, the resulting crude material was reconstitutedin MeOH/DMF (6.0 mL) and purified via preparative HPLC eluting withwater (0.05% TFA) and ACN (70-75% gradient, 0.035% TFA). The collectedfractions were stripped to dryness via rotary evaporation to yield thetitle compound (42 mg, 64%). [M+H] calc'd for C₃₅H₄₅FN₆O₇S, 713; found,713.

B.6-((1R,2S)-2-Aminocyclohexylamino)-4-(2-aminothiazol-5-yl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A solution of tert-butyl(5-(6-(((1R,2S)-2-((tert-butoxycarbonyl)amino)cyclo-hexyl)amino)-2-(2,4-dimethoxybenzyl)-7-fluoro-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-4-yl)-1,3-thiazol-2-yl)carbamate(41.5 mg, 0.058 mmol) in TFA (5 mL) was heated to 65° C. for 3 h. Afterremoval of the solvent, the resulting crude material was reconstitutedin MeOH/DMF (6.0 mL) and purified via preparative HPLC eluting withwater (0.05% TFA) and ACN (10-20% gradient, 0.035% TFA). The collectedfractions were stripped to dryness via rotary evaporation to yield thetitle compound as a TFA salt (6.7 mg, 32%). ¹H NMR (400 MHz, DMSO-d₆) δppm 1.12-2.11 (m, 9H), 3.73 (br s, 2H), 4.19 (d, J=3.79 Hz, 1H), 4.41(d, J=3.03 Hz, 2H), 6.95 (d, J=3.03 Hz, 1H), 7.77 (br s, 2H), 8.44 (s,1H), 8.93 (s, 1H). [M+H] calc'd for C₁₆H₁₉FN₆OS, 363; found, 363.

Preparation 50.(R)-2-(4-Chloro-2-(2,4-dimethoxybenzyl)-7-fluoro-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-4-methylpentanamide

A mixture of4,6-dichloro-2-(2,4-dimethoxybenzyl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one(7 g, 18.86 mmol), N-isopropyl-N-methylpropan-2-amine (14.64 mL, 94mmol), and N-isopropyl-N-methylpropan-2-amine (14.64 ml, 94 mmol) in ACN(100 mL) was stirred at 100° C. for 3 d. UPLC showed about 10% startingmaterial remained. The reaction was stopped, the solvent was removed,and the crude product was reconstituted in MeOH/DCM and dispersed onsilica gel (10 g). The solvent was evaporated and the residue waspurified on a silica gel column eluting with 1-3% MeOH in DCM over a 45min period. The collected fractions were combined and stripped todryness via rotary evaporation to yield the title compound (5.3 g, 61%).[M+H] calc'd for C₂₂H₂₆ClFN₄O₄, 465; found 465.

Example 113(R)-2-(7-Fluoro-4-(furan-2-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-4-methylpentanamide

A.(R)-2-(2-(2,4-Dimethoxybenzyl)-7-fluoro-4-(furan-2-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-4-methylpentanamide

A solution of(R)-2-(4-chloro-2-(2,4-dimethoxybenzyl)-7-fluoro-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-4-methylpentanamide(150 mg, 0.323 mmol), tributyl(furan-2-yl)stannane (138 mg, 0.387 mmol),and tetrakis(triphenylphosphine)palladium(0) (373 mg, 0.323 mmol) intoluene (1 mL) was heated to 102° C. overnight. After removal of thesolvent, the residue was diluted in MeOH/DCM (10 mL) and was purifiedvia preparative HPLC eluting with water (0.05% TFA) and ACN (45-60%gradient, 0.035% TFA). The collected fractions were stripped to drynessvia rotary evaporation to give the title compound (93.1 mg, 58%). [M+H]calc'd for C₂₆H₂₉FN₄O₅, 498; found 498.

B.(R)-2-(7-Fluoro-4-(furan-2-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-4-methylpentanamide

A solution of(R)-2-(2-(2,4-dimethoxybenzyl)-7-fluoro-4-(furan-2-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-4-methylpentanamide(93.1 mg, 0.188 mmol) in TFA (5 mL) was heated to 65° C. for 3 h. Thesolvent was removed and the resulting residue was diluted in MeOH/DCM(10 mL) and was purified via preparative HPLC eluting with water (0.05%TFA) and ACN (30%, 0.035% TFA). The collected fractions were stripped todryness via rotary evaporation to afford the title compound. ¹H NMR (400MHz, DMSO-d₆) δ ppm 0.79-0.97 (m, 6H), 1.52-1.87 (m, 3H), 4.38 (s, 2H),4.66-4.85 (m, 1H), 6.61 (dd, J=3.54, 1.77 Hz, 1H), 6.92-7.07 (m, 2H),7.36 (br s, 1H), 7.79 (dd, J=1.64, 0.63 Hz, 1H), 8.04 (dd, J=3.54, 0.51Hz, 1H), 8.32 (s, 1H). [M+H] calc'd for C₁₇H₁₉FN₄O₃, 347; found, 347.

Example 114(R)-2-(7-Fluoro-4-(furan-3-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-4-methylpentanamide

The title compound was prepared in a manner similar to EXAMPLE 70 using2-(furan-3-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane in place of1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole. ¹HNMR (500 MHz, DMSO-d₆) δ ppm 0.80-0.99 (m, 6H), 1.21-1.33 (m, 1H),1.50-1.60 (m, 1H), 1.74-1.81 (m, 1H), 4.38 (s, 2H), 4.47-4.61 (m, 1H),6.89-6.98 (m, 1H), 7.03 (d, J=7.81 Hz, 1H), 7.35 (s, 1H), 7.42 (s, 1H),7.68 (s, 1H), 8.35 (s, 1H), 8.98 (s, 1H). [M+H] calc'd for C₁₇H₁₉FN₄O₃,347; found, 347.

Example 115(R)-2-(7-Fluoro-4-(furan-2-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-4-methylpentanamide

The title compound was prepared in a manner similar to EXAMPLE 113 usingtributyl(5-methylfuran-2-yl)stannane tert-butyl in place oftributyl(furan-2-yl)stannane. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 0.84-0.97(m, 6H), 1.51-1.78 (m, 3H), 2.29-2.36 (m, 3H), 4.36 (s, 2H), 4.64-4.86(m, 1H), 6.22 (dd, J=3.28, 1.01 Hz, 1H), 6.92 (d, J=8.08 Hz, 1H), 7.01(br s, 1H), 7.41 (br s, 1H), 7.97 (d, J=3.03 Hz, 1H), 8.26 (s, 1H).[M+H] calc'd for C₁₈H₂₁FN₄O₃, 361; found, 361.

Example 116(R)-2-(4-(5-Cyanothiophen-2-yl)-7-fluoro-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-4-methylpentanamide

A.(R)-2-(4-(5-Cyanothiophen-2-yl)-2-(2,4-dimethoxybenzyl)-7-fluoro-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-4-methylpentanamide

A solution of(R)-2-(4-chloro-2-(2,4-dimethoxybenzyl)-7-fluoro-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-4-methylpentanamide(114 mg, 0.245 mmol), 5-cyanothiophen-2-ylboronic acid (113 mg, 0.736mmol), tris(dibenzylideneacetone)di-palladium(0) (13.47 mg, 0.015 mmol),and 2-(dicyclohexylphosphino)biphenyl (5.16 mg, 0.015 mmol) in dioxane(2 mL) and DMF (0.5 mL) was heated to 160° C. under microwaveirradiation for 45 min. UPLC showed 50% conversion. The reaction mixturewas subsequently heated at 160° C. under microwave irradiation for 45min. Additional 5-cyanothiophen-2-ylboronic acid (113 mg, 0.736 mmol)was added and the reaction mixture was heated at 160° C. under microwaveirradiation for 60 min. After removal of the solvent, the resultingcrude material was reconstituted in MeOH/DMF (6.0 mL) and purified viapreparative HPLC eluting with water (0.05% TFA) and ACN (40-80%gradient, 0.035% TFA). The collected fractions were stripped to drynessvia rotary evaporation to yield the title compound. [M+H] calc'd forC₂₇H₂₈FN₅O₄S, 538; found, 538.

B.(R)-2-(4-(5-Cyanothiophen-2-yl)-7-fluoro-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-4-methylpentanamide

A solution of(R)-2-(4-(5-cyanothiophen-2-yl)-2-(2,4-dimethoxybenzyl)-7-fluoro-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-4-methylpentanamide(68 mg, 0.126 mmol) in TFA (2 mL) was heated to 65° C. for 3 h. Afterremoval of the solvent, the resulting crude material was reconstitutedin MeOH/DCM (3.0 mL) and purified via preparative HPLC eluting withwater (0.05% TFA) and ACN (40%, 0.035% TFA). The collected fractionswere combined and the solvent was removed via rotary evaporation toyield the title compound (8.3 mg, 17%). ¹H NMR (500 MHz, DMSO-d₆) δ ppm0.86-0.96 (m, 6H), 1.53-1.62 (m, 1H), 1.67-1.88 (m, 2H), 4.45 (s, 2H),4.50-4.57 (m, 1H), 6.96-7.06 (m, 1H), 7.32-7.54 (m, 2H), 7.86-8.02 (m,1H), 8.61 (s, 1H), 9.00-9.15 (m, 1H). [M+H] calc'd for C₁₈H₁₈FN₅O₂S,388; found, 388.

Example 117(R)-2-(4-(4-Cyanothiophen-2-yl)-7-fluoro-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-4-methylpentanamide

The title compound was prepared in a manner similar to EXAMPLE 116 using4-cyanothiophen-2-ylboronic acid in place of 5-cyanothiophen-2-ylboronicacid. ¹H NMR (500 MHz, DMSO-d₆) δ ppm 0.80-0.96 (m, 6H), 1.55-1.66 (m,1H), 1.65-1.86 (m, 2H), 4.44 (s, 2H), 4.51-4.64 (m, 1H), 6.99 (s, 1H),7.04-7.20 (m, 1H), 7.32 (d, J=8.30 Hz, 1H), 7.37 (s, 1H), 8.53-8.68 (m,1H), 9.24 (s, 1H). [M+H] calc'd for C₁₈H₁₈FN₅O₂S, 388; found, 388.

Example 118(R)-2-(7-Fluoro-3-oxo-4-(thiazol-5-yl)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-4-methylpentanamide

The title compound was prepared in a manner similar to EXAMPLE 113 using5-(tributylstannyl)thiazole in place of tributyl(furan-2-yl)stannane. ¹HNMR (400 MHz, DMSO-d₆) δ ppm 0.77-0.98 (m, 6H), 1.53-1.68 (m, 1H),1.71-1.84 (m, 2H), 4.42 (s, 2H), 4.52-4.66 (m, 1H), 6.95 (br s, 1H),7.18 (d, J=8.59 Hz, 1H), 7.34 (br s, 1H), 8.46 (s, 1H), 9.11 (s, 1H),9.46 (s, 1H). [M+H] calc'd for C₁₆H₁₈FN₅O₂S, 364; found, 364.

Example 119(R)-2-(7-Fluoro-4-(isothiazol-5-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-4-methylpentanamide

The title compound was prepared in a manner similar to EXAMPLE 116 using5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isothiazole in place of5-cyanothiophen-2-ylboronic acid. ¹H NMR (500 MHz, DMSO-d₆) δ ppm0.77-0.97 (m, 6H), 1.56-1.64 (m, 1H), 1.67-1.86 (m, 2H), 4.45 (s, 2H),4.49-4.62 (m, 1H), 7.00 (s, 1H), 7.33 (d, J=8.30 Hz, 1H), 7.44 (s, 1H),8.53-8.65 (m, 2H), 8.91 (d, J=1.46 Hz, 1H). [M+H] calc'd forC₁₆H₁₈FN₅O₂S, 364; found, 364.

Example 1206-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-1,1-dimethyl-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A.4,6-Dichloro-2-(2,4-dimethoxybenzyl)-7-fluoro-1,1-dimethyl-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

To a solution of4,6-dichloro-2-(2,4-dimethoxybenzyl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one(500 mg, 1.347 mmol) in DMF (5 mL) at 0° C. was added sodium hydride(53.9 mg, 1.347 mmol) and iodomethane (0.084 mL, 1.347 mmol). Themixture was stirred at 0° C. for 1 h, then diluted to EtOAc (200 mL) andwashed with brine (200 mL) and water (200 mL). The organic phase wasdried and concentrated to a residue, which was purified by reverse phasepreparative HPLC to give the title compound as one of the products (50mg, 9%, mono-methylated product was observed). [M+H] calc'd forC₁₈H₁₇Cl₂FN₂O₃, 400.2; found, 399.4.

B. tert-Butyl(1S,2R)-2-(4-chloro-2-(2,4-dimethoxybenzyl)-7-fluoro-1,1-dimethyl-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate

In a 10 mL sealed cap glass vial,4,6-dichloro-2-(2,4-dimethoxybenzyl)-7-fluoro-1,1-dimethyl-1H-pyrrolo[3,4-c]pyridin-3(2H)-one(50 mg, 0.125 mmol) and tert-butyl (1S,2R)-2-aminocyclohexylcarbamate(53.2 mg, 0.250 mmol) were dissolved in ACN (2 mL).N-ethyldiisopropylamine (0.033 mL, 0.188 mmol) was added, the cap wassealed, and the reaction mixture heated at 95° C. for 72 h. The reactionmixture was subsequently purified by preparative HPLC and basified togive the title compound as a light yellow solid (40 mg, 55%). [M+H]calc'd for C₂₉H₃₈ClFN₄O₅, 578.1; found, 577.4.

C. tert-Butyl(1S,2R)-2-(2-(2,4-dimethoxybenzyl)-7-fluoro-1,1-dimethyl-4-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate

In a sealed tube, a mixture of tert-butyl(1S,2R)-2-(4-chloro-2-(2,4-dimethoxybenzyl)-7-fluoro-1,1-dimethyl-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate(30 mg, 0.052 mmol), Na₂CO₃ aq (2M, 0.065 mL, 0.130 mmol),1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole(12.98 mg, 0.062 mmol), bis(triphenylphosphine)palladium chloride (3.65mg, 5.20 μmol), and DMF (1 mL) was heated at 160° C. for 0.5 h in amicrowave oven. The reaction mixture was then heated at 160° C. for anadditional 4 h in a microwave oven and was subsequently purified bypreparative HPLC to give the title compound as a light yellow solid (5mg, 18%). [M+H] calc'd for C₂₈H₃₅FN₆O₃, 524; found 524.

D.6-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-1,1-dimethyl-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A solution of tert-butyl(1S,2R)-2-(2-(2,4-dimethoxybenzyl)-7-fluoro-1,1-dimethyl-4-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclo-hexylcarbamate(5 mg, 9.57 μmol) in TFA (1 mL) was heated at 60° C. for 0.5 h. Thereaction mixture was subsequently purified by preparative HPLC and theproduct lyophilized to give the title compound as a TFA salt (2 mg,56%). [M+H] calc'd for C₁₉H₂₅FN₆, 374; found, 374.

Example 121((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-4-(1-methyl-1H-pyrazol-3-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

In a 30 mL sealed cap glass vial, tert-butyl(1S,2R)-2-(4-chloro-2-(2,4-dimethoxybenzyl)-7-fluoro-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate(350 mg, 0.637 mmol),1-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole(172 mg, 0.829 mmol) and PdCl₂(PPh₃)₂ (44.7 mg, 0.064 mmol) weredissolved in dioxane (5 mL). An aqueous solution of Na₂CO₃ (2M, 0.5 mL)was added and the cap was sealed. The reaction mixture was heated at 85°C. for 4 h, then diluted with water (5 mL), and extracted with EtOAc(2×30 mL). The organic phase was dried over Na₂SO₄ and the solventevaporated. The resulting residue was treated with TFA (4 mL) and heatedat 80° C. for 1.5 h to remove the protecting groups. Next, TFA wasevaporated and the product was dissolved in DMSO (8 mL) and purified bypreparative HPLC. The pure fractions were combined, concentrated, andlyophilized to give a TFA salt of the title compound as a white solid(52.3 mg, 24%). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.40-1.95 (m, 8H), 3.64(br s, 1H), 3.92 (s, 2H), 4.28-4.49 (m, 3H), 6.76 (d, J=5.31 Hz, 1H),7.42 (d, J=2.27 Hz, 1H), 7.72 (d, J=2.27 Hz, 1H), 7.98 (br s, 3H), 8.39(s, 1H). [M+H] calc'd for C₁₇H₂₁FN₆O, 345; found, 345.

Example 1226-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-4-(2-methylthiazol-5-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A.6-((1R,2S)-2-Aminocyclohexylamino)-4-bromo-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A mixture of tert-butyl(1S,2R)-2-(4-chloro-2-(2,4-dimethoxybenzyl)-7-fluoro-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate(200 mg, 0.364 mmol) and hydrobromic acid in HOAc (10 mL) was stirred at90° C. for 6 h. The mixture was concentrated under reduced pressure, andthe resulting crude material was reconstituted in MeOH (1.0 mL) and waspurified via preparative HPLC eluting with water (0.05% TFA) and ACN(15-30% gradient, 0.035% TFA). The collected fractions were combined andACN was removed via rotary evaporation. The resulting aqueous solutionwas neutralized with saturated aqueous NaHCO₃, washed with EtOAc (2×200mL), dried over Na₂SO₄, and filtered. The organic phase was stripped todryness via rotary evaporation to yield the title compound (38 mg, 30%).[M+H] calc'd for C₁₃H₁₆BrFN₄O, 343; found, 343.

B.6-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-4-(2-methylthiazol-5-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A solution of6-((1R,2S)-2-aminocyclohexylamino)-4-bromo-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one(38 mg, 0.111 mmol), 2-methylthiazole-5-carboxylic acid (15.85 mg, 0.111mmol), silver(I) acetate (18.48 mg, 0.111 mmol), and copper(II) chloride(14.89 mg, 0.111 mmol) in toluene (1.8 mL) and DMA (0.2 mL) was heatedto 135° C. overnight. The reaction mixture was filtered through a pad ofCelite and the solvent was removed in vacuo. The resulting crudematerial was reconstituted in MeOH/DMF (10.0 mL) and purified viapreparative HPLC eluting with water (0.05% TFA) and ACN (50-90%gradient, 0.035% TFA). The collected fractions were combined and thesolvent was stripped to dryness via rotary evaporation to yield thetitle compound as a TFA salt (2.3 mg, 6%). ¹H NMR (500 MHz, CDCl₃) δ ppm1.37-1.85 (m, 8H) 2.93 (s, 2H) 2.97-3.08 (m, 3H) 4.22-4.42 (m, 2H) 6.52(s, 1H) 7.53 (d, J=4.39 Hz, 1H) 7.72 (br s, 1H) 8.08 (br s, 1H) 8.27 (s,1H) [M+H] calc'd for C₁₇H₂₀FN₅OS, 362; found, 362.

Example 1236-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-7-fluoro-4-(5-methylthiophen-2-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A. tert-Butyl(3R,4R)-4-(4-chloro-2-(2,4-dimethoxybenzyl)-7-fluoro-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)tetrahydro-2H-pyran-3-ylcarbamate

A mixture of4,6-dichloro-2-(2,4-dimethoxybenzyl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one(320 mg, 0.862 mmol), tert-butyl(3R,4R)-4-aminotetrahydro-2H-pyran-3-ylcarbamate (280 mg, 1.293 mmol)and DIPEA (0.226 mL, 1.293 mmol) in ACN (5 mL) was stirred at 85° C.overnight. UPLC indicated the presence of starting material, so themixture was stirred at 85° C. overnight. UPLC showed about 50%conversion. Additional stirring at 85° C. for 3 d and at 100° C.overnight did not appreciably increase the conversion, so the reactionwas stopped and the solvent was removed. The resulting crude materialwas reconstituted in MeOH/DMF (10 mL) and purified via preparative HPLCeluting with water (0.05% TFA) and ACN (50%, 0.035% TFA). The collectedfractions were combined and the ACN was removed via rotary evaporation.The resulting aqueous solution was neutralized with saturated aqueousNaHCO₃, washed with EtOAc (2×200 mL), dried over Na₂SO₄, and filtered.The organic phase was stripped to dryness via rotary evaporation to givethe title compound (51 mg, 11%). [M+H] calc'd for C₂₆H₃₂ClFN₄O₆, 552;found, 552.

B. tert-Butyl(3R,4R)-4-(2-(2,4-dimethoxybenzyl)-7-fluoro-4-(5-methylthiophen-2-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)tetrahydro-2H-pyran-3-ylcarbamate

A solution of tert-butyl(3R,4R)-4-(4-chloro-2-(2,4-dimethoxybenzyl)-7-fluoro-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)tetrahydro-2H-pyran-3-ylcarbamate(51 mg, 0.093 mmol),4,4,5,5-tetramethyl-2-(5-methylthiophen-2-yl)-1,3,2-dioxaborolane (104mg, 0.463 mmol), and bis(triphenylphosphine)palladium chloride (65.0 mg,0.093 mmol) in dioxane (1 mL) and saturated Na₂CO₃ aq (1 mL) was heatedto 140° C. for 40 min. After filtering out the solids, the solvent wasremoved from the filtrate. The resulting residue was dissolved in MeOHand DCM (10 mL) and was purified via preparative HPLC eluting with water(0.05% TFA) and ACN (80%, 0.035% TFA). The collected fractions werecombined and solvent was stripped to dryness via rotary evaporation togive the title compound (31 mg, 55%). [M+H] calc'd for C₃₁H₃₇FN₄O₆S,613; found, 613.

C.6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-7-fluoro-4-(5-methylthiophen-2-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A solution of tert-butyl(3R,4R)-4-(2-(2,4-dimethoxybenzyl)-7-fluoro-4-(5-methylthiophen-2-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)tetrahydro-2H-pyran-3-ylcarbamate(31 mg, 0.051 mmol) in TFA (10 mL) was heated to 80° C. for 1 h. Afterthe solvent was removed, the residue was dissolved in MeOH and DCM (8mL) and was purified via preparative HPLC eluting with water (0.05% TFA)and ACN (15-30% gradient, 0.035% TFA). The collected fractions werecombined and the solvent was stripped to dryness via rotary evaporationto give the title compound as a TFA salt (13.5 mg, 74%). ¹H NMR (500MHz, DMSO-d₆) δ ppm 1.78 (d, J=13.18 Hz, 1H), 2.03-2.18 (m, 1H), 2.46(s, 3H), 3.17 (d, J=4.88 Hz, 1H), 3.55-3.65 (m, 1H), 3.75 (d, J=13.18Hz, 1H), 3.85 (br s, 1H), 3.96-4.06 (m, 2H), 4.41 (d, J=7.81 Hz, 2H),6.84 (d, J=2.44 Hz, 1H), 7.22 (d, J=4.88 Hz, 1H), 7.92 (br s, 2H), 8.47(s, 1H), 8.83 (d, J=3.42 Hz, 1H). [M+H] calc'd for C₁₇H₁₉FN₄O₂S, 363;found, 363.

Example 1246-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-1-methyl-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A. 2,6-Dichloro-4-((3,5-dimethoxybenzylimino)methyl)-5-fluoronicotinicacid

A. To a solution of (2,4-dimethoxyphenyl)methanamine (4.4 g, 26.6 mmol)in MeOH (50 mL) was added4,6-dichloro-7-fluoro-1-hydroxyfuro[3,4-c]pyridin-3(1H)-one (6.0 g, 25.3mmol). The mixture was stirred for 0.5 h, filtered, and washed withpetroleum ether to give the title compound as a white solid (5.8 g,60%). ¹H-NMR (CDCl₃, 400 MHz) δ 3.75 (s, 3H), 3.79 (s, 3H), 3.93 (s,2H), 6.30 (s, 1H), 6.40-6.42 (m, 2H), 7.12 (d, J=8.4 Hz, 1H).

B.4,6-Dichloro-2-(3,5-dimethoxybenzyl)-7-fluoro-1-methyl-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

To a mixture of2,6-dichloro-4-((3,5-dimethoxybenzylimino)methyl)-5-fluoronicotinic acid(5.8 g, 25.3 mmol) in THF (120 mL) was added methyl-lithium (60.0 mL,126.6 mmol) drop wise at −78° C. After the addition was completed, themixture was stirred for an additional 2 h. The reaction mixture wasacidified with 1N HCl to pH 7 and THF was removed under reducedpressure. The mixture was extracted with EtOAc, washed with brine, driedover anhydrous Na₂SO₄, and purified by silica gel chromatography elutingwith PE-EtOAc (5:1) to give the title compound as a white solid (0.93 g,16%). ¹H-NMR (CDCl₃, 400 MHz) δ 1.58 (d, J=6.8 Hz, 3H), 3.79 (s, 3H),3.84 (s, 3H), 4.35 (d, J=14.4 Hz, 1H), 4.52 (q, J=6.8 Hz, 1H), 5.07 (d,J=14.4 Hz, 1H), 6.43-6.45 (m, 2H), 7.28 (d, J=9.2 Hz, 1H). [M+H] calc'dfor C₁₇H₁₅Cl₂FN₂O₃, 386; found, 385.

C.6-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-1-methyl-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A mixture of6-((1R,2S)-2-aminocyclohexylamino)-2-(2,4-dimethoxybenzyl)-7-fluoro-1-methyl-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one(20 mg, 0.039 mmol) and TFA (1 mL) was heated at 60° C. for 2 h.Following reaction, the mixture was purified by preparative HPLC elutingwith water (0.05% TFA) and ACN (15-25% gradient, 0.035% TFA) to give thetitle compound as a TFA salt (10 mg, 71%). ¹H NMR (500 MHz, DMSO-d₆) δppm 1.41 (d, J=6.59 Hz, 3H), 1.46 (d, J=7.02 Hz, 2H), 1.60-1.84 (m, 5H),3.68 (br s, 1H), 3.89 (s, 2H), 4.44 (br s, 1H), 4.71 (q, J=6.65 Hz, 1H),6.52 (br s, 1H), 6.73 (d, J=6.53 Hz, 1H), 7.72 (br s, 2H), 8.24-8.32 (m,1H), 8.46 (s, 1H), 8.82 (s, 1H). [M+H] calc'd for C₁₈H₂₃FN₆O, 359;found, 359.

Example 1256-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-4-(1-(difluoromethyl)-1H-pyrazol-4-yl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A. tert-Butyl6-((3R,4R)-3-(tert-butoxycarbonylamino)tetrahydro-2H-pyran-4-ylamino)-4-chloro-7-fluoro-3-oxo-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxylate

A mixture of tert-butyl4,6-dichloro-7-fluoro-3-oxo-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxylate(1.42 g, 4.43 mmol), tert-butyl(3R,4R)-4-aminotetrahydro-2H-pyran-3-ylcarbamate (1.15 g, 5.52 mmol),diisopropylethylamine (3.87 mL, 22.16 mmol) in DMSO (10 mL) and2-propanol (40 mL) were heated to 100° C. in an oil bath for 20 h. Thesolution was then concentrated and the resulting oil was dissolved inwater (50 mL) and heated in an oil bath to 50° C. for 1 h then allowedto cool to RT. The solution was subsequently heated to 50° C. for 15min, allowed to cool to RT, again heated to 50° C. for 15 min, andallowed to cool to RT. The resulting precipitate was filtered and rinsedwith water to give the title compound as a pale pinkish-white solid(1.90 g, 86%, 4:1 mixture with regioisomer) which was used in the nextstep without further purification. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.36(s, 9H), 1.50 (s, 3H), 1.59-1.61 (m, 1H), 1.97-1.99 (m, 1H), 1.97-1.99(m, 1H), 3.46-3.49 (m, 2H), 3.80-3.83 (m, 3H), 4.31-4.33 (m, 1H), 4.73(s, 1H), 6.59 (d, J=7.30 Hz, 1H), 7.43 (d, J=7.30 Hz, 1H). [M+H] calc'dfor C₂₂H₃₀ClFN₄O₆, 501; found, 501.

B. tert-Butyl6-((3R,4R)-3-(tert-butoxycarbonylamino)tetrahydro-2H-pyran-4-ylamino)-4-(1-(difluoromethyl)-1H-pyrazol-4-yl)-7-fluoro-3-oxo-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxylate

A mixture of tert-butyl6-((3R,4R)-3-(tert-butoxycarbonylamino)tetrahydro-2H-pyran-4-ylamino)-4-chloro-7-fluoro-3-oxo-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxylate(500 mg, 0.998 mmol), 1-(difluoromethyl)-1H-pyrazol-4-ylboronic acid(808 mg, 4.99 mmol), bis(triphenylphosphine)palladium chloride (70.1 mg,0.100 mmol) in dioxane (15 mL) and 2M saturated sodium carbonate (2 mL)were heated to 100° C. in a microwave for 30 min. The solution wasconcentrated and was purified by preparatory HPLC eluting with water (10mM NH₄HCO₃) and ACN/water (80/20 v/v, 15-30% gradient, 10 mM NH₄HCO₃) togive the title compound as a white solid (132 mg, 23%). ¹H NMR (400 MHz,DMSO-d₆) δ ppm 1.35 (s, 9H), 1.52 (s, 9H), 1.55-1.56 (m, 1H), 2.46-2.47(m, 1H), 3.57-3.59 (m, 2H), 3.81-3.84 (m, 3H), 4.61-4.62 (m, 1H), 4.78(s, 2H), 6.61 (d, J=6.35 Hz, 1H), 7.15 (d, J=6.83 Hz, 1H), 7.97 (s, 1H),8.54 (s, 1H), 9.24 (s, 1H). [M+H] calc'd for C₂₆H₃₃F₃N₆O₆, 583; found,583.

C.6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-4-(1-(difluoromethyl)-1H-pyrazol-4-yl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

tert-Butyl6-((3R,4R)-3-(tert-butoxycarbonylamino)tetrahydro-2H-pyran-4-ylamino)-4-(1-(difluoromethyl)-1H-pyrazol-4-yl)-7-fluoro-3-oxo-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxylate(126 mg, 0.998 mmol) was dissolved in 2-propanol (5 mL) and the solutionwas heated to 75° C. with a heating block. Then 2M HCl (2.5 mL) wasadded, the temperature was lowered to 65° C., and the reaction mixturewas stirred for 3 h. The solution was concentrated and purified bypreparatory HPLC eluting with water (10 mM NH₄HCO₃) and ACN/water (80/20v/v, 10-50% gradient, 10 mM NH₄HCO₃) to give the title compound as awhite solid (79 mg, 96%). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.75-1.77 (m,1H), 2.09-2.12 (m, 1H), 3.60-3.63 (m, 1H), 3.76-3.77 (m, 1H), 3.88-3.98(m, 3H), 4.44 (d, J=6.35 Hz, 2H), 4.54-4.55 (m, 1H), 7.17 (d, J=5.86 Hz,1H), 7.89 (br s, 1H), 8.54 (s, 1H), 8.58 (s, 1H), 9.43 (s, 1H). [M+H]calc'd for C₁₆H₁₇F₃N₆O₂, 383; found, 383.

Example 126(R)-2-(7-Fluoro-3-oxo-4-(thiophen-2-yl)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-4-methylpentanamide

The title compound was prepared in a manner similar to EXAMPLE 113 usingtributyl(thiophen-2-yl)stannane in place oftributyl(furan-2-yl)stannane. ¹H NMR (500 MHz, DMSO-d₆) δ ppm 0.80-0.99(m, 6H), 1.51-1.84 (m, 3H), 4.40 (s, 2H), 4.59-4.76 (m, 1H), 6.99 (br s,1H), 7.06-7.17 (m, 2H), 7.34 (br s, 1H), 7.61 (d, J=4.88 Hz, 1H), 8.40(s, 1H), 8.93-9.05 (m, 1H). [M+H] calc'd for C₁₇H₁₉FN₄O₂S, 363; found,363.

Preparation 51: tert-Butyl6-((3R,4R)-3-(tert-butoxycarbonylamino)tetrahydro-2H-pyran-4-ylamino)-4-chloro-7-fluoro-3-oxo-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxylate

A mixture of tert-butyl4,6-dichloro-7-fluoro-3-oxo-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxylate(1.24 g, 3.85 mmol), tert-butyl(3R,4R)-4-aminotetrahydro-2H-pyran-3-ylcarbamate (1.00 g, 4.62 mmol),diisopropylethylamine (3.36 mL, 19.27 mmol) in DMSO (10 mL) and2-propanol (40 mL) were heated to 100° C. in an oil bath for 20 h. Thereaction was repeated on the same scale and both reaction solutions werecombined and concentrated. The mixture was purified via silica gel flashchromatography eluting with EtOAc and hexanes (10-50% EtOAc gradient) togive the title compound as a pale pinkish-white solid (510 mg, 13%). ¹HNMR (400 MHz, DMSO-d₆) δ ppm 1.36 (s, 9H), 1.50 (s, 3H), 1.59-1.61 (m,1H), 1.97-1.99 (m, 1H), 1.97-1.99 (m, 1H), 3.46-3.49 (m, 2H), 3.80-3.83(m, 3H), 4.31-4.33 (m, 1H), 4.73 (s, 1H), 6.59 (d, J=7.30 Hz, 1H), 7.43(d, J=7.30 Hz, 1H). [M+H] calc'd for C₂₂H₃₀ClFN₄O₆, 501; found, 501.

Example 1276-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-7-fluoro-4-(thiophen-2-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A. tert-Butyl6-((3R,4R)-3-(tert-butoxycarbonylamino)tetrahydro-2H-pyran-4-ylamino)-7-fluoro-3-oxo-4-(thiophen-2-yl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxylate

A solution of tert-butyl6-((3R,4R)-3-(tert-butoxycarbonylamino)tetrahydro-2H-pyran-4-ylamino)-4-chloro-7-fluoro-3-oxo-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxylate(50 mg, 0.1 mmol), tributyl(thiophen-2-yl)stannane (44.7 mg, 0.12 mmol)and tetrakis(triphenylphosphine)palladium(0) (115 mg, 0.1 mmol) intoluene (3 mL) was heated to 102° C. for 24 h. The solid was filteredthough a pad of Celite, and resulting crude material was reconstitutedin MeOH/DCM (20 mL) and purified via preparative HPLC. The collectedfractions were combined and stripped to dryness via rotary evaporationto yield the title compound (30 mg, 55%).

B.6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-7-fluoro-4-(thiophen-2-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A solution of tert-butyl6-((3R,4R)-3-(tert-butoxycarbonylamino)tetrahydro-2H-pyran-4-ylamino)-7-fluoro-3-oxo-4-(thiophen-2-yl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxylate(30 mg, 0.055 mmol) in TFA/DCM (1:1, 10 mL) was stirred at RT for 2 h.The solvent was removed and the resulting crude material wasreconstituted in MeOH/DCM (20 mL) and purified via preparative HPLC. Thecollected fractions were combined and stripped to dryness via rotaryevaporation to yield the title compound (16 mg, 85%). ¹H NMR (500 MHz,DMSO-d₆) δ ppm 1.79 (d, J=9.76 Hz, 1H), 2.12 (qd, J=12.94, 5.13 Hz, 1H),3.56-3.68 (m, 1H), 3.75 (d, J=11.72 Hz, 1H), 3.89 (br s, 1H), 4.02 (d,J=11.72 Hz, 2H), 4.28-4.37 (m, 1H), 4.38-4.49 (m, 2H), 7.10-7.20 (m,1H), 7.28 (d, J=4.88 Hz, 1H), 7.59-7.70 (m, 1H), 7.93 (br s, 2H), 8.52(s, 1H), 9.02 (dd, J=3.91, 0.98 Hz, 1H). [M+H] calc'd for C₁₆H₁₇FN₄O₂S,349; found, 349.

Example 1286-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-7-fluoro-4-(thiazol-5-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A TFA salt of the title compound was prepared in a manner similar toEXAMPLE 127 using 5-(tributylstannyl)thiazole in place oftributyl(thiophen-2-yl)stannane. ¹H NMR (500 MHz, DMSO-d₆) δ ppm 1.78(dd, J=13.67, 4.39 Hz, 1H), 2.04-2.20 (m, 1H), 3.53-3.66 (m, 1H),3.69-3.85 (m, 2H), 4.01 (d, J=11.72 Hz, 2H), 4.25-4.38 (m, 1H),4.41-4.55 (m, 2H), 7.38 (s, 1H), 7.94 (br s, 2H), 8.62 (s, 1H), 9.15 (s,1H), 9.52 (s, 1H). [M+H] calc'd for C₁₅H₁₆FN₅O₂S, 350; found, 350.

Example 1296-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-4-(thiophen-2-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

In a 30 mL sealed cap glass vial, tert-butyl(1S,2R)-2-(4-chloro-2-(2,4-dimethoxybenzyl)-7-fluoro-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate(300 mg, 0.546 mmol),4,4,5,5-tetramethyl-2-(thiophen-2-yl)-1,3,2-dioxaborolane (172 mg, 0.820mmol), and trans-dichloro-bis(triphenylphosphine)palladium-II (38.4 mg,0.055 mmol) were dissolved in dioxane (5 mL). An aqueous solution of 2NNa₂CO₃ (0.5 mL) was added, the cap was sealed, and the mixture wasallowed to react at 85° C. for 3 h. The reaction mixture wassubsequently diluted with water (5 mL) and extracted into EtOAc (2×30mL). The organic layer was dried over sodium sulfate and evaporated. Theresulting residue was treated with TFA (4 mL) and heated at 80° C. for 1h to remove the protecting groups. Next, TFA was evaporated from thereaction mixture. The product was reconstituted in DMSO (8 mL) and wasthen purified via preparative HPLC eluting with water (0.05% TFA) andACN (15-45% gradient, 0.035% TFA). The pure fractions were combined andevaporated to a minimal volume. Saturated aq NaHCO₃ (10 mL) was addedand the mixture was extracted with EtOAc (3×25 mL). The organic layerswere combined, dried over sodium sulfate, and evaporated to give thetitle compound as a pale yellow solid (83 mg, 44%). ¹H NMR (400 MHz,DMSO-d₆) δ ppm 1.16-1.80 (m, 8H), 3.18 (br s, 1H), 3.86-4.11 (m, 1H),4.39 (s, 2H), 6.60 (d, J=6.57 Hz, 1H), 7.13 (dd, J=5.05, 3.79 Hz, 1H),7.60 (dd, J=5.18, 1.14 Hz, 1H), 8.39 (s, 1H), 9.00 (dd, J=3.79, 1.01 Hz,1H). [M+H] calc'd for C₁₇H₁₉FN₄OS, 347; found, 347.

Example 1306-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-7-fluoro-4-(4-(trifluoromethyl)-1H-imidazol-1-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

In a 10 mL sealed cap glass vial, tert-butyl6-((3R,4R)-3-(tert-butoxycarbonylamino)tetrahydro-2H-pyran-4-ylamino)-4-chloro-7-fluoro-3-oxo-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxylate(60 mg, 0.120 mmol), 4-(trifluoromethyl)-1H-imidazole (48.9 mg, 0.359mmol) and K₂CO₃ (66.2 mg, 0.479 mmol) were dissolved in ACN (2 mL). Thecap was sealed and the mixture was reacted at 100° C. for 16 h. Thereaction mixture was subsequently filtered through a Buchner funnel toremove un-dissolved K₂CO₃. The solids were washed with ACN (2×5 mL) andthe filtrate was evaporated to give a residue, which was treated withTFA (2 mL) at RT for 20 min to remove the protecting groups. Next, TFAwas evaporated from the reaction mixture. The product was reconstitutedin DMSO (5 mL) and was then purified by preparative HPLC eluting withwater (0.05% TFA) and ACN (15-45% gradient, 0.035% TFA). The purefractions were combined, evaporated to a minimal volume, and lyophilizedto give a TFA salt of the title compound as a brown solid (4.2 mg,8.8%). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.67 (m, 1H), 2.05 (td, J=12.88,7.33 Hz, 1H), 3.30-3.90 (m, 4H), 3.78-3.99 (m, 2H), 4.44 (s, 2H), 6.49(br s, 2H), 7.54 (d, J=5.56 Hz, 1H), 7.85 (br s, 2H), 8.67-8.80 (m, 2H).[M+H] calc'd for C₁₆H₁₆F₄N₆O₂, 401; found, 401.

Example 1316-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-4-(4-methyl-1H-imidazol-1-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

In a 10 mL sealed cap glass vial, tert-butyl(1S,2R)-2-(4-chloro-2-(2,4-dimethoxybenzyl)-7-fluoro-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate(50 mg, 0.091 mmol), 4-methyl-1H-imidazole (22.43 mg, 0.273 mmol) andK₂CO₃ (50.3 mg, 0.364 mmol) were dissolved in ACN (2 mL). The cap wassealed and the mixture was reacted at 100° C. for 16 h. The reactionmixture was subsequently filtered through a Buchner funnel to removeun-dissolved solids. The solids were washed with ACN (2×5 mL) and thefiltrate was evaporated to give a residue, which was treated with TFA (4mL) and heated at 80° C. for 1 h to remove the protecting groups. Next,TFA was evaporated from the reaction mixture. The resulting residue wasreconstituted in DMSO (5 mL) and purified via preparative HPLC elutingwith water (0.05% TFA) and ACN (15-65% gradient, 0.035% TFA). The purefractions were combined, evaporated to a minimal volume, and lyophilizedto give a TFA salt of the title compound as a white solid (7.2 mg, 23%).¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.20-1.65 (m., 8H), 3.65-3.79 (m, 5H),4.15 (s, 2H), 6.40 (d, 1H), 6.51 (d, 1H), 6.73 (m, 1H), 6.97 (d, 1H),7.26 (d, 1H), 8.68 (br s, 1H). [M+H] calc'd for C₁₇H₂₁FN₆O, 345; found,345.

Preparation 52: 3-Methyl-5-(tributylstannyl)isothiazole

To a cold (−78° C.) solution of 3-methylisothiazole (100 mg, 1.0 mmol)in anhydrous THF (2.0 mL) was added n-butyllithium (0.693 mL, 1.1 mmol)dropwise. After stirring for 60 min at −78° C., a solution oftributylchlorostannane (0.326 mL, 1.210 mmol) in anhydrous THF (0.5 mL)was added to the reaction mixture. The reaction mixture was stirred for30 min at −78° C. and then allowed to warm to RT over a 2 to 3 h period.Saturated aq NaHCO₃ was added and the aqueous phase was extracted withEtOAc (3×50 mL). The combined organic phase was dried over anhydrousNa₂SO₄, filtered, and evaporated in vacuo. The residue was purified bysilica gel column chromatography (9:1 Hexane/EtOAc, Flash 60 column) togive the title compound. ¹H NMR (500 MHz, CDCl₃) δ ppm 0.86-0.94 (m,9H), 1.05-1.21 (m, 6H), 1.26-1.38 (m, 6H), 1.44-1.65 (m, 6H), 2.56 (s,3H), 6.97-7.04 (m, 1H).

Example 1326-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-7-fluoro-4-(3-methylisothiazol-5-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A. tert-Butyl6-((3R,4R)-3-(tert-butoxycarbonylamino)tetrahydro-2H-pyran-4-ylamino)-7-fluoro-4-(3-methylisothiazol-5-yl)-3-oxo-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxylate

A solution of tert-butyl6-((3R,4R)-3-(tert-butoxycarbonylamino)tetrahydro-2H-pyran-4-ylamino)-4-chloro-7-fluoro-3-oxo-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxylate(10 mg, 0.02 mmol), 3-methyl-5-(tributylstannyl)isothiazole (23.25 mg,0.06 mmol) and tetrakis(triphenylphosphine)palladium(0) (23.07 mg, 0.02mmol) in toluene (3 mL) was heated to 120° C. for 45 min under microwaveirradiation. The reaction mixture was poured into water and extractedwith EtOAc. The organic extracts were dried over anhydrous Na₂SO₄,filtered, and evaporated in vacuo. After removal of solvent, theresulting crude material was reconstituted in DMF and purified viapreparative HPLC eluting with water (0.05% TFA) and ACN (55-80%gradient, 0.035% TFA). The collected fractions were combined and ACN wasremoved via rotary evaporation. The resulting aq solution wasneutralized with saturated aq NaHCO₃ and washed with EtOAc (2×50 mL),dried over anhydrous Na₂SO₄, filtered, and the organic phase stripped todryness via rotary evaporation to give the title compound. [M+H] calc'dfor C₂₆H₃₄FN₅O₆S, 564; found, 564.

B.6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-7-fluoro-4-(3-methylisothiazol-5-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

To a solution of tert-butyl6-((3R,4R)-3-(tert-butoxycarbonylamino)tetrahydro-2H-pyran-4-ylamino)-7-fluoro-4-(3-methylisothiazol-5-yl)-3-oxo-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxylate(5.5 mg, 9.76 μmol) in DCM (2.0 mL) was added TFA (2.0 mL, 26.0 mmol).The reaction mixture was stirred at RT for 1 h, and concentrated invacuo. The resulting crude material was reconstituted in DMF andpurified via preparative HPLC eluting with water (0.05% TFA) and ACN(55-80% gradient, 0.035% TFA). The collected fractions were combined andthe ACN was removed via rotary evaporation. The resulting aq solutionwas neutralized with saturated aq NaHCO₃, washed with EtOAc (2×50 mL),dried over anhydrous Na₂SO₄, filtered, and the organic phase stripped todryness via rotary evaporation. The residue was recrystallized fromTHF/hexane to give a TFA salt of the title compound. [M+H] calc'd forC₁₆H₁₈FN₅O₂S, 364; found, 364.

Preparation 53: 1:2-Methyl-5-(tributylstannyl)thiazole

To a cold (−78° C.) solution of 2-methylthiazole (2.80 g, 28.2 mmol) inanhydrous THF (100 mL) was added butyllithium (19.41 mL, 31.1 mmol)dropwise. After stirring for 60 min at −78° C., a solution oftributylchlorostannane (9.14 mL, 33.9 mmol) in anhydrous THF was addedto the reaction mixture. The reaction mixture was stirred for 30 min at−78° C. and then allowed to warm to RT over a 2 to 3 h period. Saturatedaq NaHCO₃ was added and the aqueous phase was extracted with ether(3×200 mL). The combined organic phase was dried over anhydrous Na₂SO₄,filtered, and evaporated in vacuo. The crude product was purified on asilica gel column eluting with 10-50% EtOAc in Hexane over a 60 minperiod. The fractions were collected and solvent was removed in vacuo togive the title compound as a yellow oil (72%). ¹H NMR (500 MHz, DMSO-d₆)δ ppm 0.71-0.92 (m, 9H), 0.96-1.18 (m, 6H), 1.23-1.38 (m, 6H), 1.40-1.64(m, 6H), 2.69 (s, 3H), 7.56 (d, J=12.69 Hz, 1H).

Example 1336-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-7-fluoro-4-(2-methylthiazol-5-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A TFA salt of the title compound was prepared in a manner similar toEXAMPLE 132 using 2-methyl-5-(tributylstannyl)thiazole in place of3-methyl-5-(tributylstannyl)isothiazole. ¹H NMR (500 MHz, DMSO-d₆) δ ppm1.24 (s, 1H), 1.73 (d, J=12.69 Hz, 1H), 1.93-2.03 (m, 1H), 2.57-2.71 (m,4H), 3.38-3.44 (m, 1H), 3.48-3.55 (m, 1H), 3.67 (d, J=11.72 Hz, 1H),3.82-3.97 (m, 2H), 4.22 (br s, 1H), 4.43 (s, 2H), 7.06 (br s, 1H), 8.52(s, 1H), 9.21-9.34 (m, 1H). [M+H] calc'd for C₁₆H₁₈FN₅O₂S, 364; found,364.

Example 134(R)-2-(7-Fluoro-4-(2-methylthiazol-5-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-4-methylpentanamide

The title compound was prepared in a manner similar to EXAMPLE 113 using2-methyl-5-(tributylstannyl)thiazole in place oftributyl(furan-2-yl)stannane. ¹H NMR (500 MHz, DMSO-d₆) δ ppm 0.74-0.98(m, 6H), 1.54-1.63 (m, 1H), 1.64-1.83 (m, 2H), 2.61-2.68 (m, 3H), 4.41(s, 2H), 4.56 (ddd, J=10.50, 8.30, 4.15 Hz, 1H), 6.97 (s, 1H), 7.19 (d,J=7.81 Hz, 1H), 7.35 (s, 1H), 8.45 (s, 1H), 9.22 (s, 1H). [M+H] calc'dfor C₁₇H₂₀FN₅O₂S, 378; found, 378.

Example 1356-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-4-(5-chlorothiophen-2-yl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

To a solution of6-((3R,4R)-3-aminotetrahydro-2H-pyran-4-ylamino)-7-fluoro-4-(thiophen-2-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one(12 mg, 0.034 mmol) in DCM (3 mL) was added pyridine (8.17 mg, 0.103mmol) and 1-chloropyrrolidine-2,5-dione (4.60 mg, 0.034 mmol). Thereaction mixture was stirred at RT for 3 h. The reaction mixture wassubsequently diluted with MeOH (3 mL) and was purified via preparativeHPLC eluting with water (0.05% TFA) and ACN (45-70% gradient, 0.035%TFA). The collected fractions were combined and the solvent was removedvia rotary evaporation. The resulting product was purified a second timeusing a gradient eluent of 15-45% ACN in 0.035% TFA (aq). The collectedfractions were combined and the solvent was removed via rotaryevaporation to yield a TFA salt of the title compound (2 mg, 15%). ¹HNMR (500 MHz, CD₃OD) δ ppm 1.92 (d, J=13.18 Hz, 1H), 2.14 (dd, J=12.69,4.88 Hz, 1H), 3.56-3.66 (m, 2H), 3.65-3.78 (m, 1H), 3.90 (d, J=12.20 Hz,1H), 4.04-4.19 (m, 3H), 4.37-4.47 (m, 1H), 6.99 (d, J=3.91 Hz, 1H), 8.80(d, J=3.91 Hz, 1H). [M+H] calc'd for C₁₆H₁₆ClFN₄O₂S, 383; found, 383.

Example 1366-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-4-(1-cyclopropyl-1H-pyrazol-4-yl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one

A 2 mL microwave vial was charged with tert-butyl6-((3R,4R)-3-(tert-butoxycarbonylamino)tetrahydro-2H-pyran-4-ylamino)-4-chloro-7-fluoro-3-oxo-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxylate(55 mg, 0.11 mmol),1-cyclopropyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole(77 mg, 0.329 mmol), and bis(triphenylphosphine)palladium chloride(15.41 mg, 0.022 mmol) and placed under an inert environment. Dioxane(1.1 mL) was added and the yellow slurry was degassed for 5 min. To theslurry was then added Na₂CO₃ (220 μL, 0.439 mmol) which caused thereaction slurry to turn orange. The mixture was degassed an additional 3min. The vessel was capped and the reaction mixture was heated to 80° C.for 4 h. The reaction mixture was subsequently diluted with EtOAc (10mL) and washed with water (8 mL) followed by brine (8 mL). The organicphase was collected, dried over Na₂SO₄, and concentrated to an oil,which was diluted with DCM (2 mL) and treated with HCl (4 M in dioxane,1 mL). The mixture was stirred for 1 h at RT, and then concentrated. Theresidue was diluted with MeOH (2 mL) and was purified via preparativeHPLC to give a TFA salt of the title compound as a white solid. ¹H NMR(DMSO-d₆) δ ppm 1.75 (t, 1H), 2.03-2.17 (m, 1H), 3.57-3.67 (m, 1H), 3.78(br s, 1H), 3.82-3.88 (m, 1H), 3.93-4.02 (m, 2H), 4.39 (d, J=5.3 Hz,2H), 4.45-4.54 (m, 1H), 4.82 (d, J=5.8 Hz, 2H), 5.15 (dd, J=17.2, 1.5Hz, 1H), 5.22 (dd, J=10.2, 1.4 Hz, 1H), 6.04 (dddd, J=16.8, 10.6, 5.8,5.7 Hz, 1H), 7.09 (d, J=5.3 Hz, 1H), 7.93 (d, J=4.3 Hz, 3H), 8.32 (s,1H), 8.40 (s, 1H), 8.85-9.03 (m, 1H). [M+H] calc'd for C₁₈H₂₁FN₆O₂, 373;found, 373.

TABLE 1, below, lists SYK inhibition data for many of the compoundsdescribed in the examples, where larger pIC₅₀ values represent higherpotency. The compounds were tested in accordance with the assaydescribed on page 59 of the specification.

TABLE 1 SYK Inhibition (pIC₅₀) for Example (Ex) Compounds Ex pIC₅₀ 1 8.12 6.9 3 7.6 4 7.8 5 6.2 6 6.3 7 6.0 8 8.1 9 5.1 10 <4.7 11 5.9 12 5.7 138.7 14 6.9 15 6.0 16 5.5 17 7.4 18 7.1 19 6.6 20 6.7 21 6.3 22 5.7 238.7 24 7.6 25 9.0 26 7.5 27 7.4 28 8.6 29 8.5 30 8.4 31 8.6 32 5.4 337.3 34 6.5 35 7.3 36 7.6 37 6.0 38 6.2 39 5.5 40 6.6 41 5.9 42 6.8 435.3 44 6.2 45 6.1 46 5.8 47 8.6 48 6.1 49 <4.7 50 8.6 51 7.2 52 7.2 535.8 54 6.6 55 7.8 56 5.6 57 7.8 58 5.8 59 7.1 60 7.8 61 7.2 62 8.0 638.1 64 8.0 65 8.0 66 6.3 67 7.4 68 7.0 69 6.8 70 8.8 71 8.1 72 7.5 738.1 74 8.3 75 9.1 76 9.3 77 7.5 78 8.4 79 7.7 80 5.5 81 8.5 82 9.2 836.6 84 7.7 85 8.4 86 5.6 87 7.2 88 8.5 89 8.4 90 8.0 91 6.6 92 7.9 938.0 94 8.5 95 5.4 96 6.7 97 6.8 98 5.7 99 8.5 100 6.8 101 7.2 102 8.4103 6.9 104 8.7 105 9.0 106 8.6 107 6.3 108 8.6 109 8.5 110 7.3 111 8.1112 8.7 113 6.7 114 6.6 115 6.5 116 8.1 117 7.9 118 7.9 119 7.8 120 6.6121 5.4 122 6.2 123 8.1 124 7.6 125 8.0 126 8.1 127 8.2 128 7.7 129 8.4130 5.0 131 <4.7 132 8.4 133 7.6 134 135 136 7.5

As used in this specification and the appended claims, singular articlessuch as “a,” “an,” and “the,” may refer to a single object or to aplurality of objects unless the context clearly indicates otherwise.Thus, for example, reference to a composition containing “a compound”may include a single compound or two or more compounds. It is to beunderstood that the above description is intended to be illustrative andnot restrictive. Many embodiments will be apparent to those of skill inthe art upon reading the above description. Therefore, the scope of theinvention should be determined with reference to the appended claims andincludes the full scope of equivalents to which such claims areentitled. The disclosures of all articles and references, includingpatents, patent applications and publications, are herein incorporatedby reference in their entirety and for all purposes.

1. A method of treating a disease or condition in a subject for which aSYK inhibitor is indicated, the method comprising administering to thesubject an effective amount of a compound of Formula 1,

or a pharmaceutically acceptable salt thereof, wherein: G is selectedfrom N and C(R⁵); L¹ and L² are each independently selected from —NH—and a bond; R¹ and R² are each independently selected from hydrogen,halo, C₁₋₃ alkyl, and C₁₋₃ haloalkyl, or R¹ and R², together with theatom to which they are attached, form a C₃₋₆ cycloalkyl; R³ is selectedfrom C₂₋₆ alkyl, C₃₋₈ cycloalkyl, C₂₋₅ heterocyclyl, and C₁₋₉heteroaryl, each optionally substituted with from one to fivesubstituents independently selected from halo, oxo, —NO₂, —CN, R⁶, andR⁷; R⁴ is selected from C₃₋₈ cycloalkyl, C₂₋₅ heterocyclyl, C₆₋₁₄ aryl,and C₁₋₉ heteroaryl, each optionally substituted with from one to fivesubstituents independently selected from halo, oxo, —CN, R⁶, and R⁷; R⁵is selected from hydrogen, halo, —CN, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄alkynyl, C₂₋₅ heterocyclyl, C₁₋₅ heteroaryl, and R¹⁰, wherein the alkyl,alkenyl, alkynyl moieties are each optionally substituted with from oneto five substituents independently selected from halo, —CN, oxo, andR¹⁰, and wherein the heterocyclyl moiety has 3 to 6 ring atoms and theheteroaryl moiety has 5 or 6 ring atoms, and the heterocyclyl andheteroaryl moieties are each optionally substituted with from one tofour substituents independently selected from halo, —NO₂, —CN, C₁₋₄alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₁₋₄ haloalkyl, and R¹⁰; each R⁶ isindependently selected from −OR⁸, —N(R⁸)R⁹, —NR⁸C(O)R⁹, —C(O)R⁸,—C(O)OR⁸, —C(O)N(R⁸)R⁹, —C(O)N(R⁸)OR⁹, —C(O)N(R⁸)S(O)₂R⁹, —N(R⁸)S(O)₂R⁹,—S(O)_(n)R⁸, and —S(O)₂N(R⁸)R⁹; each R⁷ is independently selected fromC₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₆ cycloalkyl-(CH₂)_(m)—,C₆₋₁₄ aryl-(CH₂)_(m)—, C₂₋₅ heterocyclyl-(CH₂)_(m)—, and C₁₋₉heteroaryl-(CH₂)_(m)—, each optionally substituted with from one to fivesubstituents independently selected from halo, oxo, —NO₂, —CN, C₁₋₆alkyl, C₁₋₆ haloalkyl, and R¹⁰; each R⁸ and R⁹ is independently selectedfrom hydrogen or from C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₆cycloalkyl-(CH₂)_(m)—, C₆₋₁₄ aryl-(CH₂)_(m)—, C₂₋₅heterocyclyl-(CH₂)_(m)—, and C₁₋₉ heteroaryl-(CH₂)_(m)—, each optionallysubstituted with from one to five substituents independently selectedfrom halo, oxo, —NO₂, —CN, C₁₋₆ alkyl, C₁₋₆ haloalkyl, and R¹⁰; each R¹⁰is independently selected from —OR¹¹, —N(R¹¹)R¹², N(R¹¹)C(O)R¹²,C(O)R¹¹, C(O)OR¹¹, —C(O)N(R¹¹)R¹², —C(O) N(R¹¹)OR¹²,—C(O)N(R¹¹)S(O)₂R¹², —NR¹¹S(O)_(n)R¹¹, and —S(O)₂N(R¹¹)R¹²; each R¹¹ andR¹² is independently selected from hydrogen and C₁₋₆ alkyl; each n isindependently selected from 0, 1 and 2; and each m is independentlyselected from 0, 1, 2, 3, and 4; wherein each of the aforementionedheteroaryl moieties has one to four heteroatoms independently selectedfrom N, O, and S, and each of the aforementioned heterocyclyl moietiesis saturated or partially unsaturated and has one or two heteroatomsindependently selected from N, O, and S.
 2. A method according to claim1, wherein L¹ is —NH—. 3-4. (canceled)
 5. A method according to claim 1,wherein L² is a bond.
 6. (canceled)
 7. A method according to claim 1,wherein G is C(R⁵).
 8. A method according to claim 1, wherein R¹ and R²are both hydrogen.
 9. A method according to claim 1, wherein R³ is C₃₋₈cycloalkyl, optionally substituted with from one to five substituentsindependently selected from halo, oxo, —NO₂, —CN, R⁶, and R⁷. 10.(canceled)
 11. A method according to claim 9, wherein R³ is2-amino-cyclohex-1-yl optionally substituted with from one to foursubstituents independently selected from halo, oxo, —NO₂, —CN, R⁶, andR⁷. 12-15. (canceled)
 16. A method according to claim 1, wherein R³ isC₂₋₅ heterocyclyl optionally substituted with from one to fivesubstituents independently selected from halo, oxo, —NO₂, —CN, R⁶, andR⁷.
 17. (canceled)
 18. A method according to claim 16, wherein R³ is3-aminotetrahydro-2H-pyran-4-yl optionally substituted with from one tofour substituents independently selected from halo, oxo, —NO₂, —CN, R⁶,and R⁷. 19-21. (canceled)
 22. A method according to claim 1, wherein R⁴is C₁₋₉ heteroaryl optionally substituted with from one to fivesubstituents independently selected from halo, oxo, —CN, R⁶, and R⁷. 23.A method according to claim 22, wherein R⁴ is a monocyclic C₂₋₄heteroaryl optionally substituted with from one to four substituentsindependently selected from halo, —CN, R⁶, and R⁷.
 24. A methodaccording to claim 23, wherein R⁴ is selected from pyrrolyl, furanyl,thiopheneyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, isothiazolyl,and thiazolyl, each optionally substituted with from one to threesubstituents independently selected from halo, —CN, R⁶, and R⁷.
 25. Amethod according to claim 24, wherein R⁴ is selected from thiopheneyl,pyrazolyl, isothiazolyl, and thiazolyl, each optionally substituted withfrom one to three substituents independently selected from halo, —CN,R⁶, and R⁷.
 26. A method according to claim 25, wherein R⁴ is pyrazolyloptionally substituted with from one to three substituents independentlyselected from halo, —CN, R⁶, and R⁷.
 27. A method according to claim 26,wherein R⁴ is pyrazol-4-yl optionally substituted with from one to threesubstituents independently selected from halo, —CN, R⁶, and R⁷.
 28. Amethod according to claim 22, wherein R⁴ is substituted with methyl,ethyl, cyclopropyl or C₁₋₂ haloalkyl.
 29. (canceled)
 30. A methodaccording to claim 1, wherein R⁵ is selected from hydrogen and halo. 31.A method according to claim 30, wherein R⁵ is selected from chloro andfluoro.
 32. A method according to claim 1, wherein the compound isselected from the following compounds:2-((1R,2S)-2-Aminocyclohexylamino)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one;2-((1R,2S)-2-Aminocyclohexylamino)-4-(3-fluorophenylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one;2-((1R,2S)-2-Aminocyclohexylamino)-4-(3-chlorophenylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one;4-(1H-Indazol-6-ylamino)-2-((1R,2S)-2-aminocyclohexylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one;2-((1R,2S)-2-aminocyclohexylamino)-4-(3-(trifluoromethyl)phenylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one;cis-2-(2-aminocyclohexylamino)-4-(3-(trifluoromethyl)phenylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one;2-(1-Methyl-1H-pyrazol-4-yl)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one;2-(4-Ethylpiperazin-1-yl)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one;2-(Cyclohexylamino)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one;cis-2-(2-Hydroxycyclohexylamino)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one;2-(3-Aminopiperidin-1-yl)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one;6-((1R,2S)-2-Aminocyclohexylamino)-4-(m-tolylamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;2-((1R,2S)-2-Aminocyclohexylamino)-4-(1-methyl-1H-pyrazol-4-yl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one;2-((1R,2S)-2-Aminocyclohexylamino)-4-(1-isobutyl-1H-pyrazol-4-yl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one;2-((1R,2S)-2-Aminocyclohexylamino)-4-phenyl-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one;2-((1R,2S)-2-Aminocyclohexylamino)-4-(benzo[b]thiophen-3-yl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one;2-((1R,2S)-2-Aminocyclohexylamino)-4-(1-ethyl-1H-pyrazol-4-yl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one;2-((1R,2S)-2-Aminocyclohexylamino)-4-(1-benzyl-1H-pyrazol-4-yl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one;2-((1R,2S)-2-Aminocyclohexylamino)-4-(imidazo[1,2-a]pyridin-3-yl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one;2-((1R,2S)-2-Aminocyclohexylamino)-4-(1-propyl-1H-pyrazol-4-yl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one;2-((1R,2S)-2-Aminocyclohexylamino)-4-(1-(2-methoxyethyl)-1H-pyrazol-4-yl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one;4-(1H-Indazol-6-ylamino)-6-((1R,2S)-2-aminocyclohexylamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;6-((1R,2S)-2-Aminocyclohexylamino)-4-(4-fluoro-3-methylphenylamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;6-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-4-(m-tolylamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;6-((1R,2S)-2-Aminocyclohexylamino)-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;6-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;6-((1R,2S)-2-Aminocyclohexylamino)-7-chloro-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;6-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-4-(pyrazolo[1,5-a]pyridin-3-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;2-(2-(Aminomethyl)piperidin-1-yl)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one;6-((1R,2S)-2-Aminocyclohexylamino)-4-(3-(methylsulfonyl)phenylamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;6-((1R,2S)-2-Aminocyclopentylamino)-4-(3-(methylsulfonyl)phenylamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;(R)-4-Methyl-2-(4-(3-(methylsulfonyl)phenylamino)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)pentanamide;(R)-4-Methyl-2-(4-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)pentanamide;2-((1R,2S)-2-(Dimethylamino)cyclohexylamino)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one;2-((1R,2S)-2-(Methylamino)cyclohexylamino)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one;2′-((1R,2S)-2-Aminocyclohexylamino)-4′-(m-tolylamino)spiro[cyclopropane-1,7′-pyrrolo[3,4-d]pyrimidin]-5′(6′H)-one;2-(2-Aminoethylamino)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one;2-(2-Amino-2-methylpropylamino)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one;2-(5-oxo-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-ylamino)acetamide;2-((2-Aminoethyl)(methyl)amino)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one;2-(Pyrrolidin-2-ylmethylamino)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one;2-(3-Aminopyrrolidin-1-yl)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one;2-((1R,2S)-2-Aminocyclohexylamino)-4-(1,5-dimethyl-1H-pyrazol-4-yl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one;2-((1R,2S)-2-Aminocyclohexylamino)-4-(1H-indol-2-yl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one;2-((1R,2S)-2-Aminocyclohexylamino)-4-(1H-pyrazol-5-yl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one;2-(3-Aminopropyl)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one;6-((1R,2S)-2-Aminocyclohexylamino)-4-(benzofuran-3-yl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;6-((1R,2S)-2-aminocyclohexylamino)-7-fluoro-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;6-((1R,2S)-2-aminocyclohexylamino)-4-(benzo[b]thiophen-3-yl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;6-((1S,2R)-2-Aminocyclohexylamino)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;(R)-6-(2-Amino-3-ethoxypropylamino)-4-(m-tolylamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;(R)-6-(2-Amino-3-ethoxypropylamino)-7-fluoro-4-(m-tolylamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;6-(2-Amino-3,3,3-trifluoropropylamino)-4-(m-tolylamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;(R)-4-Methyl-2-(3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)pentanamide;6-(cis-4-Aminotetrahydrofuran-3-ylamino)-4-(m-tolylamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;6-((1R,2S)-2-Aminocyclohexylamino)-4-(1-ethyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;6-((1R,2S)-2-Aminocyclohexylamino)-4-(1-ethyl-1H-pyrazol-4-yl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;6-((1R,2S)-2-Aminocyclohexylamino)-4-(1-cyclopropyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;6-((1R,2S)-2-Aminocyclohexylamino)-4-(1-(difluoromethyl)-1H-pyrazol-4-yl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;6-((1R,2S)-2-Aminocyclohexylamino)-4-(1-cyclopropyl-1H-pyrazol-4-yl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;cis-6-(2-Aminocyclohexylamino)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;6-(cis-2-Amino-4,4-difluorocyclopentylamino)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;6-(cis-2-Amino-3,3-difluorocyclohexylamino)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;6-(cis-2-Amino-3,3-difluorocyclohexylamino)-4-(1-(difluoromethyl)-1H-pyrazol-4-yl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;6-(cis-2-amino-3,3-difluorocyclohexylamino)-4-(1-cyclopropyl-1H-pyrazol-4-yl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;(R)-2-(7-Fluoro-4-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-4-methylpentanamide;(R)-2-(4-(1-(Difluoromethyl)-1H-pyrazol-4-yl)-7-fluoro-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-4-methylpentanamide;(R)-2-(4-(1-Cyclopropyl-1H-pyrazol-4-yl)-7-fluoro-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-4-methylpentanamide;(R)-2-(4-(Benzofuran-3-yl)-7-fluoro-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-4-methylpentanamide;(R)-2-(7-Fluoro-3-oxo-4-(pyrazolo[1,5-a]pyridin-3-yl)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-4-methylpentanamide;6-((1R,2S)-2-Aminocyclohexylamino)-7-chloro-4-(m-tolylamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;6-((1R,2S)-2-Aminocyclohexylamino)-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-7-carbonitrile;(R)-6-(2-Amino-3-methoxypropylamino)-4-(m-tolylamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;(R)-6-(2-Amino-3-methoxypropylamino)-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-7-carbonitrile;(R)-6-(2-Amino-3-methoxypropylamino)-7-fluoro-4-(m-tolylamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;7-Acryloyl-6-((1R,2S)-2-aminocyclohexylamino)-4-(m-tolylamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;6-((1R,2S)-2-Aminocyclohexylamino)-7-iodo-4-(m-tolylamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;6-((1R,2S)-2-Aminocyclohexylamino)-7-(1H-pyrazol-4-yl)-4-(m-tolylamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;6-(cis-2-Amino-3,3-difluorocyclohexylamino)-4-(m-tolylamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;6-((1R,2S)-2-Aminocyclohexylamino)-7-(1-methyl-1H-pyrazol-5-yl)-4-(m-tolylamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-4-(m-tolylamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;6-((3R,4R)-4-Aminotetrahydro-2H-pyran-3-ylamino)-4-(m-tolylamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;tert-Butyl(1S,2R)-2-(3-oxo-7-phenyl-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate;6-((1R,2S)-2-Aminocyclohexylamino)-7-methyl-4-(m-tolylamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-7-fluoro-4-(m-tolylamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;6-((1R,2S)-2-Aminocyclohexylamino)-7-methyl-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;(R)-6-(2-Amino-3-methoxypropylamino)-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-7-fluoro-4-(pyrazolo[1,5-a]pyridin-3-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-4-(1-(difluoromethyl)-1H-pyrazol-4-yl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-4-(benzofuran-3-yl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;(S)-6-(3-Aminopyrrolidin-1-yl)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;(S)-6-(3-Aminopiperidin-1-yl)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;6-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-4-(1-isopropyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;7-Fluoro-4,6-bis(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;6-((1R,2S)-2-Aminocyclohexylamino)-7-bromo-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;2-((1R,2S)-2-Aminocyclohexylamino)-4-(1-(4-fluorophenyl)-1H-pyrazol-4-yl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one;(R)-6-(2-Amino-3-methoxypropylamino)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-7-fluoro-4-(thiophen-3-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-7-fluoro-4-(4-methylthiophen-2-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;6-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-4-(4-methylthiophen-2-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;6-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-4-(thiophen-3-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;(R)-2-(7-Fluoro-4-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-N,4-dimethylpentanamide;6-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-4-(5-methylthiophen-2-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;(R)-2-(7-Fluoro-4-(4-methylthiophen-2-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-4-methylpentanamide;(R)-2-(7-Fluoro-3-oxo-4-(thiophen-3-yl)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-4-methylpentanamide;(R)-2-(7-Fluoro-4-(5-methylthiophen-2-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-4-methylpentanamide;6-((1R,2S)-2-Aminocyclohexylamino)-4-(2-aminothiazol-5-yl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;(R)-2-(7-Fluoro-4-(furan-2-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-4-methylpentanamide;(R)-2-(7-Fluoro-4-(furan-3-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-4-methylpentanamide;(R)-2-(7-Fluoro-4-(5-methylfuran-2-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-4-methylpentanamide;(R)-2-(4-(5-Cyanothiophen-2-yl)-7-fluoro-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-4-methylpentanamide;(R)-2-(4-(4-Cyanothiophen-2-yl)-7-fluoro-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-4-methylpentanamide;(R)-2-(7-Fluoro-3-oxo-4-(thiazol-5-yl)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-4-methylpentanamide;(R)-2-(7-Fluoro-4-(isothiazol-5-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-4-methylpentanamide;6-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-1,1-dimethyl-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-4-(1-methyl-1H-pyrazol-3-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;6-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-4-(2-methylthiazol-5-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-7-fluoro-4-(5-methylthiophen-2-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;6-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-1-methyl-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;(R)-2-(7-Fluoro-3-oxo-4-(thiophen-2-yl)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-4-methylpentanamide;6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-7-fluoro-4-(thiophen-2-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-7-fluoro-4-(thiazol-5-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;6-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-4-(thiophen-2-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-7-fluoro-4-(4-(trifluoromethyl)-1H-imidazol-1-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;6-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-4-(4-methyl-1H-imidazol-1-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-7-fluoro-4-(3-methylisothiazol-5-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-7-fluoro-4-(2-methylthiazol-5-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;(R)-2-(7-Fluoro-4-(2-methylthiazol-5-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-4-methylpentanamide;6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-4-(5-chlorothiophen-2-yl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-4-(1-cyclopropyl-1H-pyrazol-4-yl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;a stereoisomer of any of the aforementioned compounds; and apharmaceutically acceptable salt of any of the aforementioned compoundsor stereoisomers. 33-36. (canceled)
 37. A method of treating a diseaseor condition in a subject, the method comprising administering to thesubject an effective amount of a compound of Formula 1,

or a pharmaceutically acceptable salt thereof, wherein: G is selectedfrom N and C(R⁵); L¹ and L² are each independently selected from —NH—and a bond; R¹ and R² are each independently selected from hydrogen,halo, C₁₋₃ alkyl, and C₁₋₃ haloalkyl, or R¹ and R², together with theatom to which they are attached, form a C₃₋₆ cycloalkyl; R³ is selectedfrom C₂₋₆ alkyl, C₃₋₈ cycloalkyl, C₂₋₅ heterocyclyl, and C₁₋₉heteroaryl, each optionally substituted with from one to fivesubstituents independently selected from halo, oxo, —NO₂, —CN, R⁶, andR⁷; R⁴ is selected from C₃₋₈ cycloalkyl, C₂₋₅ heterocyclyl, C₆₋₁₄ aryl,and C₁₋₉ heteroaryl, each optionally substituted with from one to fivesubstituents independently selected from halo, oxo, —CN, R⁶, and R⁷; R⁵is selected from hydrogen, halo, —CN, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄alkenyl, C₂₋₅ heterocyclyl, C₁₋₅ heteroaryl, and R¹⁰, wherein the alkyl,alkenyl, alkynyl moieties are each optionally substituted with from oneto five substituents independently selected from halo, —CN, oxo, andR¹⁰, and wherein the heterocyclyl moiety has 3 to 6 ring atoms and theheteroaryl moiety has 5 or 6 ring atoms, and the heterocyclyl andheteroaryl moieties are each optionally substituted with from one tofour substituents independently selected from halo, —NO₂, —CN, C₁₋₄alkyl, C₂₋₄ alkenyl, C₂₋₄ alkenyl, C₁₋₄ haloalkyl, and R¹⁰; each R⁶ isindependently selected from —OR⁸, —N(R⁸)R⁹, —NR⁸C(O)R⁹, —C(O)R⁸,—C(O)OR⁸, —C(O)N(R⁸)R⁹, —C(O)N(R⁸)OR⁹, —C(O)N(R⁸)S(O)₂R⁹, —N(R⁸)S(O)₂R⁹,—S(O)_(n)R⁸, and —S(O)₂N(R⁸)R⁹; each R⁷ is independently selected fromC₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₆ cycloalkyl-(CH₂)_(m)—,C₆₋₁₄ aryl-(CH₂)_(m)—, C₂₋₅ heterocyclyl-(CH₂)_(m)—, and C₁₋₉heteroaryl-(CH₂)_(m)—, each optionally substituted with from one to fivesubstituents independently selected from halo, oxo, —NO₂, —CN, C₁₋₆alkyl, C₁₋₆ haloalkyl, and R¹⁰; each R⁸ and R⁹ is independently selectedfrom hydrogen or from C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkenyl, C₃₋₆cycloalkyl-(CH₂)_(m)—, C₆₋₁₄ aryl-(CH₂)_(m)—, C₂₋₅heterocyclyl-(CH₂)_(m)—, and C₁₋₉ heteroaryl-(CH₂)_(m)—, each optionallysubstituted with from one to five substituents independently selectedfrom halo, oxo, —NO₂—CN, C₁₋₆ alkyl, C₁₋₆ haloalkyl, and R¹⁰; each R¹⁰is independently selected from —OR¹¹, —N(R¹¹)R¹², —N(R¹¹)C(O)R¹²;—C(O)R¹¹; —C(O)OR¹¹, —C(O)N(R¹¹)R¹²; —C(O) N(R¹¹)OR¹²,—C(O)N(R¹¹)S(O)₂R¹², —NR S(O)₂R¹², —S(O)_(n)R¹¹, and —S(O)₂N(R¹¹)R¹²;each R¹¹ and R¹² is independently selected from hydrogen and C₁₋₆ alkyl;each n is independently selected from 0, 1 and 2; and each m isindependently selected from 0, 1, 2, 3, and 4; wherein each of theaforementioned heteroaryl moieties has one to four heteroatomsindependently selected from N, O, and S, and each of the aforementionedheterocyclyl moieties is saturated or partially unsaturated and has oneor two heteroatoms independently selected from N, O, and S; wherein thedisease or condition is selected from allergic rhinitis, allergicasthma, atopic dermatitis, rheumatoid arthritis, multiple sclerosis,systemic lupus erythematosus, psoriasis, immune thrombocytopenicpurpura, inflammatory bowel disease, chronic obstructive pulmonarydisease, thrombosis, a hematological malignancy, and an epithelialcancer.
 38. (canceled)
 39. A method according to claim 37, wherein thehematological malignancy is selected from acute myeloid leukemia, B-cellchronic lymphocytic leukemia, B-cell lymphoma, and T-cell lymphoma. 40.A method according to claim 37, wherein the epithelial cancer isselected from lung cancer, pancreatic cancer, and colon cancer.
 41. Amethod according to claim 37, the method further comprisingadministering to the subject at least one additional pharmacologicallyactive agent.
 42. A method according to claim 41, wherein the additionalpharmacologically active agent is a DMARD.
 43. A method according toclaim 42, wherein the DMARD is methotrexate.